

Preoperative versus Postoperative Chemoradiotherapy

New England Journal of Medicine

351, 1731-1740

DOI: [10.1056/nejmoa040694](https://doi.org/10.1056/nejmoa040694)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Chemoradiotherapy for Rectal Cancer "When, Why, and How?. New England Journal of Medicine, 2004, 351, 1790-1792.	13.9	53
3	Management and imaging of low rectal carcinoma. Surgical Oncology, 2004, 13, 55-61.	0.8	25
5	Multimodality approaches for rectal cancer. Current Problems in Cancer, 2004, 28, 316-342.	1.0	1
6	Multimodality Therapy of Rectal Cancer. , 2005, , 203-213.		0
7	Immunohistochemical Analysis of Thymidylate Synthase, Thymidine Phosphorylase, and Dihydropyrimidine Dehydrogenase in Rectal Cancer (cUICC II/III). American Journal of Surgical Pathology, 2005, 29, 1304-1309.	2.1	34
8	Möglichkeiten und Entwicklungen der neoadjuvanten und adjuvanten Therapie des Rektumkarzinoms. Visceral Medicine, 2005, 21, 119-129.	0.5	0
9	Vorgehen beim lokoregionären Rezidiv des Rektumkarzinoms. Visceral Medicine, 2005, 21, 151-156.	0.5	0
10	Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. Annals of Surgery, 2005, 241, 829-838.	2.1	341
11	Predictive Markers in Physiology and Anatomy for Outcomes in Rectal Cancer Patients. , 2005, , 51-56.		0
12	Gemcitabine Radiosensitization for Rectal Cancer. Cancer Journal (Sudbury, Mass), 2005, 11, 110-112.	1.0	0
13	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1363-1370.	0.4	77
14	Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 346-353.	0.4	107
15	Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?. International Journal of Radiation Oncology Biology Physics, 2005, 63, 745-752.	0.4	99
16	Treatment and Survival from Colorectal Cancer: The Experience of Patients at South Australian Teaching Hospitals Between 1980 and 2002. Clinical Oncology, 2005, 17, 372-381.	0.6	14
17	ILEOSTOMY CLOSURE WITHOUT CONTRAST STUDY IS SAFE IN SELECTED PATIENTS. ANZ Journal of Surgery, 2005, 75, 218-219.	0.3	13
18	P53 abnormalities and outcomes in colorectal cancer: a systematic review. British Journal of Cancer, 2005, 92, 1813-1813.	2.9	15
19	A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. British Journal of Cancer, 2005, 93, 993-998.	2.9	61
20	Complications after Preoperative Combined Modality Therapy and Radical Resection of Locally Advanced Rectal Cancer: A 14-Year Experience from a Specialty Service. Journal of the American College of Surgeons, 2005, 200, 876-882.	0.2	70

#	ARTICLE	IF	CITATIONS
22	The Emerging Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Primary and Recurrent Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2005, 201, 948-956.	0.2	24
23	Presence of distal intramural spread after preoperative combined-modality therapy for adenocarcinoma of the rectum: What is now the appropriate distal resection margin?. <i>Surgery</i> , 2005, 138, 658-664.	1.0	44
24	Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. <i>British Journal of Surgery</i> , 2005, 92, 756-763.	0.1	231
26	Radiation and chemoradiation therapy for esophageal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2005, 92, 239-245.	0.8	10
27	Multimodal Treatment of Gastrointestinal Tract Tumors: Consequences for Surgery. <i>World Journal of Surgery</i> , 2005, 29, 940-948.	0.8	21
28	Comparative Analysis of the Effects of Belly Board and Bladder Distension in Postoperative Radiotherapy of Rectal Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 601-605.	1.0	29
30	Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801). <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1389-1396.	0.7	17
31	Long-Term Anorectal Dysfunction After Postoperative Radiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1343-1352.	0.7	113
34	Practice Parameters for the Management of Rectal Cancer (Revised). <i>Diseases of the Colon and Rectum</i> , 2005, 48, 411-423.	0.7	199
38	Radiochimiothérapie des cancers du rectum: Le préopératoire définitivement. <i>Acta Endoscopica</i> , 2005, 35, 243-243.	0.0	0
39	Advances in surgical technique for primary rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2005, 1, 43-50.	1.0	0
40	Chemoradiation for localized rectal cancer: Neoadjuvant versus adjuvant approaches. <i>Current Colorectal Cancer Reports</i> , 2005, 1, 51-57.	1.0	1
41	Chemotherapy in Rectal Cancer. , 2005, , 215-220.		0
42	Preoperative Chemoradiation in Rectal Cancer: Why We Need a Common Language. <i>Oncology Research and Treatment</i> , 2005, 28, 237-240.	0.8	4
43	Advances in Treatment of Colorectal Cancer. <i>American Surgeon</i> , 2005, 71, 892-900.	0.4	1
44	T4 Rectal Cancer: Analysis of Patient Outcome after Surgical Excision. <i>American Surgeon</i> , 2005, 71, 901-904.	0.4	17
45	10 Anhang: Adressen für Ärzte und Patienten. , 2005, , .		0
46	Modern Aspects of Radiation Oncology for Rectal Cancer. , 2005, , 221-225.		0

#	ARTICLE	IF	CITATIONS
47	(Neo-)adjuvant treatments in colorectal cancer. <i>Annals of Oncology</i> , 2005, 16, ii133-ii140.	0.6	10
48	CHEMORADIOTHERAPY FOR COLORECTAL CANCER. <i>Gut</i> , 2005, 54, 1194-1202.	6.1	76
49	Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer. <i>Acta Oncol</i> , 2005, 44, 921-923.	0.8	18
50	High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: A phase I trial. <i>Acta Oncol</i> , 2005, 44, 224-229.	0.8	16
51	Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results. EORTC 22921. <i>Journal of Clinical Oncology</i> , 2005, 23, 5620-5627.	0.8	534
52	Impact of Short-Term Preoperative Radiotherapy on Health-Related Quality of Life and Sexual Functioning in Primary Rectal Cancer: Report of a Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 1847-1858.	0.8	583
53	Cetuximab. <i>Nature Reviews Drug Discovery</i> , 2005, 4, S10-S11.	21.5	76
54	Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer. <i>Cancer Research</i> , 2005, 65, 4881-4887.	0.4	248
55	Neoadjuvant chemoradiation treatment impairs accuracy of MRI staging in rectal carcinoma. <i>Gut</i> , 2005, 55, 1214-1215.	6.1	12
56	Combined-Modality Neoadjuvant Therapy for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5450-5451.	0.8	3
57	An Embarrassment of Riches: Neoadjuvant Therapy of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1339-1341.	0.8	2
60	Preoperative versus postoperative treatment for locally advanced rectal carcinoma. <i>Future Oncology</i> , 2005, 1, 209-220.	1.1	4
61	Chemoradiotherapy for Rectal Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 509-511.	18.9	9
63	Multidisciplinary treatment of synchronous primary rectal and prostate cancers. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 271-274.	4.3	15
64	Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 4905-4912.	0.8	48
65	Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. <i>British Journal of Cancer</i> , 2005, 92, 655-661.	2.9	33
66	Occurrence of Second Cancers in Patients Treated With Radiotherapy for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6126-6131.	0.8	238
67	Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point. <i>Journal of Clinical Oncology</i> , 2005, 23, 3475-3479.	0.8	161

#	ARTICLE	IF	CITATIONS
68	A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods. <i>Clinical Cancer Research</i> , 2005, 11, 5440-5443.	3.2	46
69	Preoperative Radio-Chemotherapy Treatment in Locally Advanced Rectal Carcinoma. Results of 8-Year Follow-Up. <i>Oncology Research and Treatment</i> , 2005, 28, 267-269.	0.8	4
70	Colorectal cancer. <i>Lancet, The</i> , 2005, 365, 153-165.	6.3	1,030
71	Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial. Implication for subsequent local excision. <i>Radiotherapy and Oncology</i> , 2005, 76, 234-240.	0.3	92
72	The multidisciplinary rectal cancer treatment: Main convergences, controversial aspects and investigational areas which support the need for an European Consensus. <i>Radiotherapy and Oncology</i> , 2005, 76, 241-250.	0.3	48
73	Primary radical external beam radiotherapy of rectal adenocarcinoma: Long term outcome of 271 patients. <i>Radiotherapy and Oncology</i> , 2005, 77, 126-132.	0.3	81
75	The role of the pathologist. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 351-359.	2.2	2
76	Is sphincter saving an important end-point?. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 367-371.	2.2	2
77	Radiotherapy in rectal cancer: technical aspects and regimens. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 373-388.	2.2	1
78	Chemotherapy in rectal cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 389-400.	2.2	2
79	Principles of Total Mesorectal Excision for Rectal Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2005, 16, 117-127.	0.2	0
80	Clinical Staging of Rectal Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2005, 16, 104-116.	0.2	3
81	Treatment of Unresectable/Recurrent Rectal Cancer with External Beam and/or Intraoperative Radiation Techniques. <i>Seminars in Colon and Rectal Surgery</i> , 2005, 16, 155-161.	0.2	0
83	Endoscopic Ultrasound for Luminal Malignancies. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2005, 15, 399-429.	0.6	4
84	Current Management of Rectal Cancer: Total Mesorectal Excision (Nerve Sparing) Technique and Clinical Outcome. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 137-155.	0.6	11
85	Improving Rectal Cancer Outcomes with Chemotherapy. <i>Seminars in Colon and Rectal Surgery</i> , 2005, 16, 162-169.	0.2	2
86	Abdominoperineal Resection for Rectal Cancer: Historic Perspective and Current Issues. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 569-586.	0.6	28
87	Endoscopic ultrasonography in the diagnosis and management of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 585-597.	1.5	10

#	ARTICLE	IF	CITATIONS
88	Adverse Effects of Preoperative Radiation Therapy for Rectal Cancer: Long-Term Follow-Up of the Swedish Rectal Cancer Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 8697-8705.	0.8	359
89	Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8688-8696.	0.8	1,102
90	Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2005, 92, 1215-1220.	2.9	74
91	A phase II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2005, 16, 1140-1146.	0.6	133
92	Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. <i>Annals of Oncology</i> , 2005, 16, 1898-1905.	0.6	124
93	Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1826-1838.	0.8	325
94	Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. <i>European Journal of Cancer</i> , 2005, 41, 2861-2867.	1.3	17
95	Gastrointestinal cancer: recent developments in medical oncology. <i>European Journal of Surgical Oncology</i> , 2005, 31, 453-460.	0.5	25
96	Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer. <i>European Journal of Surgical Oncology</i> , 2005, 31, 969-976.	0.5	6
99	An Overview of Approaches to Adjuvant Therapy for Colorectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2005, 5, S11-S18.	1.0	14
100	Preoperative Chemoradiation Therapy Shows Improved Clinical Benefit in Patients with Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 163-165.	1.0	0
101	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer. <i>Annals of Oncology</i> , 2005, 16, i20-i21.	0.6	28
102	Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 1114-1123.	13.9	2,458
103	Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. <i>British Journal of Cancer</i> , 2006, 94, 363-371.	2.9	95
104	Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. <i>International Journal of Hyperthermia</i> , 2006, 22, 301-318.	1.1	21
105	The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer. Abbreviations: 5-FU 5-fluorouracil LV Leucovorin APR abdomino-perineal resection. <i>International Journal of Hyperthermia</i> , 2006, 22, 399-406.	1.1	16
106	A multimodality approach to localized rectal cancer. <i>Annals of Oncology</i> , 2006, 17, x129-x134.	0.6	10
107	Sphincter saving is the primary objective for local treatment of cancer of the lower rectum. <i>Lancet Oncology</i> , The, 2006, 7, 775-777.	5.1	21

#	ARTICLE	IF	CITATIONS
108	Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial. <i>Radiotherapy and Oncology</i> , 2006, 79, 52-58.	0.3	24
109	Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. <i>Radiotherapy and Oncology</i> , 2006, 80, 4-12.	0.3	95
110	A pilot study of accelerated preoperative hyperfractionated pelvic irradiation with or without low-dose preoperative prophylactic liver irradiation in patients with locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2006, 80, 27-32.	0.3	11
111	Distal rectal cancer: Sphincter-sparing is also a challenge for the radiation oncologist. <i>Radiotherapy and Oncology</i> , 2006, 80, 1-3.	0.3	18
112	The management of rectal cancer in a resource poor environment – A review. <i>International Journal of Surgery</i> , 2006, 4, 127-130.	1.1	3
113	Surgical Treatment of Rectal Cancer: Radical Resection. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 95-107.	0.6	10
114	Staging and Prognosis of Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 129-146.	0.6	40
115	Radiation Therapy for Gastrointestinal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 287-320.	0.9	8
116	Advances in Chemotherapy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 808-821.	2.4	22
117	Neoadjuvant and Adjuvant Therapy for Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 147-157.	0.6	33
118	Guidelines for Colonoscopy Surveillance After Cancer Resection: A Consensus Update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2006, 130, 1865-1871.	0.6	352
119	Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. <i>Clinical Colorectal Cancer</i> , 2006, 5, 413-421.	1.0	15
120	Gene Expression Levels of Epidermal Growth Factor Receptor, Survivin, and Vascular Endothelial Growth Factor as Molecular Markers of Lymph Node Involvement in Patients with Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 305-311.	1.0	11
121	Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer. <i>World Journal of Surgical Oncology</i> , 2006, 4, 83.	0.8	5
122	Surgical Management of Pulmonary Metastases from Colorectal Cancer in 153 Patients. <i>Annals of Surgical Oncology</i> , 2006, 13, 1538-1544.	0.7	112
123	Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. <i>Annals of Oncology</i> , 2006, 17, 246-251.	0.6	114
124	The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. <i>Annals of Oncology</i> , 2006, 17, 361-371.	0.6	73
125	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 668-674.	0.8	432

#	ARTICLE	IF	CITATIONS
126	Efficacy of 3-dimensional endorectal ultrasonography compared with conventional ultrasonography and computed tomography in preoperative rectal cancer staging. <i>American Journal of Surgery</i> , 2006, 192, 89-97.	0.9	94
127	Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. <i>American Journal of Surgery</i> , 2006, 192, 873-877.	0.9	72
128	Review of randomised trials using the post-randomised consent (Zelen's) design. <i>Contemporary Clinical Trials</i> , 2006, 27, 305-319.	0.8	125
130	Radiation therapy and combined modality treatment of gastrointestinal carcinomas. <i>Cancer Treatment Reviews</i> , 2006, 32, 119-138.	3.4	28
131	Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. <i>European Journal of Surgical Oncology</i> , 2006, 32, 55-64.	0.5	116
132	Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3cm of the anal verge. <i>European Journal of Surgical Oncology</i> , 2006, 32, 162-167.	0.5	42
133	Pre-operative combined modality therapy in the management of locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2006, 32, 259-268.	0.5	15
134	Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. <i>European Journal of Surgical Oncology</i> , 2006, 32, 1201-1208.	0.5	36
135	Modern management of rectal cancer: A 2006 update. <i>World Journal of Gastroenterology</i> , 2006, 12, 3186.	1.4	111
136	Urethral Cancer. , 2006, , 27-37.		1
137	Comparison of the Efficacy of Oral Capecitabine versus Bolus 5-FU in Preoperative Radiotherapy of Locally Advanced Rectal Cancer. <i>Journal of Korean Medical Science</i> , 2006, 21, 52.	1.1	32
138	24 Endoanal and Endorectal Sonography. , 2006, , .		0
139	Oxaliplatin with Raltitrexed and Preoperative Radiotherapy in T3-T4 Extraperitoneal Rectal Cancer. A Dose Finding Study. <i>Tumori</i> , 2006, 92, 474-480.	0.6	2
143	Induction Chemoradiation for Rectal Cancer. <i>Archives of Surgery</i> , 2006, 141, 1246.	2.3	12
144	Preoperative Versus Postoperative Chemoradiotherapy for Rectal Cancer. <i>Yearbook of Oncology</i> , 2006, 2006, 300-303.	0.1	0
145	A Defunctioning Stoma in the Treatment of Lower Third Rectal Carcinoma. <i>Acta Chirurgica Belgica</i> , 2006, 106, 40-43.	0.2	17
146	Prognostic Value of Histologic Tumor Regression, Thymidylate Synthase, Thymidine Phosphorylase, and Dihydropyrimidine Dehydrogenase in Rectal Cancer UICC Stage II/III After Neoadjuvant Chemoradiotherapy. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1169-1174.	2.1	26
148	Survival of Rectal Cancer Patients in Belgium 1997-1998 and the Potential Benefit of a National Project. <i>Acta Chirurgica Belgica</i> , 2006, 106, 149-157.	0.2	22

#	ARTICLE	IF	CITATIONS
149	Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 219-224.	0.6	158
150	Acute Proctocolitis With Commencement of Neoadjuvant Chemoradiation for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 534-535.	0.6	2
151	External Beam Radiotherapy for Perirectal Angiomyxoma Results in a Dramatic Clinical Response and Allows a Patient to Avoid Abdominoperineal Resection. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 318-319.	0.6	11
152	Phase II Trial of Preoperative Chemoradiation With a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 435-441.	0.6	19
153	Treatment options for colorectal cancer in the elderly. Aging Health, 2006, 2, 931-942.	0.3	0
155	Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiation Oncology, 2006, 1, 25.	1.2	41
156	Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiation Oncology, 2006, 1, 5.	1.2	10
157	The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Disease, 2006, 8, 23-33.	0.7	90
158	Does gum chewing reduce postoperative ileus following open colectomy for left-sided colon and rectal cancer? - a prospective randomized controlled trial. Colorectal Disease, 2006, 8, 64-70.	0.7	93
159	Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Disease, 2006, 8, 430-435.	0.7	33
160	Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum. Apmis, 2006, 114, 201-210.	0.9	24
161	MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. British Journal of Cancer, 2006, 94, 351-357.	2.9	266
162	Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. British Journal of Cancer, 2006, 94, 976-981.	2.9	73
163	Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase II study. British Journal of Cancer, 2006, 94, 1809-1815.	2.9	36
164	The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 365-382.	1.0	45
165	Short Course Preoperative Radiotherapy for Rectal Cancer. Clinical Oncology, 2006, 18, 591-593.	0.6	0
166	COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 466-472.	0.4	47
167	Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. International Journal of Radiation Oncology Biology Physics, 2006, 64, 461-465.	0.4	60

#	ARTICLE	IF	CITATIONS
168	Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 709-716.	0.4	106
169	A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 725-729.	0.4	15
170	Prognostic factors for disease-free survival in patients with T3â€“4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1122-1128.	0.4	67
171	Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1188-1196.	0.4	54
172	Distal intramural spread of rectal cancer after preoperative radiotherapy: The results of a multicenter randomized clinical study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 182-188.	0.4	38
173	MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 445-451.	0.4	55
174	Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 705-712.	0.4	38
175	Definition and delineation of the clinical target volume for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1129-1142.	0.4	203
176	A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1462-1470.	0.4	27
177	A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 201-205.	0.4	71
178	Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating doseâ€“volume relationships and role for inverse planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 505-513.	0.4	132
179	Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 424-429.	0.4	45
180	Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 319-320.	0.4	46
181	Phase II study of capecitabine (Xeloda®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 762-771.	0.4	110
182	Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1143-1151.	0.4	39
183	Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1384-1390.	0.4	96
184	Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: A matched-pair analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1378-1383.	0.4	81
185	Can Rectal Cancers With Pathologic T0 After Neoadjuvant Chemoradiation (ypT0) Be Treated by Transanal Excision Alone?. <i>Annals of Surgical Oncology</i> , 2006, 13, 347-352.	0.7	43

#	ARTICLE	IF	CITATIONS
186	A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. <i>Annals of Surgical Oncology</i> , 2006, 13, 1047-1053.	0.7	160
187	Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions. <i>Annals of Surgical Oncology</i> , 2006, 13, 1021-1034.	0.7	49
190	Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2006, 20, 1197-1202.	1.3	90
191	Minimal Access Colorectal Surgery: Is It Truly Minimally Invasive?. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 144-145.	0.7	6
192	Treatment of Rectal Cancer Without Radiotherapy?. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 143.	0.7	1
194	Role of Radiotherapy With Surgery for T3 and Resectable T4 Rectal Cancer: Evidence From Randomized Trials. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 302-310.	0.7	74
195	Imaging Techniques Contribute to Increased Surgical Rescue of Relapse in the Follow-Up of Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 478-484.	0.7	35
196	A Patient's Race/Ethnicity Does Not Explain the Underuse of Appropriate Adjuvant Therapy in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 319-329.	0.7	57
197	Long-Term Results After Neoadjuvant Radiochemotherapy for Locally Advanced Resectable Extraperitoneal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 311-318.	0.7	43
198	Influence of Intraoperative and Postoperative Radiotherapy on Functional Outcome in Patients Undergoing Standard and Deep Anterior Resection for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 557-567.	0.7	34
199	Postoperative Chemotherapy May Not Be Necessary for Patients With ypN0-Category After Neoadjuvant Chemoradiotherapy of Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1284-1292.	0.7	102
200	Preoperative Tegafur Suppositories for Resectable Rectal Cancer: Phase II Trial. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1602-1610.	0.7	7
201	Value of Intraoperative Radiotherapy in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1257-1265.	0.7	59
202	Preoperative Chemoradiotherapy with Concomitant Small Field Boost Irradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Phase II Study (KROG 04-01). <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1684-1691.	0.7	13
203	Diagnosis and therapy of rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2006, 38, 129-134.	0.3	1
204	Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection. <i>International Journal of Colorectal Disease</i> , 2006, 21, 582-589.	1.0	2
205	“Fast-track” rehabilitation after rectal cancer resection. <i>International Journal of Colorectal Disease</i> , 2006, 21, 547-553.	1.0	82
206	Late small bowel toxicity after adjuvant treatment for rectal cancer. <i>International Journal of Colorectal Disease</i> , 2006, 21, 209-220.	1.0	44

#	ARTICLE	IF	CITATIONS
207	Short-term preoperative radiotherapy in rectal cancer patients leads to a reduction of the detectable number of lymph nodes in resection specimens. <i>Langenbeck's Archives of Surgery</i> , 2006, 391, 364-368.	0.8	18
208	Preoperative assessment of the circumferential margin in rectal cancer is more informative in treatment planning than the T stage. <i>Techniques in Coloproctology</i> , 2006, 10, 171-176.	0.8	18
209	Neoadjuvant Interstitial High-Dose-Rate (HDR) Brachytherapy Combined with Systemic Chemotherapy in Patients with Breast Cancer. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 22-29.	1.0	10
211	Maintenance Chemotherapy after Chemoradiation Improves Survival of Patients with Locally Advanced Pancreatic Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 210-215.	1.0	14
215	Patterns of Failure and Survival for Nonoperative Treatment of Stage c0 Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2006, 10, 1319-1329.	0.9	336
216	Stratifying risks for patients with localized rectal cancer: Do all stage II patients require adjuvant radiation or chemoradiation?. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 151-159.	1.0	1
217	Sphincter and rectal preservation approaches for early stage distal rectal cancers. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 161-167.	1.0	1
218	Preoperative and adjuvant treatment of localized rectal cancer. <i>Current Oncology Reports</i> , 2006, 8, 167-173.	1.8	9
220	What's New in Colon and Rectal Surgery. <i>Journal of the American College of Surgeons</i> , 2006, 202, 485-494.	0.2	2
221	5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results. <i>Archives of Medical Research</i> , 2006, 37, 860-865.	1.5	10
223	Combined Vascular Endothelial Growth Factor-Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical Practice. <i>Seminars in Oncology</i> , 2006, 33, S35-S40.	0.8	84
224	Should Preoperative or Postoperative Therapy Be Administered in the Management of Rectal Cancer?. <i>Seminars in Oncology</i> , 2006, 33, 64-69.	0.8	13
225	Neoadjuvant Therapy in the Treatment of Solid Tumors. <i>Current Problems in Surgery</i> , 2006, 43, 462-551.	0.6	0
226	Guidelines for Colonoscopy Surveillance after Cancer Resection: A Consensus Update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 160-167.	157.7	110
227	Developments in the use of chemoradiotherapy in rectal cancer. <i>Colorectal Disease</i> , 2006, 8, 14-17.	0.7	18
228	Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. <i>British Journal of Surgery</i> , 2006, 93, 872-878.	0.1	317
229	Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. <i>British Journal of Surgery</i> , 2006, 93, 1215-1223.	0.1	1,104
230	Adjuvant radiotherapy for rectal cancer. <i>British Journal of Surgery</i> , 2006, 93, 1035-1037.	0.1	6

#	ARTICLE	IF	CITATIONS
231	Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery (Br J Surg 2006; 93: 609-615). British Journal of Surgery, 2006, 93, 1023-1023.	0.1	3
232	Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?. Cancer, 2006, 106, 1694-1700.	2.0	75
233	Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. Journal of Surgical Oncology, 2006, 93, 145-150.	0.8	93
234	Is surgery-only the adequate treatment approach for T2N0 rectal cancer?. Journal of Surgical Oncology, 2006, 93, 350-354.	0.8	9
235	Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. Journal of Surgical Oncology, 2006, 93, 529-533.	0.8	37
236	Preoperative staging for rectal cancer. BMJ: British Medical Journal, 2006, 333, 766-767.	2.4	7
237	Prognostic Significance of Vascular Endothelial Growth Factor and Cyclooxygenase-2 in Patients with Rectal Cancer Treated with Preoperative Radiotherapy. Oncology, 2006, 71, 312-319.	0.9	40
240	A complex case of rectal neuroendocrine carcinoma with terminal delirium. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 408-413.	1.7	4
246	Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ: British Medical Journal, 2006, 333, 779.	2.4	757
247	Weekly oxaliplatin and preoperative radiotherapy as a new neoadjuvant therapy for locally-advanced rectal cancer. Annals of Oncology, 2006, 17, 1173.	0.6	0
252	Treatment of Rectal Cancer. New England Journal of Medicine, 2006, 355, 2486-2488.	13.9	3
253	Predictors of Recurrence in Patients With T2 and Early T3, NO Adenocarcinoma of the Rectum Treated by Surgery Alone. Journal of Clinical Oncology, 2006, 24, 4078-4084.	0.8	80
254	Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901. Journal of Clinical Oncology, 2006, 24, 2557-2562.	0.8	126
255	Aneuploidy-Dependent Massive Deregulation of the Cellular Transcriptome and Apparent Divergence of the Wnt/ β -catenin Signaling Pathway in Human Rectal Carcinomas. Cancer Research, 2006, 66, 267-282.	0.4	53
256	Short course continuous, hyperfractionated, accelerated radiation therapy (CHART) as preoperative treatment for rectal cancer. Acta Oncologica, 2006, 45, 1079-1085.	0.8	20
257	The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer. Oncologist, 2006, 11, 630-640.	1.9	18
258	Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Annals of Oncology, 2006, 17, 1103-1110.	0.6	71
259	Reply to Letter to the Editor "Weekly oxaliplatin and pre-operative radiotherapy as a new neoadjuvant therapy for locally advanced rectal cancer"™, by T. Watanabe et al. (Ann Oncol 2006; 17: 1173). Annals of Oncology, 2006, 17, 1173-1174.	0.6	0

#	ARTICLE	IF	CITATIONS
260	Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 4062-4068.	0.8	83
261	Prognostic Markers of Local Relapse in Rectal Cancer: Are We Any Further Forward?. <i>Journal of Clinical Oncology</i> , 2006, 24, 4049-4050.	0.8	23
262	Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. <i>Journal of Clinical Oncology</i> , 2006, 24, 4620-4625.	0.8	1,551
263	Biological Basis of Combined Radio- and Chemotherapy. , 2006, , 3-17.		4
264	Dosimetric characterization of a novel intracavitary mold applicator for Ir192 high dose rate endorectal brachytherapy treatment. <i>Medical Physics</i> , 2006, 33, 4515-4526.	1.6	38
265	Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144. <i>Journal of Clinical Oncology</i> , 2006, 24, 3542-3547.	0.8	159
266	Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012. <i>Journal of Clinical Oncology</i> , 2006, 24, 650-655.	0.8	236
267	Alternative clinical end points in rectal cancer—are we getting closer?. <i>Annals of Oncology</i> , 2006, 17, 1239-1248.	0.6	82
268	Patterns of Care for Adjuvant Therapy in a Random Population-Based Sample of Patients Diagnosed with Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2006, 101, 2308-2318.	0.2	83
269	CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. <i>British Journal of Cancer</i> , 2006, 95, 710-716.	2.9	23
270	Reply: Adjuvant chemoradiotherapy is no alternative to intensified neoadjuvant chemoradiotherapy for local and systemic control in patients with locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2006, 95, 951-952.	2.9	0
271	Rectal cancer irradiation. Long course, short course or something else?. <i>Acta Oncologica</i> , 2006, 45, 1013-1017.	0.8	29
273	Organ Preservation for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1014-1020.	0.8	88
274	Commentary: Rectal Cancer—An Evolution of Treatment. <i>Oncologist</i> , 2007, 12, 1319-1320.	1.9	0
275	A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. <i>British Journal of Cancer</i> , 2007, 96, 551-558.	2.9	51
276	MRI demonstration of the effect of neoadjuvant radiotherapy on rectal carcinoma. <i>Acta Oncologica</i> , 2007, 46, 989-995.	0.8	7
277	Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. <i>Acta Oncologica</i> , 2007, 46, 937-944.	0.8	87
278	Multidisciplinary treatment of rectal cancer: medical oncology. <i>Annals of Oncology</i> , 2007, 18, ix114-ix121.	0.6	8

#	ARTICLE	IF	CITATIONS
279	Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii23-ii24.	0.6	6
280	Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2007, 25, 2313-2321.	0.8	25
281	Omission of concurrent chemoradiation after a response to neoadjuvant chemotherapy in locally advanced rectal cancer with a synchronous liver metastasis: a note of caution. <i>British Journal of Radiology</i> , 2007, 80, e257-e259.	1.0	7
282	Neoadjuvant Radiochemotherapy for Rectal Cancer. <i>Digestive Diseases</i> , 2007, 25, 56-66.	0.8	1
283	Preoperative Treatment Combining Capecitabine with Radiation Therapy in Rectal Cancer: A GERCOR Phase II Study. <i>Oncology</i> , 2007, 73, 169-176.	0.9	25
284	Management of Locally Advanced Primary and Recurrent Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2007, 20, 255-264.	0.5	47
285	Multidisciplinary Teams in the Management of Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2007, 20, 143-147.	0.5	37
286	Does postoperative radiochemotherapy improve survival in patients with rectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 82-83.	4.3	0
287	Rectal Carcinoma: MRI with Histologic Correlation Before and After Chemoradiation Therapy. <i>American Journal of Roentgenology</i> , 2007, 188, 442-451.	1.0	123
288	Extramural Depth of Tumor Invasion at Thin-Section MR in Patients with Rectal Cancer: Results of the MERCURY Study. <i>Radiology</i> , 2007, 243, 132-139.	3.6	441
289	Corrections to "Multidisciplinary treatment of rectal cancer: medical oncology". <i>Annals of Oncology</i> , 2007, 18, 1908-1915.	0.6	13
290	Sphincter-Sparing Resection for Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2007, 20, 203-212.	0.5	17
291	Laparoscopic Approaches to Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2007, 20, 237-248.	0.5	19
292	Adjuvant Therapy for Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2007, 20, 167-181.	0.5	9
293	The Survivin Isoform Survivin-3B is Cytoprotective and can Function as a Chromosomal Passenger Complex Protein. <i>Cell Cycle</i> , 2007, 6, 1501-1508.	1.3	54
294	Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4379-4386.	0.8	437
295	Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy. <i>Oncologist</i> , 2007, 12, 465-477.	1.9	89
296	The rationale for and the current role of chemoradiotherapy. <i>Journal of Radiotherapy in Practice</i> , 2007, 6, 11-19.	0.2	7

#	ARTICLE	IF	CITATIONS
297	The TME Trial After a Median Follow-up of 6 Years. <i>Annals of Surgery</i> , 2007, 246, 693-701.	2.1	1,020
298	Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5810-5815.	3.2	39
299	Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. <i>The Cochrane Library</i> , 2007, , CD002102.	1.5	135
300	Multidisciplinary Management of Patients with Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 6890s-6893s.	3.2	7
301	Radiation Therapy in Stage II and III Rectal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 6903s-6908s.	3.2	18
302	New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6913s-6920s.	3.2	31
303	Adjuvant Management of Rectal Cancer: The More We Learn, the Less We Know. <i>Journal of Clinical Oncology</i> , 2007, 25, 4339-4340.	0.8	19
304	Integrative decisions in rectal cancer. <i>Annals of Oncology</i> , 2007, 18, ix127-ix131.	0.6	12
305	Preoperative Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2665.	3.8	13
306	Current Surgical Management of Rectal Cancer. <i>Digestive Surgery</i> , 2007, 24, 115-119.	0.6	12
307	Presurgical Chemotherapy in Patients Being Considered for Liver Resection. <i>Oncologist</i> , 2007, 12, 825-839.	1.9	93
308	Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 1255-1259.	0.8	30
309	Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?. <i>Oncology Reports</i> , 2007, 18, 369.	1.2	5
310	& amp; 19: Transanal Techniques /. , 2007, , 415-428.		2
311	Is the timing of chemotherapy important in patients undergoing preoperative radiotherapy for rectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 150-151.	4.3	0
313	Sphincter Preservation in Four Consecutive Phase II Studies of Preoperative Chemoradiation: Analysis of 247 T3 Rectal Cancer Patients. <i>Tumori</i> , 2007, 93, 160-169.	0.6	13
314	Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen. <i>Visceral Medicine</i> , 2007, 23, 360-366.	0.5	1
316	Radiotherapy in colorectal cancer. , 0, , 110-135.		1

#	ARTICLE	IF	CITATIONS
317	Patterns of recurrence following therapy for rectal cancer. , 0, , 233-247.		0
318	Concomitant Occurrence of Facial Cutaneous and Parotid Gland Metastases from Rectal Cancer after Preoperative Chemoradiotherapy. <i>Oncology Research and Treatment</i> , 2007, 30, 324-326.	0.8	3
319	Beckeneviszeration beim rezidierten und lokal weit fortgeschrittenen Rektumkarzinom. <i>Visceral Medicine</i> , 2007, 23, 332-339.	0.5	1
320	As in Fly Fishing, "Matching the Hatch" Should Govern the Management of Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2007, 246, 702-704.	2.1	6
321	Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2007, 245, 259-266.	2.1	65
322	Comparative Outcome Between Chemoradiotherapy and Lateral Pelvic Lymph Node Dissection Following Total Mesorectal Excision in Rectal Cancer. <i>Annals of Surgery</i> , 2007, 246, 754-762.	2.1	72
323	A Prospective Pathologic Analysis Using Whole-Mount Sections of Rectal Cancer Following Preoperative Combined Modality Therapy. <i>Annals of Surgery</i> , 2007, 245, 88-93.	2.1	123
324	A Phase II Study of Preoperative Capecitabine and Radiation Therapy in Patients With Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 340-345.	0.6	24
325	Capecitabine and Radiotherapy as Neoadjuvant Treatment for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 649-655.	0.6	15
326	Rectal Cancer Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 204-209.	1.0	10
327	Postoperative Irradiation for Rectal Cancer Increases the Risk of Small Bowel Obstruction After Surgery. <i>Annals of Surgery</i> , 2007, 245, 553-559.	2.1	25
328	Current Issues in Rectal Cancer Chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 198-203.	1.0	1
330	The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 3-19.	0.4	104
331	Combined Modality Therapy of Rectal Cancer. , 2007, , .		0
332	Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. <i>American Journal of Surgery</i> , 2007, 193, 389-394.	0.9	58
333	Understanding variation in the management of rectal cancer: the potential of a surgeon-initiated database. <i>American Journal of Surgery</i> , 2007, 194, 559-562.	0.9	14
334	Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer?. <i>European Journal of Cancer</i> , 2007, 43, 2301-2306.	1.3	39
335	Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. <i>European Journal of Surgical Oncology</i> , 2007, 33, 452-458.	0.5	117

#	ARTICLE	IF	CITATIONS
336	A population-based study of radiotherapy in a cohort of patients with rectal cancer diagnosed between 1996 and 2000. <i>European Journal of Surgical Oncology</i> , 2007, 33, 993-997.	0.5	10
338	Recent Evidences of the Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Colorectal Cancer. <i>Journal of Surgical Education</i> , 2007, 64, 114-119.	1.2	4
339	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumorigenic cells?. <i>Radiotherapy and Oncology</i> , 2007, 83, 316-325.	0.3	51
340	A special device (double-hole belly board) and optimal radiation technique to reduce testicular radiation exposure in radiotherapy of rectal cancer. <i>Radiotherapy and Oncology</i> , 2007, 84, 320-327.	0.3	11
341	Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: Report of a randomised trial. <i>Radiotherapy and Oncology</i> , 2007, 84, 217-225.	0.3	149
342	Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: Four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. <i>Radiotherapy and Oncology</i> , 2007, 85, 379-384.	0.3	21
343	Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. <i>Lancet Oncology</i> , The, 2007, 8, 625-633.	5.1	199
344	The future of the TNM staging system in colorectal cancer: time for a debate?. <i>Lancet Oncology</i> , The, 2007, 8, 651-657.	5.1	148
345	Rectal Cancer: MR Imaging before Neoadjuvant Chemotherapy and Radiation Therapy for Prediction of Tumor-Free Circumferential Resection Margins and Long-term Survival1. <i>Radiology</i> , 2007, 243, 744-751.	3.6	63
347	Contemporary Imaging for Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 369-388.	0.6	4
348	Role of Preoperative Local and Distant Staging in Rectal Cancer. <i>Oncology Research and Treatment</i> , 2007, 30, 141-145.	0.8	30
349	Improvement of Staging by Combining Tumor and Treatment Parameters: The Value for Prognostication in Rectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 997-1003.	2.4	37
350	Radiotherapy for localized rectal cancer. <i>Annals of Oncology</i> , 2007, 18, ix105-ix113.	0.6	4
351	Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 26, 110-117.	0.8	204
353	Late adverse effects of radiation therapy for rectal cancer – a systematic overview. <i>Acta Oncologica</i> , 2007, 46, 504-516.	0.8	195
354	Cetuximab in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 243-256.	1.4	18
355	A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Caplri-RT) as neoadjuvant treatment of locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2007, 96, 912-917.	2.9	103
356	Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. <i>Annals of Oncology</i> , 2007, 18, 738-744.	0.6	137

#	ARTICLE	IF	CITATIONS
357	Early Changes in Apparent Diffusion Coefficient Predict the Quantitative Antitumoral Activity of Capecitabine, Oxaliplatin, and Irradiation in HT29 Xenografts in Athymic Nude Mice. <i>Neoplasia</i> , 2007, 9, 392-400.	2.3	25
358	Colorectal Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 114-129.	1.4	55
359	Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 424-431.	0.7	18
360	Advanced Radiation Therapy Technologies in the Treatment of Rectal and Anal Cancer: Intensity-Modulated Photon Therapy and Proton Therapy. <i>Clinical Colorectal Cancer</i> , 2007, 6, 348-356.	1.0	39
361	Mitomycin-C/5-Fluorouracil/Leucovorin and Hyperfractionated Radiation Therapy for Rectal Carcinoma: A Phase II Study with Long-Term Follow-up. <i>Clinical Colorectal Cancer</i> , 2007, 6, 436-441.	1.0	3
362	Combined-Modality Therapy for Rectal Cancer: Future Prospects. <i>Clinical Colorectal Cancer</i> , 2007, 6, 625-633.	1.0	3
363	Surgical Management of Rectal Cancer. <i>Seminars in Oncology</i> , 2007, 34, 241-249.	0.8	36
365	Assessment of T staging and mesorectal fascia status using high-resolution MRI in rectal cancer with rectal distention. <i>World Journal of Gastroenterology</i> , 2007, 13, 4141.	1.4	52
368	Câncero ano-retal: aspectos atuais II - câncer colorretal - fatores de riscos e prevenção. <i>Revista Brasileira De Coloproctologia</i> , 2007, 27, 459-473.	0.2	10
369	Urodynamic outcome of waterjet-assisted total mesorectal excision. <i>British Journal of Surgery</i> , 2007, 94, 1543-1547.	0.1	3
370	The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. <i>British Journal of Surgery</i> , 2007, 95, 33-49.	0.1	115
371	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. <i>Cancer</i> , 2007, 109, 1750-1755.	2.0	294
372	A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2007, 95, 652-662.	0.8	75
373	Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. <i>Journal of Surgical Oncology</i> , 2007, 96, 207-212.	0.8	49
374	Quality of life after rectal resection and multimodality therapy. <i>Journal of Surgical Oncology</i> , 2007, 96, 684-692.	0.8	59
375	Impact of pre- and postoperative multimodality therapy on rectal cancer. <i>Journal of Surgical Oncology</i> , 2007, 96, 665-670.	0.8	6
376	Is There a Role for Radiotherapy in Operable Rectal Cancer?. <i>Clinical Oncology</i> , 2007, 19, 687-692.	0.6	7
377	Is There a Limit to Dose Escalation for Rectal Cancer?. <i>Clinical Oncology</i> , 2007, 19, 730-737.	0.6	4

#	ARTICLE	IF	CITATIONS
378	Local Excision after Radio(chemo)therapy for Rectal Cancer: is it Safe?. <i>Clinical Oncology</i> , 2007, 19, 693-700.	0.6	29
379	External Beam Radiotherapy and High Dose Rate Brachytherapy for Medically Unfit and Elderly Patients. <i>Clinical Oncology</i> , 2007, 19, 706-710.	0.6	11
380	Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 378-384.	0.4	90
381	Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 369-377.	0.4	82
382	Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1008-1019.	0.4	69
383	Phase I Trial of Preoperative Hypofractionated Intensity-Modulated Radiotherapy with Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1389-1393.	0.4	50
384	Patterns of Failure and Local Control After Intraoperative Electron Boost Radiotherapy to the Presacral Space in Combination with Total Mesorectal Excision in Patients with Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1381-1388.	0.4	48
385	Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer: Phase I Trial Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 472-478.	0.4	135
386	Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1455-1461.	0.4	101
387	Radiation Pneumonitis and Fibrosis: Mechanisms Underlying its Pathogenesis and Implications for Future Research: In Regard to Tsoutsou and Koukourkis (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq1 1 0.784314 rgBT /Ove4lock 10Tf 50 377		
388	In Response to Dr. Morgan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1581-1582.	0.4	0
389	Preoperative Therapy for Lower Rectal Cancer and Modifications in Distance From Anal Sphincter. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 370-375.	0.4	18
390	Rectal Cancer Delivery of Radiotherapy in Adequate Time and With Adequate Dose is Influenced by Treatment Center, Treatment Schedule, and Gender and is Prognostic Parameter for Local Control: Results of the Study CAO/ARO/AIO-94: Reply to Two Letters to the Editor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1580-1581.	0.4	1
391	Post Hoc, Ergo Propter Hoc. in Regard to Fietkau et al. (<i>Int J Radiat Oncol Biol Phys</i> 2007;67:1008-1019). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1581.	0.4	0
392	Clinical Parameters Predicting Pathologic Tumor Response After Preoperative Chemoradiotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1167-1172.	0.4	112
393	Phase I Trial of Neoadjuvant Preoperative Chemotherapy With S-1 and Irinotecan Plus Radiation in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1442-1447.	0.4	30
394	In Regards to Bujko et al. (<i>Int J Radiat Oncol Biol Phys</i> 2007;68:313-316). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 639-640.	0.4	3
395	Local Excision versus Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S110.	0.4	0

#	ARTICLE	IF	CITATIONS
396	An individual patient data meta-analysis of adjuvant therapy with uracil+tegafur (UFT) in patients with curatively resected rectal cancer. <i>British Journal of Cancer</i> , 2007, 96, 1170-1177.	2.9	59
397	Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2007, 97, 1333-1337.	2.9	46
398	Methylene blue injection into the rectal artery as a simple method to improve lymph node harvest in rectal cancer. <i>Modern Pathology</i> , 2007, 20, 797-801.	2.9	49
399	Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2007, 51, 283-288.	0.6	9
400	Saving the sphincter in rectal cancer: are we prepared to change practice?. <i>Colorectal Disease</i> , 2007, 9, 302-308.	0.7	10
401	Accurate staging, selective preoperative therapy and optimal surgery improves outcome in rectal cancer: a review of the recent evidence. <i>Colorectal Disease</i> , 2007, 9, 290-301.	0.7	85
402	Factors affecting anastomotic complications following anterior resection in rectal cancer. <i>Colorectal Disease</i> , 2007, 9, 801-807.	0.7	35
403	Quality Indicators for the Care of Colorectal Cancer in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S277-84.	1.3	13
404	Adjuvant Treatment of Colorectal Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 168-185.	157.7	227
407	Laparoscopy for metastatic colorectal cancer. <i>Surgical Oncology</i> , 2007, 16, 15-24.	0.8	4
408	State of the art and recent advance in the treatment of resectable nonmetastatic rectal cancer. <i>Surgical Oncology</i> , 2007, 16, 125-128.	0.8	3
409	Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy. <i>Surgical Oncology</i> , 2007, 16, 83-89.	0.8	14
410	Future Chemoradiation Strategies in Pancreatic Cancer. <i>Seminars in Oncology</i> , 2007, 34, 335-346.	0.8	33
412	Locally Advanced Rectal Cancer: What Is the Evidence for Induction Chemoradiation?. <i>Oncologist</i> , 2007, 12, 1309-1318.	1.9	37
413	Prognostic Significance of Circumferential Resection Margin Following Total Mesorectal Excision and Adjuvant Chemoradiotherapy in Patients with Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 462-469.	0.7	76
414	Complications Associated with Neoadjuvant Radiotherapy in the Multidisciplinary Treatment of Retroperitoneal Sarcomas. <i>Annals of Surgical Oncology</i> , 2007, 14, 577-582.	0.7	32
415	The Potential of Restaging in the Prediction of Pathologic Response After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 455-461.	0.7	125
416	Update of Carcinoembryonic Antigen Radioimmunotherapy with ¹³¹ I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group. <i>Annals of Surgical Oncology</i> , 2007, 14, 2577-2590.	0.7	74

#	ARTICLE	IF	CITATIONS
417	Analysis of Early Postoperative Morbidity Among Patients with Rectal Cancer Treated with and without Neoadjuvant Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 1744-1751.	0.7	34
418	Location of Rectal Cancer Within the Circumference of the Rectum Does Not Influence Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2007, 14, 2257-2262.	0.7	8
419	Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 1870-1877.	0.7	83
420	Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy?. <i>Annals of Surgical Oncology</i> , 2007, 14, 2766-2772.	0.7	163
422	Does Radiation Prevent 5-Fluorouracil-Induced Colitis in the Early Phase of Radiochemotherapy?. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 459-463.	1.0	7
423	Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 227-235.	1.0	87
427	PET imaging with [18F]3- ¹⁸ F-deoxy-3- ¹⁸ F-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 878-883.	3.3	113
428	Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1576-1582.	3.3	13
430	Prognostic Groups in 1,676 Patients with T3 Rectal Cancer Treated without Preoperative Radiotherapy. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 156-167.	0.7	68
431	The Status of Radical Proctectomy and Sphincter-Sparing Surgery in the United States. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1119-1127.	0.7	61
432	Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1342-1353.	0.7	127
433	Complications of elective surgery for rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007, 39, 8-14.	0.3	7
437	Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy. <i>Journal of Gastroenterology</i> , 2007, 42, 730-736.	2.3	28
438	Acceptance of neoadjuvant short-term radiotherapy: a survey under surgeons and radiotherapists. <i>Langenbeck's Archives of Surgery</i> , 2007, 392, 525-533.	0.8	5
439	Optimised surgery (so-called TME surgery) and high-resolution MRI in the planning of treatment of rectal carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2007, 392, 179-188.	0.8	17
440	Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. <i>International Journal of Colorectal Disease</i> , 2007, 22, 457-465.	1.0	18
441	Risk factors for clinical anastomotic leakage and postoperative mortality in elective surgery for rectal cancer. <i>International Journal of Colorectal Disease</i> , 2007, 22, 919-927.	1.0	108
442	Influence of the neo-adjuvant radiochemotherapy as a factor in the surgical treatment of rectal cancer by expert surgeon. A comparative study. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1233-1238.	1.0	7

#	ARTICLE	IF	CITATIONS
443	Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer. <i>International Journal of Colorectal Disease</i> , 2007, 23, 67-76.	1.0	10
444	Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2007, 23, 37-45.	1.0	26
445	Current Options for the Management of Rectal Cancer. <i>Current Treatment Options in Oncology</i> , 2007, 8, 331-338.	1.3	33
446	Update on neoadjuvant strategies for rectal cancer patients. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 158-165.	1.0	0
447	Outcome of Rectal Cancer Surgery After the Introduction of Preoperative Radiotherapy in a Low-Volume Hospital. <i>Journal of Gastrointestinal Cancer</i> , 2007, 38, 63-70.	0.6	6
448	Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group. <i>Clinical and Translational Oncology</i> , 2007, 9, 183-191.	1.2	9
451	Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 961-969.	0.9	77
452	Local Excision for ypT2 Rectal Cancer—Much Ado About Something. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1431-1440.	0.9	39
453	Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1534-1540.	0.9	15
454	Multimodal treatment of rectal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 1049-1070.	1.0	19
455	Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S71.	0.4	9
457	The accuracy of Multi-detector row CT for the assessment of tumor invasion of the mesorectal fascia in primary rectal cancer. <i>Abdominal Imaging</i> , 2008, 33, 604-610.	2.0	68
458	Sphincter-Preserving Operations Following Preoperative Chemoradiation: An Alternative to Abdominoperineal Resection for Lower Rectal Cancer?. <i>World Journal of Surgery</i> , 2008, 32, 1116-1123.	0.8	33
459	Radiochemotherapy in Combination with Regional Hyperthermia in Preirradiated Patients with Recurrent Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 163-168.	1.0	39
460	Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 450-456.	1.0	46
461	Can an FDG-PET/CT Predict Tumor Clearance of the Mesorectal Fascia after Preoperative Chemoradiation of Locally Advanced Rectal Cancer?. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 457-464.	1.0	54
462	Radiotherapy in Pancreatic Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 557-564.	1.0	14
466	Analysis of Anal Sphincter Preservation Rate According to Tumor Level and Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 176-182.	0.9	9

#	ARTICLE	IF	CITATIONS
467	Routine Contrast Imaging of Low Pelvic Anastomosis Prior to Closure of Defunctioning Ileostomy: is it Necessary?. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1227-1231.	0.9	51
468	Radical Redo Surgery for Local Rectal Cancer Recurrence Improves Overall Survival: A Single Center Experience. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1232-1238.	0.9	36
469	Long-Term Results of Transanal Excision After Neoadjuvant Chemoradiation for T2 and T3 Adenocarcinomas of the Rectum. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1797-1806.	0.9	100
470	The future of TNM staging in rectal cancer: The era of neoadjuvant therapy. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 147-154.	1.0	7
471	The potential role of intensity modulated radiation therapy in the management of localized rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 203-210.	1.0	0
472	Is local excision adequate for stage I rectal cancer?. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 224-229.	1.0	0
473	Intensity-modulated radiation therapy for gastrointestinal tumors. <i>Current Oncology Reports</i> , 2008, 10, 206-211.	1.8	2
474	Recent advances in the treatment of localized rectal cancer. <i>Current Oncology Reports</i> , 2008, 10, 220-224.	1.8	3
476	Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 488-497.	1.0	20
477	Correspondence. <i>Techniques in Coloproctology</i> , 2008, 12, 73-78.	0.8	15
480	PET/CT and Histopathologic Response to Preoperative Chemoradiation Therapy in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 21-25.	0.7	77
481	Absence of Lymph Nodes in the Resected Specimen After Radical Surgery for Distal Rectal Cancer and Neoadjuvant Chemoradiation Therapy: What does it Mean?. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 277-283.	0.7	90
482	The Impact of 18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography on the Staging and Management of Primary Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 997-1003.	0.7	64
483	Laparoscopic Resection of Rectal Cancer: A Comparison of Surgical and Oncologic Outcomes Between Extraperitoneal and Intraperitoneal Disease Locations. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 844-851.	0.7	37
484	Postoperative Radiotherapy for Stage IIIA Rectal Cancer: Is It Justified?. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1459-1466.	0.7	10
485	Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. <i>International Journal of Colorectal Disease</i> , 2008, 23, 139-145.	1.0	44
486	Incidence, consequences, and risk factors for anastomotic dehiscence after colorectal surgery: a prospective monocentric study. <i>International Journal of Colorectal Disease</i> , 2008, 23, 265-270.	1.0	364
487	Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. <i>International Journal of Colorectal Disease</i> , 2008, 23, 243-249.	1.0	22

#	ARTICLE	IF	CITATIONS
488	Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?. International Journal of Colorectal Disease, 2008, 23, 257-264.	1.0	37
489	Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer—a review focusing on open questions. International Journal of Colorectal Disease, 2008, 23, 227-236.	1.0	11
490	Female fertility and colorectal cancer. International Journal of Colorectal Disease, 2008, 23, 735-743.	1.0	49
491	Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. International Journal of Colorectal Disease, 2008, 23, 1073-1079.	1.0	17
492	Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. International Journal of Colorectal Disease, 2008, 23, 1233-1241.	1.0	13
493	Laparoscopic surgery for rectal cancer: oncological results and clinical outcome of 225 patients. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 2229-2237.	1.3	23
494	The role of COX-2 in rectal cancer treated with preoperative radiotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 499-505.	1.4	8
495	Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. Journal of Surgical Oncology, 2008, 97, 8-13.	0.8	50
496	Resection margins in modern rectal cancer surgery. Journal of Surgical Oncology, 2008, 98, 611-615.	0.8	31
497	A modern regimen of preoperative concurrent chemo-radiation therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2008, 98, 167-174.	0.8	14
498	Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer, 2008, 112, 362-371.	2.0	52
499	Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer, 2008, 112, 789-799.	2.0	53
500	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 2008, 112, 2518-2519.	2.0	0
501	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 2008, 112, 2519-2519.	2.0	0
502	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008, 113, 57-64.	2.0	228
503	Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer. Cancer, 2008, 113, 879-886.	2.0	61
504	Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. British Journal of Surgery, 2008, 95, 229-236.	0.1	358
505	Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. British Journal of Surgery, 2008, 95, 206-213.	0.1	88

#	ARTICLE	IF	CITATIONS
506	Local excision and endoscopic posterior mesorectal resection <i>versus</i> low anterior resection in T1 rectal cancer. <i>British Journal of Surgery</i> , 2008, 95, 375-380.	0.1	24
507	Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. <i>British Journal of Surgery</i> , 2008, 95, 1534-1540.	0.1	109
508	mRNA Expression of Platelet-Derived Growth Factor Receptor- β^2 and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1544-1550.	0.4	16
509	Chemoradiotherapy for Rectal Cancer: An Updated Analysis of Factors Affecting Pathological Response. <i>Clinical Oncology</i> , 2008, 20, 176-183.	0.6	166
510	Adjuvant Brachytherapy Removes Survival Disadvantage of Local Disease Extension in Stage IIIC Endometrial Cancer: A SEER Registry Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 134-138.	0.4	35
511	Preoperative Chemoradiotherapy for Rectal Cancer: Randomized Trial Comparing Oral Uracil and Tegafur and Oral Leucovorin Vs. Intravenous 5-Fluorouracil and Leucovorin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 102-110.	0.4	33
512	Randomized, Multicenter, Phase IIB Study of Preoperative Chemoradiotherapy in T3 Mid-Distal Rectal Cancer: Raltitrexed + Oxaliplatin + Radiotherapy Versus Cisplatin + 5-Fluorouracil + Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 403-412.	0.4	37
513	The Dose-Volume Relationship of Small Bowel Irradiation and Acute Grade 3 Diarrhea During Chemoradiotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 413-418.	0.4	138
514	Role of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 735-743.	0.4	68
515	Phase II Study of Preoperative Helical Tomotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 728-734.	0.4	65
516	Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1081-1086.	0.4	138
517	ACR Appropriateness Criteria on Resectable Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1427-1430.	0.4	7
518	Phase III Trial of Concurrent Capecitabine and Oxaliplatin With Preoperative Intensity-Modulated Radiotherapy in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 748-755.	0.4	30
519	Radiotherapy for Rectal Cancer Is Associated With Reduced Serum Testosterone and Increased FSH and LH. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 722-727.	0.4	44
520	Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1175-1180.	0.4	74
521	Interval Between Surgery and Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Does Delayed Surgery Have an Impact on Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1181-1188.	0.4	194
522	Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 99-107.	0.4	396
523	Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 650-657.	0.4	31

#	ARTICLE	IF	CITATIONS
524	Infusional 5-Fluorouracil and ZD1839 (Gefitinibâ€“Iressa) in Combination With Preoperative Radiotherapy in Patients With Locally Advanced Rectal Cancer: A Phase I and II Trial (1839IL/0092). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 644-649.	0.4	56
525	Phase I Study of Oxaliplatin in Combination With Capecitabine and Radiotherapy as Postoperative Treatment for Stage II and III Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 671-677.	0.4	3
526	Phase I Study of Preoperative Radiation Therapy With Concurrent Infusional 5-Fluorouracil and Oxaliplatin Followed by Surgery and Postoperative 5-Fluorouracil Plus Leucovorin for T3/T4 Rectal Adenocarcinoma: ECOG E1297. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 108-113.	0.4	24
527	Management of Rectal Cancer: Short- vs. Long-Course Preoperative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 636-643.	0.4	45
528	Preoperative staging of rectal cancer. <i>Acta OncolÃ³gica</i> , 2008, 47, 20-31.	0.8	167
529	Positron Emission Tomography Detection of Distant Metastatic or Synchronous Disease in Patients with Locally Advanced Rectal Cancer Receiving Preoperative Chemoradiation. <i>Annals of Surgical Oncology</i> , 2008, 15, 704-711.	0.7	49
530	Lateral Lymph Node Metastasis Is a Major Cause of Locoregional Recurrence in Rectal Cancer Treated with Preoperative Chemoradiotherapy and Curative Resection. <i>Annals of Surgical Oncology</i> , 2008, 15, 729-737.	0.7	266
531	Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. <i>Annals of Surgical Oncology</i> , 2008, 15, 2773-2786.	0.7	60
532	Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?. <i>Annals of Surgical Oncology</i> , 2008, 15, 3308-3315.	0.7	48
533	Intersphincteric Resection for Very Low Rectal Adenocarcinoma: Univariate and Multivariate Analyses of Risk Factors for Recurrence. <i>Annals of Surgical Oncology</i> , 2008, 15, 2668-2676.	0.7	50
534	Impact of Time Duration After Neoadjuvant Therapy to Surgery on Response and Outcome in Rectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2008, 15, 2636-2638.	0.7	1
535	Diabetes Mellitus Affects Response to Neoadjuvant Chemoradiotherapy in the Management of Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1931-1936.	0.7	51
536	An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2661-2667.	0.7	294
537	Laparoscopic-Assisted Versus Open Abdominoperineal Resection for Low Rectal Cancer: A Prospective Randomized Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 2418-2425.	0.7	262
538	Health-Related Quality of Life Outcomes in Disease-Free Survivors of Mid-Low Rectal Cancer After Curative Surgery. <i>Annals of Surgical Oncology</i> , 2008, 15, 1846-1854.	0.7	50
539	Magnetic Resonance Imaging in Locoregional Staging of Rectal Adenocarcinoma. <i>Seminars in Ultrasound, CT and MRI</i> , 2008, 29, 433-453.	0.7	6
540	Generalized Maximally Selected Statistics. <i>Biometrics</i> , 2008, 64, 1263-1269.	0.8	212
541	Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. <i>Cancer Gene Therapy</i> , 2008, 15, 625-635.	2.2	50

#	ARTICLE	IF	CITATIONS
542	Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. <i>British Journal of Cancer</i> , 2008, 98, 143-147.	2.9	78
543	Inequity in colorectal cancer treatment and outcomes: a population-based study. <i>British Journal of Cancer</i> , 2008, 99, 266-274.	2.9	32
544	Cost-effectiveness of adjuvant chemotherapy with uracil+tegafur for curatively resected stage III rectal cancer. <i>British Journal of Cancer</i> , 2008, 99, 1232-1238.	2.9	14
545	Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. <i>Ecological Management and Restoration</i> , 2008, 21, 437-444.	0.2	22
546	How do we manage early rectal cancer? A national questionnaire survey among members of the ACPGBI after the preliminary results of the MRC CR07/NCIC CO16 randomized trial. <i>Colorectal Disease</i> , 2008, 10, 357-362.	0.7	16
547	Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. <i>Colorectal Disease</i> , 2008, 10, 563-568.	0.7	114
548	Magnetic resonance imaging in rectal cancer downstaged using neoadjuvant chemoradiation: accuracy of prediction of tumour stage and circumferential resection margin status. <i>Colorectal Disease</i> , 2008, 10, 479-489.	0.7	69
549	The Multidisciplinary Management of Rectal Cancer. <i>Colorectal Disease</i> , 2008, 10, 311-313.	0.7	8
550	Effect of Neoadjuvant Therapy on Local Recurrence after Resection of Pancreatic Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2008, 206, 451-457.	0.2	67
551	The Use of Capecitabine in the Combined-Modality Therapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 99-104.	1.0	3
552	Early Clinical Results from Chemoradiation with 5-Fluorouracil and Oxaliplatin for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 325-330.	1.0	4
553	Role of Combined-Modality Therapy in the Management of Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 369-375.	1.0	15
554	Local Excision for Rectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 376-385.	1.0	27
556	Microarray-Based Prediction of Tumor Response to Neoadjuvant Radiochemotherapy of Patients With Locally Advanced Rectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 53-61.	2.4	128
557	Systemic Treatment of Colorectal Cancer. <i>Gastroenterology</i> , 2008, 134, 1296-1310.e1.	0.6	418
558	The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2008, 6, 222-231.	0.8	37
559	Chemo-radiotherapy in locally advanced rectal cancer: What is the optimal strategy?. <i>European Journal of Cancer</i> , Supplement, 2008, 6, 70-73.	2.2	4
560	â€œLiver Firstâ€™ Approach in the Treatment of Colorectal Cancer with Synchronous Liver Metastases. <i>Digestive Surgery</i> , 2008, 25, 430-435.	0.6	144

#	ARTICLE	IF	CITATIONS
561	Preoperative Chemoradiation Followed by Transanal Excision for Rectal Cancer. <i>Journal of Surgical Research</i> , 2008, 148, 244-250.	0.8	35
562	Prognostic factors and preoperative radiation therapy associated with sphincter preservation in patients with resectable rectal cancer. <i>American Journal of Surgery</i> , 2008, 195, 239-243.	0.9	13
563	What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?. <i>Journal of Clinical Oncology</i> , 2008, 26, 303-312.	0.8	885
564	Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. <i>Cancer Letters</i> , 2008, 272, 221-225.	3.2	35
565	Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. <i>European Journal of Cancer</i> , 2008, 44, 1710-1716.	1.3	87
566	A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study. <i>European Journal of Cancer</i> , 2008, 44, 1693-1700.	1.3	21
568	Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 410-417.	0.5	27
569	Survival and treatment trends of rectal cancer patients in a population with suboptimal local control. <i>European Journal of Surgical Oncology</i> , 2008, 34, 655-661.	0.5	3
570	Ultrasound Staging of Rectal Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2008, 29, 427-432.	0.7	16
571	Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. <i>Radiotherapy and Oncology</i> , 2008, 86, 428-434.	0.3	31
572	Short-course preoperative radiotherapy with delayed surgery in rectal cancer – A retrospective study. <i>Radiotherapy and Oncology</i> , 2008, 87, 343-349.	0.3	199
573	The 5Å–5Gy with delayed surgery in non-resectable rectal cancer: A new treatment option. <i>Radiotherapy and Oncology</i> , 2008, 87, 311-313.	0.3	14
574	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 361-366.	0.3	8
575	Evidence and research in rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 449-474.	0.3	92
576	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study. <i>Radiotherapy and Oncology</i> , 2008, 89, 263-269.	0.3	13
577	Surgery vs surgery and chemotherapy for colorectal liver metastases. <i>Lancet, The</i> , 2008, 372, 202-203.	6.3	3
578	Surgery vs surgery and chemotherapy for colorectal liver metastases – Authors' reply. <i>Lancet, The</i> , 2008, 372, 203.	6.3	1
579	Neoadjuvant Chemoradiation for Rectal Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2008, 19, 197-202.	0.2	0

#	ARTICLE	IF	CITATIONS
580	The Role of Radiation Therapy for Colorectal Cancer. <i>Gastroenterology Clinics of North America</i> , 2008, 37, 269-285.	1.0	5
581	Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient. <i>Seminars in Colon and Rectal Surgery</i> , 2008, 19, 239-246.	0.2	2
582	Multidisciplinary Treatment of Cancer of the Rectum: A European Approach. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 533-551.	0.6	10
583	IGRT in rectal cancer. <i>Acta Oncologica</i> , 2008, 47, 1317-1324.	0.8	46
584	Complementary Assessment of Abdominopelvic Disorders with PET/CT and MRI. <i>PET Clinics</i> , 2008, 3, 435-449.	1.5	2
585	Bowel dysfunction after treatment for rectal cancer. <i>Acta Oncologica</i> , 2008, 47, 994-1003.	0.8	81
586	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , 2008, 19, vi1-vi8.	0.6	59
587	Can Performance of Sphincter-Sparing Surgery Serve as an Outcome Measure for Rectal Cancer?. <i>Seminars in Colon and Rectal Surgery</i> , 2008, 19, 30-36.	0.2	0
588	Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3687-3694.	0.8	412
589	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , 2008, 19, vii266-vii272.	0.6	11
590	Systematic Review and Meta-Analysis of the Role of Defunctioning Stoma in Low Rectal Cancer Surgery. <i>Annals of Surgery</i> , 2008, 248, 52-60.	2.1	512
592	Coloproctology. , 2008, , .		2
593	Prognostic Implications of the Distribution of Lymph Node Metastases in Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2106-2111.	0.8	90
594	Improved Outcome of Patients with Colorectal Cancer: The Ljubljana University Medical Centre Experience. <i>Digestive Surgery</i> , 2008, 25, 158-163.	0.6	0
595	Early distant relapse after optimal local control in locally advanced rectal cancer. <i>International Seminars in Surgical Oncology</i> , 2008, 5, 18.	1.1	2
596	Response to Preoperative Short-Course Radiotherapy in Locally Advanced Rectal Cancer: Value of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography. <i>Onkologie</i> , 2008, 31, 166-172.	1.1	20
597	Preoperative Short-Course Radiotherapy in Locally Advanced Rectal Cancer: The Attitude on How to Use Radiotherapy in Rectal Cancer is Changing. <i>Onkologie</i> , 2008, 31, 165-165.	1.1	1
598	Preoperative Staging of Rectal Tumors: What is the Most Optimal Staging Method?. <i>Onkologie</i> , 2008, 31, 222-223.	1.1	3

#	ARTICLE	IF	CITATIONS
599	Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to \hat{I}^3 -Radiation by Targeting Nuclear Factor- $\hat{I}B$ -Regulated Gene Products. <i>Clinical Cancer Research</i> , 2008, 14, 2128-2136.	3.2	201
600	Capecitabine plus oxaliplatin for the treatment of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 161-174.	1.1	9
601	Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2008, 98, 1204-1209.	2.9	76
602	Neoadjuvant Treatment of Rectal Carcinoma: Assessment of Health Care Services by Physicians and Lay Persons. <i>Journal of Clinical Oncology</i> , 2008, 26, 4866-4868.	0.8	14
603	Rectal Cancer at the Crossroads: The Dilemma of Clinically Staged T3, NO, MO Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 350-351.	0.8	23
604	A Systematic Approach to the Interpretation of Preoperative Staging MRI for Rectal Cancer. <i>American Journal of Roentgenology</i> , 2008, 191, 1827-1835.	1.0	244
605	Doing our best: surgery for rectal cancer. <i>Gut</i> , 2008, 57, 1643-1645.	6.1	3
606	Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii31-ii32.	0.6	25
607	The "good"™, the "bad"™, and the "ugly"™ rectal cancers. <i>Acta OncolÃ³gica</i> , 2008, 47, 5-8.	0.8	91
608	Chemoradiotherapy Followed by Surgery in Rectal Cancer: Improved Local Control Using a Moderately High Pelvic Radiation Dose. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 112-121.	0.6	11
609	MRI for Detection of Extramural Vascular Invasion in Rectal Cancer. <i>American Journal of Roentgenology</i> , 2008, 191, 1517-1522.	1.0	156
610	UFT (tegafur"uracil) in rectal cancer. <i>Annals of Oncology</i> , 2008, 19, 1371-1378.	0.6	16
611	Nonmetastatic Pancreatic Cancer: Many Trials, Little Progress. <i>Journal of Clinical Oncology</i> , 2008, 26, 3100-3100.	0.8	6
612	cT3N0 Rectal Cancer: Potential Overtreatment With Preoperative Chemoradiotherapy Is Warranted. <i>Journal of Clinical Oncology</i> , 2008, 26, 368-373.	0.8	214
615	Endorectal Ultrasound: Its Role in the Diagnosis and Treatment of Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2008, 21, 167-177.	0.5	34
616	USPIO-enhanced MR Imaging for Nodal Staging in Patients with Primary Rectal Cancer: Predictive Criteria. <i>Radiology</i> , 2008, 246, 804-811.	3.6	157
617	Mesorectal Fascia Invasion after Neoadjuvant Chemotherapy and Radiation Therapy for Locally Advanced Rectal Cancer: Accuracy of MR Imaging for Prediction. <i>Radiology</i> , 2008, 246, 454-462.	3.6	170
618	Patterns of Recurrence Following Liver Resection for Colorectal Metastases. <i>Archives of Surgery</i> , 2008, 143, 743.	2.3	52

#	ARTICLE	IF	CITATIONS
620	Endoscopic transanal vacuum-assisted rectal drainage (ETVARD): an optimized therapy for major leaks from extraperitoneal rectal anastomoses. <i>Endoscopy</i> , 2008, 40, 192-199.	1.0	73
624	Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 389.	2.3	84
625	Local excision and transanal endoscopic microsurgery in the management of rectal cancer with a focus on early carcinoma. <i>Future Oncology</i> , 2008, 4, 113-124.	1.1	3
626	Treatment options for esophageal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3197-3210.	0.9	8
627	Emerging role of intensity-modulated radiation therapy in anorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 585-593.	1.1	15
628	Comparison of dose calculation algorithms for colorectal cancer brachytherapy treatment with a shielded applicator. <i>Medical Physics</i> , 2008, 35, 4824-4830.	1.6	10
629	A retrospective comparison of concurrent bolus 5-fluorouracil or raltitrexed in preoperative chemoradiation for locally advanced rectal cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2008, 1, 28-33.	0.6	1
630	Surgical treatment for rectal cancer: An international perspective on what the medical gastroenterologist needs to know. <i>World Journal of Gastroenterology</i> , 2008, 14, 3281.	1.4	34
631	Recent advances in the management of rectal cancer. <i>British Journal of Hospital Medicine (London)</i> , 2008, 10, 10-11.	0.2	1
632	Pre-Operative Radiochemotherapy for Rectal Cancer.. <i>Acta Chirurgica Belgica</i> , 2008, 108, 518-523.	0.2	2
633	Prediction of Treatment Outcome by CD44v6 After Total Mesorectal Excision in Locally Advanced Rectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 54-61.	1.0	25
634	Early Oral Feeding After Major Digestive Surgery. <i>Annals of Surgery</i> , 2008, 248, 1108-1109.	2.1	0
635	PET-CT in Radiation Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 352-362.	0.6	63
636	Komplikationsmanagement von Leckagen nach extraperitonealen rektalen Anastomosen. <i>Chirurgische Gastroenterologie Interdisziplinär</i> , 2008, 24, 134-140.	0.0	1
637	Polypoid Lesions of the Gallbladder. <i>Annals of Surgery</i> , 2008, 248, 1110-1111.	2.1	3
638	Preoperative Capecitabine and Accelerated Intensity-Modulated Radiotherapy in Locally Advanced Rectal Cancer: A Phase II Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 264-270.	0.6	50
639	APER Rate Has Multiple Limitations as an Indicator of Quality in Rectal Cancer Surgery. <i>Annals of Surgery</i> , 2008, 248, 1105.	2.1	3
640	CONSORT and QUOROM Statements Revisited. <i>Annals of Surgery</i> , 2008, 248, 1107-1108.	2.1	5

#	ARTICLE	IF	CITATIONS
641	CONSORT and QUOROM Statements Revisited. <i>Annals of Surgery</i> , 2008, 248, 1106-1107.	2.1	15
642	Unresectable Colorectal Cancer Can Be Cured With Multimodality Therapy. <i>Annals of Surgery</i> , 2008, 248, 592-598.	2.1	70
643	Early Oral Feeding After Major Digestive Surgery. <i>Annals of Surgery</i> , 2008, 248, 1109-1110.	2.1	0
644	Molecular Signature for Lymphatic Metastasis in Colorectal Carcinomas. <i>Annals of Surgery</i> , 2008, 247, 803-810.	2.1	32
645	Optimal Surgery Time After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancers. <i>Annals of Surgery</i> , 2008, 248, 243-251.	2.1	106
646	APER Rate Has Multiple Limitations as an Indicator of Quality in Rectal Cancer Surgery. <i>Annals of Surgery</i> , 2008, 248, 1105-1106.	2.1	0
647	Colon and rectum. , 0, , 159-173.		0
648	PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer. <i>Cancer Imaging</i> , 2008, 8, S46-S51.	1.2	19
649	Circulating Cell-Free DNA in Plasma of Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation: A Potential Diagnostic Tool for Therapy Monitoring. <i>Disease Markers</i> , 2008, 25, 159-165.	0.6	59
650	Successful Downstaging of High Rectal and Recto-Sigmoid Cancer by Neo-Adjuvant Chemo-Radiotherapy. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S348.	0.2	11
651	Gene expression of colorectal cancer: Preoperative genetic diagnosis using endoscopic biopsies. <i>International Journal of Oncology</i> , 2008, , .	1.4	4
652	C�ncer ano-retal: aspectos atuais III - c�ncer de reto - terap�utica neoadjuvante. <i>Revista Brasileira De Coloproctologia</i> , 2008, 28, 108-118.	0.2	1
653	Recent advances in the management of carcinoma of the rectum. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 49.	1.0	7
654	Retrospective Long-Term Results and Prognostic Factors of Postoperative Treatment for UICC Stages II and III Rectal Cancer. <i>Tumori</i> , 2009, 95, 675-682.	0.6	2
655	A practice survey of the evolution of rectal cancer management. <i>Bulletin Du Cancer</i> , 2009, 96, E45-E51.	0.6	1
657	Colorectal Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 843-8.	0.6	27
658	Multidisciplinary treatment of resectable rectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 383-394.	1.4	4
659	Getting Knit-PI3Ky: PIK3CA Mutation Status to Direct Multimodality Therapy?. <i>Clinical Cancer Research</i> , 2009, 15, 6748-6750.	3.2	2

#	ARTICLE	IF	CITATIONS
660	Is Preoperative Chemoradiotherapy Still the Treatment of Choice for Rectal Cancer?. <i>Journal of Clinical Oncology</i> , 2009, 27, 5115-5116.	0.8	13
661	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2467-2478.	0.9	6
662	Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. <i>Annals of Oncology</i> , 2009, 20, 906-912.	0.6	56
663	Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. , 2009, , CD006041.		74
664	Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer—Invited Critique. <i>Archives of Surgery (Chicago, Ill: 1920)</i> , 2009, 144, 134.	1.5	0
665	Advances in Radiotherapy in Operable Rectal Cancer. <i>Digestive Surgery</i> , 2009, 26, 187-199.	0.6	12
666	Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03. <i>Journal of Clinical Oncology</i> , 2009, 27, 5124-5130.	0.8	796
667	Lymph Node Dissection in Rectal Carcinoma: TME and What Else?. <i>Oncology Research and Treatment</i> , 2009, 32, 57-61.	0.8	3
668	Can Dynamic MR Imaging Predict Response in Patients with Rectal Cancer Undergoing Cetuximab-Based Neoadjuvant Chemoradiation?. <i>Oncology Research and Treatment</i> , 2009, 32, 86-93.	0.8	16
672	Complications of Perineal Surgery. <i>Clinics in Colon and Rectal Surgery</i> , 2009, 22, 051-059.	0.5	17
673	Locally Advanced Rectal Cancer: MR Imaging for Restaging after Neoadjuvant Radiation Therapy with Concomitant Chemotherapy Part I. Are We Able to Predict Tumor Confined to the Rectal Wall?. <i>Radiology</i> , 2009, 252, 71-80.	3.6	150
674	Overview of Systemic Therapy for Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2009, 22, 251-256.	0.5	62
675	Locally Advanced Rectal Cancer: MR Imaging for Restaging after Neoadjuvant Radiation Therapy with Concomitant Chemotherapy Part II. What Are the Criteria to Predict Involved Lymph Nodes?. <i>Radiology</i> , 2009, 252, 81-91.	3.6	120
676	Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. <i>Acta Oncologica</i> , 2009, 48, 368-376.	0.8	54
677	Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv54-iv56.	0.6	56
678	HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 689-699.	0.7	73
679	Helical Tomotherapy Significantly Reduces Dose to Normal Tissues When Compared to 3D-CRT for Locally Advanced Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 379-385.	0.8	4
680	A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 528-533.	0.6	3

#	ARTICLE	IF	CITATIONS
682	Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: A prospective evaluation of a single institutional experience. <i>Surgery</i> , 2009, 145, 486-494.	1.0	56
683	Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. <i>Pathology International</i> , 2009, 59, 857-862.	0.6	11
684	Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. <i>BMC Cancer</i> , 2009, 9, 50.	1.1	74
688	Postoperative Morbidity with Diversion after Low Anterior Resection in the Era of Neoadjuvant Therapy: A Single Institution Experience. <i>Journal of the American College of Surgeons</i> , 2009, 209, 114-118.	0.2	39
691	Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence. <i>Cancer Genetics and Cytogenetics</i> , 2009, 190, 57-65.	1.0	18
692	Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2009, 193, 19-28.	1.0	26
693	Preoperative chemoradiation <i>versus</i> radiation alone for stage II and III resectable rectal cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2009, 124, 2966-2972.	2.3	93
694	GLUT1 expression and response to chemoradiotherapy in rectal cancer. <i>International Journal of Cancer</i> , 2009, 125, 2778-2782.	2.3	44
695	Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. <i>Cancer</i> , 2009, 115, 5432-5440.	2.0	65
696	Macroscopic assessment of mesorectal excision. <i>Cancer</i> , 2009, 115, 4890-4894.	2.0	6
697	Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 1093-1101.	1.9	61
698	Factors associated with anastomotic recurrence after total mesorectal excision in rectal cancer patients. <i>Journal of Surgical Oncology</i> , 2009, 99, 58-64.	0.8	53
699	Nationwide outcome registrations to improve quality of care in rectal surgery. An initiative of the European society of surgical oncology. <i>Journal of Surgical Oncology</i> , 2009, 99, 491-496.	0.8	34
700	The prognostic impact of the number of lymph nodes retrieved after neoadjuvant chemoradiotherapy with mesorectal excision for rectal cancer. <i>Journal of Surgical Oncology</i> , 2009, 100, 1-7.	0.8	35
701	Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: Is it essential for patients with ypT0-2N0?. <i>Journal of Surgical Oncology</i> , 2009, 100, 387-391.	0.8	41
702	Non-operative management of rectal cancer after neoadjuvant chemoradiation. <i>British Journal of Surgery</i> , 2009, 96, 125-127.	0.1	105
703	Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. <i>British Journal of Surgery</i> , 2009, 96, 1066-1075.	0.1	247
704	Circumferential resection margin as a prognostic factor in rectal cancer. <i>British Journal of Surgery</i> , 2009, 96, 1348-1357.	0.1	185

#	ARTICLE	IF	CITATIONS
705	Dosimetric study of five-field intensity-modulated radiotherapy compared with conventional three-dimensional conformal radiotherapy for rectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 607-610.	0.1	1
710	Laparoscopic surgery for the curative treatment of rectal cancer: results of a Chinese three-center caseâ€“control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 854-861.	1.3	18
711	Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 1081-1087.	1.3	118
712	The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. <i>International Journal of Colorectal Disease</i> , 2009, 24, 191-200.	1.0	79
713	Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6Âcm from anal verge. <i>International Journal of Colorectal Disease</i> , 2009, 24, 401-407.	1.0	4
714	The morbidity surrounding reversal of defunctioning ileostomies: a systematic review of 48 studies including 6,107 cases. <i>International Journal of Colorectal Disease</i> , 2009, 24, 711-723.	1.0	335
715	Laparoscopic or open surgery for the cancer of the middle and lower rectum short-term outcomes of a comparative non-randomised study. <i>International Journal of Colorectal Disease</i> , 2009, 24, 761-769.	1.0	25
716	ETVARD (endoscopic transanal vacuum-assisted rectal drainage) leads to complete but delayed closure of extraperitoneal rectal anastomotic leakage cavities following neoadjuvant radiochemotherapy. <i>International Journal of Colorectal Disease</i> , 2009, 24, 819-825.	1.0	45
717	Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2009, 24, 741-748.	1.0	50
718	Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. <i>International Journal of Colorectal Disease</i> , 2009, 24, 777-788.	1.0	9
719	Quality management in rectal carcinoma: what is feasible?. <i>International Journal of Colorectal Disease</i> , 2009, 24, 931-942.	1.0	24
720	Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer?. <i>International Journal of Colorectal Disease</i> , 2009, 24, 1181-1186.	1.0	33
721	Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 1261-1269.	1.0	12
722	Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 1451-1458.	1.0	31
723	Implementing patient decision support tools: Moving beyond academia?. <i>Patient Education and Counseling</i> , 2009, 76, 120-125.	1.0	15
724	Radiation therapy in the elderly: More side effects and complications?. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 70-78.	2.0	49
725	Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 148-153.	0.4	132
726	Radiation Fields of Neoadjuvant Concurrent Chemoradiotherapy for Rectal Cancer: In Regard to Yu et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;71:1175â€“1180). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 639.	0.4	2

#	ARTICLE	IF	CITATIONS
727	Histologic Response Grading After Chemoradiation in Locally Advanced Rectal Cancer: A Proposal for Standardized Reporting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 971-973.	0.4	8
728	Curcumin Modulates the Radiosensitivity of Colorectal Cancer Cells by Suppressing Constitutive and Inducible NF- κ B Activity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 534-542.	0.4	166
729	Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. <i>Investigational New Drugs</i> , 2009, 27, 262-268.	1.2	10
730	Combined Modality Therapy in the Elderly Population. <i>Current Treatment Options in Oncology</i> , 2009, 10, 195-204.	1.3	13
731	Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 151-157.	1.0	2
732	Optimizing rectal cancer surgery by total mesorectal excision and "cylindrical" extralevator techniques for abdominoperineal excision. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 219-223.	1.0	3
733	Imaging for staging and response assessment in rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 224-231.	1.0	0
734	Choosing between short-course preoperative radiotherapy and long-course chemoradiation therapy. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 232-239.	1.0	0
735	Are there alternatives to radical surgery in rectal cancer?. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 240-246.	1.0	0
736	Staging, prognostic factors, and therapy of localized rectal cancer. <i>Current Oncology Reports</i> , 2009, 11, 167-174.	1.8	5
737	Postoperative Morbidity Following Chemoradiation for Locally Advanced Low Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 657-667.	0.9	24
738	Neoadjuvant therapy for advanced rectal carcinoma in China: Whether radiochemotherapy is superior to radiotherapy?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2009, 21, 295-303.	0.7	0
739	Colonoscopic ultrasound is associated with a learning phenomenon despite previous rigid probe experience. <i>Indian Journal of Gastroenterology</i> , 2009, 28, 96-98.	0.7	1
740	Gold markers for tumor localization and target volume delineation in radiotherapy for rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 127-133.	1.0	22
741	Molecular targeted treatment and radiation therapy for rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 371-378.	1.0	50
742	Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 364-370.	1.0	4
743	Impact of 18F-FDG-PET/CT on Staging and Irradiation of Patients with Locally Advanced Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 260-265.	1.0	29
750	Reduced Lymph Node Yield in Rectal Carcinoma Specimen After Neoadjuvant Radiochemotherapy Has No Prognostic Relevance. <i>World Journal of Surgery</i> , 2009, 33, 340-7.	0.8	75

#	ARTICLE	IF	CITATIONS
751	Factors Associated with Local Recurrence After Neoadjuvant Chemoradiation with Total Mesorectal Excision for Rectal Cancer. <i>World Journal of Surgery</i> , 2009, 33, 1741-1749.	0.8	31
752	Accuracy of MRI and ¹⁸ F-FDG PET/CT for Restaging After Preoperative Concurrent Chemoradiotherapy for Rectal Cancer. <i>World Journal of Surgery</i> , 2009, 33, 2688-2694.	0.8	49
753	Development of a synoptic MRI report for primary rectal cancer. <i>Implementation Science</i> , 2009, 4, 79.	2.5	7
754	Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results. <i>Radiation Oncology</i> , 2009, 4, 67.	1.2	16
755	Rectal cancer staging post neoadjuvant therapy – how should the changes be assessed?. <i>Histopathology</i> , 2009, 54, 713-721.	1.6	68
756	High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. <i>British Journal of Cancer</i> , 2009, 101, 116-123.	2.9	50
757	Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). <i>British Journal of Cancer</i> , 2009, 101, 924-934.	2.9	25
758	Complete pathologic response after preoperative rectal cancer chemoradiotherapy. <i>ANZ Journal of Surgery</i> , 2009, 79, 481-484.	0.3	18
759	Impact of laparoscopic surgery on the long-term outcomes for patients with rectal cancer. <i>ANZ Journal of Surgery</i> , 2009, 79, 817-823.	0.3	21
760	The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. <i>Colorectal Disease</i> , 2009, 11, 264-269.	0.7	45
761	Preoperative neoadjuvant therapy for curable rectal cancer – reaching a consensus 2008. <i>Colorectal Disease</i> , 2009, 11, 245-248.	0.7	23
762	Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neoadjuvant downstaging. <i>Colorectal Disease</i> , 2009, 11, 759-767.	0.7	21
763	Standardized surgery for colonic cancer: complete mesocolic excision and central ligation – technical notes and outcome. <i>Colorectal Disease</i> , 2009, 11, 354-364.	0.7	1,233
764	Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity. <i>Colorectal Disease</i> , 2010, 12, 549-554.	0.7	6
765	Pathological Response after Chemoradiation for T3 Rectal Cancer. <i>Colorectal Disease</i> , 2009, 12, e24-30.	0.7	2
766	Watch and wait policy remains experimental for the management of rectal cancer. <i>Colorectal Disease</i> , 2010, 12, 833-833.	0.7	7
767	Neoadjuvant Treatment With Single-Agent Cetuximab Followed by 5-FU, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 466-472.	0.4	79
768	Preoperative Radiation Treatment for Rectal Cancer: Comparison of Target Coverage and Small Bowel NTCP in Conventional vs. 3D-Conformal Planning. <i>Medical Dosimetry</i> , 2009, 34, 75-81.	0.4	12

#	ARTICLE	IF	CITATIONS
769	Regression of Rectal Cancer with Radiotherapy with or without Concurrent Capecitabine â€” Optimising the Timing of Surgical Resection. <i>Clinical Oncology</i> , 2009, 21, 23-31.	0.6	43
770	Chemoradiotherapy in Gastrointestinal Malignancies. <i>Clinical Oncology</i> , 2009, 21, 543-556.	0.6	22
771	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 160-182.	2.0	14
772	Radiation Changes Do Not Interfere With Postchemoradiation Restaging of Patients With Rectal Cancer by FDG PET/CT Before Curative Surgical Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 60-66.	0.4	32
773	Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 818-823.	0.4	55
774	Carcinoembryonic Antigen as a Predictor of Pathologic Response and a Prognostic Factor in Locally Advanced Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy and Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 810-817.	0.4	75
775	Lymph Node Ratio as a Prognostic Factor in Patients With Stage III Rectal Cancer Treated With Total Mesorectal Excision Followed by Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 796-802.	0.4	77
776	Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 824-830.	0.4	425
777	In Response to Cox et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 638-639.	0.4	1
778	Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1487-1493.	0.4	104
779	Generic Planning Target Margin for Rectal Cancer Treatment Setup Variation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1470-1475.	0.4	13
780	Preoperative Helical Tomotherapy and Megavoltage Computed Tomography for Rectal Cancer: Impact on the Irradiated Volume of Small Bowel. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1476-1480.	0.4	63
781	Neoadjuvant Treatment Does Not Influence Perioperative Outcome in Rectal Cancer Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 129-136.	0.4	23
782	Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 421-427.	0.4	38
783	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinicalâ€”Pathologic Score Correlates With Global Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1437-1443.	0.4	4
784	Biomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 673-688.	0.4	215
785	Acute and long-term gastrointestinal consequences of chemotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009, 23, 113-124.	1.0	60
786	Preoperative staging of rectal cancer. <i>Future Oncology</i> , 2009, 5, 1295-1306.	1.1	7

#	ARTICLE	IF	CITATIONS
787	The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay. <i>Radiation Oncology</i> , 2009, 4, 61.	1.2	7
788	Long-Term Oncologic Results and Complications After Preoperative Chemoradiotherapy for Rectal Cancer: A Single-Institution Experience After a Median Follow-Up of 95 Months. <i>Annals of Surgical Oncology</i> , 2009, 16, 893-899.	0.7	26
789	Oncologic Outcomes After Radical Surgery Following Preoperative Chemoradiotherapy for Locally Advanced Lower Rectal Cancer: Abdominoperineal Resection Versus Sphincter-Preserving Procedure. <i>Annals of Surgical Oncology</i> , 2009, 16, 1266-1273.	0.7	38
790	Operative Safety and Oncologic Outcomes of Anal Sphincter-Preserving Surgery with Mesorectal Excision for Rectal Cancer: 931 Consecutive Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2009, 16, 900-909.	0.7	25
791	Laparoscopic Resection for Rectal Cancer: A Review. <i>Annals of Surgical Oncology</i> , 2009, 16, 3038-3047.	0.7	111
792	Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2009, 16, 3488-3498.	0.7	283
793	Urologic Complications of Composite Resection Following Combined Modality Treatment of Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 2759-2764.	0.7	14
794	Adjuvant and Neoadjuvant Therapy for Colorectal Carcinoma. , 2009, , 911-918.		0
795	Locally Advanced Rectal Cancer: MR Imaging in Prediction of Response after Preoperative Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2009, 250, 730-739.	3.6	207
796	The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. <i>British Journal of Radiology</i> , 2009, 82, 321-327.	1.0	33
797	Future directions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates. <i>Cancer Treatment Reviews</i> , 2009, 35, 547-552.	3.4	18
798	The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1175-1183.	1.3	171
799	E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1871-1876.	1.3	19
800	Prediction of rectal lymph node metastasis by pelvic computed tomography measurement. <i>European Journal of Surgical Oncology</i> , 2009, 35, 168-173.	0.5	29
801	Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 13-21.e5.	2.4	122
802	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2245-2258.	0.9	12
803	Prospective assessment of EUS criteria for lymphadenopathy associated with rectal cancer. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 896-903.	0.5	39
804	Oncologic Outcomes. , 2009, , 117-124.		0

#	ARTICLE	IF	CITATIONS
805	Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. The Cochrane Library, 2009, , CD006269.	1.5	41
806	The Multidisciplinary Management of Rectal Cancer. Surgical Clinics of North America, 2009, 89, 177-215.	0.5	34
807	Comparison of Treatment Received Versus Long-Standing Guidelines for Stage III Colon and Stage II/III Rectal Cancer Patients Diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clinical Colorectal Cancer, 2009, 8, 141-145.	1.0	29
808	Improved Patient and Regimen Selection in Locally Advanced Rectal Cancer: Who, How, and What Next?. Clinical Colorectal Cancer, 2009, 8, 194-199.	1.0	6
811	Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. Journal of Clinical Oncology, 2009, 27, 3020-3026.	0.8	487
812	Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment. Radiotherapy and Oncology, 2009, 92, 221-225.	0.3	54
813	Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiotherapy and Oncology, 2009, 92, 210-214.	0.3	114
814	Target volume shape variation during hypo-fractionated preoperative irradiation of rectal cancer patients. Radiotherapy and Oncology, 2009, 92, 202-209.	0.3	65
815	Rectal cancer multidisciplinary management: Evidences and future landscape. Radiotherapy and Oncology, 2009, 92, 145-147.	0.3	22
816	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiotherapy and Oncology, 2009, 92, 353-361.	0.3	49
817	MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiotherapy and Oncology, 2009, 93, 279-284.	0.3	28
818	Management of rectal cancer: part II. Community Oncology, 2009, 6, 265-270.	0.2	0
819	Preoperative Chemoradiotherapy for Rectal Cancer. Journal of the Chinese Medical Association, 2009, 72, 169-170.	0.6	1
820	Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncology, The, 2009, 10, 1053-1062.	5.1	253
821	Rectal cancer: optimum treatment leads to optimum results. Lancet, The, 2009, 373, 790-792.	6.3	11
822	Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, The, 2009, 373, 811-820.	6.3	1,292
823	Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. Lancet, The, 2009, 373, 821-828.	6.3	906
824	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.3	275

#	ARTICLE	IF	CITATIONS
825	Rectal cancer. Journal of the Royal College of Surgeons of Edinburgh, 2009, 7, 162-169.	0.8	16
826	Preoperative Versus Postoperative Adjuvant Therapy for Adenocarcinoma of the Pancreas. Advances in Surgery, 2009, 43, 189-198.	0.6	2
827	Can Unresectable Colorectal Cancer Be Cured?. Advances in Surgery, 2009, 43, 211-219.	0.6	5
828	Radiotherapy in the Treatment of Resectable Rectal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 629-638.	0.6	8
829	Aggressive Angiomyxoma of the Vulva. Journal of Lower Genital Tract Disease, 2009, 13, 46-50.	0.9	25
830	Reconstruction of Pelvic Exenteration Defects with Anterolateral Thigh Vastus Lateralis Muscle Flaps. Plastic and Reconstructive Surgery, 2009, 124, 1177-1185.	0.7	57
831	Factors Associated With Sphincter-Preserving Surgery for Rectal Cancer at National Comprehensive Cancer Network Centers. Annals of Surgery, 2009, 250, 260-267.	2.1	49
832	Multislice CT as a Primary Screening Tool for the Prediction of an Involved Mesorectal Fascia and Distant Metastases in Primary Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 928-934.	0.7	37
833	Analysis of Clinical Factors Associated with Anal Function after Intersphincteric Resection for Very Low Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 64-70.	0.7	122
834	Lymphatic Vessel Density as Predictive Marker for the Local Recurrence of Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 513-519.	0.7	7
835	Treatment for Patients with Rectal Cancer and a Clinical Complete Response to Neoadjuvant Therapy. Diseases of the Colon and Rectum, 2009, 52, 863-871.	0.7	31
836	The Effect of Preoperative Chemoradiotherapy on Lymph Node Harvest After Total Mesorectal Excision for Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 1470-1474.	0.7	21
837	Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 1054-1064.	0.7	95
838	A Twenty-Year Experience with Adenocarcinoma of the Anal Canal. Diseases of the Colon and Rectum, 2009, 52, 1375-1380.	0.7	56
839	The Impact of Hospital Volume on Surgical Outcome in Patients with Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 1542-1549.	0.7	36
840	Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer. Annals of Surgery, 2009, 250, 582-589.	2.1	316
841	Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection. Annals of Surgery, 2009, 249, 236-242.	2.1	206
842	Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anti-Cancer Drugs, 2009, 20, 519-524.	0.7	29

#	ARTICLE	IF	CITATIONS
843	Incidence and mortality by colorectal cancer in Spain during 1951â€“2006 and its relationship with behavioural factors. <i>European Journal of Cancer Prevention</i> , 2009, 18, 436-444.	0.6	26
844	Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer. <i>Archives of Surgery (Chicago, Ill: 1920)</i> , 2009, 144, 129.	1.5	14
845	Diverting Stoma After Low Anterior Resection. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 412-418.	0.7	108
846	A Study into External Rectal Anatomy. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 87-90.	0.7	28
847	Preoperative Radiotherapy is Associated with Worse Functional Results After Coloanal Anastomosis for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 2004-2014.	0.7	82
848	Differences Between Clinical Trial Participants and Patients in a Population-Based Registry. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 425-437.	0.7	37
849	The Role of Carcinoembriogenic Antigen in Predicting Response and Survival to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1137-1143.	0.7	102
850	Lymph Node Size in Rectal Cancer Following Neoadjuvant Chemoradiationâ€”Can We Rely on Radiologic Nodal Staging After Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1278-1284.	0.7	66
851	A Comparison Between the Treatment of Low Rectal Cancer in Japan and the Netherlands, Focusing on the Patterns of Local Recurrence. <i>Annals of Surgery</i> , 2009, 249, 229-235.	2.1	184
852	Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 838-881.	2.3	289
853	The Challenges of Colorectal Cancer Survivorship. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 883-894.	2.3	236
854	Colorectal cancer mortality in Spain: trends and projections for 1985â€“2019. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 92-100.	0.8	30
855	Therapeutic management of colorectal cancer in elderly patients: an update. <i>Aging Health</i> , 2009, 5, 345-358.	0.3	0
857	Increasing the Rates of Complete Response to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer: Results of a Prospective Study Using Additional Chemotherapy During the Resting Period. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1927-1934.	0.7	193
858	The Role of Capecitabine in the Management of Tumors of the Digestive System. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 1-11.	0.4	5
859	INVITED COMMENTARY. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 2014-2015.	0.7	0
860	Impact of Tumor Response on Survival After Radiochemotherapy in Locally Advanced Rectal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 562-568.	2.1	54
861	Chemotherapy for the Elderly Patient With Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 241-252.	1.0	18

#	ARTICLE	IF	CITATIONS
862	Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative Chemoradiation. <i>Annals of Surgery</i> , 2010, 251, 261-264.	2.1	75
863	The Severity of Neural Invasion Is a Crucial Prognostic Factor in Rectal Cancer Independent of Neoadjuvant Radiochemotherapy. <i>Annals of Surgery</i> , 2010, 252, 797-804.	2.1	67
864	Postoperative Complications Following Surgery for Rectal Cancer. <i>Annals of Surgery</i> , 2010, 251, 807-818.	2.1	387
865	Influence of Preoperative Chemoradiotherapy on the Number of Lymph Nodes Retrieved in Rectal Cancer. <i>Annals of Surgery</i> , 2010, 252, 336-340.	2.1	98
866	Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for Standardization. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1692-1698.	0.7	341
867	Can CT Replace MRI in Preoperative Assessment of the Circumferential Resection Margin in Rectal Cancer?. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 308-314.	0.7	54
868	Does a Rectal Cancer of the Upper Third Behave More Like a Colon or a Rectal Cancer?. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 761-770.	0.7	44
869	Combined Modality Therapy for Rectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 253-261.	1.0	20
870	Oncologic Outcomes of Robotic-Assisted Total Mesorectal Excision for the Treatment of Rectal Cancer. <i>Annals of Surgery</i> , 2010, 251, 882-886.	2.1	150
871	Pathologic Complete Response of Primary Tumor Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2010, 252, 998-1004.	2.1	164
872	The Short-term Effect of Neoadjuvant Chemoradiation on Anorectal Function in Low and Midrectal Cancer: Analysis Using Preoperative Manometric Data. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 445-449.	0.7	8
873	Anal Function and Intersphincteric Resection. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 958.	0.7	0
874	Fewer Than 12 Lymph Nodes Can be Expected in a Surgical Specimen After High-Dose Chemoradiation Therapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1023-1029.	0.7	68
875	Local Excision of T1 Rectal Cancer: Where Are We Now?. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1231-1233.	0.7	5
876	Temporal and Regional Variations in the Use of Preoperative Radiation Therapy for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 443-447.	0.6	7
878	Reply to R. Glynne-Jones et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e307-e307.	0.8	0
881	Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1432-1438.	0.7	41
882	Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2010, 1, 23-29.	0.8	4

#	ARTICLE	IF	CITATIONS
883	Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. <i>Oncology Reports</i> , 2010, 24, 1285-90.	1.2	14
885	Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy. <i>Oncology Letters</i> , 2010, 1, 641-647.	0.8	10
886	Radiation Therapy for Rectal Cancer: Current Status and Future Directions. <i>Cancer Control</i> , 2010, 17, 25-34.	0.7	16
887	Long-term Anorectal Function after Postoperative Chemoradiotherapy in High-Risk Rectal Cancer Patients. <i>Tumori</i> , 2010, 96, 34-41.	0.6	8
888	Local Excision After Preoperative Chemoradiation Results in an Equivalent Outcome to Total Mesorectal Excision in Selected Patients with T3 Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 441-447.	0.7	107
889	Locally Recurrent Rectal Cancer: Prognostic Factors and Long-Term Outcomes of Multimodal Therapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 152-162.	0.7	70
890	Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment?. <i>Annals of Surgical Oncology</i> , 2010, 17, 838-845.	0.7	32
891	Management of Recurrent Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 1343-1356.	0.7	113
892	Downstaging Without Complete Pathologic Response After Neoadjuvant Treatment Improves Cancer Outcomes for cIII but not cII Rectal Cancers. <i>Annals of Surgical Oncology</i> , 2010, 17, 1758-1766.	0.7	45
893	Stromal CXCR4 and CXCL12 Expression is Associated with Distant Recurrence and Poor Prognosis in Rectal Cancer After Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 2051-2058.	0.7	48
894	Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2863-2869.	0.7	100
895	Distal Margins in Radical Resections for Rectal Cancer after Chemoradiation Therapy: How Short Is Long Enough?. <i>Digestive Surgery</i> , 2010, 27, 185-189.	0.6	25
896	Preoperative Radiochemotherapy in T3 Operable Low Rectal Cancers: A Gold Standard?. <i>World Journal of Surgery</i> , 2010, 34, 1609-1614.	0.8	8
897	Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 567-573.	1.1	0
899	High-Grade Acute Organ Toxicity During Preoperative Radiochemotherapy as Positive Predictor for Complete Histopathologic Tumor Regression in Multimodal Treatment of Locally Advanced Rectal Cancer*. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 30-35.	1.0	30
900	Combination of Ionising Irradiation and Hyperthermia Activates Programmed Apoptotic and Necrotic Cell Death Pathways in Human Colorectal Carcinoma Cells. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 587-599.	1.0	52
901	Induction Chemotherapy before Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 658-664.	1.0	28
903	Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 824-830.	0.4	177

#	ARTICLE	IF	CITATIONS
904	Late Side Effects and Quality of Life After Radiotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1005-1011.	0.4	214
905	Tumor Volume Changes Assessed by Three-Dimensional Magnetic Resonance Volumetry in Rectal Cancer Patients After Preoperative Chemoradiation: The Impact of the Volume Reduction Ratio on the Prediction of Pathologic Complete Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1018-1025.	0.4	78
906	Accurate Prediction of Pathological Rectal Tumor Response after Two Weeks of Preoperative Radiochemotherapy Using 18F-Fluorodeoxyglucose-Positron Emission Tomography-Computed Tomography Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 392-399.	0.4	76
907	Predicting Grade 3 Acute Diarrhea During Radiation Therapy for Rectal Cancer Using a Cutoff-Dose Logistic Regression Normal Tissue Complication Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 66-72.	0.4	40
908	Tumor Volume Reduction Rate Measured by Magnetic Resonance Volumetry Correlated With Pathologic Tumor Response of Preoperative Chemoradiotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 164-171.	0.4	78
909	Complications After Sphincter-Saving Resection in Rectal Cancer Patients According to Whether Chemoradiotherapy Is Performed Before or After Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 156-163.	0.4	30
910	Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2010, 25, 197-204.	1.0	78
911	Modified neoadjuvant short-course radiation therapy in uT3 rectal carcinoma: low local recurrence rate with unchanged overall survival and frequent morbidity. <i>International Journal of Colorectal Disease</i> , 2010, 25, 109-117.	1.0	5
912	Comparison of the erectile function in male patients with rectal cancer treated by preoperative radiotherapy followed by surgery and surgery alone. <i>International Journal of Colorectal Disease</i> , 2010, 25, 619-624.	1.0	28
913	Neoadjuvant chemoradiotherapy, sepsis and neutrophil levels following radical excision of rectal cancer. <i>International Journal of Colorectal Disease</i> , 2010, 25, 723-729.	1.0	1
914	Current perioperative practice in rectal surgery in Austria and Germany. <i>International Journal of Colorectal Disease</i> , 2010, 25, 855-863.	1.0	18
915	Practicability of quality goals for the treatment of rectal cancer. <i>International Journal of Colorectal Disease</i> , 2010, 25, 1093-1102.	1.0	10
916	Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?. <i>International Journal of Colorectal Disease</i> , 2010, 25, 1103-1110.	1.0	18
917	Laparoscopic TME in rectal cancer – electronic supplementary: op-video. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 181-183.	0.8	13
918	Quality assurance of pelvic autonomic nerve-preserving surgery for advanced lower rectal cancer – preliminary results of a randomized controlled trial. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 607-613.	0.8	9
919	Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 1031-1038.	0.8	33
920	Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1681-1689.	1.2	23
921	A nationwide audit of the use of radiotherapy for rectal cancer in Italy. <i>Techniques in Coloproctology</i> , 2010, 14, 229-235.	0.8	19

#	ARTICLE	IF	CITATIONS
922	Radiothérapie seule ou associée aux traitements médicaux dans les cancers du rectum. <i>Oncologie</i> , 2010, 12, 37-40.	0.2	0
923	Cancers du bas rectum: comment améliorer la conservation sphinctérienne ?. <i>Oncologie</i> , 2010, 12, 28-33.	0.2	0
924	Fast-track surgery for colonic and rectal resections in Austria – Results from a survey on the perioperative anaesthesia management. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010, 42, 83-90.	0.3	0
925	Rectal cancer: the impact of lymph node dissection and preoperative radiation in the era of total mesorectal excision. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010, 42, 159-163.	0.3	0
926	Adjuvant and neoadjuvant therapy in colorectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010, 42, 283-286.	0.3	0
931	Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 933-938.	1.3	43
932	Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3cm of the rectum after neoadjuvant therapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2700-2707.	1.3	91
933	Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. <i>Supportive Care in Cancer</i> , 2010, 18, 601-608.	1.0	50
935	Intestinal permeability, vitamin A absorption, alpha-tocopherol, and neopterin in patients with rectal carcinoma treated with chemoradiation. <i>Medical Oncology</i> , 2010, 27, 690-696.	1.2	11
936	The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment. <i>Clinical and Translational Oncology</i> , 2010, 12, 339-345.	1.2	10
937	Update on the surgical pathology standards on rectal cancer diagnosis, staging and quality assessment of surgery. <i>Clinical and Translational Oncology</i> , 2010, 12, 431-436.	1.2	7
938	SEOM clinical guidelines for the adjuvant treatment of colorectal cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 724-728.	1.2	14
939	Multidisciplinary management in rectal cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 805-818.	1.2	1
940	Short-course versus long-course neoadjuvant radiotherapy for lower rectal cancer: a systematic review. <i>Irish Journal of Medical Science</i> , 2010, 179, 165-171.	0.8	7
941	How Might Knowledge of the Molecular Biology of Rectal Cancer Aid Us in Deciding Treatment?. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 221-227.	1.0	1
942	Optimal Adjuvant Therapy for Patients with Resected Rectal Cancers. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 180-182.	1.0	0
943	Preoperative Chemoradiotherapy Does Not Necessarily Reduce Lymph Node Retrieval in Rectal Cancer Specimens – Results from a Prospective Evaluation with Extensive Pathological Work-up. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 96-103.	0.9	35
944	Adequate Length of the Distal Resection Margin in Rectal Cancer: From the Oncological Point of View. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1331-1337.	0.9	78

#	ARTICLE	IF	CITATIONS
945	Fertility Preservation for Young Women with Rectal Cancer—A Combined Approach from One Referral Center. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1476.	0.9	1
947	Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. <i>Colorectal Disease</i> , 2010, 12, 2-24.	0.7	11
948	Controversial aspects of rectal cancer surgery following preoperative chemoradiation. <i>Colorectal Disease</i> , 2010, 12, 25-29.	0.7	7
949	Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine. <i>Colorectal Disease</i> , 2010, 12, 37-46.	0.7	16
950	Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers. <i>World Journal of Surgical Oncology</i> , 2010, 8, 23.	0.8	15
951	A new sensitivity-preferred strategy to build prediction rules for therapy response of cancer patients using gene expression data. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 100, 132-139.	2.6	7
952	Effects of Obesity in Rectal Cancer Surgery. <i>Journal of the American College of Surgeons</i> , 2010, 211, 55-60.	0.2	64
953	Gene Signature Is Associated with Early Stage Rectal Cancer Recurrence. <i>Journal of the American College of Surgeons</i> , 2010, 211, 187-195.	0.2	15
954	The role of targeted agents in preoperative chemoradiation for rectal cancer. <i>Cancer</i> , 2010, 116, 3537-3548.	2.0	28
955	Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. <i>British Journal of Surgery</i> , 2010, 97, 383-390.	0.1	98
956	Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases (<i>Br J Surg</i> 2010; 97: 383-390). <i>British Journal of Surgery</i> , 2010, 97, 390-390.	0.1	2
957	Long-term outcomes and quality of life after rectal carcinoma surgery. <i>British Journal of Surgery</i> , 2010, 97, 1295-1303.	0.1	79
958	Magnetic resonance imaging-detected lymph nodes close to the mesorectal fascia are rarely a cause of margin involvement after total mesorectal excision. <i>British Journal of Surgery</i> , 2010, 97, 1431-1436.	0.1	44
959	Rectum-conserving surgery in the era of chemoradiotherapy. <i>British Journal of Surgery</i> , 2010, 97, 1752-1764.	0.1	137
960	Current neoadjuvant strategies in rectal cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 321-326.	0.8	32
961	Salvage of pelvic recurrence of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 649-660.	0.8	15
962	The impact of preoperative chemoradiotherapy on advanced low rectal cancer. <i>Journal of Surgical Oncology</i> , 2010, 102, 771-777.	0.8	24
963	Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2010, 15, 51-59.	0.3	12

#	ARTICLE	IF	CITATIONS
964	Chronic Radiation Enteritis. <i>Clinical Oncology</i> , 2010, 22, 70-83.	0.6	222
965	Whose Guidelines are they Anyway?. <i>Clinical Oncology</i> , 2010, 22, 261-264.	0.6	2
966	Gene Expression Profiles of Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor and Hypoxia-inducible Factor-1 with Special Reference to Local Responsiveness to Neoadjuvant Chemoradiotherapy and Disease Recurrence After Rectal Cancer Surgery. <i>Clinical Oncology</i> , 2010, 22, 272-280.	0.6	41
967	Preoperative or Postoperative Therapy for Stage II or III Rectal Cancer: An Updated Practice Guideline. <i>Clinical Oncology</i> , 2010, 22, 265-271.	0.6	47
968	ACR Appropriateness Criteria®: Rectal Cancer—Metastatic Disease at Presentation. <i>Current Problems in Cancer</i> , 2010, 34, 201-210.	1.0	11
969	Preoperative Capecitabine and Pelvic Radiation in Locally Advanced Rectal Cancer—Is it Equivalent to 5-FU Infusion Plus Leucovorin and Radiotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1413-1419.	0.4	34
970	Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients With Prior Pelvic Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 60-65.	0.4	115
971	Radiation Dose—Volume Effects in the Stomach and Small Bowel. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S101-S107.	0.4	457
972	Pathologic Nodal Classification Is the Most Discriminating Prognostic Factor for Disease-Free Survival in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy and Curative Resection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1158-1165.	0.4	86
973	Preoperative Radiotherapy of Advanced Rectal Cancer With Capecitabine and Oxaliplatin With or Without Cetuximab: A Pooled Analysis of Three Prospective Phase I-II Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 472-478.	0.4	53
974	Sorafenib and Radiation: A Promising Combination in Colorectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 213-220.	0.4	31
975	Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 868-878.	0.4	22
976	A Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1184-1192.	0.4	82
977	Validated Nomograms based on Six Large European Trials for the Prediction of Local Control, Distant Metastases, and Survival for Locally Advanced Rectal Cancer Patients after Long Course Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S54-S55.	0.4	0
978	Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?. <i>World Journal of Surgical Oncology</i> , 2010, 8, 27.	0.8	18
979	Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients. <i>Radiation Oncology</i> , 2010, 5, 118.	1.2	11
980	Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. <i>Radiation Oncology</i> , 2010, 5, 17.	1.2	128
981	Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. <i>Radiation Oncology</i> , 2010, 5, 47.	1.2	119

#	ARTICLE	IF	CITATIONS
982	The role of radiotherapy in multimodal treatment of pancreatic carcinoma. <i>Radiation Oncology</i> , 2010, 5, 64.	1.2	44
983	Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. <i>Radiation Oncology</i> , 2010, 5, 88.	1.2	25
984	CD133 expression in rectal cancer after preoperative chemoradiotherapy. <i>Cancer Science</i> , 2010, 101, 906-912.	1.7	29
985	Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon- β . <i>British Journal of Cancer</i> , 2010, 103, 1163-1172.	2.9	15
986	Meta-analysis: Perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma. <i>Journal of Digestive Diseases</i> , 2010, 11, 208-214.	0.7	3
987	Preoperative chemoradiation vs radiation alone for stage II and III resectable rectal cancer: a meta-analysis. <i>Colorectal Disease</i> , 2010, 12, 1075-1083.	0.7	17
988	Neoadjuvant chemoradiotherapy and rectal cancer: can the UK watch and wait with Brazil?. <i>Colorectal Disease</i> , 2010, 12, 33-36.	0.7	21
989	Rectal Cancer Multidisciplinary Treatment: Evidences, Consensus and Perspectives. <i>Tumori</i> , 2010, 96, 185-190.	0.6	1
990	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. <i>Medical Radiology</i> , 2010, , 37-57.	0.0	0
991	Comparison between Intensified Neoadjuvant Treatment and Standard Preoperative Chemoradiation for Rectal Cancer. <i>Tumori</i> , 2010, 96, 11-16.	0.6	3
992	The Use of Pelvic Radiation in Stage II Rectal Cancer: A Population-Based Analysis. <i>American Surgeon</i> , 2010, 76, 1092-1095.	0.4	7
993	The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer. <i>American Surgeon</i> , 2010, 76, 1163-1166.	0.4	5
995	Lymph node retrieval after resection of rectal cancer following preoperative chemoradiotherapy. <i>Medicina (Lithuania)</i> , 2010, 46, 299.	0.8	7
996	Resultados del tratamiento con neoadyuvancia del c�ncer de recto localmente avanzado. <i>Revista Chilena De Cirugia</i> , 2010, 62, .	0.1	1
997	Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. <i>Tumori</i> , 2010, 96, 568-576.	0.6	9
999	Radiation Therapy for Colorectal Cancer. <i>Journal of the Korean Medical Association</i> , 2010, 53, 592.	0.1	4
1000	Preoperative chemoradiation and extended pelvic lymphadenectomy for rectal cancer: Two distinct principles. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 95.	0.8	14
1001	Chemotherapy for Colorectal Cancer. <i>Journal of the Korean Medical Association</i> , 2010, 53, 582.	0.1	4

#	ARTICLE	IF	CITATIONS
1002	Preoperative Radiotherapy and Concurrent Chemotherapy with Bolus 5-Fluorouracil for Rectal Cancer: A Prospective Analysis of 98 Patients. <i>Tumori</i> , 2010, 96, 709-712.	0.6	2
1003	Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer. <i>Oncology Letters</i> , 2010, 1, 189-194.	0.8	4
1004	Target Volume Delineation for Preoperative Radiotherapy of Rectal Cancer: Inter-Observer Variability and Potential Impact of FDG-PET/CT Imaging. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 393-398.	0.8	35
1005	Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. <i>Journal of Clinical Pathology</i> , 2010, 63, 873-878.	1.0	28
1008	Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy. <i>Radiographics</i> , 2010, 30, 503-516.	1.4	103
1009	Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2010, 15, 577-583.	1.9	84
1010	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v82-v86.	0.6	86
1011	A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2010, 15, 845-851.	1.9	55
1012	Is the NSABP R-03 Study in Line With Other Chemoradiation Studies?. <i>Journal of Clinical Oncology</i> , 2010, 28, e305-e306.	0.8	1
1013	Effectiveness of Neoadjuvant Radiotherapy in the Treatment of Locally Advanced Rectal Cancer: A Single-Center Experience in 263 Patients. <i>Digestive Surgery</i> , 2010, 27, 217-223.	0.6	6
1014	Accurate Staging, Selective Preoperative Therapy and Optimal Surgery Can Deliver a Good Oncological and Functional Outcome in Low Rectal Cancer. <i>Digestive Surgery</i> , 2010, 27, 182-184.	0.6	1
1015	Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging-Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 859-865.	0.8	404
1016	Retroperitoneal and Lateral Pelvic Lymphadenectomy Mapped by Lymphoscintigraphy for Rectal Adenocarcinoma Staging. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 746-753.	0.6	10
1017	Octreotide Acetate in Prevention of Chemoradiation-Induced Diarrhea in Anorectal Cancer: Randomized RTOG Trial 0315. <i>Journal of the National Cancer Institute</i> , 2010, 102, 547-556.	3.0	36
1018	Analysis of patients with complete histopathological tumour regression after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. <i>Archive of Oncology</i> , 2010, 18, 3-7.	0.2	0
1019	Adjuvant chemotherapy in rectal cancer—“an issue or a nonissue?”. <i>Annals of Oncology</i> , 2010, 21, 1739-1741.	0.6	19
1020	Phase II Study of Pre-Operative Radiotherapy with Capecitabine and Oxaliplatin for Rectal Cancer and Carcinoembryonic Antigen as a Predictor of Pathological Tumour Response. <i>Journal of International Medical Research</i> , 2010, 38, 645-654.	0.4	12
1021	Preoperative chemoradiotherapy for rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 129-130.	12.5	14

#	ARTICLE	IF	CITATIONS
1022	Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2064-2069.	0.8	250
1023	Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes. <i>Journal of Clinical Oncology</i> , 2010, 28, 256-263.	0.8	204
1024	Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 439-450.	1.1	6
1025	Bacillus Calmette-Guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. <i>Autophagy</i> , 2010, 6, 46-60.	4.3	74
1026	Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. <i>Annals of Oncology</i> , 2010, 21, 1743-1750.	0.6	141
1027	Imaging as a surveillance tool in rectal cancer. <i>Expert Review of Medical Devices</i> , 2010, 7, 99-112.	1.4	3
1028	High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers. <i>World Journal of Gastroenterology</i> , 2010, 16, 4436.	1.4	12
1029	Case 19-2010. <i>New England Journal of Medicine</i> , 2010, 362, 2411-2419.	13.9	0
1030	MRI in T staging of rectal cancer: How effective is it?. <i>Indian Journal of Radiology and Imaging</i> , 2010, 20, 118-121.	0.3	17
1031	Cetuximab and chemoradiation for rectal cancer—“is the water getting muddy?”. <i>Acta Oncologica</i> , 2010, 49, 278-286.	0.8	64
1032	Local Excision Following Pre-operative Chemoradiotherapy-induced Downstaging for Selected cT3 Distal Rectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 754-760.	0.6	22
1033	A Pilot Feasibility Study of TNFerade, a Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer. <i>Oncology</i> , 2010, 79, 382-388.	0.9	29
1034	Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. <i>Modern Pathology</i> , 2010, 23, 961-971.	2.9	17
1035	Restaging Locally Advanced Rectal Cancer with MR Imaging after Chemoradiation Therapy. <i>Radiographics</i> , 2010, 30, 699-716.	1.4	84
1036	S3 Guidelines for Colorectal Carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2010, 48, 65-136.	0.2	91
1038	Chemoradiotherapy in Rectal Cancer. <i>Current Drug Therapy</i> , 2010, 5, 211-219.	0.2	0
1040	Enterocutaneous Fistula Associated with Malignancy and Prior Radiation Therapy. <i>Clinics in Colon and Rectal Surgery</i> , 2010, 23, 176-181.	0.5	17
1042	Complete Clinical Response after Neoadjuvant Chemoradiation for Distal Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 829-845.	0.6	65

#	ARTICLE	IF	CITATIONS
1043	Laparoscopic Total Mesorectal Excision for Rectal Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2010, 21, 75-80.	0.2	2
1044	18F-FDG PET bio-metabolic monitoring of neoadjuvant therapy effects in rectal cancer: Focus on nodal disease characteristics. <i>Radiotherapy and Oncology</i> , 2010, 97, 212-216.	0.3	15
1045	Minimizing the Therapy-Related Morbidity in the Rectal Cancer Patient. <i>Seminars in Colon and Rectal Surgery</i> , 2010, 21, 120-125.	0.2	0
1046	Randomized Clinical Trials in Rectal and Anal Cancers. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 205-223.	0.6	8
1047	Targeted Therapeutic Agents for Colorectal Cancer. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 601-613.	1.0	22
1048	Optimal Follow-Up to Curative Colon and Rectal Cancer Surgery: How and for How Long?. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 861-873.	0.6	6
1049	Multidisciplinary Approach to Recurrent/Unresectable Rectal Cancer: How to Prepare for the Extent of Resection. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 847-859.	0.6	17
1050	Abdominoperineal Resections for Rectal Cancer: Reducing the Risk of Local Recurrence. <i>Seminars in Colon and Rectal Surgery</i> , 2010, 21, 81-86.	0.2	2
1051	Heilung und Restitution: Teil 2 von 3: Anastomosenheilung. <i>Perioperative Medizin</i> , 2010, 2, 137-147.	0.1	1
1052	Treatment of Colorectal Cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 359-388.	0.1	0
1053	Rektumkarzinom. <i>DoctorConsult - the Journal Wissen Fur Klinik Und Praxis</i> , 2010, 1, 23-29.	0.0	0
1054	Nonoperative Management of Rectal Cancer: Current Perspectives. <i>Clinical Colorectal Cancer</i> , 2010, 9, 83-88.	1.0	11
1055	A Phase I Study of Bortezomib in Combination With Standard 5-Fluorouracil and External-Beam Radiation Therapy for the Treatment of Locally Advanced or Metastatic Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 119-125.	1.0	27
1056	Timing of Adjuvant and Neoadjuvant Therapy in Colorectal Cancers. <i>Clinical Colorectal Cancer</i> , 2010, 9, 144-149.	1.0	13
1057	Staging rectal cancer. <i>Radiologia</i> , 2010, 52, 18-29.	0.3	10
1058	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
1059	T4 and Recurrent Rectal Cancer. , 2010, , 109-121.		1
1060	Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2. <i>Journal of Clinical Oncology</i> , 2010, 28, 1638-1644.	0.8	686

#	ARTICLE	IF	CITATIONS
1061	XRCC1 Gene Polymorphism for Prediction of Response and Prognosis in the Multimodality Therapy of Patients with Locally Advanced Rectal Cancer. <i>Journal of Surgical Research</i> , 2010, 164, e61-e66.	0.8	23
1063	Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2010, 14, 530-534.	0.6	51
1064	Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. <i>Cancer Treatment Reviews</i> , 2010, 36, 400-409.	3.4	9
1065	Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. <i>Cancer Treatment Reviews</i> , 2010, 36, 539-549.	3.4	37
1066	Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum – Toxicity and complications of the treatment. <i>European Journal of Surgical Oncology</i> , 2010, 36, 251-256.	0.5	4
1067	Clinical outcome in 520 consecutive Danish rectal cancer patients treated with short course preoperative radiotherapy. <i>European Journal of Surgical Oncology</i> , 2010, 36, 237-243.	0.5	12
1068	A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. <i>European Journal of Surgical Oncology</i> , 2010, 36, 244-250.	0.5	50
1069	Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1061-1065.	0.5	67
1070	Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1180-1186.	0.5	55
1071	Preoperative decision making for rectal cancer. <i>American Journal of Surgery</i> , 2010, 200, 426-432.	0.9	18
1072	The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. <i>American Journal of Surgery</i> , 2010, 200, 440-445.	0.9	26
1073	Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. <i>Pharmacogenomics</i> , 2010, 11, 747-761.	0.6	35
1074	Preoperative evaluation and treatment of rectal cancer. <i>Community Oncology</i> , 2010, 7, 131-135.	0.2	0
1075	Colorectal cancer OncoGuia. <i>Clinical and Translational Oncology</i> , 2010, 12, 188-210.	1.2	10
1076	KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2010, 94, 76-81.	0.3	90
1077	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. <i>Radiotherapy and Oncology</i> , 2010, 94, 375-383.	0.3	32
1078	Prognostic impact of peritonealisation in rectal cancer treated with preoperative chemoradiotherapy: Extraperitoneal versus intraperitoneal rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 94, 353-358.	0.3	9
1079	Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: Sequential perfusion-CT findings. <i>Radiotherapy and Oncology</i> , 2010, 94, 156-160.	0.3	31

#	ARTICLE	IF	CITATIONS
1080	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 95, 303-307.	0.3	26
1081	The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer. <i>Radiotherapy and Oncology</i> , 2010, 97, 205-211.	0.3	29
1082	Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. <i>Radiotherapy and Oncology</i> , 2010, 96, 339-346.	0.3	50
1083	Colorectal cancer. <i>Lancet, The</i> , 2010, 375, 1030-1047.	6.3	1,318
1084	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	3.4	15
1085	Clinical Staging: Endoscopic Techniques. , 2010, , 1-19.		0
1086	Chemotherapy: Concurrent Delivery with Radiation Therapy. , 2010, , 165-174.		0
1087	Chemotherapy: Adjuvant and Neoadjuvant Approaches. , 2010, , 175-187.		0
1088	Radiation Therapy: Adjuvant vs. Neoadjuvant Therapy. , 2010, , 223-234.		0
1089	Radiation Therapy: Short Versus Long Course. , 2010, , 235-247.		0
1090	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. <i>Lancet Oncology, The</i> , 2010, 11, 241-248.	5.1	305
1091	Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. <i>Lancet Oncology, The</i> , 2010, 11, 637-645.	5.1	852
1092	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2010, 11, 835-844.	5.1	1,532
1093	Pretherapy Imaging of Rectal Cancers: ERUS or MRI?. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 733-741.	0.6	23
1094	The Natural History of Rectal Cancer 1908-2008: The Evolving Treatment of Rectal Cancer into the Twenty-First Century. <i>Seminars in Colon and Rectal Surgery</i> , 2010, 21, 56-74.	0.2	5
1095	Chemoradiation for Rectal Cancer: Rationale, Approaches, and Controversies. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 803-818.	0.6	5
1096	Adenocarcinoma of the Esophagogastric Junction. <i>Recent Results in Cancer Research</i> , 2010, , .	1.8	5
1097	Low Anterior Resection: Alternative Anastomotic Techniques. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 761-775.	0.6	1

#	ARTICLE	IF	CITATIONS
1098	Rectal cancer radiotherapy: Towards European consensus. <i>Acta Oncol</i> 2010, 49, 1206-1216.	0.8	32
1100	Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum. <i>International Journal of Hyperthermia</i> , 2010, 26, 108-117.	1.1	27
1101	The Role of Neoadjuvant Therapy in Sphincter-Saving Surgery for Mid and Distal Rectal Cancer. <i>Cancer Investigation</i> , 2010, 28, 259-267.	0.6	7
1102	Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2773-2780.	0.8	702
1103	Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2142-2143.	0.8	54
1104	Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1623-1631.	3.2	37
1105	Spectral Presaturation Inversion Recovery MR Imaging Sequence after Gadolinium Injection to Differentiate Fibrotic Scar Tissue and Neoplastic Strands in the Mesorectal Fat in Patients Undergoing Restaging of Rectal Carcinoma after Neoadjuvant Chemo- and Radiation Therapy. <i>Academic Radiology</i> , 2011, 18, 1365-1375.	1.3	6
1106	Bowel Function After Rectal Cancer Surgery: A Review of the Evidence. <i>Seminars in Colon and Rectal Surgery</i> , 2011, 22, 235-242.	0.2	3
1107	Multimodality Treatment and Timing for Rectal Cancer in Hereditary Colorectal Cancer Patients. <i>Seminars in Colon and Rectal Surgery</i> , 2011, 22, 137-140.	0.2	0
1108	Maximizing Rectal Cancer Results: TEM and TATA Techniques to Expand Sphincter Preservation. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 501-520.	0.6	49
1109	Accuracy of endoscopic ultrasound in staging and restaging patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 666-670.	0.7	30
1110	Histopathologic Analysis of the Anal Sphincter after Chemoradiation for Low Rectal Cancer. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 296-299.	0.2	3
1111	Adjuvant radiotherapy for rectal cancer: Recent results, new questions. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 17-22.	0.7	7
1112	The current landscape of locally advanced rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 649-659.	12.5	76
1113	Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 465-470.	0.8	6
1114	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. <i>Pharmacogenomics Journal</i> , 2011, 11, 214-226.	0.9	63
1115	Gastric Adenocarcinoma Surgery and Adjuvant Therapy. <i>Surgical Clinics of North America</i> , 2011, 91, 1039-1077.	0.5	25
1116	The current abdominoperineal resection: Oncological problems and surgical modifications for low rectal cancer. <i>Journal of Visceral Surgery</i> , 2011, 148, e85-e93.	0.4	38

#	ARTICLE	IF	CITATIONS
1117	Locally Advanced Rectal Cancer. <i>Drugs</i> , 2011, 71, 1153-1177.	4.9	27
1118	Case 13-2011. <i>New England Journal of Medicine</i> , 2011, 364, 1658-1668.	13.9	0
1119	A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. <i>Pharmacogenomics Journal</i> , 2011, 11, 437-443.	0.9	30
1120	Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer: Are current margin guidelines adequate for conformal therapy?. <i>Practical Radiation Oncology</i> , 2011, 1, 85-94.	1.1	19
1121	Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. <i>Carcinogenesis</i> , 2011, 32, 1824-1831.	1.3	85
1122	Tumeurs digestives : c'lon â€” rectum. , 2011, , 359-386.		0
1123	EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5161-5169.	3.2	42
1124	Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study. <i>Acta Oncol'gica</i> , 2011, 50, 1151-1157.	0.8	28
1125	The Right Study Design Is Needed to Find out which Patients Benefit from Preoperative Chemoradiotherapy for Intermediate Staged Rectal Cancer. <i>Onkologie</i> , 2011, 34, 6-8.	1.1	2
1126	<i>Gastrointestinal Oncology</i> . , 2011, , .		2
1127	Chemotherapy in Rectal Cancer: Variation in Utilization and Development of an Evidence-based Benchmark Rate of Optimal Chemotherapy Utilization. <i>Clinical Colorectal Cancer</i> , 2011, 10, 102-107.	1.0	6
1128	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 245-257.	1.0	20
1129	Nonoperative Approach to Locally Advanced Rectal Cancer After Neoadjuvant Combined Modality Therapy: Challenges and Opportunities From a Surgical Perspective. <i>Clinical Colorectal Cancer</i> , 2011, 10, 291-297.	1.0	6
1130	Progress in the Treatment of Locally Advanced Clinically Resectable Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 227-237.	1.0	10
1131	A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. <i>Cancer Letters</i> , 2011, 310, 134-139.	3.2	20
1133	Validity and reliability of the MSKCC Bowel Function instrument in a sample of Italian rectal cancer patients. <i>European Journal of Surgical Oncology</i> , 2011, 37, 589-596.	0.5	18
1134	Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 207-213.	1.0	57
1135	Amputation abdomino-p'rin'ale dans la prise en charge des cancers du bas rectum (1)Â: probl'omatique carcinologique et technique d'™ex'r'se. <i>Journal De Chirurgie Visc'rale</i> , 2011, 148, 98-107.	0.0	1

#	ARTICLE	IF	CITATIONS
1136	Oncological and Functional Outcomes of Intersphincteric Resection for Low Rectal Cancer. <i>Journal of Surgical Research</i> , 2011, 170, e93-e98.	0.8	41
1137	Neoadjuvant chemotherapy in lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 23-31.	0.2	3
1138	18F-FLT-PET for detection of rectal cancer. <i>Radiotherapy and Oncology</i> , 2011, 98, 357-359.	0.3	22
1139	Assessing the effectiveness of a guideline recommendation for pre-operative radiochemotherapy in rectal cancer. <i>Radiotherapy and Oncology</i> , 2011, 99, 142-147.	0.3	7
1140	The ESTRO Breur Lecture 2010: Toward a tailored patient approach in rectal cancer. <i>Radiotherapy and Oncology</i> , 2011, 100, 15-21.	0.3	20
1141	Preoperative Chemoradiotherapy (CRT) Followed by Laparoscopic Surgery for Rectal Cancer: Predictors of the Tumor Response and the Long-Term Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 431-438.	0.4	40
1142	Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 677-683.	0.4	57
1143	KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1032-1038.	0.4	46
1144	Late Patient-Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase III Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1017-1024.	0.4	87
1145	Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1025-1031.	0.4	16
1146	Tolerability of Combined Modality Therapy for Rectal Cancer in Elderly Patients Aged 75 Years and Older. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e735-e741.	0.4	60
1147	Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1319-1327.	0.4	24
1148	Quantification of Organ Motion During Chemoradiotherapy of Rectal Cancer Using Cone-Beam Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e431-e438.	0.4	36
1149	Abdominoperineal resection does not decrease quality of life in patients with low rectal cancer. <i>Clinics</i> , 2011, 66, 1035-1040.	0.6	29
1150	Nonoperative Management of Distal Rectal Cancer After Chemoradiation: Experience with the "Watch & Wait" Protocol. , 0, , .		4
1151	Radiation Therapy for Colorectal Adenocarcinoma: External Beam and Intraoperative Radiation Therapy. , 2011, , 185-200.		0
1152	Cancers of the Colon, Rectum, and Anus. <i>Medical Radiology</i> , 2011, , 777-799.	0.0	0
1153	MR imaging of the rectum, 3T vs. 1.5T. , 0, , 150-163.		0

#	ARTICLE	IF	CITATIONS
1154	Role of Tumor Tissue Analysis in Rectal Cancer Pharmacogenetics. , 0, , .		1
1155	Side Effects of Neoadjuvant Treatment in Locally Advanced Rectal Cancer. , 0, , .		0
1156	Tumor Markers of Neo-Adjuvant Chemo-Radiation Response in Rectal Cancer. , 2011, , .		0
1157	Expression of Hypoxia-inducible Factor 1 \pm Predicts Clinical Outcome after Preoperative Hyperthermo-chemoradiotherapy for Locally Advanced Rectal Cancer. Journal of Radiation Research, 2011, 52, 821-827.	0.8	19
1158	Predictors of Sensitivity to Preoperative Chemoradiotherapy of Rectal Adenocarcinoma. Tumori, 2011, 97, 717-723.	0.6	16
1159	Selection Criteria for the Radical Treatment of Locally Advanced Rectal Cancer. International Journal of Surgical Oncology, 2011, 2011, 1-9.	0.3	7
1160	Capecitabine in the management of colorectal cancer. Cancer Management and Research, 0, , 79.	0.9	11
1161	Ã€ propos de la 53e rÃ©union de l'American Society for Therapeutic Radiology and Oncology (Astro) Miami (Ã©tats-Unis), 2-6 octobre 2011. Bulletin Du Cancer, 2011, 98, 1524-1528.	0.6	0
1162	Laparoscopic Resection for Rectal Cancer and Circumferential Margin: Is It Time to Move on?. Diseases of the Colon and Rectum, 2011, 54, 1049-1052.	0.7	0
1164	Morbidity after Closure of a Defunctioning Loop Ileostomy. Acta Chirurgica Belgica, 2011, 111, 136-141.	0.2	44
1165	Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone. Annals of Surgery, 2011, 253, 711-719.	2.1	524
1166	Tailoring treatment of rectal adenocarcinoma. Anti-Cancer Drugs, 2011, 22, 362-370.	0.7	6
1167	New directions in neoadjuvant therapy for rectal cancer. Anti-Cancer Drugs, 2011, 22, 351-361.	0.7	0
1168	Accuracy of Endoscopic Ultrasound to Assess Tumor Response After Neoadjuvant Treatment in Rectal Cancer: Can We Trust the Findings?. Diseases of the Colon and Rectum, 2011, 54, 1141-1146.	0.7	42
1169	Prone or Lithotomy Positioning During an Abdominoperineal Resection for Rectal Cancer Results in Comparable Oncologic Outcomes. Diseases of the Colon and Rectum, 2011, 54, 939-946.	0.7	61
1170	Patient-Reported Outcomes After Neoadjuvant Chemoradiotherapy for Rectal Cancer. Annals of Surgery, 2011, 253, 71-77.	2.1	95
1171	Accuracy of Gadofosveset-enhanced MRI for Nodal Staging and Restaging in Rectal Cancer. Annals of Surgery, 2011, 253, 539-545.	2.1	128
1172	The need for effective radiosensitizing agents. Anti-Cancer Drugs, 2011, 22, 308-310.	0.7	7

#	ARTICLE	IF	CITATIONS
1173	Significance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy. American Journal of Surgical Pathology, 2011, 35, 127-134.	2.1	90
1174	Transanal Endoscopic Microsurgery for Residual Rectal Cancer After Neoadjuvant Chemoradiation Therapy Is Associated With Significant Immediate Pain and Hospital Readmission Rates. Diseases of the Colon and Rectum, 2011, 54, 545-551.	0.7	143
1175	Does Neoadjuvant Therapy Alter KRAS and/or MSI Results in Rectal Adenocarcinoma Testing?. American Journal of Surgical Pathology, 2011, 35, 1327-1330.	2.1	21
1176	The Prognostic Value of Lymph Node Ratio After Neoadjuvant Chemoradiation and Rectal Cancer Surgery. Diseases of the Colon and Rectum, 2011, 54, 171-175.	0.7	35
1177	Postgraduate Multidisciplinary Development Program: Impact on the Interpretation of Pelvic MRI in Patients With Rectal Cancer: A Clinical Audit in West Denmark. Diseases of the Colon and Rectum, 2011, 54, 328-334.	0.7	8
1178	Neoadjuvant Therapy in Rectal Cancer. Diseases of the Colon and Rectum, 2011, 54, 901-912.	0.7	91
1179	Antiproteasomal agents in rectal cancer. Anti-Cancer Drugs, 2011, 22, 341-350.	0.7	9
1180	Oxaliplatin as a radiosensitizing agent in rectal cancer. Anti-Cancer Drugs, 2011, 22, 317-323.	0.7	7
1181	Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. Anti-Cancer Drugs, 2011, 22, 185-190.	0.7	5
1182	Irinotecan and radiosensitization in rectal cancer. Anti-Cancer Drugs, 2011, 22, 324-329.	0.7	19
1183	The Role of Carcinoembryonic Antigen After Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer. Diseases of the Colon and Rectum, 2011, 54, 245-252.	0.7	55
1184	Prognostic Value of Tumor Response to Neoadjuvant Therapy in Rectal Carcinoma. Diseases of the Colon and Rectum, 2011, 54, 401-411.	0.7	40
1185	Antiepidermal growth factor receptor radiosensitizers in rectal cancer. Anti-Cancer Drugs, 2011, 22, 330-340.	0.7	10
1186	Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer. Anti-Cancer Drugs, 2011, 22, 311-316.	0.7	14
1187	Optimal Timing of Surgery After Chemoradiation for Advanced Rectal Cancer. Annals of Surgery, 2011, 254, 97-102.	2.1	272
1188	Timing of Radiation Therapy, Lymph Node Retrieval, and Survival in Rectal Cancer. Diseases of the Colon and Rectum, 2011, 54, 526-534.	0.7	4
1189	Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. International Journal of Oncology, 2011, 38, 655-63.	1.4	83
1190	Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World Journal of Gastroenterology, 2011, 17, 1674.	1.4	73

#	ARTICLE	IF	CITATIONS
1191	Superiority of laparoscopic rectal surgery: Towards a new era. <i>World Journal of Gastrointestinal Surgery</i> , 2011, 3, 142.	0.8	0
1192	Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. <i>International Journal of Oncology</i> , 2011, 40, 583-91.	1.4	16
1193	Influence of pT3 Subgroups on Outcome of R0-Resected Colorectal Tumors. <i>Southern Medical Journal</i> , 2011, 104, 722-730.	0.3	6
1194	Individualized magnetic resonance imaging-based neoadjuvant chemoradiation for middle and lower rectal carcinoma. <i>Colorectal Disease</i> , 2011, 13, 39-47.	0.7	11
1195	Management and results of complications after anterior resection with colonic pouch reconstruction for rectal cancer. <i>Colorectal Disease</i> , 2011, 13, 284-289.	0.7	5
1196	Changes in the management and outcome of rectal cancer over a 10-year period in Oxford. <i>Colorectal Disease</i> , 2011, 13, 1004-1008.	0.7	7
1197	Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. <i>Colorectal Disease</i> , 2011, 13, 989-998.	0.7	21
1198	Histological grading of tumour regression and radiation colitis in locally advanced rectal cancer following neoadjuvant therapy: a critical appraisal. <i>Colorectal Disease</i> , 2011, 13, 1100-1106.	0.7	38
1199	Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients. <i>Colorectal Disease</i> , 2011, 13, 1344-1350.	0.7	8
1200	Does long-course radiotherapy influence postoperative perineal morbidity after abdominoperineal resection of the rectum for cancer?. <i>Colorectal Disease</i> , 2011, 13, 1407-1412.	0.7	17
1201	Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. <i>Colorectal Disease</i> , 2011, 13, 1353-1360.	0.7	30
1202	Commentary on Murad-Regadas etÂal.. <i>Colorectal Disease</i> , 2011, 13, 1351-1352.	0.7	0
1203	South Australian clinical registry for metastatic colorectal cancer. <i>ANZ Journal of Surgery</i> , 2011, 81, 352-357.	0.3	49
1204	Surgical oncology issues in locally advanced rectal cancer. <i>ANZ Journal of Surgery</i> , 2011, 81, 790-796.	0.3	2
1205	Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer. <i>Cancer Science</i> , 2011, 102, 1257-1263.	1.7	61
1206	Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy?. <i>Histopathology</i> , 2011, 59, 650-659.	1.6	16
1207	Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. <i>Surgery</i> , 2011, 149, 56-64.	1.0	63
1208	Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: Are they comparable?. <i>Surgery</i> , 2011, 150, 980-984.	1.0	14

#	ARTICLE	IF	CITATIONS
1209	Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials. <i>Surgery</i> , 2011, 150, 466-473.	1.0	183
1210	Rectal cancer surgery: A brief history. <i>Surgical Oncology</i> , 2011, 20, 223-230.	0.8	45
1211	Clinical impact of lymph node status in rectal cancer. <i>Surgical Oncology</i> , 2011, 20, e227-e233.	0.8	21
1212	Introduction: Current Controversies in Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 167-168.	1.0	0
1213	How Low is Low? Evolving Approaches to Sphincter-Sparing Resection Techniques. <i>Seminars in Radiation Oncology</i> , 2011, 21, 185-195.	1.0	2
1214	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. <i>Seminars in Radiation Oncology</i> , 2011, 21, 196-202.	1.0	8
1215	Beyond 5-Fluorouracil: The Emerging Role of Newer Chemotherapeutics and Targeted Agents with Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2011, 21, 203-211.	1.0	4
1216	T3N0 Rectal Cancer: Radiation for All?. <i>Seminars in Radiation Oncology</i> , 2011, 21, 212-219.	1.0	21
1217	Point: Short-Course Radiation Therapy Is Preferable in the Neoadjuvant Treatment of Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 220-227.	1.0	30
1218	Counterpoint: Long-Course Chemoradiation Is Preferable in the Neoadjuvant Treatment of Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 228-233.	1.0	15
1219	Nonoperative Approaches to Rectal Cancer: A Critical Evaluation. <i>Seminars in Radiation Oncology</i> , 2011, 21, 234-239.	1.0	101
1220	Unique Considerations in the Patient With Rectal Cancer. <i>Seminars in Oncology</i> , 2011, 38, 542-551.	0.8	18
1221	The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. <i>BMC Surgery</i> , 2011, 11, 34.	0.6	69
1222	Extending the role of Transanal Endoscopic Microsurgery (TEM) in rectal cancer. <i>Colorectal Disease</i> , 2011, 13, 32-36.	0.7	28
1223	Molecular Diagnosis of Response to Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2011, 212, 1008-1017e1.	0.2	31
1224	Pushing the Envelope Beyond a Centimeter in Rectal Cancer: Oncologic Implications of Close, But Negative Margins. <i>Journal of the American College of Surgeons</i> , 2011, 213, 589-595.	0.2	50
1225	Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: A randomised double blinded, placebo controlled pilot study. <i>Clinical Nutrition</i> , 2011, 30, 567-570.	2.3	32
1226	Pelvic exenteration for men with locally advanced rectal cancer: A morbidity analysis of complicated cases. <i>Asian Journal of Surgery</i> , 2011, 34, 115-120.	0.2	10

#	ARTICLE	IF	CITATIONS
1227	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3163-3172.	0.8	439
1228	The role of radiochemotherapy in the multimodal treatment of pancreatic ductal adenocarcinoma: Standard procedure or individual decision?. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 260-264.	0.3	0
1229	Prognostic Value of Quality of Life and Pain in Patients with Locally Recurrent Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 989-996.	0.7	68
1230	2010 SSO John Wayne Clinical Research Lecture: Rectal Cancer Outcome Improvements in Europe: Population-Based Outcome Registrations will Conquer the World. <i>Annals of Surgical Oncology</i> , 2011, 18, 691-696.	0.7	11
1231	Effectiveness of Image-Guided Radiotherapy for Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 380-385.	0.7	9
1232	Radiation-Induced Bowel Complications: Laparoscopic Versus Open Staging of Gynecologic Malignancy. <i>Annals of Surgical Oncology</i> , 2011, 18, 782-791.	0.7	28
1233	Using Gene Expression Profiling to Predict Response and Prognosis in Gastrointestinal Cancers—The Promise and the Perils. <i>Annals of Surgical Oncology</i> , 2011, 18, 1484-1491.	0.7	28
1234	Clinicopathological Assessment of Locally Recurrent Rectal Cancer and Relation to Local Re-Recurrence. <i>Annals of Surgical Oncology</i> , 2011, 18, 1015-1022.	0.7	18
1235	Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer Decreases Distant Recurrence and Could Eradicate Local Recurrence. <i>Annals of Surgical Oncology</i> , 2011, 18, 1590-1598.	0.7	165
1236	The Impact of the Introduction of Total Mesorectal Excision on Local Recurrence Rate and Survival in Rectal Cancer: Long-Term Results. <i>Annals of Surgical Oncology</i> , 2011, 18, 1899-1906.	0.7	88
1237	Diffusion-Weighted MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 2224-2231.	0.7	335
1238	Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment. <i>Annals of Surgical Oncology</i> , 2011, 18, 2442-2452.	0.7	16
1239	Mucinous Rectal Cancer: Effectiveness of Preoperative Chemoradiotherapy and Prognosis. <i>Annals of Surgical Oncology</i> , 2011, 18, 2232-2239.	0.7	77
1240	Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 2783-2789.	0.7	34
1241	Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2011, 18, 2461-2468.	0.7	114
1242	MRI-Based Indications for Neoadjuvant Radiochemotherapy in Rectal Carcinoma: Interim Results of a Prospective Multicenter Observational Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 2790-2799.	0.7	36
1243	Clinical Significance of Pre- to Post-Chemoradiotherapy s-CEA Reduction Ratio in Rectal Cancer Patients Treated with Preoperative Chemoradiotherapy and Curative Resection. <i>Annals of Surgical Oncology</i> , 2011, 18, 3271-3277.	0.7	42
1244	Recurrence Rates and Prognostic Factors in ypNO Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision. <i>Annals of Surgical Oncology</i> , 2011, 18, 3666-3672.	0.7	40

#	ARTICLE	IF	CITATIONS
1245	Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies. <i>Annals of Surgical Oncology</i> , 2011, 18, 3686-3693.	0.7	81
1246	Protective Effects of Melatonin and Octreotide Against Radiation-Induced Intestinal Injury. <i>Digestive Diseases and Sciences</i> , 2011, 56, 359-367.	1.1	19
1247	True local recurrences do not metastasize. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 161-176.	2.7	12
1248	Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI. <i>Molecular Imaging and Biology</i> , 2011, 13, 1011-1019.	1.3	27
1249	Laparoscopic resection for rectal cancer: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 278-283.	1.3	30
1250	Laparoscopic total mesorectal excision following long course chemoradiotherapy for locally advanced rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 1753-1760.	1.3	13
1251	Laparoscopic extraperitoneal rectal cancer surgery: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 2423-2440.	1.3	35
1252	Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2011, 26, 45-51.	1.0	29
1253	Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. <i>International Journal of Colorectal Disease</i> , 2011, 26, 153-164.	1.0	4
1254	Signet ring cell histology and non-circumferential tumors predict pathological complete response following neoadjuvant chemoradiation in rectal cancers. <i>International Journal of Colorectal Disease</i> , 2011, 26, 23-27.	1.0	26
1255	Laparoscopic-assisted versus open surgery for rectal cancer: a meta-analysis of randomized controlled trials on oncologic adequacy of resection and long-term oncologic outcomes. <i>International Journal of Colorectal Disease</i> , 2011, 26, 415-421.	1.0	110
1256	Surgical resection of locally advanced primary transverse colon cancerâ€™not a worse outcome in stage II tumor. <i>International Journal of Colorectal Disease</i> , 2011, 26, 859-865.	1.0	6
1257	Evaluation of quality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management. <i>International Journal of Colorectal Disease</i> , 2011, 26, 903-909.	1.0	11
1258	Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer. <i>International Journal of Colorectal Disease</i> , 2011, 26, 911-917.	1.0	6
1259	Prognostic significance of lateral lymph node dissection in node positive low rectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2011, 26, 881-889.	1.0	18
1260	High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1019-1023.	1.0	24
1261	Î²-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1127-1134.	1.0	16
1262	Extended abdominoperineal excision vs. standard abdominoperineal excision in rectal cancerâ€™a systematic overview. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1227-1240.	1.0	125

#	ARTICLE	IF	CITATIONS
1263	Factors affecting management decisions in rectal cancer in clinical practice: results from a national survey. <i>Techniques in Coloproctology</i> , 2011, 15, 45-51.	0.8	13
1264	Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. <i>Angiogenesis</i> , 2011, 14, 481-489.	3.7	19
1265	Long-term urinary adverse effects of pelvic radiotherapy. <i>World Journal of Urology</i> , 2011, 29, 35-41.	1.2	57
1266	Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 100-107.	1.0	23
1267	Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 120-126.	1.0	9
1268	Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 225-230.	1.0	27
1270	MDCT with multiplanar reconstruction in the preoperative local staging of rectal tumor. <i>Abdominal Imaging</i> , 2011, 36, 31-37.	2.0	34
1271	Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. <i>Abdominal Imaging</i> , 2011, 36, 38-45.	2.0	37
1272	Diffusion-weighted Magnetic Resonance Imaging for Detecting Lymph Node Metastasis of Rectal Cancer. <i>World Journal of Surgery</i> , 2011, 35, 895-899.	0.8	96
1273	Risk Factors for Persistent Anal Incontinence After Restorative Proctectomy in Rectal Cancer Patients with Anal Incontinence: Prospective Cohort Study. <i>World Journal of Surgery</i> , 2011, 35, 1918-1924.	0.8	11
1274	Multidisciplinary Discussion and Management of Rectal Cancer: A Population-based Study. <i>World Journal of Surgery</i> , 2011, 35, 2125-2133.	0.8	38
1275	Locally Advanced Mid/Low Rectal Cancer with Synchronous Liver Metastases. <i>World Journal of Surgery</i> , 2011, 35, 2788-2795.	0.8	29
1277	Gastric Cancer. <i>Current Problems in Cancer</i> , 2011, 35, 97-127.	1.0	10
1278	Immunexpression of Ki-67 and p53 in Rectal Cancer Tissue After Treatment with Neoadjuvant Chemoradiation. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 34-39.	0.6	4
1279	Radiotherapy in rectal cancer: development, adequacy and radiotherapy utilisation rate. A comparative analysis with the most frequent tumour sites. <i>Clinical and Translational Oncology</i> , 2011, 13, 115-120.	1.2	0
1280	Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 862-868.	1.2	1
1281	(Neo-)Adjuvant radiochemotherapy in stage II/III rectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 90-93.	0.3	1
1282	Neoadjuvant Therapy for Rectal Cancer: The Impact of Longer Interval Between Chemoradiation and Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 444-450.	0.9	130

#	ARTICLE	IF	CITATIONS
1283	Effects of Postoperative Adjuvant Radiotherapy on Recurrence and Survival in Stage III Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 963-970.	0.9	12
1284	Preoperative Radiotherapy Combined with Capecitabine Chemotherapy in Chinese Patients with Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1858-1865.	0.9	4
1285	What is the Impact of the Addition of Oxaliplatin to 5-Fluorouracil-Based Preoperative Chemoradiation in Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 1-4.	1.0	1
1286	One Size Does Not Fit All: Planning Volumes for Radiotherapy in Rectal Cancer—Should We Tailor Radiotherapy Fields to Stage and Risk?. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 89-96.	1.0	0
1287	Why and How Should We Measure the Long-Term Consequences of Rectal Cancer Treatment?. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 97-104.	1.0	1
1288	Updates on Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 200-210.	1.0	0
1289	Update on Treatment Advances in Combined-Modality Therapy for Anal and Rectal Carcinomas. <i>Current Oncology Reports</i> , 2011, 13, 177-185.	1.8	9
1290	Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). <i>BMC Cancer</i> , 2011, 11, 346.	1.1	93
1291	Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. <i>BMC Cancer</i> , 2011, 11, 363.	1.1	40
1292	Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. <i>BMC Cancer</i> , 2011, 11, 64.	1.1	99
1293	Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. <i>BMC Cancer</i> , 2011, 11, 98.	1.1	13
1294	Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. <i>World Journal of Surgical Oncology</i> , 2011, 9, 117.	0.8	24
1295	Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. <i>Radiation Oncology</i> , 2011, 6, 105.	1.2	81
1296	Radiotherapy and "new" drugs—new side effects?. <i>Radiation Oncology</i> , 2011, 6, 177.	1.2	53
1297	Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. <i>Radiation Oncology</i> , 2011, 6, 49.	1.2	100
1298	Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. <i>Radiation Oncology</i> , 2011, 6, 63.	1.2	76
1299	Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29. <i>Radiation Oncology</i> , 2011, 6, 93.	1.2	34
1300	Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. <i>Radiation Oncology</i> , 2011, 6, 99.	1.2	35

#	ARTICLE	IF	CITATIONS
1301	Psychological well-being outcomes in disease-free survivors of mid- to low rectal cancer following curative surgery. <i>Psycho-Oncology</i> , 2011, 20, 706-714.	1.0	21
1302	¹⁸ Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2011, 103, 17-24.	0.8	31
1303	High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved?. <i>Journal of Surgical Oncology</i> , 2011, 103, 105-109.	0.8	80
1304	The role of radiation therapy in the control of locoregional and metastatic cancer. <i>Journal of Surgical Oncology</i> , 2011, 103, 627-638.	0.8	7
1305	Prognostic impact of the Lymph node ratio in rectal cancer patients who underwent preoperative chemoradiation. <i>Journal of Surgical Oncology</i> , 2011, 104, 53-58.	0.8	30
1306	Postoperative adjuvant chemotherapy in patients with ypN+ after preoperative chemoradiation for rectal cancer: Need for randomized trials. <i>Journal of Surgical Oncology</i> , 2011, 104, 859-860.	0.8	3
1307	Local staging of rectal cancer: A review of imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1012-1019.	1.9	80
1308	Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile?. <i>Cancer</i> , 2011, 117, 2853-2862.	2.0	39
1309	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , 2011, 117, 3118-3125.	2.0	93
1310	Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. <i>Cancer</i> , 2011, 117, 3703-3712.	2.0	122
1311	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. <i>Cancer</i> , 2011, 117, 3713-3722.	2.0	51
1312	<i>EGFR</i> and <i>HER3</i> mRNA expression levels predict distant metastases in locally advanced rectal cancer. <i>International Journal of Cancer</i> , 2011, 128, 2938-2946.	2.3	18
1313	Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. <i>British Journal of Surgery</i> , 2011, 98, 418-426.	0.1	90
1314	Outcomes following a limited approach to radiotherapy in rectal cancer. <i>British Journal of Surgery</i> , 2011, 98, 1483-1488.	0.1	15
1315	Outcomes following surgery without radiotherapy for rectal cancer. <i>British Journal of Surgery</i> , 2011, 99, 137-143.	0.1	68
1316	Combined Modality Therapy Including Intraoperative Electron Irradiation for Locally Recurrent Colorectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 143-150.	0.4	117
1317	A Phase II Trial of Neoadjuvant Preoperative Chemoradiotherapy With S-1 Plus Irinotecan and Radiation in Patients With Locally Advanced Rectal Cancer: Clinical Feasibility and Response Rate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 677-683.	0.4	52
1318	Phase I Study of Preoperative Chemoradiation With S-1 and Oxaliplatin in Patients With Locally Advanced Resectable Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 684-689.	0.4	7

#	ARTICLE	IF	CITATIONS
1319	Oxaliplatin Plus Dual Inhibition of Thymidilate Synthase During Preoperative Pelvic Radiotherapy for Locally Advanced Rectal Carcinoma: Long-Term Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 670-676.	0.4	25
1320	Preoperative Chemoradiation With Irinotecan and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: Long-Term Results of a Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1171-1178.	0.4	35
1321	Predictive Factors of Tumor Response After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 483-491.	0.4	68
1322	Bevacizumab, Capecitabine, Amifostine, and Preoperative Hypofractionated Accelerated Radiotherapy (HypoArc) for Rectal Cancer: A Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 492-498.	0.4	28
1323	Impact of Sequencing of Postmastectomy Radiotherapy and Breast Reconstruction on Timing and Rate of Complications and Patient Satisfaction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 392-397.	0.4	45
1324	Patterns of Response After Preoperative Treatment in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 698-704.	0.4	16
1325	Nuclear Factor κ -Light Chain-Enhancer of Activated B Cells is Activated by Radiotherapy and is Prognostic for Overall Survival in Patients With Rectal Cancer Treated With Preoperative Fluorouracil-Based Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 705-711.	0.4	17
1326	Evaluation of Biologic Effective Dose and Schedule of Fractionation for Preoperative Radiotherapy for Rectal Cancer: Meta-Analyses and Meta-Regression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 985-991.	0.4	29
1327	Adoption of Preoperative Radiation Therapy for Rectal Cancer From 2000 to 2006: A Surveillance, Epidemiology, and End Results Patterns-of-Care Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 978-984.	0.4	18
1328	Preoperative Chemoradiation for Rectal Cancer Using Capecitabine and Celecoxib Correlated With Posttreatment Assessment of Thymidilate Synthase and Thymidine Phosphorylase Expression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1377-1382.	0.4	10
1329	Will There be a Future Role for Radiation in the Neo-Adjuvant Therapy for Rectal Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 643-644.	0.4	3
1330	Clinical Significance of CD133 and Hypoxia Inducible Factor-1 α Gene Expression in Rectal Cancer after Preoperative Chemoradiotherapy. <i>Clinical Oncology</i> , 2011, 23, 323-332.	0.6	32
1331	Chemoradiation therapy in the management of gastrointestinal malignancies. <i>Future Oncology</i> , 2011, 7, 409-426.	1.1	7
1332	Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 1515-1518.	0.6	1
1334	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 107-113.	12.5	28
1335	Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy. <i>International Journal of Hyperthermia</i> , 2011, 27, 482-490.	1.1	18
1336	Reply to R. Glynne-Jones. <i>Journal of Clinical Oncology</i> , 2011, 29, 4060-4061.	0.8	0
1337	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Genes Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4145-4154.	3.2	28

#	ARTICLE	IF	CITATIONS
1338	Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3469-3477.	3.2	51
1339	Preoperative Chemoradiotherapy Using Concurrent Capecitabine and Irinotecan in Magnetic Resonance Imaging-Defined Locally Advanced Rectal Cancer: Impact on Long-Term Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2011, 29, 1042-1049.	0.8	48
1340	Absence of MMP2 Expression Correlates with Poor Clinical Outcomes in Rectal Cancer, and Is Distinct from MMP1-Related Outcomes in Colon Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4167-4176.	3.2	29
1341	Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging-Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study. <i>Oncologist</i> , 2011, 16, 614-620.	1.9	142
1342	Challenging the Feasibility and Clinical Significance of Current Guidelines on Lymph Node Examination in Rectal Cancer in the Era of Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 4568-4573.	0.8	80
1343	Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy. <i>Cancers</i> , 2011, 3, 2176-2194.	1.7	30
1344	Neoadjuvant Treatment in Rectal Cancer: Actual Status. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-12.	1.6	24
1345	Colon Cancer Survival With Herbal Medicine and Vitamins Combined With Standard Therapy in a Whole-Systems Approach. <i>Integrative Cancer Therapies</i> , 2011, 10, 240-259.	0.8	38
1346	Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 875-883.	0.8	58
1347	Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. <i>Annals of Oncology</i> , 2011, 22, 650-656.	0.6	74
1348	Which Patients Benefit from Preoperative Chemoradiotherapy for Intermediate Staged Rectal Cancer?. <i>Onkologie</i> , 2011, 34, 36-41.	1.1	2
1351	Appendiceal Mucocele in an Elderly Patient: How Much Surgery?. <i>Case Reports in Gastroenterology</i> , 2011, 5, 516-522.	0.3	8
1352	Rectal Cancer Trials: No Movement. <i>Journal of Clinical Oncology</i> , 2011, 29, 2746-2748.	0.8	9
1353	Rectal Cancer: Assessment of Complete Response to Preoperative Combined Radiation Therapy with Chemotherapy- Conventional MR Volumetry versus Diffusion-weighted MR Imaging. <i>Radiology</i> , 2011, 260, 734-743.	3.6	234
1354	The Future of Rectal Cancer: Let's Do the Right Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 4057-4059.	0.8	9
1355	Short-Course Versus Standard Chemoradiation in T3 Rectal Cancer. <i>Oncologist</i> , 2011, 16, 717-721.	1.9	2
1356	Reply to M. Mohiuddin et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 2737-2738.	0.8	3
1357	Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. <i>British Journal of Cancer</i> , 2011, 105, 1654-1662.	2.9	49

#	ARTICLE	IF	CITATIONS
1358	Reproducibility of Depth of Extramural Tumor Spread and Distance to Circumferential Resection Margin at Rectal MRI: Enhancement of Clinical Guidelines for Neoadjuvant Therapy. <i>American Journal of Roentgenology</i> , 2011, 197, 1360-1366.	1.0	32
1359	Clinical MRI of the Abdomen. , 2011, , .		12
1360	Comparison of conventional and three-dimensional conformal CT planning techniques for preoperative chemoradiotherapy for locally advanced rectal cancer. <i>British Journal of Radiology</i> , 2011, 84, 173-178.	1.0	8
1361	Gender-specific Acute Organ Toxicity during Intensified Preoperative Radiochemotherapy for Rectal Cancer. <i>Oncologist</i> , 2011, 16, 621-631.	1.9	22
1362	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). <i>Annals of Oncology</i> , 2011, 22, 2424-2430.	0.6	57
1363	Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: Implications for adaptive dose escalation strategies. <i>Acta Oncologica</i> , 2012, 51, 318-324.	0.8	24
1364	Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T ₂ -weighted and PET/CT imaging. <i>British Journal of Radiology</i> , 2012, 85, 577-586.	1.0	105
1365	Intersphincteric Resection for Low Rectal Cancer: An Overview. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-4.	0.3	10
1366	Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. <i>Gut</i> , 2012, 61, 179-192.	6.1	234
1367	An evaluation of four CT-MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patients. <i>British Journal of Radiology</i> , 2012, 85, 61-68.	1.0	59
1368	Recently Published Indicators Allow for Comparison of Radiation Treatment Rates Relative to Evidence-Based Guidelines for Rectal Cancer. <i>Current Oncology</i> , 2012, 19, 175-176.	0.9	2
1369	Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. <i>Journal of Clinical Pathology</i> , 2012, 65, 687-692.	1.0	24
1370	Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	0.7	68
1371	Neo adjuvant chemo-radiotherapy and rectal cancer: Can India follow the West?. <i>Journal of Cancer Research and Therapeutics</i> , 2012, 8, 209.	0.3	8
1372	Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?. <i>Annals of Oncology</i> , 2012, 23, 2517-2526.	0.6	50
1373	Management of local rectal cancer: evidence, controversies and future perspectives in radiotherapy. <i>Colorectal Cancer</i> , 2012, 1, 163-177.	0.8	2
1374	Evaluating the Quality of Colorectal Cancer Care in the State of Florida: Results From the Florida Initiative for Quality Cancer Care. <i>Journal of Oncology Practice</i> , 2012, 8, 239-245.	2.5	13
1375	Positron Emission Tomography for Predicting Pathologic Response After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 334-339.	0.6	24

#	ARTICLE	IF	CITATIONS
1376	Noadjuvant Accelerated Concomitant Boost Radiotherapy and Multidrug Chemotherapy in Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 424-431.	0.6	16
1377	Impact of preoperative radiotherapy on survival in locally advanced rectal cancer. <i>European Journal of Cancer Prevention</i> , 2012, 21, 139-146.	0.6	6
1378	Treatment of locally advanced rectal cancer: Controversies and questions. <i>World Journal of Gastroenterology</i> , 2012, 18, 5521.	1.4	36
1379	MR Imaging for Preoperative Evaluation of Primary Rectal Cancer: Practical Considerations. <i>Radiographics</i> , 2012, 32, 389-409.	1.4	181
1380	A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. <i>Personalized Medicine</i> , 2012, 9, 547-557.	0.8	71
1381	Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. <i>Annals of Oncology</i> , 2012, 23, 2627-2633.	0.6	101
1382	Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 225-236.	0.4	38
1383	Short-term results of laparoscopic surgery after preoperative chemoradiation for clinically staged T_3 and T_4 rectal cancer. <i>Asian Journal of Endoscopic Surgery</i> , 2012, 5, 157-163.	0.4	7
1384	Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone. <i>International Journal of Hyperthermia</i> , 2012, 28, 707-714.	1.1	41
1385	Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer: Making Progress. <i>Journal of Clinical Oncology</i> , 2012, 30, 3777-3778.	0.8	54
1386	Elevated preoperative CEA is associated with worse survival in stage III rectal cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 266-274.	2.9	54
1387	Long-Term Follow-Up of a Paradigm-Changing Study: The Paradigm Still Holds. <i>Journal of Clinical Oncology</i> , 2012, 30, 1901-1903.	0.8	4
1388	Association between Anal Function and Therapeutic Effect after Preoperative Chemoradiotherapy followed by Intersphincteric Resection. <i>Digestive Surgery</i> , 2012, 29, 439-445.	0.6	12
1389	Progress in Rectal Cancer Treatment. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-15.	1.5	6
1390	Current Status of Intensified Neo-Adjuvant Systemic Therapy in Locally Advanced Rectal Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 47.	1.3	5
1391	Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-12.	0.3	13
1392	The Current State of Targeted Agents in Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-14.	0.3	8
1393	A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-7.	0.3	2

#	ARTICLE	IF	CITATIONS
1394	Intensity-Modulated Radiation Therapy for Rectal Carcinoma Can Reduce Treatment Breaks and Emergency Department Visits. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-7.	0.3	31
1395	Approach to Rectal Cancer Surgery. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-9.	0.3	4
1396	Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. <i>Annals of Oncology</i> , 2012, 23, 1525-1530.	0.6	140
1397	Rectal cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 441-447.	1.1	35
1398	An innovative approach for locally advanced stage III cutaneous melanoma. <i>Melanoma Research</i> , 2012, 22, 257-262.	0.6	13
1399	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. <i>Oncology Reports</i> , 2012, 27, 1849-56.	1.2	55
1400	Controversies in Radiation for Upper Rectal Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1567-1572.	2.3	14
1401	Tumor Scatter After Neoadjuvant Therapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 1206-1212.	0.7	60
1402	Pathologic Complete Response After FOLFOX7 in a Locally Advanced Rectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 87-88.	1.1	1
1403	Hypoxia-Related Proteins in Patients With Rectal Cancer Undergoing Neoadjuvant Combined Modality Therapy. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 990-995.	0.7	23
1405	Multidisciplinary Management of Early-Stage Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1577-1585.	2.3	4
1406	A Survival Analysis of the Liver-First Reversed Management of Advanced Simultaneous Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2012, 256, 772-779.	2.1	97
1407	Response prediction in the multimodality therapy of locally advanced rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 49-55.	0.8	1
1408	Evaluation of the Impact of Implementing the Prone Jackknife Position for the Perineal Phase of Abdominoperineal Excision of the Rectum. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 316-321.	0.7	24
1409	Optimal Lymph Node Harvest in Rectal Cancer (UICC Stages II and III) after Preoperative 5-FU-based Radiochemotherapy. Acetone Compression is a New and Highly Efficient Method. <i>American Journal of Surgical Pathology</i> , 2012, 36, 202-213.	2.1	34
1410	Pretreatment High-Resolution Rectal MRI and Treatment Response to Neoadjuvant Chemoradiation. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 371-377.	0.7	24
1411	Whole-Mount Pathologic Analysis of Rectal Cancer Following Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2012, 256, 274-279.	2.1	38
1412	Tumor Scatter and the Invisible Margin. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 1203-1205.	0.7	1

#	ARTICLE	IF	CITATIONS
1413	Is an Elective Diverting Colostomy Warranted in Patients With an Endoscopically Obstructing Rectal Cancer Before Neoadjuvant Chemotherapy?. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 249-255.	0.7	16
1414	Chromosomal Copy Number Alterations Are Associated with Persistent Lymph Node Metastasis After Chemoradiation in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 677-685.	0.7	16
1415	Hydroxymethylglutaryl-Coenzyme A Synthase 2 Expression Is Associated With Chemoradiotherapy Responses in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 686-694.	0.7	13
1416	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. <i>Annals of Surgery</i> , 2012, 256, 111-116.	2.1	63
1417	Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2012, 256, 965-972.	2.1	325
1418	Diversion with Neoadjuvant vs Surgery with Adjuvant Treatment for Obstructing Rectal Cancer?. <i>Diseases of the Colon and Rectum</i> , 2012, 55, e346.	0.7	1
1419	Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 695-702.	0.7	12
1420	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 287-289.	0.8	0
1421	microRNA expression is able to predict response to chemoradiotherapy in rectal cancer. <i>Molecular and Clinical Oncology</i> , 2012, 1, 137-142.	0.4	36
1423	Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1528-1564.	2.3	138
1424	Magnetic resonance imaging (MRI) versus computed tomography (CT) for the diagnosis of lymph node metastasis in preoperative rectal cancer. <i>The Cochrane Library</i> , 0, , .	1.5	1
1425	Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. <i>Radiology and Oncology</i> , 2012, 46, 252-7.	0.6	14
1426	A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial. <i>Yearbook of Oncology</i> , 2012, 2012, 142-144.	0.1	0
1427	The CROSS trial: end of the debate on neoadjuvant therapy for esophageal cancer?. <i>Clinical Practice (London, England)</i> , 2012, 9, 607-609.	0.1	0
1428	Organ-preserving therapy for rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 537-547.	0.8	0
1429	A century of abdominoperineal excision for rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 25-35.	0.8	3
1430	Role of radiotherapy for resectable rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 413-422.	0.8	0
1431	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2012, , 9-18.		0

#	ARTICLE	IF	CITATIONS
1432	Endorectal ultrasound for preoperative staging. , 2012, , 13-23.		0
1433	Selective non-operative management of distal rectal cancer: The Watch & Wait Protocol. , 2012, , 43-53.		2
1434	What Is the Role of IMRT and IGRT in Rectal Cancer?. , 2012, , 129-148.		0
1435	Intersphincteric resection of low rectal tumors: Experience from a German Cancer Center. , 2012, , 145-152.		0
1436	What Prognostic Clinical Factors Must Be Considered Before Treatment?. , 2012, , 21-26.		1
1437	How Can We Identify Tumour Penetration?. , 2012, , 59-65.		0
1438	When Should Preoperative Short-Course Radiotherapy or Long-Course Chemoradiotherapy Be Performed?. , 2012, , 105-116.		0
1441	Functional disorders after rectal cancer resection: does a rehabilitation programme improve anal continence and quality of life?. Colorectal Disease, 2012, 14, 1231-1237.	0.7	69
1442	Improved local control of rectal cancer reduces distant metastases. Colorectal Disease, 2012, 14, e668-78.	0.7	38
1443	Quality of rectal cancer surgery and its relationship to surgeon and hospital caseload: a population-based study. Colorectal Disease, 2012, 14, e692-700.	0.7	17
1444	Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Disease, 2012, 14, e701-7.	0.7	117
1445	The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa. Clinical Cancer Research, 2012, 18, 4919-4930.	3.2	174
1446	Outcomes of unselected patients with pathologic T3N0 rectal cancer. Radiotherapy and Oncology, 2012, 105, 214-219.	0.3	10
1447	Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer. Journal of Clinical Oncology, 2012, 30, 4558-4565.	0.8	360
1448	Postoperative adjuvant chemotherapy in rectal cancer operated for cure.. The Cochrane Library, 2012, , CD004078.	1.5	156
1449	Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer. International Journal of Clinical Oncology, 2012, 17, 482-490.	1.0	14
1450	Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology, The, 2012, 13, 579-588.	5.1	428
1451	Capecitabine in the treatment of rectal cancer. Lancet Oncology, The, 2012, 13, 560-561.	5.1	4

#	ARTICLE	IF	CITATIONS
1452	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 679-687.	5.1	585
1453	Rectal cancer—the times they are a-changing. <i>Lancet Oncology</i> , The, 2012, 13, 651-653.	5.1	9
1454	PG 1.01 Rectal cancer: what is the aim of multimodal therapy?. <i>European Journal of Cancer</i> , 2012, 48, S1.	1.3	0
1455	PG 1.02 Clinically relevant study end points in rectal cancer. <i>European Journal of Cancer</i> , 2012, 48, S1.	1.3	1
1456	PG 1.03 Neoadjuvant treatment: Do we need radiotherapy?. <i>European Journal of Cancer</i> , 2012, 48, S1-S2.	1.3	1
1457	MRI After Treatment of Locally Advanced Rectal Cancer: How to Report Tumor Response—the MERCURY Experience. <i>American Journal of Roentgenology</i> , 2012, 199, W486-W495.	1.0	158
1458	Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now: Table 1. <i>Journal of Clinical Pathology</i> , 2012, 65, 867-871.	1.0	48
1459	Contemporary perioperative care strategies. <i>British Journal of Surgery</i> , 2012, 100, 38-54.	0.1	39
1462	Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 926-932.	1.0	22
1463	Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 865-872.	1.0	5
1464	Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 833-838.	1.0	8
1465	Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Radiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 124-129.	0.4	90
1466	Rectal Cancer: Mucinous Carcinoma on Magnetic Resonance Imaging Indicates Poor Response to Neoadjuvant Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 842-848.	0.4	61
1467	Prognostic Significance of Human Apurinic/Apyrimidinic Endonuclease (APE/Ref-1) Expression in Rectal Cancer Treated With Preoperative Radiochemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 130-137.	0.4	8
1468	Preoperative Single Fraction Partial Breast Radiotherapy for Early-Stage Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 37-42.	0.4	68
1469	X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 138-144.	0.4	29
1470	Repeated Positron Emission Tomography-Computed Tomography and Perfusion-Computed Tomography Imaging in Rectal Cancer: Fluorodeoxyglucose Uptake Corresponds With Tumor Perfusion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 849-855.	0.4	11
1471	Stage-to-Stage Comparison of Preoperative and Postoperative Chemoradiotherapy for T3 Mid or Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 856-862.	0.4	18

#	ARTICLE	IF	CITATIONS
1472	Value of Diffusion-Weighted Magnetic Resonance Imaging for Prediction and Early Assessment of Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: Preliminary Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 863-870.	0.4	178
1473	Reduced Acute Bowel Toxicity in Patients Treated With Intensity-Modulated Radiotherapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1981-1987.	0.4	161
1474	Acute Toxicity of Radiochemotherapy in Rectal Cancer Patients: A Risk Particularly for Carriers of the TGF β 1 Pro25 variant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 149-157.	0.4	20
1475	Phase II Study of Preoperative Helical Tomotherapy With a Simultaneous Integrated Boost for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 142-148.	0.4	44
1476	Four-Week Neoadjuvant Intensity-Modulated Radiation Therapy With Concurrent Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer Patients: A Validation Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 587-593.	0.4	30
1477	Correlation in Rectal Cancer Between Clinical Tumor Response After Neoadjuvant Radiotherapy and Sphincter or Organ Preservation: 10-Year Results of the Lyon R 96-02 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e165-e171.	0.4	82
1478	Quality Assessment in Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 773-781.	0.4	38
1479	Fractures of the Sacrum After Chemoradiation for Rectal Carcinoma: Incidence, Risk Factors, and Radiographic Evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 694-699.	0.4	53
1480	Long-Term Follow-Up of Preoperative Pelvic Radiation Therapy and Concomitant Boost Irradiation in Locally Advanced Rectal Cancer Patients: A Multi-Institutional Phase II Study (KROG 04-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 955-961.	0.4	19
1481	Upregulation of Trefoil Factor 3 (TFF3) After Rectal Cancer Chemoradiotherapy Is an Adverse Prognostic Factor and a Potential Therapeutic Target. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1151-1158.	0.4	19
1482	Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer: Do All Patients Benefit From Waiting Longer Than 6 Weeks?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1159-1165.	0.4	76
1483	Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation Doses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 949-954.	0.4	100
1484	In Reply to Samuelian et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 570.	0.4	1
1485	In Reply to Prabhu et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 569-570.	0.4	0
1486	Molecular Markers Predict Distant Metastases After Adjuvant Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e577-e584.	0.4	6
1487	In Reply to Vassiliou and Kountourakis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 570-571.	0.4	0
1488	Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 10-13.	0.3	70
1489	Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 4-9.	0.3	65

#	ARTICLE	IF	CITATIONS
1490	Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: A planning study with clinical implications. <i>Radiotherapy and Oncology</i> , 2012, 102, 30-37.	0.3	56
1491	Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers. <i>Radiotherapy and Oncology</i> , 2012, 102, 1-3.	0.3	20
1492	Primary staging and response assessment postchemoradiotherapy in rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 57-70.	0.8	1
1493	Pelvic exenteration for advanced rectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 255-262.	0.8	1
1494	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	0.6	1,233
1495	The Therapeutic and Adverse Effects of Modified Radiation Fields for Patients With Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 255-262.	1.0	2
1496	352. Gene and MicroRNA Expression Predictive of Tumour Response in Patients Treated with Preoperative Chemoradiotherapy for Rectal Cancer. <i>European Journal of Surgical Oncology</i> , 2012, 38, 839.	0.5	0
1497	Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: A single institution experience. <i>European Journal of Surgical Oncology</i> , 2012, 38, 677-682.	0.5	54
1498	Randomized Controlled Trials in Surgical Oncology:. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 449-466.	0.6	4
1499	Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 3089-3096.	0.7	61
1500	Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages IIâ€“III rectal cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 592-598.	1.2	5
1501	Totally laparoscopic strategies for the management of colorectal cancer with synchronous liver metastasis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 2571-2578.	1.3	44
1502	Preoperative versus Postoperative Radiotherapy for Rectal Cancer in a Decision Analysis and Outcome Prediction Model. <i>Annals of Surgical Oncology</i> , 2012, 19, 4150-4160.	0.7	3
1503	Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy. <i>Magnetic Resonance Imaging</i> , 2012, 30, 848-853.	1.0	33
1504	Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-Î²B expression in vitro and in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 12-20.	2.5	48
1505	MRI features of the complete histopathological response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. <i>Clinical Radiology</i> , 2012, 67, 546-552.	0.5	22
1506	Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 45-52.	1.0	51
1507	Preoperative Radiation Therapy for Upper Rectal CancerT3,T4/Nx: Selectivity Essential. <i>Clinical Colorectal Cancer</i> , 2012, 11, 88-92.	1.0	15

#	ARTICLE	IF	CITATIONS
1508	Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity. <i>Clinical Colorectal Cancer</i> , 2012, 11, 93-100.	1.0	64
1509	Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2012, 48, 37-45.	1.3	67
1510	What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?. <i>European Journal of Cancer</i> , 2012, 48, 1781-1790.	1.3	93
1511	Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer – impact on long-term quality of life. <i>European Journal of Surgical Oncology</i> , 2012, 38, 472-477.	0.5	18
1512	Neoplasms of the Small and Large Intestine. , 2012, , 1278-1289.		1
1513	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. <i>BMC Cancer</i> , 2012, 12, 137.	1.1	46
1514	Intraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer. <i>BMC Cancer</i> , 2012, 12, 592.	1.1	54
1515	Visual Aids for Multimodal Treatment Options to Support Decision Making of Patients with Colorectal Cancer. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 118.	1.5	7
1516	Resectable Rectal Cancer: Which Patient Does Not Need Preoperative Radiotherapy?. <i>Digestive Diseases</i> , 2012, 30, 118-125.	0.8	17
1517	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. <i>Drug Metabolism Reviews</i> , 2012, 44, 148-172.	1.5	117
1519	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , 2012, 30, 1620-1627.	0.8	357
1520	Neoadjuvant Short- or Long-Term Radio(chemo)therapy for Rectal Cancer: How and Who Should Be Treated?. <i>Digestive Diseases</i> , 2012, 30, 102-108.	0.8	23
1521	Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. <i>Journal of Clinical Oncology</i> , 2012, 30, 3827-3833.	0.8	725
1522	The Role of Capecitabine in Locally Advanced Rectal Cancer Treatment. <i>Drugs</i> , 2012, 72, 1057-1073.	4.9	24
1523	Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. <i>International Journal of Oncology</i> , 2012, 41, 1643-1652.	1.4	43
1524	Evaluation of Lymphadenectomy in Patients Receiving Neoadjuvant Radiotherapy for Rectal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3713-3718.	0.7	15
1525	Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. <i>Oncology Reports</i> , 2012, 28, 855-861.	1.2	23
1526	Long-term Outcome of Local Excision after Complete Pathological Response to Neoadjuvant Chemoradiation Therapy for Rectal Cancer. <i>World Journal of Surgery</i> , 2012, 36, 2481-2487.	0.8	32

#	ARTICLE	IF	CITATIONS
1527	Dynamic modulated brachytherapy (DMBT) for rectal cancer. <i>Medical Physics</i> , 2013, 40, 011718.	1.6	42
1528	Complete Pathologic Response after Combined Modality Treatment for Rectal Cancer and Long-Term Survival: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2012, 19, 2822-2832.	0.7	204
1529	Complete Response after Neoadjuvant Therapy in Rectal Cancer: To Operate or Not to Operate?. <i>Digestive Diseases</i> , 2012, 30, 109-117.	0.8	27
1530	Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. <i>Lancet Oncology</i> , 2012, 13, e525-e536.	5.1	138
1532	Synchronous presentation of advanced rectal and intermediate-risk prostate cancers: a multidisciplinary approach. <i>Community Oncology</i> , 2012, 9, 67-72.	0.2	2
1533	Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: Results from two French tertiary centres. <i>Digestive and Liver Disease</i> , 2012, 44, 350-354.	0.4	30
1534	Nuclear factor- κ B predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. <i>Digestive and Liver Disease</i> , 2012, 44, 617-622.	0.4	10
1535	Short-term outcomes of the prone perineal approach for extra-levator abdomino-perineal excision (eAPE). <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2012, 10, 342-346.	0.8	31
1536	Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2012, 17, 376-383.	0.3	2
1537	Impact of Age and Comorbidities on the Treatment of Gastrointestinal Malignancies. <i>Seminars in Radiation Oncology</i> , 2012, 22, 311-320.	1.0	11
1538	Gastrointestinal System Cancers. , 2012, , 357-406.		0
1539	Role of the MET-HGF axis in colorectal cancer: precepts and prospects. <i>Colorectal Cancer</i> , 2012, 1, 329-341.	0.8	6
1540	Treatment of colorectal cancer in older patients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 716-725.	8.2	43
1541	Laparoscopic Versus Open Total Mesorectal Excision for Middle and Low Rectal Cancer: A Meta-analysis of Results of Randomized Controlled Trials. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2012, 22, 674-684.	0.5	26
1542	Influence of Neoadjuvant Radiotherapy on Anastomotic Leak After Restorative Resection for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1750-1757.	0.9	39
1543	Concurrent Chemoradiotherapy Followed by Metastasectomy Converts to Survival Benefit in Stage IV Rectum Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1888-1896.	0.9	16
1544	Controversy. <i>Colon and Rectum</i> , 2012, 6, 251-255.	0.0	2
1545	Combination of Irinotecan and 5-Fluorouracil with Radiation in Locally Advanced Rectal Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 467-471.	0.6	3

#	ARTICLE	IF	CITATIONS
1546	Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. <i>Clinical Colorectal Cancer</i> , 2012, 11, 268-274.	1.0	6
1547	Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer. <i>Practical Radiation Oncology</i> , 2012, 2, e77-e84.	1.1	8
1548	Short-term Results and Long-term Oncologic Outcomes between Neoadjuvant Chemoradiotherapy and Adjuvant Postoperative Chemoradiotherapy for Stage III Rectal Cancer: A Case-matched Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 2494-2499.	0.7	7
1552	Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1848-1857.	3.3	53
1553	Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1555-1560.	1.0	11
1554	Manuscript "close shave" margins do not increase rectal cancer recurrence after sphincter-saving surgery without neoadjuvant therapy by Lim et al.. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1691-1692.	1.0	0
1555	Management of synchronous rectal and prostate cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1501-1508.	1.0	17
1556	Multidisciplinary management of colorectal cancer enhances access to multimodal therapy and compliance with National Comprehensive Cancer Network (NCCN) guidelines. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1531-1538.	1.0	48
1557	Increased use of multidisciplinary treatment modalities adds little to the outcome of rectal cancer treated by optimal total mesorectal excision. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1275-1283.	1.0	10
1558	Close distal margins do not increase rectal cancer recurrence after sphincter-saving surgery without neoadjuvant therapy. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1285-1294.	1.0	21
1559	Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1295-1301.	1.0	9
1561	How does preoperative radiotherapy affect the rate of sphincter-sparing surgery in rectal cancer?. <i>Surgical Oncology</i> , 2012, 21, e103-e109.	0.8	17
1562	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. <i>Annals of Surgical Oncology</i> , 2012, 19, 2471-2476.	0.7	22
1564	Intersphincteric Resection for Low Rectal Tumors. , 2012, , .		0
1565	Multidisciplinary Management of Rectal Cancer. , 2012, , .		5
1566	Impact of solitary single glandular appearance on tumor recurrence in patients with rectal cancer after preoperative chemoradiotherapy. <i>Journal of Radiation Oncology</i> , 2012, 1, 363-372.	0.7	1
1567	ACR Appropriateness Criteria "Resectable Rectal Cancer. <i>Radiation Oncology</i> , 2012, 7, 161.	1.2	21
1568	Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging. A prospective clinical study. <i>Radiation Oncology</i> , 2012, 7, 124.	1.2	28

#	ARTICLE	IF	CITATIONS
1569	Implementation of HybridArc treatment technique in preoperative radiotherapy of rectal cancer: dose patterns in target lesions and organs at risk as compared to helical Tomotherapy and RapidArc. <i>Radiation Oncology</i> , 2012, 7, 120.	1.2	14
1570	Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience. <i>Radiation Oncology</i> , 2012, 7, 110.	1.2	38
1571	Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2012, 7, 28.	1.2	86
1572	Preoperative Radiotherapy in Carcinoma Rectum. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 302-307.	0.3	0
1573	Molecular and Microscopic Analysis of Bacteria and Viruses in Exhaled Breath Collected Using a Simple Impaction and Condensing Method. <i>PLoS ONE</i> , 2012, 7, e41137.	1.1	38
1574	P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer. <i>PLoS ONE</i> , 2012, 7, e45388.	1.1	83
1575	Effects of Preoperative Radiochemotherapy with Capecitabine for Resectable Locally Advanced Rectal Cancer in Elderly Patients. <i>Tumori</i> , 2012, 98, 622-629.	0.6	15
1576	Are Patients with Resectable Rectal Cancer Better Off in the Era of Multidisciplinary Care?. <i>Annals of Oncology</i> , 2012, 23, ix208.	0.6	0
1577	Are Community Hospitals Meeting the Same Standards as Academic Hospitals for the Multimodal Management of Rectal Cancer?. <i>American Surgeon</i> , 2012, 78, 1172-1177.	0.4	4
1578	Influence of Body Mass Index on Postoperative Complications after Rectal Resection for Carcinoma. <i>Southern Medical Journal</i> , 2012, 105, 493-499.	0.3	12
1579	Biology of Rectal Cancer—The Rationale for Targeted Therapy. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 383-392.	0.2	3
1580	Sphincter-preserving surgery after preoperative radiochemotherapy for T3 low rectal cancers. <i>Oncology Letters</i> , 2012, 3, 1336-1340.	0.8	8
1581	Quantitative Assessment of Tumor Responses after Radiation Therapy in a DLD-1 Colon Cancer Mouse Model Using Serial Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>Yonsei Medical Journal</i> , 2012, 53, 1147.	0.9	7
1582	Short-term outcomes after laparoscopic surgery following preoperative chemoradiotherapy for rectal cancer. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2012, 83, 281.	1.1	2
1583	Complications as indicators of quality assurance after 401 consecutive colorectal cancer resections: the importance of surgeon volume in developing colorectal cancer units in India. <i>World Journal of Surgical Oncology</i> , 2012, 10, 15.	0.8	4
1584	Does Chemotherapy Prior to Emergency Surgery Affect Patient Outcomes? Examination of 1912 Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 11-18.	0.7	15
1585	Role of Radiation in Intermediate-Risk Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 126-130.	0.7	7
1586	A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial. <i>Annals of Surgical Oncology</i> , 2012, 19, 384-391.	0.7	291

#	ARTICLE	IF	CITATIONS
1587	Referral Rate to Oncologists and its Variation by Hospital for Colorectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 714-721.	0.7	6
1588	Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2842-2852.	0.7	187
1589	Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. <i>Journal of Clinical Oncology</i> , 2012, 30, 1926-1933.	0.8	1,673
1590	Multimodal treatment strategies for locally advanced rectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 481-494.	1.1	12
1591	Toward the Non-surgical Management of Locally Advanced Rectal Cancer. <i>Current Oncology Reports</i> , 2012, 14, 267-276.	1.8	7
1592	Evaluation of lymph node metastases: Comparison of gadofluorine Mâ€enhanced MRI and diffusionâ€weighted MRI in a rabbit VX2 rectal cancer model. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1179-1186.	1.9	5
1593	Rectal Cancer: MR imaging of the mesorectal fascia and effect of chemoradiation on assessment of tumor involvement. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 658-663.	1.9	25
1594	TS and DPD mRNA levels on formalinâ€fixed paraffinâ€embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2012, 105, 529-534.	0.8	8
1595	Reirradiation to the pelvis for recurrent rectal cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 637-642.	0.8	59
1596	Metastases to retroperitoneal or lateral pelvic lymph nodes indicated unfavorable survival and high pelvic recurrence rates in a cohort of 102 patients with low rectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 653-658.	0.8	25
1597	Longâ€term outcomes in patients with locally advanced rectal cancer treated with preoperative chemoradiation followed by curative surgical resection. <i>Journal of Surgical Oncology</i> , 2012, 106, 659-666.	0.8	26
1598	Failure patterns correlate with the tumor response after preoperative chemoradiotherapy for locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2012, 106, 667-673.	0.8	15
1599	Systematic review of outcomes after intersphincteric resection for low rectal cancer. <i>British Journal of Surgery</i> , 2012, 99, 603-612.	0.1	189
1600	The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. <i>British Journal of Surgery</i> , 2012, 99, 993-1001.	0.1	116
1601	Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. <i>British Journal of Surgery</i> , 2012, 99, 918-928.	0.1	512
1602	Critical appraisal of the â€wait and seeâ€™ approach in rectal cancer for clinical complete responders after chemoradiation. <i>British Journal of Surgery</i> , 2012, 99, 897-909.	0.1	220
1603	The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy (<i>Br J Surg</i> 2012; 99: 993â€1001). <i>British Journal of Surgery</i> , 2012, 99, 1001-1001.	0.1	2
1604	Critical appraisal of the â€wait and seeâ€™ approach in rectal cancer for clinical complete responders after chemoradiation (<i>Br J Surg</i> 2012; 99: 897â€909). <i>British Journal of Surgery</i> , 2012, 99, 910-910.	0.1	3

#	ARTICLE	IF	CITATIONS
1605	Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 3501-3511.	2.0	111
1606	Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy?. <i>Cancer</i> , 2012, 118, 4961-4968.	2.0	25
1607	Examining stage IIB survival in a population-based cohort of patients with colorectal cancer. <i>Cancer</i> , 2012, 118, 5973-5981.	2.0	0
1608	Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3.		0
1609	Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 377-382.	1.0	10
1610	Clinical outcome of rectal cancer in patients 80 years treated in southern France (PACA region) between 2002 and 2005. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 383-387.	1.0	5
1611	Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 551-557.	1.0	17
1616	Lymph Node Retrieval after Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1573-1580.	0.9	55
1619	Do We Need Intensity-Modulated Radiation Therapy (IMRT) Routinely in the Preoperative Setting for Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 99-104.	1.0	0
1620	Potential Novel Drugs to Combine with Radiation in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 105-117.	1.0	0
1621	What is the Best Way to Produce Consensus and Buy in to Guidelines for Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 83-89.	1.0	4
1622	The Importance of the Pathologist's Role in Assessment of the Quality of the Mesorectum. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 90-98.	1.0	78
1623	Laboratory Blood Data Have a Significant Impact on Tumor Response and Outcome in Preoperative Chemoradiotherapy for Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 236-243.	0.6	27
1624	Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 471-480.	1.2	2
1626	Preoperative Treatment Does Not Improve the Therapeutic Results of Abdominosacral Amputation of the Rectum. <i>World Journal of Surgery</i> , 2012, 36, 1686-1692.	0.8	4
1627	Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group G103-53. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 25-32.	1.1	16
1628	A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 727-736.	1.0	16
1629	Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma. <i>International Journal of Colorectal Disease</i> , 2012, 27, 737-749.	1.0	10

#	ARTICLE	IF	CITATIONS
1630	Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancerâ€”treatment results at 5-year follow-up. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 801-807.	0.8	62
1631	The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 543-555.	0.8	41
1632	A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 151-155.	1.4	19
1633	Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case. <i>Surgery Today</i> , 2012, 42, 75-79.	0.7	2
1634	Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. <i>Surgery Today</i> , 2012, 42, 460-469.	0.7	41
1635	Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. <i>Surgery Today</i> , 2012, 42, 713-719.	0.7	39
1636	Cost of care for colorectal cancer in Ireland: a health care payer perspective. <i>European Journal of Health Economics</i> , 2012, 13, 511-524.	1.4	45
1637	Effect of radical surgery combined with pre- or postoperative radiotherapy in treatment of resectable rectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 384-390.	0.1	2
1638	Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation¹. <i>Colorectal Disease</i> , 2012, 14, 62-67.	0.7	28
1639	Apoptotic proteins as prognostic markers and indicators of radiochemosensitivity in stage II/III rectal cancers. <i>Colorectal Disease</i> , 2012, 14, e64-71.	0.7	10
1640	The safe distal tumourâ€”free margin after sphincter preserving resection for rectal cancer: an ongoing debate. <i>Colorectal Disease</i> , 2012, 14, 131-132.	0.7	4
1641	Adherence to Treatment Guidelines in Stage II/III Rectal Cancer in Alberta, Canada. <i>Clinical Oncology</i> , 2012, 24, e9-e17.	0.6	22
1642	Image-guided Radiotherapy for Rectal Cancer â€” A Systematic Review. <i>Clinical Oncology</i> , 2012, 24, 250-260.	0.6	32
1643	Imaging for Target Volume Delineation in Rectal Cancer Radiotherapy â€” A Systematic Review. <i>Clinical Oncology</i> , 2012, 24, 52-63.	0.6	34
1644	Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: Lessons from a systematic review of recent randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 21-28.	2.0	59
1645	Use of adjuvant chemotherapy in stage C (III) rectal cancer: Comparison of data from matched patients in a teaching hospital's clinicoâ€”pathological database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 346-355.	0.7	1
1646	Adjuvant therapy. <i>Medicine</i> , 2012, 40, 1-4.	0.2	0
1647	The principles of cancer treatment by chemotherapy. <i>Surgery</i> , 2012, 30, 186-190.	0.1	20

#	ARTICLE	IF	CITATIONS
1648	CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. <i>Surgery</i> , 2012, 151, 564-570.	1.0	40
1649	Shifting concepts in rectal cancer management. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 173-202.	157.7	90
1650	A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?. <i>Colorectal Disease</i> , 2012, 14, 567-571.	0.7	133
1651	Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?. <i>Colorectal Disease</i> , 2012, 14, 714-720.	0.7	108
1652	Current practice in preoperative therapy and surgical management of locally advanced rectal cancer: a bi-national survey. <i>Colorectal Disease</i> , 2012, 14, 814-820.	0.7	10
1653	Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. <i>Colorectal Disease</i> , 2012, 14, 294-298.	0.7	92
1654	Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. <i>Colorectal Disease</i> , 2012, 14, e277-96.	0.7	138
1655	Posterior urethral complications of the treatment of prostate cancer. <i>BJU International</i> , 2012, 110, 304-325.	1.3	110
1656	Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 Tj ETQq0 0 0 rgBT /Overlock 10 TF cancer - NEOPANC. <i>BMC Cancer</i> , 2012, 12, 112.	1.1	12
1657	Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment. <i>Annals of Surgical Oncology</i> , 2012, 19, 1199-1205.	0.7	64
1658	Is Adjuvant Chemotherapy Really Needed After Curative Surgery for Rectal Cancer Patients Who are Node-Negative After Neoadjuvant Chemoradiotherapy?. <i>Annals of Surgical Oncology</i> , 2012, 19, 1206-1212.	0.7	46
1659	Radiation-Induced Apoptosis of Peripheral Blood Lymphocytes is Correlated with Histological Regression of Rectal Cancer in Response to Preoperative Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 1192-1198.	0.7	17
1660	Lymphovascular Invasion is a Significant Prognosticator in Rectal Cancer Patients Who Receive Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision. <i>Annals of Surgical Oncology</i> , 2012, 19, 1213-1221.	0.7	39
1661	Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2012, 19, 2212-2223.	0.7	440
1662	Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using 18FDG-PET/CT. <i>Annals of Surgical Oncology</i> , 2012, 19, 2178-2185.	0.7	40
1663	The prognostic value of grade of regression and oncocyctic change in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2012, 105, 130-134.	0.8	18
1664	Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: Diffusion-weighted 3 tesla MR imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 110-116.	1.9	112
1665	Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy. <i>Medical Oncology</i> , 2012, 29, 168-173.	1.2	7

#	ARTICLE	IF	CITATIONS
1666	Postoperative Adjuvant Chemotherapy for Stage II Colorectal Cancer: A Systematic Review of 12 Randomized Controlled Trials. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 646-655.	0.9	46
1668	Emergency Surgery in Patients Who Have Undergone Recent Radiotherapy is Associated With Increased Complications and Mortality: Review of 536 Patients. <i>World Journal of Surgery</i> , 2012, 36, 31-38.	0.8	6
1669	Partial Pathologic Response and Nodal Status as Most Significant Prognostic Factors for Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy. <i>World Journal of Surgery</i> , 2012, 36, 675-683.	0.8	56
1670	The role of lateral lymph node dissection in the management of lower rectal cancer. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 353-361.	0.8	13
1671	Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 387-395.	1.2	10
1672	Laparoscopic versus open surgery for rectal cancer after neoadjuvant chemoradiation: a matched case-control study of short-term outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 154-161.	1.3	32
1673	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 1-29.	1.0	658
1674	Quality of surgical care, local recurrence, and survival in patients with low- and midrectal cancers following multimodal therapy. <i>International Journal of Colorectal Disease</i> , 2012, 27, 111-120.	1.0	11
1675	Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. <i>Cancer</i> , 2013, 119, 26-35.	2.0	46
1676	Does geography influence the treatment and outcomes of colorectal cancer? A population-based analysis. <i>World Journal of Surgical Oncology</i> , 2013, 11, 140.	0.8	10
1677	Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume. <i>World Journal of Surgical Oncology</i> , 2013, 11, 65.	0.8	16
1678	A comparison of dosimetric parameters between tomotherapy and three-dimensional conformal radiotherapy in rectal cancer. <i>Radiation Oncology</i> , 2013, 8, 181.	1.2	13
1679	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. <i>Radiation Oncology</i> , 2013, 8, 176.	1.2	27
1680	Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy. <i>Radiation Oncology</i> , 2013, 8, 114.	1.2	27
1681	Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2013, 8, 90.	1.2	36
1682	Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. <i>Radiation Oncology</i> , 2013, 8, 86.	1.2	38
1683	Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. <i>Radiation Oncology</i> , 2013, 8, 43.	1.2	61
1684	Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. <i>Radiation Oncology</i> , 2013, 8, 10.	1.2	14

#	ARTICLE	IF	CITATIONS
1685	Preoperative chemoradiotherapy for locally advanced gastric cancer. <i>Radiation Oncology</i> , 2013, 8, 6.	1.2	18
1686	SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. <i>Tumor Biology</i> , 2013, 34, 1107-1117.	0.8	34
1687	Evolving Role of Neoadjuvant Therapy in Rectal Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 350-364.	1.3	28
1688	Volume and outcome in rectal cancer surgery: the importance of quality management. <i>International Journal of Colorectal Disease</i> , 2013, 28, 197-206.	1.0	39
1689	Lateral Lymph Node Dissection for Lower Rectal Cancer. <i>World Journal of Surgery</i> , 2013, 37, 1808-1813.	0.8	32
1690	Exercise, Energy Balance, and Cancer. , 2013, , .		4
1691	Perioperative outcomes after ultra low anterior resection in the era of neoadjuvant chemoradiotherapy. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 90-97.	0.7	6
1692	Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. <i>BMC Cancer</i> , 2013, 13, 200.	1.1	25
1693	Who Benefits From Adjuvant Radiation Therapy for Gastric Cancer? A Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 330-335.	0.4	51
1694	Neoadjuvant Radiotherapy for Rectal Cancer: Adherence to Evidence-Based Guidelines in Clinical Practice. <i>World Journal of Surgery</i> , 2013, 37, 639-645.	0.8	18
1695	Short-course preoperative radiotherapy combined with chemotherapy in resectable locally advanced rectal cancer: local control and quality of life. <i>Radiologia Medica</i> , 2013, 118, 1397-1411.	4.7	8
1696	Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single institution experience. <i>Radiologia Medica</i> , 2013, 118, 570-582.	4.7	3
1697	Multidisciplinary Management of Rectal Cancer: the OSTRICH. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1863-1868.	0.9	83
1698	Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 488-493.	0.9	17
1699	Pathological Complete Response After Neoadjuvant Therapy for Rectal Cancer and the Role of Adjuvant Therapy. <i>Current Oncology Reports</i> , 2013, 15, 152-161.	1.8	11
1700	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013, 30, 610.	1.2	7
1701	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). <i>Medical Oncology</i> , 2013, 30, 581.	1.2	11
1702	Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer. <i>Clinical and Translational Oncology</i> , 2013, 15, 294-299.	1.2	2

#	ARTICLE	IF	CITATIONS
1703	Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Supportive Care in Cancer, 2013, 21, 2869-2877.	1.0	4
1706	Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. Current Colorectal Cancer Reports, 2013, 9, 116-125.	1.0	0
1707	Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?. Current Colorectal Cancer Reports, 2013, 9, 126-129.	1.0	0
1708	MRI-Based Assessment of Tumor Regression in Rectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 136-145.	1.0	3
1709	Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?. Current Colorectal Cancer Reports, 2013, 9, 146-156.	1.0	0
1710	Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications. Current Colorectal Cancer Reports, 2013, 9, 157-167.	1.0	7
1711	Utilization of preoperative radiation therapy in the management of rectal cancer: A population-based analysis. Practical Radiation Oncology, 2013, 3, e121-e126.	1.1	3
1712	CT Colonography Atlas. Medical Radiology, 2013, , .	0.0	0
1713	The emerging role of FDG PET/CT in rectal cancer management: is it time to use the technique for early prognostication?. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 652-656.	3.3	12
1714	Chronological Improvement in Survival Following Rectal Cancer Surgery: A Large-Scale, Single-Center Study. World Journal of Surgery, 2013, 37, 2693-2699.	0.8	7
1715	Laparoscopic Surgery for Rectal Cancer: Outcomes in 513 Patients. World Journal of Surgery, 2013, 37, 883-892.	0.8	17
1716	Selective Use of Preoperative Chemoradiotherapy for T3 Rectal Cancer Can Be Justified: Analysis of Local Recurrence. World Journal of Surgery, 2013, 37, 220-226.	0.8	10
1717	Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemotherapy and Pharmacology, 2013, 71, 1201-1207.	1.1	32
1718	Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypTONO) after neoadjuvant chemoradiation therapy?. European Radiology, 2013, 23, 3440-3449.	2.3	72
1719	Locally advanced rectal cancer: diffusion-weighted MR tumour volumetry and the apparent diffusion coefficient for evaluating complete remission after preoperative chemoradiation therapy. European Radiology, 2013, 23, 3345-3353.	2.3	73
1720	Predictive value of 18FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. International Journal of Colorectal Disease, 2013, 28, 1217-1224.	1.0	39
1721	Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. International Journal of Colorectal Disease, 2013, 28, 511-517.	1.0	27
1722	Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. International Journal of Colorectal Disease, 2013, 28, 527-535.	1.0	37

#	ARTICLE	IF	CITATIONS
1723	Comment on the editorial of Sautter-Bihl et al. in Strahlentherapie und Onkologie 2013 189:105-110. Strahlentherapie Und Onkologie, 2013, 189, 697-699.	1.0	1
1724	Reply to the letter of Junginger et al. Strahlenther Onkol 2013 DOI 10.1007/s00066-013-0353-y. Strahlentherapie Und Onkologie, 2013, 189, 700-701.	1.0	0
1726	Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Disease, 2013, 15, 552-557.	0.7	26
1727	Surgical management and chemoradiotherapy of T1 rectal cancer. Digestive Endoscopy, 2013, 25, 11-15.	1.3	3
1728	Relationship between nutritional status and immediate complications in patients undergoing colorectal surgery. Journal of Coloproctology, 2013, 33, 083-091.	0.1	4
1729	Clinical implication of additional selective lateral lymph node excision in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy. International Journal of Colorectal Disease, 2013, 28, 1667-1674.	1.0	42
1730	Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiotherapy and Oncology, 2013, 108, 32-39.	0.3	29
1731	Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer. European Journal of Radiology, 2013, 82, e662-e668.	1.2	81
1732	Pacientes con cáncer de recto localmente avanzado en tratamiento neoadyuvante con quimiorradioterapia en el Instituto Nacional de Cancerología durante 2010. Revista Colombiana De Cancerología, 2013, 17, 18-24.	0.0	0
1733	Adjuvant treatment for rectal cancer: Short-course radiation vs. long-course chemoradiation. Seminars in Colon and Rectal Surgery, 2013, 24, 155-158.	0.2	0
1734	Colorectal Cancer Metastases. Surgical Oncology Clinics of North America, 2013, 22, 289-298.	0.6	10
1735	Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases. Surgery, 2013, 154, 528-535.	1.0	19
1736	Prediction of Lymphovascular Invasion in Rectal Cancer by Preoperative CT. American Journal of Roentgenology, 2013, 201, 985-992.	1.0	22
1737	Endorectal Ultrasound. , 2013, , 759-768.		0
1738	SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clinical and Translational Oncology, 2013, 15, 991-995.	1.2	11
1739	Current treatment of rectal cancer adapted to the individual patient. Reports of Practical Oncology and Radiotherapy, 2013, 18, 353-362.	0.3	10
1740	Biopsy Specimens Obtained 7 Days After Starting Chemoradiotherapy (CRT) Provide Reliable Predictors of Response to CRT for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1232-1238.	0.4	24
1741	Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge. European Journal of Cancer, 2013, 49, 2311-2320.	1.3	88

#	ARTICLE	IF	CITATIONS
1742	Effect of Preoperative Radio(chemo)therapy on Long-term Functional Outcome in Rectal Cancer Patients: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 1816-1828.	0.7	168
1743	Challenges in the neoadjuvant treatment of rectal cancer: Balancing the risk of recurrence and quality of life. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2013, 17, 675-685.	0.6	33
1744	Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: Preliminary results of a monoinstitutional prospective study. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1071-1078.	0.5	65
1745	MRI-defined height of rectal tumours. <i>British Journal of Surgery</i> , 2013, 101, 127-132.	0.1	41
1746	Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Colorectal Disease</i> , 2013, 15, 428-435.	0.7	11
1747	Review of bowel dysfunction of rectal cancer patients during the first five years after sphincter-preserving surgery: A population in need of nursing attention. <i>European Journal of Oncology Nursing</i> , 2013, 17, 681-692.	0.9	27
1748	Rectal and Anal Cancer. <i>Medical Radiology</i> , 2013, , 167-184.	0.0	1
1749	Diarrhoea in irradiated patients: A prospective multicentre observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 933-937.	0.4	9
1750	Do MRI Reports Contain Adequate Preoperative Staging Information for End Users to Make Appropriate Treatment Decisions for Rectal Cancer?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1148-1155.	0.7	33
1751	Long-term quality-of-life after neoadjuvant short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2013, 108, 326-330.	0.3	23
1754	Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis. <i>BMC Cancer</i> , 2013, 13, 388.	1.1	9
1755	Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. <i>BMC Surgery</i> , 2013, 13, 43.	0.6	22
1756	Short-term effects of neoadjuvant chemoradiation therapy on anorectal function in rectal cancer patients: a pilot study. <i>Radiation Oncology</i> , 2013, 8, 203.	1.2	7
1757	Long-term Results of Rectal Cancer Surgery with a Systematical Operative Approach. <i>Annals of Surgical Oncology</i> , 2013, 20, 1806-1815.	0.7	55
1758	Restaging locally advanced rectal cancer by different imaging modalities after preoperative chemoradiation: a comparative study. <i>Radiation Oncology</i> , 2013, 8, 278.	1.2	14
1759	Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan. <i>Radiation Oncology</i> , 2013, 8, 258.	1.2	11
1762	Need for objective and reproducible criteria in histopathological assessment of total mesorectal excision specimens: lessons from a national improvement project. <i>Colorectal Disease</i> , 2013, 15, 1351-1358.	0.7	15
1763	Regionale Therapie maligner Tumoren. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
1764	Reconstructing the Irradiated Rectum. , 2013, , 113-122.		0
1765	Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer. <i>Clinical Radiology</i> , 2013, 68, e524-e531.	0.5	48
1766	Preoperative chemoradiotherapy in patients with rectal cancer - 3D conformal external beam radiotherapy (EBRT). <i>Hellenike Cheirourgike Acta Chirurgica Hellenica</i> , 2013, 85, 175-179.	0.1	0
1767	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. <i>Annals of Oncology</i> , 2013, 24, 718-725.	0.6	81
1768	The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e15-e19.	0.4	57
1769	Outcomes Following Proctectomy. <i>Surgical Clinics of North America</i> , 2013, 93, 89-106.	0.5	24
1770	Magnetic Resonance Imaging of Rectal Cancer. <i>Radiologic Clinics of North America</i> , 2013, 51, 121-131.	0.9	28
1771	Intersphincteric resection for very low rectal cancer: a systematic review. <i>Surgery Today</i> , 2013, 43, 838-847.	0.7	57
1772	Multiple malignancies in a single patient. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 155-158.	1.0	1
1773	Diffusion-weighted MRI in locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 117-122.	1.0	87
1774	Rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 105-110.	1.0	11
1775	T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer. <i>European Radiology</i> , 2013, 23, 253-261.	2.3	39
1776	Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 131-138.	1.2	29
1777	Positron Emission Tomography with [18F]-3-Deoxy-3-fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2013, 15, 106-113.	1.3	22
1778	Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 48-54.	0.3	25
1779	Neoadjuvant therapy before surgical treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 45-59.	2.2	7
1780	Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 67-75.	0.3	4
1781	Current treatment of rectal cancer: The watch-and-wait method. Are we there yet?. <i>Seminars in Colon and Rectal Surgery</i> , 2013, 24, 147-150.	0.2	0

#	ARTICLE	IF	CITATIONS
1782	Perioperative chemotherapy for resectable colorectal liver metastases: Where now?. <i>European Journal of Surgical Oncology</i> , 2013, 39, 807-811.	0.5	37
1783	InÂVitro and InÂVivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 469-476.	0.4	55
1784	Combined modality therapy: Is it necessary for everyone?. <i>Seminars in Colon and Rectal Surgery</i> , 2013, 24, 151-154.	0.2	0
1785	Disparity in the use of combined modality therapy for rectal cancer in the older adult. <i>Journal of Geriatric Oncology</i> , 2013, 4, 90-97.	0.5	7
1786	High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients. <i>Brachytherapy</i> , 2013, 12, 457-462.	0.2	12
1787	Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2013, 24, 119-124.	0.2	5
1788	Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e419-e426.	0.6	47
1789	Predictors of response in locally advanced rectal cancer following concurrent chemoradiotherapy. <i>Biomarkers and Genomic Medicine</i> , 2013, 5, 18-22.	0.2	2
1790	Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size. <i>Academic Radiology</i> , 2013, 20, 79-89.	1.3	1
1791	Molecular markers for targeted neoadjuvant rectal cancer therapy. <i>Colorectal Cancer</i> , 2013, 2, 321-331.	0.8	1
1792	Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 523-528.	0.4	48
1793	Small Bowel Dose Parameters Predicting Grade 3 Acute Toxicity in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiation: An Independent Validation Study Comparing Peritoneal Space Versus Small Bowel Loop Contouring Techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1225-1231.	0.4	52
1794	MRI Predictive Factors for Tumor Response in Rectal Cancer Following Neoadjuvant Chemoradiation Therapy - Implications for Induction Chemotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 505-511.	0.4	63
1795	Phase 1 Trial of Neoadjuvant Radiation Therapy Before Prostatectomy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 88-93.	0.4	15
1796	Adjuvant chemotherapy. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 72-79.	2.2	1
1797	Modern chemoradiation and chemotherapy protocols for locally advanced rectal cancer: The current and future standards of care. <i>Seminars in Colon and Rectal Surgery</i> , 2013, 24, 132-141.	0.2	0
1798	Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: A meta analysis. <i>European Journal of Cancer</i> , 2013, 49, 843-851.	1.3	57
1799	Mortality Risk After Preoperative Versus Postoperative Chemotherapy and Radiotherapy in Lymph Node-Positive Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 374-381.	0.9	5

#	ARTICLE	IF	CITATIONS
1800	Magnetic Resonance Imaging of Rectal Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2013, 21, 385-408.	0.6	30
1801	Phase III study of preoperative chemoradiation with 5-FU plus oxaliplatin in patients with locally advanced rectal cancer. <i>Cancer Science</i> , 2013, 104, 111-115.	1.7	15
1802	Prognostic significance of apical lymph node metastasis in patients with node-positive rectal cancer. <i>Colorectal Disease</i> , 2013, 15, e13-20.	0.7	20
1803	miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. <i>International Journal of Colorectal Disease</i> , 2013, 28, 247-260.	1.0	65
1804	Elevated CEA Levels and Low Distance of the Tumor from the Anal Verge are Predictors of Incomplete Response to Chemoradiation in Patients with Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 864-871.	0.7	66
1805	The Optimal Staging of Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 24-30.	1.0	0
1806	The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 283-305.	2.0	8
1807	Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. <i>The Cochrane Library</i> , 2013, , CD006041.	1.5	136
1808	Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2860-2867.	1.3	51
1810	Long-Term Results of 2 Adjuvant Trials Reveal Differences in Chemosensitivity and the Pattern of Metastases Between Colon Cancer and Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 54-61.	1.0	35
1811	Past, present, and future of radiotherapy for the benefit of patients. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 52-60.	12.5	289
1812	Extended Lymphadenectomy in Colon Cancer is Crucial. <i>World Journal of Surgery</i> , 2013, 37, 1789-1798.	0.8	39
1813	Radiation Therapy in Anal and Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 525-543.	0.6	9
1814	Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens. <i>American Journal of Surgery</i> , 2013, 205, 289-292.	0.9	29
1815	Sporadische Tumoren des Kolorektums. , 2013, , 611-661.		0
1816	Overview of Colorectal Cancer. , 2013, , 1-28.		0
1817	Quality Research in Radiation Oncology Analysis of Clinical Performance Measures in the Management of Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 355-362.	0.4	5
1818	Abdominoperineal resection and low anterior resection: comparison of long-term oncologic outcome in matched patients with lower rectal cancer. <i>International Journal of Colorectal Disease</i> , 2013, 28, 493-501.	1.0	27

#	ARTICLE	IF	CITATIONS
1819	Modern Rectal Cancer Multidisciplinary Treatment: The Role of Radiation and Surgery. <i>Annals of Surgical Oncology</i> , 2013, 20, 2921-2928.	0.7	30
1820	Magnetic Resonance Imaging of Anorectal Diseases. , 2013, , 35-45.		0
1821	Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. <i>British Journal of Surgery</i> , 2013, 100, 933-939.	0.1	239
1822	Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: The French randomised trial ACCORD12/0405 PRODIGE 2. <i>European Journal of Cancer</i> , 2013, 49, 82-89.	1.3	51
1823	Controverse. <i>Colon and Rectum</i> , 2013, 7, 241-244.	0.0	0
1824	Is Restaging with Chest and Abdominal CT Scan after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Necessary?. <i>Annals of Surgical Oncology</i> , 2013, 20, 155-160.	0.7	19
1825	The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 500-508.	0.7	61
1826	Robotic versus laparoscopic surgery for midâ€“low rectal cancer after neoadjuvant chemoradiation therapy: comparison of oncologic outcomes. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1689-1698.	1.0	63
1827	Sphincter-sparing surgery for adenocarcinoma of the distal 3Âcm of the true rectum: results after neoadjuvant therapy and minimally invasive radical surgery or local excision. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 4469-4477.	1.3	43
1828	Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. <i>Cancer</i> , 2013, 119, 1106-1112.	2.0	16
1829	The role of faecal diversion in low rectal cancer: a review of 1791 patients having rectal resection with anastomosis for cancer, with and without a proximal stoma. <i>Colorectal Disease</i> , 2013, 15, e309-16.	0.7	48
1830	Accuracy of magnetic resonance imaging in the preâ€“operative staging of rectal adenocarcinoma: Experience from a regional Australian cancer center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 318-323.	0.7	8
1831	Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. <i>Cancer Medicine</i> , 2013, 2, 185-195.	1.3	36
1832	Early Outcomes for Rectal Cancer Surgery in the Republic of Ireland Following a National Centralization Program. <i>Annals of Surgical Oncology</i> , 2013, 20, 3414-3421.	0.7	23
1833	Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 3877-3884.	0.7	18
1834	Staging of colorectal cancer. <i>Imaging</i> , 2013, 22, 20110078.	0.0	1
1835	Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 869-876.	1.0	9
1836	Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: Thermoâ€“surgical ablation. <i>Journal of Surgical Oncology</i> , 2013, 107, 144-147.	0.8	3

#	ARTICLE	IF	CITATIONS
1837	Loop ileostomy closure after laparoscopic versus open surgery: is there a difference?. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 90-94.	1.3	35
1838	Non-operative management for locally advanced rectal cancer: critical review and future perspective. Colorectal Cancer, 2013, 2, 359-370.	0.8	0
1839	Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. Molecular and Clinical Oncology, 2013, 1, 190-194.	0.4	17
1840	Effect of Belly Board with Bladder Compression Device on Small Bowel Displacement from the Radiotherapy Field for Rectal Cancer. Onkologie, 2013, 36, 4-4.	1.1	3
1841	Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?. Oncology, 2013, 84, 191-199.	0.9	29
1842	Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open, 2013, 3, e003055.	0.8	72
1844	Staging of colorectal cancer. Imaging, 2013, 22, 20120024.	0.0	0
1845	A Study of Inflammation-Based Predictors of Tumor Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Oncology, 2013, 85, 27-32.	0.9	47
1846	Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Gastroenterology Report, 2013, 1, 186-192.	0.6	4
1849	A Novel Risk-Adjusted Nomogram for Rectal Cancer Surgery Outcomes. JAMA Surgery, 2013, 148, 769.	2.2	49
1850	Tumor Regression Grades: Can They Influence Rectal Cancer Therapy Decision Tree?. International Journal of Surgical Oncology, 2013, 2013, 1-8.	0.3	15
1851	Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project. Gut, 2013, 62, 1005-1011.	6.1	9
1852	A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer. Frontiers in Oncology, 2013, 3, 288.	1.3	7
1853	Preoperative Chemoradiotherapy in Elderly Patients with Locally Advanced Rectal Cancer. BioMed Research International, 2013, 2013, 1-5.	0.9	7
1854	Retrospective review of rectal cancer surgery in northern Alberta. Canadian Journal of Surgery, 2013, 56, E51-E58.	0.5	1
1855	Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer. Journal of Radiation Research, 2013, 54, 1118-1124.	0.8	12
1856	Preoperative Radiation Therapy Significantly Increases Patient Eligibility for Accelerated Partial Breast Irradiation Using 3D-conformal Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 232-238.	0.6	11
1857	Cumulative Incidence of Permanent Stoma After Sphincter Preserving Low Anterior Resection of Mid and Low Rectal Cancer. Diseases of the Colon and Rectum, 2013, 56, 1134-1142.	0.7	70

#	ARTICLE	IF	CITATIONS
1858	Factors Associated With Use of Preoperative Chemoradiation Therapy for Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 572-579.	0.6	10
1859	Statin Therapy Is Associated With Improved Pathologic Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1217-1227.	0.7	61
1860	Improvements in 5-year Outcomes of Stage II/III Rectal Cancer Relative to Colon Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 558-564.	0.6	27
1861	Local Excision After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1349-1356.	0.7	157
1862	Modified Wong's Classification Improves the Accuracy of Rectal Cancer Staging by Endorectal Ultrasound and MRI. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1332-1338.	0.7	11
1863	Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies. <i>Oncologist</i> , 2013, 18, 833-842.	1.9	12
1864	Endorectal Ultrasound-Guided Fine-Needle Aspiration: A Useful Diagnostic Tool for Perirectal and Intraluminal Lesions. <i>Acta Cytologica</i> , 2013, 57, 9-18.	0.7	26
1865	Re-examination of the standardization of colon cancer surgery. <i>Gastroenterology Report</i> , 2013, 1, 113-118.	0.6	10
1867	Emergence of well differentiated neuroendocrine (carcinoid) tumours following chemoradiotherapy for rectal adenocarcinoma. <i>Colorectal Disease</i> , 2013, 15, 1544-1547.	0.7	0
1868	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013, 54, 52-60.	0.8	11
1869	Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1283-1289.	2.1	30
1870	Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2013, 258, 289-295.	2.1	94
1871	Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation. <i>Colorectal Disease</i> , 2013, 15, 674-682.	0.7	10
1872	Persisting anorectal dysfunction after rectal cancer surgery. <i>Colorectal Disease</i> , 2013, 15, e672-9.	0.7	13
1873	<i>DPYD</i>, <i>TYMS</i>, <i>TYMP</i>, <i>TK1</i>, and <i>TK2</i> Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	13
1874	Pathological Complete Response of Advanced Rectal Cancer Treated by Preoperative Chemoradiotherapy with Oral Tegafur-Uracil and Leucovorin: A Case Report. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.2	0
1875	Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer. <i>Journal of Cancer Epidemiology</i> , 2013, 2013, 1-6.	0.5	12
1876	A 12-year experience of the <sc>T</sc>rendelenburg perineal approach for abdominoperineal resection. <i>ANZ Journal of Surgery</i> , 2013, 83, 853-858.	0.3	8

#	ARTICLE	IF	CITATIONS
1877	Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. <i>Cancer</i> , 2013, 119, 1521-1527.	2.0	55
1878	Once-daily reirradiation for rectal cancer in patients who have received previous pelvic radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 512-518.	0.9	38
1879	Management and clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2006 and 2008. <i>Journal of Surgical Oncology</i> , 2013, 108, 450-456.	0.8	5
1880	Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 213-219.	0.8	24
1881	The Use of MR Imaging in Treatment Planning for Patients with Rectal Carcinoma: Have You Checked the "DISTANCE"? <i>Radiology</i> , 2013, 268, 330-344.	3.6	213
1882	Neoadjuvant Oxaliplatin and Capecitabine and Bevacizumab without Radiotherapy for Poor-risk Rectal Cancer: N-SOG 03 Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 964-971.	0.6	119
1883	Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 30-38.	0.8	104
1884	Minimally invasive surgery for locally advanced rectal cancer: recent advances and future developments. <i>Colorectal Cancer</i> , 2013, 2, 155-164.	0.8	0
1885	Locally advanced rectal cancer: new findings in anticancer therapy. <i>Colorectal Cancer</i> , 2013, 2, 585-601.	0.8	0
1886	Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 298-307.	2.3	17
1887	Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event. <i>Case Reports in Oncology</i> , 2013, 6, 609-615.	0.3	15
1888	Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer?. <i>Radiation Oncology</i> , 2013, 8, 290.	1.2	1
1889	Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 548-557.	2.3	5
1891	Current options in chemoradiotherapy for rectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 459-465.	0.8	0
1892	Is Tailoring Treatment of Rectal Cancer the Only True Benefit of Long-Course Neoadjuvant Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 264-266.	0.7	24
1894	Personalized medicine for radiation therapy. <i>Personalized Medicine</i> , 2013, 10, 107-110.	0.8	0
1895	Transanal Endoscopic Microsurgery for Residual Rectal Cancer (ypT0-2) Following Neoadjuvant Chemoradiation Therapy. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 6-13.	0.7	108
1896	CEA " A Predictor for Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 859-868.	0.7	94

#	ARTICLE	IF	CITATIONS
1897	Distribution of Residual Cancer Cells in the Bowel Wall After Neoadjuvant Chemoradiation in Patients With Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 142-149.	0.7	90
1898	Population-Based Use of Sphincter-Preserving Surgery in Patients With Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 704-710.	0.7	23
1899	Practice Parameters for the Management of Rectal Cancer (Revised). <i>Diseases of the Colon and Rectum</i> , 2013, 56, 535-550.	0.7	397
1900	Low Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 560-567.	0.7	220
1901	Geographical Disparities of Rectal Cancer Local Recurrence and Outcomes. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 850-858.	0.7	18
1902	Is Tailoring Treatment of Rectal Cancer the Only True Benefit of Long-Course Neoadjuvant Chemoradiation? Another View. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 267-270.	0.7	0
1903	Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 522-531.	2.1	64
1904	Prognosis Factors for Recurrence in Patients With Locally Advanced Rectal Cancer Preoperatively Treated With Chemoradiotherapy and Adjuvant Chemotherapy. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 416-421.	0.7	36
1905	Long-term Results of the "Liver First" Approach in Patients With Locally Advanced Rectal Cancer and Synchronous Liver Metastases. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 281-287.	0.7	57
1906	An Individualized Conditional Survival Calculator for Patients with Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 551-559.	0.7	23
1907	Intermediate-Fraction Neoadjuvant Radiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 422-432.	0.7	17
1908	Impact of Obesity on Operation Performed, Complications, and Long-term Outcomes in Terms of Restoration of Intestinal Continuity for Patients With Mid and Low Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 689-697.	0.7	41
1909	Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colon and Rectal Surgeons, and the American Society of Colon and Rectal Surgeons. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 798-802.	0.7	0
1910	Clinical Prediction of Pathological Complete Response After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 698-703.	0.7	88
1911	Circumferential Resection Margin Involvement in Stage III Rectal Cancer Patients Treated with Curative Resection Followed by Chemoradiotherapy: A Surrogate Marker for Local Recurrence?. <i>Yonsei Medical Journal</i> , 2013, 54, 131.	0.9	15
1912	Clinical analysis of concurrent 3DCRT and XELOX treatment for postoperative local recurrence of rectal carcinoma in elderly patients. <i>Przegląd Gastroenterologiczny</i> , 2013, 4, 257-261.	0.3	0
1913	Clinical impact of fat clearing technique in nodal staging of rectal cancer after preoperative chemoradiotherapy. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 85, 30.	1.1	4
1915	Optimal timing of surgery after neoadjuvant chemoradiation therapy in locally advanced rectal cancer. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 84, 338.	1.1	26

#	ARTICLE	IF	CITATIONS
1916	Surgical issues in locally advanced rectal cancer treated by preoperative chemoradiotherapy. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 84, 1.	1.1	2
1917	Respuesta patol3gica completa en pacientes sometidos a neoadyuvancia en c4ncer de recto. Revista Chilena De Cirugia, 2013, 65, 333-337.	0.1	2
1918	The Role of Diverting Stoma After an Ultra-low Anterior Resection for Rectal Cancer. Annals of Coloproctology, 2013, 29, 66.	0.5	37
1919	Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation. World Journal of Gastroenterology, 2013, 19, 5520.	1.4	42
1920	Valor pron3stico de la respuesta patol3gica a la radioquimioterapia preoperatoria en el c4ncer de recto bajo localmente avanzado. Revista Chilena De Cirugia, 2013, 65, 236-241.	0.1	3
1921	Patterns of Practice in the Radiation Therapy Management of Rectal Cancer: Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)" Tumori, 2013, 99, 61-67.	0.6	3
1922	Feasibility of Image-Guided Radiotherapy for Elderly Patients with Locally Advanced Rectal Cancer. PLoS ONE, 2013, 8, e71250.	1.1	4
1923	Rectal cancer staging: focus on the prognostic significance of the findings described by high-resolution magnetic resonance imaging. Cancer Imaging, 2013, 13, 277-297.	1.2	22
1924	Reappraisal of Pretreatment Carcinoembryonic Antigen in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. Tumori, 2013, 99, 93-99.	0.6	13
1925	Neo-adjuvant radiotherapy in rectal cancer. World Journal of Gastroenterology, 2013, 19, 8489.	1.4	51
1926	Improved Outcomes for Rectal Cancer in the Era of Preoperative Chemoradiation and Tailored Mesorectal Excision: A Series of 338 Consecutive Cases. American Surgeon, 2013, 79, 151-161.	0.4	8
1927	PET " Assessment of Oncologic Treatment Response. , 0, , .		0
1928	Postoperative Complications after Preoperative Chemoradiotherapy Combined with Hyperthermia in Locally Advanced Rectal Cancer. Progress in Medical Physics, 2014, 25, 89.	0.4	1
1929	Tumor Volume Reduction Assessed by Planning Computed Tomography in Patients with Rectal Cancer during Preoperative Chemoradiation: Impact of Residual Tumor Volume on the Prediction of Pathologic Tumor Regression. Tumori, 2014, 100, 158-162.	0.6	2
1930	Current State-of-the-Science Adjuvant and Neoadjuvant Therapy in Surgically Resected Colorectal Cancer. , 2014, , .		0
1931	Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World Journal of Gastroenterology, 2014, 20, 15820.	1.4	20
1932	S-1-Based versus Capecitabine-Based Preoperative Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer: A Matched-Pair Analysis. PLoS ONE, 2014, 9, e106162.	1.1	6
1933	Prognostic Nomograms for Predicting Survival and Distant Metastases in Locally Advanced Rectal Cancers. PLoS ONE, 2014, 9, e106344.	1.1	41

#	ARTICLE	IF	CITATIONS
1934	High Frequency of CD8 Positive Lymphocyte Infiltration Correlates with Lack of Lymph Node Involvement in Early Rectal Cancer. <i>Disease Markers</i> , 2014, 2014, 1-7.	0.6	16
1935	Adjuvant therapy for gastric cancer: Current and future directions. <i>World Journal of Gastroenterology</i> , 2014, 20, 13718.	1.4	38
1936	Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. <i>Journal of Cancer</i> , 2014, 5, 31-43.	1.2	64
1937	Overview of Radiation Therapy for Treating Rectal Cancer. <i>Annals of Coloproctology</i> , 2014, 30, 165.	0.5	42
1938	Colorectal cancer: From prevention to personalized medicine. <i>World Journal of Gastroenterology</i> , 2014, 20, 6786.	1.4	281
1939	Extended Low Hartmann Operation with Total Mesorectal Excision - Optimal Surgical Treatment in Stage IV Mid and Upper Rectal Cancer. <i>Jurnalul De Chirurgie</i> , 2014, 10, .	0.0	0
1940	Oral metastasis from rectal adenocarcinoma: case report. <i>Case Reports in Clinical Pathology</i> , 2014, 1, .	0.0	0
1941	Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 170.	0.8	2
1943	Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIb and IIIc rectal cancer treated with preoperative radiotherapy. <i>Oncotarget</i> , 2014, 5, 12459-12471.	0.8	27
1945	Can We Predict Complete or Major Response after Chemoradiotherapy for Rectal Cancer by Noninvasive Methods? Results of a Prospective Study on 61 Patients. <i>American Surgeon</i> , 2014, 80, 1136-1145.	0.4	7
1946	Laparoscopic Total Mesorectal Excision for Ultralow Rectal Cancer with Transanal Intersphincteric Dissection as a First Step: A Single-surgeon Experience. <i>American Surgeon</i> , 2014, 80, 26-30.	0.4	6
1947	The Complexity of Colorectal Cancer Biology – Putting Bricks on the Path to Personalized Medicine. , 0, , .		1
1949	Colorectal Cancer: All Hands on Deck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 83-89.	1.8	9
1950	Adjuvant Treatment in Colorectal Cancer. , 2014, , .		5
1952	Robotic Surgery. , 2014, , .		2
1953	Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. <i>Annals of Oncology</i> , 2014, 25, 2134-2146.	0.6	90
1954	Survival after pelvic exenteration for T4 rectal cancer. <i>British Journal of Surgery</i> , 2014, 102, 125-131.	0.1	53
1955	Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. <i>Colorectal Disease</i> , 2014, 16, O66-70.	0.7	36

#	ARTICLE	IF	CITATIONS
1957	Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. <i>World Journal of Surgical Oncology</i> , 2014, 12, 329.	0.8	4
1958	Tumor SUVmax Normalized to Liver Uptake on 18F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 295-302.	0.6	30
1959	Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades. <i>BMC Cancer</i> , 2014, 14, 816.	1.1	30
1960	Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2014, 110, 1002-1010.	0.8	13
1961	Lymph node metastasis of carcinomas of transverse colon including flexures. Consideration of the extramesocolic lymph node stations. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1223-1229.	1.0	79
1962	Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?. <i>BMC Cancer</i> , 2014, 14, 888.	1.1	15
1963	Nomogram to predict ypN status after chemoradiation in patients with locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2014, 111, 249-254.	2.9	30
1964	Frozen section examination may facilitate reconstructive surgery for mid and low rectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 997-1001.	0.8	13
1965	The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer. <i>Colorectal Disease</i> , 2014, 16, O16-25.	0.7	42
1966	Changes in management and outcome of patients with rectal cancer in Northern Ireland: 1996-2006. <i>Colorectal Disease</i> , 2014, 16, O58-O65.	0.7	0
1967	Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. <i>Tumor Biology</i> , 2014, 35, 11097-11105.	0.8	25
1968	Patient-reported outcomes after neoadjuvant therapy for rectal cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 901-918.	1.1	17
1969	Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 263-266.	0.1	15
1970	Neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer. <i>Gastroenterology Report</i> , 2014, 2, 37-43.	0.6	12
1971	ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. <i>British Journal of Cancer</i> , 2014, 110, 430-434.	2.9	50
1972	Dosimetric Coverage of the External Anal Sphincter by 3-Dimensional Conformal Fields in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation: Implications for the Concept of Sphincter-Preserving Radiation Therapy. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	1
1973	Diagnostic Endosonography. , 2014, , .		1
1974	Clinical Outcome of Patients with Complete Pathological Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancers: The Indian Scenario. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-6.	0.7	8

#	ARTICLE	IF	CITATIONS
1975	STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. <i>Cancers</i> , 2014, 6, 1986-2011.	1.7	80
1976	Can positron emission tomography-computed tomography predict response in locally advanced rectal cancer patients treated with induction folinic acid and 5-fluorouracil?. <i>Indian Journal of Cancer</i> , 2014, 51, 138.	0.2	2
1977	Self-reported practice patterns and knowledge of rectal cancer care among Canadian general surgeons. <i>Canadian Journal of Surgery</i> , 2014, 57, 385-390.	0.5	3
1978	Radiation therapy schedule for rectal cancer. <i>Turk Onkoloji Dergisi</i> , 2014, 29, 57-66.	0.0	0
1979	Helical Tomotherapy Combined with Capecitabine in the Preoperative Treatment of Locally Advanced Rectal Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	10
1980	Does Preoperative Radio(chemo)therapy Increase Anastomotic Leakage in Rectal Cancer Surgery? A Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-7.	0.7	23
1981	Treatment Strategy for Rectal Cancer with Synchronous Metastasis: 65 Consecutive Italian Cases from the Bologna Multidisciplinary Rectal Cancer Group. <i>Oncology</i> , 2014, 86, 135-142.	0.9	8
1982	LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/ β^2 -catenin signaling pathway. <i>Oncology Reports</i> , 2014, 31, 1839-1845.	1.2	134
1983	Determinants of recurrence after intended curative resection for colorectal cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1399-1408.	0.6	18
1984	Patterns of care of radiation therapy in patients with stage IV rectal cancer: A Surveillance, Epidemiology, and End Results analysis of patients from 2004 to 2009. <i>Cancer</i> , 2014, 120, 731-737.	2.0	8
1985	A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. <i>International Journal of Cancer</i> , 2014, 135, 379-390.	2.3	32
1986	Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1153-1160.	0.4	52
1987	Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02. <i>Radiotherapy and Oncology</i> , 2014, 113, 18-23.	0.3	26
1988	Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2014, 23, 211-221.	0.8	63
1989	Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 109, 478-482.	0.8	20
1990	Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 113, 29-34.	0.3	47
1991	Learning curve of laparoscopic low anterior resection in terms of local recurrence. <i>Journal of Surgical Oncology</i> , 2014, 110, 989-996.	0.8	33
1992	Human epidermal growth factor receptor β expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis. <i>Cancer Science</i> , 2014, 105, 818-824.	1.7	17

#	ARTICLE	IF	CITATIONS
1993	Reply to "Prognostic Stratification by Extramural Depth of Tumor Invasion of Primary Rectal Cancer Based on the Radiological Society of North America". American Journal of Roentgenology, 2014, 203, W750-W750.	1.0	1
1994	Dynamic contrast enhanced-MRI in rectal cancer: Inter- and intraobserver reproducibility and the effect of slice selection on pharmacokinetic analysis. Journal of Magnetic Resonance Imaging, 2014, 40, 715-722.	1.9	7
1995	Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer. Molecular Carcinogenesis, 2014, 53, E130-9.	1.3	17
1996	Chemoradiotherapy response in recurrent rectal cancer. Cancer Medicine, 2014, 3, 111-117.	1.3	32
1997	Literature review: preoperative radiotherapy and rectal cancer " impact on acute symptom presentation and quality of life. Journal of Clinical Nursing, 2014, 23, 333-351.	1.4	26
1998	Watch and wait for rectal cancer: where are we really at?. Colorectal Disease, 2014, 16, 332-334.	0.7	7
1999	No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiotherapy and Oncology, 2014, 113, 223-229.	0.3	238
2000	Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncology, 2014, 10, 2243-2257.	1.1	15
2003	The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Colorectal Disease, 2014, 16, 783-787.	0.7	1
2004	Should a loop ileostomy closure in rectal cancer patients be done during or after adjuvant chemotherapy?. Journal of Surgical Oncology, 2014, 109, 266-269.	0.8	26
2005	MR imaging for rectal cancer: the role in staging the primary and response to neoadjuvant therapy. Expert Review of Gastroenterology and Hepatology, 2014, 8, 703-719.	1.4	30
2006	Early and Late Toxicity of Radiotherapy for Rectal Cancer. Recent Results in Cancer Research, 2014, 203, 189-201.	1.8	41
2007	Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surgery, 2014, 14, 94.	0.6	84
2008	Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal. Radiation Oncology, 2014, 9, 260.	1.2	19
2009	Baseline neutrophil-lymphocyte ratio (≥ 2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiation Oncology, 2014, 9, 295.	1.2	75
2010	Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?. Radiation Oncology, 2014, 9, 296.	1.2	12
2011	Long-term Outcome of Local Excision After Preoperative Chemoradiation for ypT0 Rectal Cancer. Diseases of the Colon and Rectum, 2014, 57, 1245-1252.	0.7	34
2012	Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Using Reverse Transcriptase Polymerase Chain Reaction Analysis of Four Genes. Diseases of the Colon and Rectum, 2014, 57, 23-31.	0.7	45

#	ARTICLE	IF	CITATIONS
2013	Multiparametric MRI of Rectal Cancer in the Assessment of Response to Therapy. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 790-799.	0.7	77
2014	Optimizing Rectal Cancer Management. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 252-259.	0.7	32
2015	Differences in Circumferential Resection Margin Involvement After Abdominoperineal Excision and Low Anterior Resection No Longer Significant. <i>Annals of Surgery</i> , 2014, 259, 1150-1155.	2.1	38
2016	Ureteral Injuries in Colorectal Surgery. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 179-186.	0.7	117
2017	Preoperative Chemoradiotherapy Effects on Anastomotic Leakage After Rectal Cancer Resection. <i>Annals of Surgery</i> , 2014, 259, 516-521.	2.1	45
2018	Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 545-549.	0.6	9
2019	Management of rectal cancer in France in a well-defined population. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 743-747.	0.8	5
2020	Long-term Oncologic Outcomes of Laparoscopic Versus Open Surgery for Rectal Cancer. <i>Annals of Surgery</i> , 2014, 259, 139-147.	2.1	61
2021	Transanal Local Excision for Distal Rectal Cancer and Incomplete Response to Neoadjuvant Chemoradiation – Does Baseline Staging Matter?. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 1253-1259.	0.7	23
2022	Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer. <i>Annals of Surgery</i> , 2014, 259, 508-515.	2.1	65
2023	Failure of Evidence-Based Cancer Care in the United States. <i>Annals of Surgery</i> , 2014, 260, 625-632.	2.1	140
2024	Gastrointestinal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 378-386.	1.0	7
2025	Standardized Laparoscopic Sphincter-preserving Total Mesorectal Excision for Rectal Cancer. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2014, 24, 145-152.	0.4	14
2026	Restaging of Locally Advanced Rectal Cancer With Magnetic Resonance Imaging and Endoluminal Ultrasound After Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 388-395.	0.7	78
2027	R1 Rectal Resection. <i>Annals of Surgery</i> , 2014, 260, 794-800.	2.1	33
2028	SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2713-2726.	1.9	51
2029	Magnetic resonance imaging in rectal cancer: A surgeon’s perspective. <i>World Journal of Gastroenterology</i> , 2014, 20, 2030.	1.4	16
2030	Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. <i>Frontiers in Oncology</i> , 2014, 4, 50.	1.3	43

#	ARTICLE	IF	CITATIONS
2031	Preoperative chemoradiation in locally advanced rectal cancer: A comparison of bolus 5-fluorouracil/leucovorin and capecitabine. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 102.	0.5	8
2032	The role of diffusion-weighted MRI and 18F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 113, 158-165.	0.3	155
2033	Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06). <i>Cancer Research and Treatment</i> , 2014, 46, 243-249.	1.3	20
2034	The English National Low Rectal Cancer Development Programme: key messages and future perspectives. <i>Colorectal Disease</i> , 2014, 16, 173-178.	0.7	61
2035	Neoadjuvant Radiotherapy (5Å—5 Gy): Immediate Versus Delayed Surgery. <i>Recent Results in Cancer Research</i> , 2014, 203, 171-187.	1.8	31
2036	Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy. <i>Molecular and Clinical Oncology</i> , 2014, 2, 99-104.	0.4	10
2037	Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. <i>BioScience Trends</i> , 2014, 8, 11-23.	1.1	24
2038	Indian Council of Medical Research consensus document for the management of colorectal cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 192-196.	0.1	26
2039	A Comparison of Laparoscopic and Open Surgery Following Pre-operative Chemoradiation Therapy for Locally Advanced Lower Rectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 305-310.	0.6	11
2040	Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. <i>Journal of Clinical Pathology</i> , 2014, 67, 1056-1061.	1.0	23
2041	The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 188.	1.2	11
2042	Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 233.	1.2	3
2043	Coexistence of Perineural Invasion and Lymph Node Metastases Is a Poor Prognostic Factor in Patients with Locally Advanced Rectal Cancer after Preoperative Chemoradiotherapy Followed by Radical Resection and Adjuvant Chemotherapy. <i>Medical Principles and Practice</i> , 2014, 23, 465-470.	1.1	16
2044	Barium Enema and CT Volumetry for Predicting Pathologic Response to Preoperative Chemoradiotherapy in Rectal Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 715-724.	0.7	11
2045	Early-Stage Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 449-459.	0.7	37
2046	The Magnetic Resonance Imaging-Based Approach for Identification of High-Risk Patients With Upper Rectal Cancer. <i>Annals of Surgery</i> , 2014, 260, 293-298.	2.1	15
2047	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 301-305.	0.4	21
2048	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). <i>Radiotherapy and Oncology</i> , 2014, 110, 150-154.	0.3	21

#	ARTICLE	IF	CITATIONS
2049	Clinical utility of integrated positron emission tomography/computed tomography imaging in the clinical management and radiation treatment planning of locally advanced rectal cancer. <i>Practical Radiation Oncology</i> , 2014, 4, 226-232.	1.1	15
2050	Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?. <i>Surgery</i> , 2014, 155, 468-475.	1.0	30
2051	Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients. <i>Digestive and Liver Disease</i> , 2014, 46, 645-651.	0.4	7
2052	Target volume delineation in external beam partial breast irradiation: Less inter-observer variation with preoperative- compared to postoperative delineation. <i>Radiotherapy and Oncology</i> , 2014, 110, 467-470.	0.3	41
2053	Current Practices and Challenges of Adjuvant Chemotherapy in Patients with Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 49-58.	0.6	9
2054	Evidence based radiation oncology with existing technology. <i>Reports of Practical Oncology and Radiotherapy</i> , 2014, 19, 259-266.	0.3	13
2055	Effect of chemotherapy, radiation, or immunosuppression on the integrity of the intestinal anastomosis. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 105-109.	0.2	3
2056	Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 829-836.	0.4	82
2058	Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 149-157.	1.0	24
2059	Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 158-164.	1.0	28
2060	Laparoscopic Total Mesorectal Excision for Extraperitoneal Rectal Cancer: Long-Term Results of a 18-Year Single-Centre Experience. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 796-807.	0.9	9
2061	MRI-Based Treatment of Rectal Cancer: Is Prognostication of the Recurrence Risk Solid Enough to Render Radiation Redundant?. <i>Annals of Surgical Oncology</i> , 2014, 21, 197-204.	0.7	9
2062	Selective Lateral Pelvic Lymph Node Dissection in Patients with Advanced Low Rectal Cancer Treated with Preoperative Chemoradiotherapy Based on Pretreatment Imaging. <i>Annals of Surgical Oncology</i> , 2014, 21, 189-196.	0.7	205
2063	Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer. <i>Surgery Today</i> , 2014, 44, 2227-2242.	0.7	17
2064	Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 889-896.	1.0	18
2065	Pelvic Exenteration for the Treatment of Locally Advanced Colorectal and Bladder Malignancies in the Modern Era. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 782-788.	0.9	17
2066	Long-term oncologic outcome after laparoscopic surgery for rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1119-1125.	1.3	16
2067	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 513-518.	0.8	375

#	ARTICLE	IF	CITATIONS
2068	Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. <i>International Journal of Colorectal Disease</i> , 2014, 29, 301-307.	1.0	106
2069	Functional long-term results after rectal cancer surgeryâ€”technique of the athermal mesorectal excision. <i>International Journal of Colorectal Disease</i> , 2014, 29, 285-292.	1.0	2
2070	Laparoscopic Versus Open Surgery Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 617-626.	0.9	16
2071	Role of Pelvic Exenteration in the Management of Locally Advanced Primary and Recurrent Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 291-297.	0.6	8
2072	MRI and FDG-PET for Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1801-1808.	0.7	17
2073	Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 399-409.	1.2	7
2074	Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. <i>Techniques in Coloproctology</i> , 2014, 18, 699-708.	0.8	51
2075	Treatment of Stage IIâ€“III Rectal Cancer Patients. <i>Current Oncology Reports</i> , 2014, 16, 362.	1.8	9
2076	Robotic Colorectal Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 398-403.	0.9	20
2077	Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. <i>International Journal of Colorectal Disease</i> , 2014, 29, 529-538.	1.0	16
2078	Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2014, 29, 165-175.	1.0	70
2079	Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2014, 29, 193-200.	1.0	68
2080	ypN0 nodal status after neoadjuvant chemoradiotherapy for rectal carcinoma is not associated with adverse prognosis as compared with pN0 after primary surgery. <i>International Journal of Colorectal Disease</i> , 2014, 29, 231-237.	1.0	8
2081	Neoadjuvant vs Adjuvant Therapy for Resectable Pancreatic Cancer: The Evolving Role of Radiation. <i>Seminars in Radiation Oncology</i> , 2014, 24, 113-125.	1.0	17
2082	The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection. <i>American Journal of Surgery</i> , 2014, 207, 357-360.	0.9	4
2083	Impaired continence function five years after intensified chemoradiation in patients with locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2014, 40, 227-233.	0.5	16
2084	Quality Assurance in Colon and Rectal Cancer Surgery. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 11-23.	0.6	7
2085	Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1554-1562.	0.8	351

#	ARTICLE	IF	CITATIONS
2086	EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. <i>Annals of Oncology</i> , 2014, 25, 858-863.	0.6	85
2087	Preoperative therapy for rectal cancer: Short-course radiation vs. long-course chemoradiation. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 19-21.	0.2	4
2088	Non-operative management of locally advanced rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 22-25.	0.2	1
2089	Mandard Tumour Regression Grade, Perineural Invasion, Circumferential Resection Margin and Post-chemoradiation Nodal Status Strongly Predict Outcome in Locally Advanced Rectal Cancer Treated with Preoperative Chemoradiotherapy. <i>Clinical Oncology</i> , 2014, 26, 197-202.	0.6	32
2090	Sphincter-Sparing Surgery in Patients with Low-Lying Rectal Cancer: Techniques, Oncologic Outcomes, and Functional Results. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1358-1372.	0.9	57
2091	Lateral pelvic lymph node dissection can be omitted in lower rectal cancer in which the longest lateral pelvic and perirectal lymph node is less than 5â€‰%mm on MRI. <i>Journal of Surgical Oncology</i> , 2014, 109, 227-233.	0.8	16
2092	Magnetic Resonance Imaging in Rectal Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2014, 22, 165-190.	0.6	23
2093	Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria. <i>British Journal of Surgery</i> , 2014, 101, 566-572.	0.1	37
2094	Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. <i>Surgical Oncology</i> , 2014, 23, 53-60.	0.8	42
2095	Evaluation of Lateral Pelvic Nodes in Patients With Advanced Rectal Cancer. <i>American Journal of Roentgenology</i> , 2014, 202, 1245-1255.	1.0	21
2096	A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration. <i>International Journal of Colorectal Disease</i> , 2014, 29, 813-823.	1.0	77
2097	MRI of rectal carcinoma: Preoperative staging and planning of sphincter-sparing surgery. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2014, 45, 1-5.	0.3	5
2098	KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. <i>Journal of Clinical Pathology</i> , 2014, 67, 1-9.	1.0	30
2099	Reconsideration of the Indications for Adjuvant Chemotherapy for Liver Metastases from Colorectal Cancer After Initial Hepatectomy. <i>Annals of Surgical Oncology</i> , 2014, 21, 139-146.	0.7	21
2100	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2014, 25, 121-126.	0.6	27
2101	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. <i>Lancet Oncology</i> , The, 2014, 15, 184-190.	5.1	611
2102	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologistâ€™s expert review. <i>Radiotherapy and Oncology</i> , 2014, 110, 195-198.	0.3	61
2103	Clinical implication of negative conversion of predicted circumferential resection margin status after preoperative chemoradiotherapy for locally advanced rectal cancer. <i>European Journal of Radiology</i> , 2014, 83, 245-249.	1.2	7

#	ARTICLE	IF	CITATIONS
2104	Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: Pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 128-132.	0.6	7
2105	Analysis of Bevacizumab-based Preoperative Radiochemotherapy in Patients with Locally Advanced Rectal Cancer on Surgery-associated Spectrum of Complications. <i>Annals of Surgical Oncology</i> , 2014, 21, 1352-1360.	0.7	6
2106	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	1.3	349
2107	Functional Consequences of Colorectal Cancer Management. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 127-149.	0.6	20
2108	Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 34-43.	0.8	477
2109	Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: Does it work at all?. <i>Acta Oncologica</i> , 2014, 53, 865-876.	0.8	16
2110	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
2111	Immediate Surgery or Clinical Follow-Up After a Complete Clinical Response?. <i>Recent Results in Cancer Research</i> , 2014, 203, 203-210.	1.8	8
2112	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	179
2113	What is the best position for analyzing the lower and middle rectum and sphincter function in a digital rectal examination? A randomized, controlled study in men. <i>Digestive and Liver Disease</i> , 2014, 46, 1082-1085.	0.4	1
2114	Therapeutic Management and Outcome of Locoregional Recurrence After Curative Colorectal Cancer Therapy—a Single-Center Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2026-2033.	0.9	15
2115	Circumferential resection margins of rectal tumours post-radiotherapy: how can MRI aid surgical planning?. <i>Techniques in Coloproctology</i> , 2014, 18, 937-943.	0.8	9
2116	Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy. <i>British Journal of Surgery</i> , 2014, 101, 1290-1298.	0.1	33
2117	Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2014, 10, e360-e367.	2.5	9
2118	Diagnostic accuracy and prognostic impact of restaging by magnetic resonance imaging after preoperative chemoradiotherapy in patients with rectal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 24-28.	0.3	15
2119	Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. <i>Annals of Oncology</i> , 2014, 25, 2205-2210.	0.6	44
2120	Risk-Adjusted Pathologic Margin Positivity Rate As a Quality Indicator in Rectal Cancer Surgery. <i>Journal of Clinical Oncology</i> , 2014, 32, 2967-2974.	0.8	46
2121	Altered Fractionation Schedules in Radiation Treatment: A Review. <i>Seminars in Oncology</i> , 2014, 41, 730-750.	0.8	30

#	ARTICLE	IF	CITATIONS
2122	Statistical Modeling of CTV Motion and Deformation for IMRT of Early-Stage Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 664-672.	0.4	15
2123	Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer, 2014, 120, 3329-3337.	2.0	15
2124	Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Therapy, 2014, 21, 181-187.	2.2	104
2125	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	5.1	336
2126	Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer. Clinical Cancer Research, 2014, 20, 1891-1899.	3.2	298
2127	Impact of acellular mucin pools on survival in patients with complete pathological response to neoadjuvant treatment in rectal cancer. International Journal of Surgery, 2014, 12, 1123-1126.	1.1	24
2128	Stomach Cancer in Niger: First Results from the Niger Cancer Registry. Annals of Oncology, 2014, 25, ii35.	0.6	0
2129	Milestones in the Use of Combined-Modality Radiation Therapy and Chemotherapy. Journal of Clinical Oncology, 2014, 32, 1173-1179.	0.8	36
2130	Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. Journal of Surgical Oncology, 2014, 109, 659-664.	0.8	15
2131	Advances in the management of colorectal cancer: from biology to treatment. International Journal of Colorectal Disease, 2014, 29, 1031-1042.	1.0	75
2133	Role of (Chemo)-Radiotherapy in Resectable Gastric Cancer. Clinical Oncology, 2014, 26, 541-550.	0.6	12
2134	Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. Journal of Magnetic Resonance Imaging, 2014, 40, 730-737.	1.9	64
2135	Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment – A pilot study. European Journal of Surgical Oncology, 2014, 40, 1459-1466.	0.5	14
2136	Exenterative Surgery for Advanced Prostate Cancer. Current Surgery Reports, 2014, 2, 1.	0.4	0
2137	Analysis of 116 cases of rectal cancer treated by transanal local excision. World Journal of Surgical Oncology, 2014, 12, 202.	0.8	22
2138	The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer. International Journal of Colorectal Disease, 2014, 29, 1061-1068.	1.0	3
2139	Role of Genetic Polymorphisms in NFkB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 595-602.	0.4	15
2140	Comparison between magnetic resonance imaging and rigid rectoscopy in the preoperative identification of intra- and extraperitoneal rectal cancer. Colorectal Disease, 2014, 16, O379-85.	0.7	17

#	ARTICLE	IF	CITATIONS
2143	Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 515-520.	1.0	48
2146	Integrated 18F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1563-1573.	3.3	10
2147	Effectiveness of a Transanal Tube for the Prevention of Anastomotic Leakage after Rectal Cancer Surgery. <i>World Journal of Surgery</i> , 2014, 38, 1843-1851.	0.8	77
2148	Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1079-1087.	1.1	68
2149	Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2014, 29, 835-842.	1.0	6
2150	Multiple primary tumors following stage II and III rectal cancer in patients receiving radiotherapy, 1998â€”2010. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 949-955.	1.2	13
2151	Intraoperative staging by surgeons in patients with rectal cancer after preoperative chemoradiation: diagnostic accuracy and prognostic value. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1221-1227.	1.2	3
2152	Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1489-1494.	1.2	32
2153	Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1651-1660.	1.2	29
2154	Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 297-306.	1.3	65
2155	Safety and factors contributing to the difficulty of laparoscopic surgery for rectal cancer treated with preoperative chemoradiotherapy. <i>Techniques in Coloproctology</i> , 2014, 18, 247-255.	0.8	24
2156	Neoadjuvant Radiation Therapy Prior to Total Mesorectal Excision for Rectal Cancer is Not Associated with Postoperative Complications Using Current Techniques. <i>Annals of Surgical Oncology</i> , 2014, 21, 2295-2302.	0.7	14
2157	Functional results after treatment for rectal cancer. <i>Journal of Coloproctology</i> , 2014, 34, 055-061.	0.1	20
2158	Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy. <i>Cancer</i> , 2014, 120, 1733-1742.	2.0	40
2159	In situ airborne virus inactivation by microwave irradiation. <i>Science Bulletin</i> , 2014, 59, 1438-1445.	1.7	25
2160	Laparoscopic Salvage Surgery for Locally Recurrent Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1319-1326.	0.9	19
2161	NSAID Use and Anastomotic Leaks Following Elective Colorectal Surgery: a Matched Case-Control Study. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1391-1397.	0.9	36
2162	Short-Course versus Long-Course Chemoradiation in Rectal Cancerâ€”Time to Change Strategies?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 421-428.	1.3	13

#	ARTICLE	IF	CITATIONS
2163	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 164-172.	1.0	4
2164	Do Improvements in Surgical Technique Mean it is Time to be more Selective in our Approach to Neoadjuvant Radiotherapy for Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 173-179.	1.0	2
2165	Icariin Enhances Radiosensitivity of Colorectal Cancer Cells by Suppressing NF- κ B Activity. <i>Cell Biochemistry and Biophysics</i> , 2014, 69, 303-310.	0.9	33
2166	Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 34-39.	0.6	36
2167	Paradigm Shift in the Management of Rectal Cancer. <i>Indian Journal of Surgery</i> , 2014, 76, 474-481.	0.2	2
2168	Metastatic lymph node ratio can further stratify prognosis in rectal cancer patients treated with preoperative radiotherapy: a population-based analysis. <i>Tumor Biology</i> , 2014, 35, 6389-6395.	0.8	16
2169	Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance. <i>Tumor Biology</i> , 2014, 35, 6823-6830.	0.8	18
2170	Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy. <i>Tumor Biology</i> , 2014, 35, 7755-7763.	0.8	17
2171	Increasing late stage colorectal cancer and rectal cancer mortality demonstrates the need for screening: a population based study in Ireland, 1994-2010. <i>BMC Gastroenterology</i> , 2014, 14, 92.	0.8	14
2172	p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. <i>BMC Cancer</i> , 2014, 14, 241.	1.1	27
2173	Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. <i>Radiation Oncology</i> , 2014, 9, 88.	1.2	114
2174	Short-term outcomes of laparoscopically assisted surgery for rectal cancer following neoadjuvant chemoradiotherapy: a single-center experience. <i>Journal of Surgical Research</i> , 2014, 187, 438-444.	0.8	10
2175	Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. <i>Annals of Oncology</i> , 2014, 25, 1356-1362.	0.6	247
2176	Pitfalls of transanal endoscopic microsurgery for rectal cancer following neoadjuvant chemoradiation therapy. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2014, 23, 63-69.	0.6	15
2177	Management of rectal cancer: Times they are changing. <i>GE Portuguese Journal of Gastroenterology</i> , 2014, 21, 192-200.	0.3	8
2178	Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. <i>Cancer</i> , 2014, 120, 499-506.	2.0	39
2179	Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. <i>Clinical Colorectal Cancer</i> , 2014, 13, 185-191.	1.0	23
2180	Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: A systematic review. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1186-1194.	0.5	37

#	ARTICLE	IF	CITATIONS
2181	Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. <i>Journal of Clinical Oncology</i> , 2014, 32, 1927-1934.	0.8	373
2182	Current Controversies in Neoadjuvant Chemoradiation of Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 79-92.	0.6	7
2183	Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer. <i>American Journal of Surgery</i> , 2014, 208, 99-105.	0.9	16
2184	Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome. <i>Journal of Surgical Oncology</i> , 2014, 110, 463-467.	0.8	38
2185	Fragmented pattern of tumor regression and lateral intramural spread may influence margin appropriateness after TEM for rectal cancer following neoadjuvant CRT. <i>Journal of Surgical Oncology</i> , 2014, 109, 853-858.	0.8	38
2186	P6 Comparison of outcomes following minimally invasive versus transhiatal esophagectomy for esophageal cancer; a case control study. <i>European Journal of Cancer</i> , 2014, 50, S10-S11.	1.3	0
2187	P8 Preoperative radiotherapy or radiochemotherapy for locally advanced rectal cancer patients: single centre experience. <i>European Journal of Cancer</i> , 2014, 50, S11.	1.3	0
2188	Preoperative endorectal brachytherapy in the treatment of locally advanced rectal cancer: Rethinking neoadjuvant treatment. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 26-32.	0.2	0
2189	Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: Report on late toxicity and outcome. <i>Radiotherapy and Oncology</i> , 2014, 110, 155-159.	0.3	60
2190	Surveillance, Epidemiology, and End Results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer. <i>Cancer Epidemiology</i> , 2014, 38, 73-78.	0.8	22
2191	Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 767-774.	5.1	713
2192	Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1188-1195.	0.4	29
2193	P7 A single institution's experience in rectal cancer. <i>European Journal of Cancer</i> , 2014, 50, S11.	1.3	0
2194	Adjuvant chemotherapy for rectal cancer. <i>Lancet Oncology</i> , The, 2014, 15, e195-e196.	5.1	1
2195	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Resultsâ€”Medicare data, 1998â€”2007. <i>Cancer</i> , 2014, 120, 1162-1170.	2.0	43
2196	Repeatability of diffusion-weighted imaging in rectal cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 146-150.	1.9	25
2197	Amputaci3n abdominoperineal extraelevadora en posici3n prono. <i>CirugÃ±a EspaÃ±ola</i> , 2014, 92, 30-39.	0.1	4
2198	Association between surgeon characteristics and their preferences for guideline-concordant staging and treatment for rectal cancer. <i>American Journal of Surgery</i> , 2014, 208, 817-823.	0.9	17

#	ARTICLE	IF	CITATIONS
2199	Usefulness of diffusion-weighted MRI in the characterization and assessment of response to neoadjuvant therapy in rectal cancer. <i>Imaging in Medicine</i> , 2014, 6, 75-87.	0.0	0
2200	Técnicas reconstructivas tras amputación abdominoperineal extraelevadora del recto o exenteración pélvica: mallas, plastias y colgajos. <i>Cirugía Española</i> , 2014, 92, 48-57.	0.1	13
2201	Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 235-243.	2.3	14
2202	Evolving standards in preoperative staging and treatment of rectal cancer. <i>Hong Kong Medical Journal</i> , 2014, 20, 364-365.	0.1	0
2203	Evolving treatment strategies for colorectal cancer: A critical review of current therapeutic options. <i>World Journal of Gastroenterology</i> , 2014, 20, 877.	1.4	34
2204	Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 2023.	1.4	28
2205	Multidisciplinary treatment of rectal cancer in 2014: Where are we going?. <i>World Journal of Gastroenterology</i> , 2014, 20, 11249.	1.4	22
2206	Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2014, 96, 543-546.	0.3	21
2207	Management of colorectal cancer. <i>F1000prime Reports</i> , 2014, 6, 108.	5.9	86
2208	Future Directions for Monitoring Treatment Response in Colorectal Cancer. <i>Journal of Cancer</i> , 2014, 5, 44-57.	1.2	40
2209	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 513-519.	2.3	186
2210	Endoscopic Versus Radiology-Based Location of Rectal Cancer. <i>Acta Chirurgica Belgica</i> , 2014, 114, 364-369.	0.2	10
2212	Pelvic Bladder Sling for Radiotherapy. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 546-548.	0.7	1
2213	The Contemporary (Over)Treatment of Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 403-406.	0.7	7
2214	Intensity-modulated radiation therapy for patients with rectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 235-238.	0.8	2
2215	Classic and modern issues for the management and research on locally advanced rectal cancer: what are the frontiers?. <i>Colorectal Cancer</i> , 2014, 3, 465-468.	0.8	0
2216	Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. <i>Radiation Oncology</i> , 2014, 9, 70.	1.2	58
2217	Have we put the cart before the horse? Reordering treatments for rectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 311-313.	0.8	1

#	ARTICLE	IF	CITATIONS
2218	Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients. <i>Oncology Reports</i> , 2014, 31, 463-471.	1.2	18
2219	Upregulation of stromal cell-derived factor 1 \pm expression is associated with the resistance to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: Angiogenic markers of neoadjuvant chemoradiation. <i>Oncology Reports</i> , 2014, 32, 2493-2500.	1.2	12
2220	Problem of colorectal cancer in India and issues related to management. <i>Apollo Medicine</i> , 2015, 12, 190-193.	0.0	0
2221	Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1129-1134.	0.4	9
2222	Laparoscopic Low Anterior Resection and Eversion Technique Combined With a Nondog Ear Anastomosis for Mid- and Distal Rectal Neoplasms. <i>Medicine (United States)</i> , 2015, 94, e2285.	0.4	17
2223	Promises and pitfalls of total mesorectal excision: getting the best outcomes. <i>Colorectal Cancer</i> , 2015, 4, 213-220.	0.8	0
2224	Zerumbone increases oxidative stress in a thiol \hat{a} dependent <sc>ROS</sc> \hat{a} independent manner to increase <sc>DNA</sc> damage and sensitize colorectal cancer cells to radiation. <i>Cancer Medicine</i> , 2015, 4, 278-292.	1.3	51
2225	Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. <i>The Cochrane Library</i> , 2015, , .	1.5	7
2226	Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy. <i>Scientific Reports</i> , 2015, 5, 16990.	1.6	11
2227	Colorectal cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15065.	18.1	1,104
2228	Elevated Platelet Count as Predictor of Recurrence in Rectal Cancer Patients Undergoing Preoperative Chemoradiotherapy Followed by Surgery. <i>International Surgery</i> , 2015, 100, 199-207.	0.0	41
2229	Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer: Does Time to Surgery Matter?. <i>International Surgery</i> , 2015, 100, 968-973.	0.0	9
2230	Oncologic Impact of Fewer Than 12 Lymph Nodes in Patients Who Underwent Neoadjuvant Chemoradiation Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e1133.	0.4	11
2231	A comparison of the usage of anal verge and dentate line in measuring distances within the rectum. <i>International Journal of Surgery Open</i> , 2015, 1, 18-21.	0.2	6
2232	Case \hat{a} matched comparison of short and middle term survival after laparoscopic versus open rectal and rectosigmoid cancer surgery. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2015, 47, 303-311.	0.3	1
2233	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 289-297.	1.0	0
2234	Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?. <i>Radiation Oncology</i> , 2015, 10, 257.	1.2	15
2235	Lymph node identification following neoadjuvant therapy in rectal cancer: A stage \hat{a} stratified analysis using the surveillance, epidemiology, and end results (SEER) \hat{a} medicare database. <i>Journal of Surgical Oncology</i> , 2015, 112, 415-420.	0.8	4

#	ARTICLE	IF	CITATIONS
2236	Selective Approach for Upper Rectal Cancer Treatment. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 556-565.	0.7	35
2237	Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. <i>BMC Cancer</i> , 2015, 15, 767.	1.1	276
2238	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. <i>BMC Cancer</i> , 2015, 15, 764.	1.1	32
2239	CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer. <i>BMC Cancer</i> , 2015, 15, 923.	1.1	12
2240	Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. <i>BMC Cancer</i> , 2015, 15, 953.	1.1	29
2241	MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 252.	1.8	138
2242	The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. <i>Radiation Oncology</i> , 2015, 10, 198.	1.2	27
2243	Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. <i>Radiation Oncology</i> , 2015, 10, 255.	1.2	10
2244	Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. <i>Chinese Journal of Cancer</i> , 2015, 34, 394-403.	4.9	16
2245	Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 468-74.	4.9	32
2246	Volumetric Parameters Changes of Sequential 18F-FDG PET/CT for Early Prediction of Recurrence and Death in Patients With Locally Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy. <i>Clinical Nuclear Medicine</i> , 2015, 40, 930-935.	0.7	19
2247	Determinants of survival following pelvic exenteration for primary rectal cancer. <i>British Journal of Surgery</i> , 2015, 102, 1278-1284.	0.1	35
2248	Regional lymph node status after neoadjuvant chemoradiation of rectal cancer producing a complete or near complete rectal wall response. <i>Colorectal Disease</i> , 2015, 17, 595-599.	0.7	7
2249	The Anal Canal as a Risk Organ in Cervical Cancer Patients with Hemorrhoids Undergoing Whole Pelvic Radiotherapy. <i>Tumori</i> , 2015, 101, 72-77.	0.6	4
2250	Can Surgery be Avoided After Preoperative Chemoradiation for Rectal Cancer in the Era of Organ Preservation? Current Review of Literature. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 534-540.	0.6	13
2251	Use of capecitabine before and after chemoradiation in locally advanced rectal cancer: what is the evidence?. <i>Colorectal Cancer</i> , 2015, 4, 203-206.	0.8	0
2252	Effect of Multidisciplinary Cancer Conference on Treatment Plan for Patients With Primary Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 653-658.	0.7	30
2253	Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 564-569.	0.6	25

#	ARTICLE	IF	CITATIONS
2254	KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. <i>Medicine (United States)</i> , 2015, 94, e1284.	0.4	19
2255	Open Surgery Against Laparoscopic Surgery for Mid-Rectal or Low-Rectal Cancer of Male Patients. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2015, 25, 444-448.	0.4	3
2256	A population-based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 752-765.	0.9	6
2257	Tumor Budding in Colorectal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1340-1346.	2.1	95
2258	Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e2060.	0.4	9
2259	Neoadjuvant chemoradiation for rectal cancer is not associated with higher rates of thromboembolism. <i>Colorectal Disease</i> , 2015, 17, 984-989.	0.7	1
2260	The Importance of a Minimal Tumor-Free Resection Margin in Locally Recurrent Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 677-685.	0.7	32
2261	Prognostic Significance of Statin Use in Colorectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e908.	0.4	36
2262	Factors Associated With Oncologic Outcomes Following Abdominoperineal or Intersphincteric Resection in Patients Treated With Preoperative Chemoradiotherapy. <i>Medicine (United States)</i> , 2015, 94, e2060.	0.4	10
2263	Fighting for Academic Surgical Oncology. <i>Annals of Surgery</i> , 2015, 262, 701-703.	2.1	0
2264	Management of cancer of the colon and rectum. , 0, , 224-241.		0
2265	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. <i>Oncotarget</i> , 2015, 6, 8261-8270.	0.8	54
2266	Risk Factors of Permanent Stomas in Patients with Rectal Cancer after Low Anterior Resection with Temporary Stomas. <i>Yonsei Medical Journal</i> , 2015, 56, 447.	0.9	26
2267	An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. <i>Oncotarget</i> , 2015, 6, 32561-32574.	0.8	45
2268	Rectal cancer: An evidence-based update for primary care providers. <i>World Journal of Gastroenterology</i> , 2015, 21, 7659.	1.4	52
2269	URINARY DYSFUNCTION AFTER SURGICAL TREATMENT FOR RECTAL CANCER. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 180-185.	0.3	12
2270	Locally Advanced Rectal Cancer: Time for Precision Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e192-e196.	1.8	16
2271	Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis. <i>Yonsei Medical Journal</i> , 2015, 56, 82.	0.9	5

#	ARTICLE	IF	CITATIONS
2272	Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2015, 88, 15.	0.4	26
2273	Plastic and Reconstructive Surgery in the Treatment of Oncological Perineal and Genital Defects. <i>Frontiers in Oncology</i> , 2015, 5, 212.	1.3	29
2274	New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. <i>Yonsei Medical Journal</i> , 2015, 56, 1461.	0.9	31
2275	Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. <i>Oncotarget</i> , 2015, 6, 42354-42361.	0.8	64
2276	Identification of Locally Advanced Rectal Cancer with Low Risk of Local Recurrence. <i>PLoS ONE</i> , 2015, 10, e0117141.	1.1	9
2277	Impact of Postoperative Chemoradiotherapy versus Chemotherapy Alone on Recurrence and Survival in Patients with Stage II and III Upper Rectal Cancer: A Propensity Score-Matched Analysis. <i>PLoS ONE</i> , 2015, 10, e0123657.	1.1	6
2278	Evaluating Variations of Bladder Volume Using an Ultrasound Scanner in Rectal Cancer Patients during Chemoradiation: Is Protocol-Based Full Bladder Maintenance Using a Bladder Scanner Useful to Maintain the Bladder Volume?. <i>PLoS ONE</i> , 2015, 10, e0128791.	1.1	18
2279	Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0124601.	1.1	3
2280	Treating patients with advanced rectal cancer and lateral pelvic lymph nodes with preoperative chemoradiotherapy based on pretreatment imaging. <i>OncoTargets and Therapy</i> , 2015, 8, 3169.	1.0	10
2281	Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease. <i>International Scholarly Research Notices</i> , 2015, 2015, 1-10.	0.9	2
2282	Characteristics and Prognostic Significance of Preoperative Magnetic Resonance Imaging-Assessed Circumferential Margin in Rectal Cancer. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-8.	0.7	7
2283	Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	43
2284	Long-term Outcomes of Laparoscopic versus Open Surgery for Rectal Cancer: A Singlecenter Retrospective Analysis. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2015, 65, 273.	0.2	7
2285	<i>The Impact of Surgical Diversion Before Neoadjuvant Therapy for Rectal Cancer</i>. <i>American Surgeon</i> , 2015, 81, 444-449.	0.4	4
2286	Lymph Node Size Alone is Not an Accurate Predictor of Metastases in Rectal Cancer: A Node-for-Node Comparative Study of Specimens and Histology. <i>American Surgeon</i> , 2015, 81, 1263-1271.	0.4	9
2287	Anastomotic Leakage after Anterior Resection for Rectal Cancer with Mesorectal Excision: Incidence, Risk Factors, and Management. <i>American Surgeon</i> , 2015, 81, 41-47.	0.4	26
2288	Predicting Risk of Anastomotic Leak in Patients Undergoing Neo-adjuvant Radiotherapy and Low Anterior Resection for Rectal Cancer. , 2015, 05, .		1
2289	Avoiding Radical Surgery Improves Early Survival in Elderly Patients With Rectal Cancer, Demonstrating Complete Clinical Response After Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 159-171.	0.7	98

#	ARTICLE	IF	CITATIONS
2290	Value of ¹⁸ F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2015, 204, 1261-1268.	1.0	86
2291	Indications for Lateral Pelvic Lymph Node Dissection Based on Magnetic Resonance Imaging Before and After Preoperative Chemoradiotherapy in Patients with Advanced Low-Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 614-620.	0.7	140
2292	The predicting value of postoperative body temperature on long-term survival in patients with rectal cancer. <i>Tumor Biology</i> , 2015, 36, 8055-8063.	0.8	2
2293	Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: A California Cancer Registry Study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 647-652.	0.5	17
2294	Diagnostic value of preoperative CT scan to stratify colon cancer for neoadjuvant therapy. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1067-1073.	1.0	16
2295	A perspective on the current treatment strategies for locally advanced rectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 192-196.	1.2	3
2296	Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1498-1502.	2.3	19
2297	Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy. <i>Medical Radiology</i> , 2015, , .	0.0	25
2298	Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 21-27.	1.1	19
2299	MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 899-906.	1.0	41
2300	Role of intraoperative frozen section for assessing distal resection margin after anterior resection. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1081-1089.	1.0	13
2301	Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 543-548.	1.0	3
2302	Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapy. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 765-769.e1.	0.5	17
2303	How can we determine the best neoadjuvant chemoradiotherapy regimen for rectal cancer?. <i>Colorectal Cancer</i> , 2015, 4, 37-52.	0.8	0
2304	The Evolving Treatment of Rectal Cancer. , 2015, , 1-12.		5
2305	Prognostic Effect of Pretreatment Serum Carcinoembryonic Antigen Level. <i>Medicine (United States)</i> , 2015, 94, e1291.	0.4	13
2306	Real-time monitoring of tumor response to preoperative radiochemotherapy for rectal carcinoma by nonlinear optical microscopy. , 2015, , .		0
2307	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 275-280.	1.0	115

#	ARTICLE	IF	CITATIONS
2308	Predictors of Pathologic Complete Response in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation. <i>Medicine (United States)</i> , 2015, 94, e1971.	0.4	23
2309	Clinical Complete Response After Neoadjuvant Therapy in Rectal Cancer: Is Surgery Needed?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 360-368.	1.0	0
2310	Adjuvant Chemotherapy for Stage II Rectal Cancer. <i>Seminars in Oncology</i> , 2015, 42, e99-e107.	0.8	4
2311	Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer. <i>Oncology</i> , 2015, 89, 311-318.	0.9	21
2312	Prognostic Impact of Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Low Rectal Cancer Treated with Preoperative Chemoradiotherapy. <i>Digestive Surgery</i> , 2015, 32, 496-503.	0.6	54
2313	Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e2377.	0.4	1
2314	Outcomes of Neoadjuvant Chemotherapy without Radiation for Rectal Cancer. <i>Digestive Surgery</i> , 2015, 32, 275-283.	0.6	14
2315	Preoperative staging of rectal cancer with MRI: correlation with pathologic staging. <i>Journal of Coloproctology</i> , 2015, 35, 077-082.	0.1	2
2316	Randomized Trials and New Directions in Gastrointestinal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 459-464.	0.4	3
2317	Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. <i>Cancer Letters</i> , 2015, 357, 582-590.	3.2	44
2318	Incidence of Chemotherapy- and Chemoradiotherapy-Induced Amenorrhea in Premenopausal Women With Stage II/III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 31-34.	1.0	32
2319	Optimisation of Preoperative Assessment in Patients Diagnosed with Rectal Cancer. <i>Clinical Oncology</i> , 2015, 27, 225-245.	0.6	23
2320	Review on adjuvant chemotherapy for rectal cancer – why do treatment guidelines differ so much?. <i>Acta Oncologica</i> , 2015, 54, 437-446.	0.8	42
2321	Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome. <i>Annals of Surgical Oncology</i> , 2015, 22, 513-519.	0.7	42
2322	Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2015, 30, 19-29.	1.0	47
2323	Is There a Role for Adjuvant Chemotherapy in Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 70-77.	1.0	0
2324	The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 209-215.	0.7	32
2325	Consequence of Restaging After Neoadjuvant Treatment for Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 552-556.	0.7	9

#	ARTICLE	IF	CITATIONS
2326	Predictive markers of response to neoadjuvant therapy in rectal cancer. <i>Journal of Surgical Research</i> , 2015, 194, 120-126.	0.8	32
2327	The multidisciplinary approach to the treatment of rectal cancer: 2015 update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 507-517.	1.4	9
2328	Changing Operative Strategy from Abdominoperineal Resection to Sphincter Preservation in T3-4 Low Rectal Cancer after Downstaging by Neoadjuvant Chemoradiation: A Preliminary Report. <i>World Journal of Surgery</i> , 2015, 39, 1248-1256.	0.8	18
2329	Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 337-345.	1.0	17
2330	Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 217-225.	0.8	26
2331	Neoadjuvante Radiochemotherapie mit Gemcitabin/Cisplatin gefolgt von Resektion versus primärer Resektion bei resektablem Pankreaskopfkarcinom. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 7-16.	1.0	255
2332	Improved quality of care for patients undergoing an abdominoperineal excision for rectal cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 201-207.	0.5	15
2333	Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. <i>International Journal of Colorectal Disease</i> , 2015, 30, 367-373.	1.0	12
2334	ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer. <i>Journal of Surgical Oncology</i> , 2015, 111, 243-247.	0.8	6
2335	Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. <i>Updates in Surgery</i> , 2015, 67, 47-53.	0.9	14
2336	The principles of cancer treatment by chemotherapy. <i>Surgery</i> , 2015, 33, 131-135.	0.1	12
2337	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. <i>Clinical Cancer Research</i> , 2015, 21, 1583-1590.	3.2	8
2338	Effects of Preoperative Chemoradiotherapy on the Likelihood of Sphincter Preservation Surgery in Locally Advanced Distal Rectal Cancer: A Longitudinal Study Based on Pelvic Magnetic Resonance Imaging. <i>Annals of Surgical Oncology</i> , 2015, 22, 2159-2167.	0.7	8
2339	Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 719-728.	1.2	11
2340	Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial. <i>Medical Oncology</i> , 2015, 32, 70.	1.2	8
2341	Magnetic resonance imaging and endorectal ultrasound for diagnosis of rectal lesions. <i>European Journal of Medical Research</i> , 2015, 20, 4.	0.9	30
2342	Therapeutic Results of Abdominoperineal Resection in the Prone Jackknife Position for T3-4 Low Rectal Cancers. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 551-557.	0.9	8
2343	The Neoadjuvant Treatment of Rectal Cancer: A Review. <i>Current Oncology Reports</i> , 2015, 17, 434.	1.8	14

#	ARTICLE	IF	CITATIONS
2344	Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography. <i>Radiation Oncology</i> , 2015, 10, 2.	1.2	17
2346	RLIP76 Blockade by siRNA Inhibits Proliferation, Enhances Apoptosis, and Suppresses Invasion in HT29 Colon Cancer Cells. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 579-585.	0.9	12
2347	Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. <i>World Journal of Surgical Oncology</i> , 2015, 13, 30.	0.8	16
2348	Rate of Pulmonary Metastasis Varies with Location of Rectal Cancer in the Patients Undergoing Curative Resection. <i>World Journal of Surgery</i> , 2015, 39, 759-768.	0.8	12
2349	The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 657-666.	3.3	27
2350	Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine-Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients. <i>World Journal of Surgery</i> , 2015, 39, 1257-1267.	0.8	9
2351	Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea. <i>Radiation Oncology</i> , 2015, 10, 30.	1.2	13
2354	MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer. <i>European Radiology</i> , 2015, 25, 1347-1355.	2.3	119
2355	Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. <i>Targeted Oncology</i> , 2015, 10, 375-383.	1.7	17
2356	Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. <i>BMC Cancer</i> , 2015, 15, 59.	1.1	20
2357	Consensus Statement: The 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014. <i>Current Oncology</i> , 2015, 22, 113-123.	0.9	0
2358	The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Cancer Biomarkers</i> , 2015, 15, 181-188.	0.8	7
2359	Selective Non-operative Treatment in Rectal Cancer After Neoadjuvant Chemoradiation: Lessons Learned from the "Watch-and-Wait" Approach. , 2015, , 625-636.		0
2361	Radiotherapy and Chemoradiation for Rectal Cancer: State of the Art in Europe, the USA and Asia. , 2015, , 133-146.		0
2362	Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1193-1199.	1.0	14
2363	Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery± fluoropyrimidine and surgery± fluoropyrimidine± oxaliplatin. <i>European Journal of Surgical Oncology</i> , 2015, 41, 713-723.	0.5	106
2364	Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 540-547.	0.4	22
2365	Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 555-567.	0.4	58

#	ARTICLE	IF	CITATIONS
2366	Acute toxicity after a diverting stoma and spacer prior to chemoradiation in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 107-111.	0.3	2
2367	Variation in circumferential resection margin: Reporting and involvement in the South-Netherlands. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1485-1492.	0.5	13
2368	Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery. <i>Oncologist</i> , 2015, 20, 752-757.	1.9	15
2369	Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. <i>Annals of Oncology</i> , 2015, 26, 2102-2106.	0.6	37
2370	Simple criteria to predict margin involvement after chemoradiotherapy and sphincter-sparing for low rectal cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1210-1216.	0.5	3
2371	Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 291-295.	1.0	57
2372	Multidisciplinary Management of Locally Advanced Rectal Cancer—An Evolving Landscape?. <i>Clinical Colorectal Cancer</i> , 2015, 14, 251-261.	1.0	21
2373	A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. <i>Cancer Biology and Therapy</i> , 2015, 16, 1160-1171.	1.5	49
2374	Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 29-34.	1.1	0
2375	Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 219-236.	0.6	25
2376	Recent advances in multidisciplinary approach for rectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 641-649.	1.0	9
2377	Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 227-238.	1.0	32
2378	The outcome of 5-fluorouracil chemotherapy after the completion of neoadjuvant chemoradiotherapy, administered until 2 weeks before rectal cancer resection. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 475-480.	0.6	0
2379	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 957-966.	5.1	524
2380	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 979-989.	5.1	577
2381	Acute anal toxicity after whole pelvic radiotherapy in patients with asymptomatic haemorrhoids: identification of dosimetric and patient factors. <i>British Journal of Radiology</i> , 2015, 88, 20150022.	1.0	4
2382	Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. <i>Journal of Oncology Practice</i> , 2015, 11, e476-e486.	2.5	4
2383	Rectal and colon cancer: Not just a different anatomic site. <i>Cancer Treatment Reviews</i> , 2015, 41, 671-679.	3.4	239

#	ARTICLE	IF	CITATIONS
2384	Challenges Posed to Pathologists in the Detection of KRAS Mutations in Colorectal Cancers. Archives of Pathology and Laboratory Medicine, 2015, 139, 211-218.	1.2	35
2385	Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Experimental and Molecular Pathology, 2015, 98, 338-345.	0.9	25
2386	Transanal surgery for cT2T3 rectal cancer: Patient selection, adjuvant therapy, and outcomes. Seminars in Colon and Rectal Surgery, 2015, 26, 26-31.	0.2	3
2387	Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Radiotherapy and Oncology, 2015, 114, 302-309.	0.3	49
2388	Factors affecting the restaging accuracy of magnetic resonance imaging after preoperative chemoradiation in patients with rectal cancer. European Journal of Surgical Oncology, 2015, 41, 493-498.	0.5	4
2389	Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiotherapy and Oncology, 2015, 115, 246-252.	0.3	53
2390	Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. Journal of Clinical Oncology, 2015, 33, 1797-1808.	0.8	150
2391	Postoperative radiotherapy of patients with thymic epithelial tumors (TET). Strahlentherapie Und Onkologie, 2015, 191, 133-140.	1.0	12
2393	The impact of lymph node size to predict nodal metastasis in patients with rectal cancer after preoperative chemoradiotherapy. International Journal of Colorectal Disease, 2015, 30, 459-464.	1.0	11
2394	Reduced luminal circumference of tumors plays a key role in anorectal function during the early period after neoadjuvant chemoradiation therapy in rectal cancer patients. International Journal of Colorectal Disease, 2015, 30, 465-474.	1.0	0
2395	Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. International Journal of Colorectal Disease, 2015, 30, 769-774.	1.0	63
2396	Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 755-773.	1.3	120
2397	Impact of Anatomic Location on Locally Recurrent Rectal Cancer: Superior Outcome for Intraluminal Tumour Recurrence. Journal of Gastrointestinal Surgery, 2015, 19, 1123-1131.	0.9	12
2398	Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathologic Complete Response in Rectal Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 1106-1112.	0.9	53
2399	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer, 2015, 15, 60.	1.1	41
2400	Sphincter Preservation Rates After Radical Resection for Rectal Cancer in the United States Veteran Population: Opportunity for Improvement in Early Disease. Annals of Surgical Oncology, 2015, 22, 216-223.	0.7	19
2401	Quality of Life, Functional Outcomes, and Wound Complications in Patients with Soft Tissue Sarcomas Treated with Preoperative Chemoradiation: A Prospective Study. Annals of Surgical Oncology, 2015, 22, 2869-2875.	0.7	19
2402	Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Disease, 2015, 17, 748-761.	0.7	73

#	ARTICLE	IF	CITATIONS
2403	A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 88.	0.3	10
2404	Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy. <i>World Journal of Gastroenterology</i> , 2015, 21, 3274-3281.	1.4	29
2405	Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 580-587.	0.7	32
2407	Magnetic resonance imaging of rectal cancer: staging and restaging evaluation. <i>Abdominal Imaging</i> , 2015, 40, 2613-2629.	2.0	25
2408	Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?. <i>Cancer</i> , 2015, 121, 1724-1727.	2.0	23
2409	Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades. <i>International Journal of Colorectal Disease</i> , 2015, 30, 797-806.	1.0	22
2410	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 1737-1744.	0.8	30
2411	Exploiting replicative stress to treat cancer. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 405-423.	21.5	243
2412	The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. <i>Tumor Biology</i> , 2015, 36, 7675-7683.	0.8	31
2413	Texture Analysis as Imaging Biomarker of Tumoral Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients Studied with 3-T Magnetic Resonance. <i>Investigative Radiology</i> , 2015, 50, 239-245.	3.5	169
2414	American Joint Committee on Cancer and College of American Pathologists Regression Grade. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 32-44.	0.7	124
2415	Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 186-192.	0.7	23
2416	Adjuvant Chemoradiation Plus Intraoperative Radiotherapy Versus Adjuvant Chemoradiation Alone in Patients With Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 11-16.	0.6	10
2417	Clinical results and toxicity for short-course preoperative radiotherapy and total mesorectal excision in rectal cancer patients. <i>Journal of Radiation Research</i> , 2015, 56, 169-176.	0.8	9
2418	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239.	1.0	548
2419	Lymph Node Count After Preoperative Radiotherapy Is an Independently Prognostic Factor For Pathologically Lymph Node-Negative Patients With Rectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e395.	0.4	21
2421	Local iontophoretic administration of cytotoxic therapies to solid tumors. <i>Science Translational Medicine</i> , 2015, 7, 273ra14.	5.8	56
2422	In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 655-663.	1.4	24

#	ARTICLE	IF	CITATIONS
2423	Induction FOLFOX followed by preoperative hyperfractionated radiotherapy plus bolus 5-fluorouracil in locally advanced rectal carcinoma: single arm phase II study. <i>Medical Oncology</i> , 2015, 32, 108.	1.2	2
2425	“Liver-first” approach for metastatic colorectal cancer. <i>Future Oncology</i> , 2015, 11, 1233-1243.	1.1	9
2427	Practice parameters for early rectal cancer management: Italian Society of Colorectal Surgery (Societ� Italiana di Chirurgia Colo-Rettale; SICCR) guidelines. <i>Techniques in Coloproctology</i> , 2015, 19, 587-593.	0.8	13
2428	Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1456-1463.	0.5	71
2429	Multivisceral Resection for Locally Advanced Rectal Cancer: Prognostic Factors Influencing Outcome. <i>Scandinavian Journal of Surgery</i> , 2015, 104, 154-160.	1.3	11
2430	Clinical and molecular diagnosis of pathologic complete response in rectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1505-1516.	1.5	8
2431	Anastomotic leakage after curative rectal cancer resection has no impact on long-term survival: a propensity score analysis. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1667-1675.	1.0	22
2432	The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy. <i>Tumor Biology</i> , 2015, 36, 8213-8219.	0.8	18
2434	Flattened Tumor Requires a More Careful Attention for Residual Distal Cancer Spread in Locally Advanced Lower Rectal Carcinoma after Chemoradiotherapy. <i>Digestive Surgery</i> , 2015, 32, 159-165.	0.6	4
2436	Is Chemoradiotherapy Beneficial for Stage IV Rectal Cancer?. <i>Oncology</i> , 2015, 89, 14-22.	0.9	10
2437	Robotic-assisted abdominoperineal resection with bilateral pelvic lymph node dissection after neoadjuvant chemo-irradiation. <i>Surgical Practice</i> , 2015, 19, 42-44.	0.1	1
2438	NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 29-36.	0.4	83
2439	Outcomes in the surgical treatment of low rectal cancer: does neoadjuvant treatment equalize results?. <i>ANZ Journal of Surgery</i> , 2015, 85, 140-144.	0.3	3
2440	Grundlagen der gastrointestinalen Tumorerkrankungen. , 2015, , 397-459.		0
2441	Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1695-1704.	1.0	6
2442	Quality of Life After Sphincter-Preserving Rectal Cancer Resection. <i>Clinical Colorectal Cancer</i> , 2015, 14, e33-e40.	1.0	21
2443	Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1630-1635.	0.5	3
2444	How Should a Multi-disciplinary Team (MDT) Approach the Issue of Non-Operative Management in Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 352-359.	1.0	0

#	ARTICLE	IF	CITATIONS
2445	Neoadjuvant treatment intensification or adjuvant chemotherapy for locally advanced carcinoma rectum: The optimum treatment approach remains unresolved. Journal of the Egyptian National Cancer Institute, 2015, 27, 179-185.	0.6	4
2446	Salvage surgery and radiotherapy including intraoperative electron radiotherapy in isolated locally recurrent tumors: Predictors of outcome. Radiotherapy and Oncology, 2015, 116, 316-322.	0.3	8
2447	Patterns of Colorectal Cancer Care in the United States: 1990â€“2010. Journal of the National Cancer Institute, 2015, 107, .	3.0	76
2448	Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?. Journal of Clinical Oncology, 2015, 33, 1878-1880.	0.8	33
2449	Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancers. Indian Journal of Gastroenterology, 2015, 34, 310-313.	0.7	2
2450	Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROC 14-12. Radiotherapy and Oncology, 2015, 116, 202-208.	0.3	25
2451	Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature. Langenbeck's Archives of Surgery, 2015, 400, 661-673.	0.8	3
2452	Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. Investigational New Drugs, 2015, 33, 1078-1085.	1.2	2
2453	Locally advanced rectal cancer: post-chemoradiotherapy ADC histogram analysis for predicting a complete response. Acta Radiologica, 2015, 56, 1042-1050.	0.5	43
2454	Value of diffusion-weighted MR imaging in assessing response of neoadjuvant chemo and radiation therapy in locally advanced rectal cancer. Egyptian Journal of Radiology and Nuclear Medicine, 2015, 46, 553-561.	0.3	4
2455	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1015-1022.	0.4	24
2456	Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience. International Journal of Colorectal Disease, 2015, 30, 1705-1714.	1.0	6
2457	Transanal Endoscopic Microsurgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2015, 25, 617-624.	0.5	5
2458	Added value of morphologic characteristics on diffusion-weighted images for characterizing lymph nodes in primary rectal cancer. Clinical Imaging, 2015, 39, 1046-1051.	0.8	10
2459	Impact of a Structured Report Template on the Quality of MRI Reports for Rectal Cancer Staging. American Journal of Roentgenology, 2015, 205, 584-588.	1.0	104
2460	A Dosimetric Analysis of Preoperative Intensity-modulated and Image-guided Radiation Therapy with and without Simultaneous Integrated Boost for Locally Advanced Rectal Cancer. Technology in Cancer Research and Treatment, 2015, 14, 557-563.	0.8	4
2461	Comparison of endorectal ultrasound versus pelvic magnetic resonance imaging for radiation treatment planning in locally advanced rectal cancer. Practical Radiation Oncology, 2015, 5, e451-e455.	1.1	3
2462	Predictive Significance of Tumor Grade Using 256-Slice CT Whole-Tumor Perfusion Imaging in Colorectal Adenocarcinoma. Academic Radiology, 2015, 22, 1529-1535.	1.3	7

#	ARTICLE	IF	CITATIONS
2463	Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. <i>Gastroenterology Report</i> , 2015, 3, gov039.	0.6	43
2464	Prospective, Multicenter Validation Study of Magnetic Resonance Volumetry for Response Assessment After Preoperative Chemoradiation in Rectal Cancer: Can the Results in the Literature be Reproduced?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1005-1014.	0.4	43
2465	Is it safe to omit neoadjuvant chemo-radiation in mucinous rectal carcinoma?. <i>International Journal of Surgery</i> , 2015, 23, 120-127.	1.1	8
2467	Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 503-515.	1.6	3
2468	Sphincter saving and abdomino-perineal resections following neoadjuvant chemoradiation in locally advanced low rectal cancer. <i>Journal of the Egyptian National Cancer Institute</i> , 2015, 27, 19-24.	0.6	5
2469	Defining Bowel Dose Volume Constraints for Bladder Radiotherapy Treatment Planning. <i>Clinical Oncology</i> , 2015, 27, 22-29.	0.6	18
2470	The comparison of miR-155 with computed tomography and computed tomography plus serum amyloid A protein in staging rectal cancer. <i>Journal of Surgical Research</i> , 2015, 193, 764-771.	0.8	8
2471	Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 1-11.	0.3	7
2472	Nonoperative Management of Rectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 135-151.	0.9	62
2473	MS2 Virus Inactivation by Atmospheric-Pressure Cold Plasma Using Different Gas Carriers and Power Levels. <i>Applied and Environmental Microbiology</i> , 2015, 81, 996-1002.	1.4	106
2474	Pelvic radiation disease. <i>Colorectal Disease</i> , 2015, 17, 2-6.	0.7	13
2475	Stratégie chirurgicale pour les cancers du bas rectum. <i>Journal De Chirurgie Viscérale</i> , 2015, 152, 22-30.	0.0	0
2476	Surgical strategy for low rectal cancers. <i>Journal of Visceral Surgery</i> , 2015, 152, 23-31.	0.4	9
2477	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015, 137, 212-220.	2.3	94
2478	Apparent diffusion coefficient for lymph node characterization after chemoradiation therapy for locally advanced rectal cancer. <i>Acta Radiologica</i> , 2015, 56, 1446-1453.	0.5	10
2480	EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 77-83.	0.9	20
2481	Reduction in the size of enlarged pelvic lymph nodes after chemoradiation therapy is associated with fewer lymph node metastases in locally advanced rectal carcinoma. <i>Surgery Today</i> , 2015, 45, 834-840.	0.7	7
2482	Radiology Illustrated: Gastrointestinal Tract. <i>Radiology Illustrated</i> , 2015, , .	0.0	0

#	ARTICLE	IF	CITATIONS
2483	Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neoadjuvant chemoradiation. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1646-1653.	1.9	82
2484	MRI and CT for the Preoperative T and N Staging of Rectal Cancer. , 2015, , 177-193.		0
2485	Multidisciplinary Treatment of Colorectal Cancer. , 2015, , .		1
2486	A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. <i>International Journal of Clinical Oncology</i> , 2015, 20, 338-344.	1.0	1
2487	Cancer arising from the remnant mucosa of the ileoanal anastomosis leading to pouchectomy. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015212802.	0.2	5
2488	The Prognostic Value of Circumferential Resection Margin Involvement in Patients with Extraperitoneal Rectal Cancer. <i>American Surgeon</i> , 2016, 82, 348-355.	0.4	8
2489	Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer. <i>Medicine (United States)</i> , 2016, 95, e5059.	0.4	4
2490	Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation. <i>Journal of Gastrointestinal Oncology</i> , 2016, 6, 1004-1010.	0.6	2
2491	Identification of Predictive Markers for Response to Neoadjuvant Chemoradiation in Rectal Carcinomas by Proteomic Isotope Coded Protein Label (ICPL) Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 209.	1.8	20
2492	IGF-2 Growth Factor Expression in Human Rectal Adenocarcinoma. , 2016, 6, .		3
2493	Impact of neoadjuvant therapy in downstaging of lower rectal adenocarcinoma and the role of pelvic magnetic resonance in staging. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2016, 43, 102-109.	0.3	5
2494	Synchronous Rectal Adenocarcinoma and Splenic Marginal Zone Lymphoma. <i>Current Oncology</i> , 2016, 23, 70-74.	0.9	3
2495	Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. <i>Oncotarget</i> , 2016, 7, 6345-6351.	0.8	31
2496	Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 568.	1.8	16
2497	Endoscopic Criteria for Evaluating Tumor Stage after Preoperative Chemoradiation Therapy in Locally Advanced Rectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 567-573.	1.3	7
2498	NF- κ B/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival. <i>Neoplasma</i> , 2016, 63, 462-470.	0.7	10
2499	Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer: 10-year experiences at a single institution. <i>Annals of Surgical Treatment and Research</i> , 2016, 91, 178.	0.4	1
2500	Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 695.	0.8	16

#	ARTICLE	IF	CITATIONS
2501	Benefit of extraperitonization to prevent septic intraabdominal complications after distal rectal cancer surgery. <i>Journal of Peritoneum (and Other Serosal Surfaces)</i> , 2016, , .	0.1	0
2502	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 92-102.	1.8	9
2503	Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 958-967.	0.6	10
2504	Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 603-608.	0.6	22
2505	Post operative stereotactic radiosurgery for positive or close margins after preoperative chemoradiation and surgery for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 315-320.	0.6	4
2506	Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	13
2507	Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-13.	0.7	16
2508	Does Extending the Waiting Time of Low-Rectal Cancer Surgery after Neoadjuvant Chemoradiation Increase the Perioperative Complications?. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-5.	0.7	6
2509	Immunological Landscape and Clinical Management of Rectal Cancer. <i>Frontiers in Immunology</i> , 2016, 7, 61.	2.2	14
2510	The Traditional Chinese Medicine DangguiBuxue Tang Sensitizes Colorectal Cancer Cells to Chemoradiotherapy. <i>Molecules</i> , 2016, 21, 1677.	1.7	22
2511	MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection. <i>PLoS ONE</i> , 2016, 11, e0146235.	1.1	10
2512	Apparent Diffusion Coefficient Predicts Pathology Complete Response of Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. <i>PLoS ONE</i> , 2016, 11, e0153944.	1.1	31
2513	Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. <i>PLoS ONE</i> , 2016, 11, e0161475.	1.1	21
2514	A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>International Journal of Biological Sciences</i> , 2016, 12, 1022-1031.	2.6	158
2515	Knowledge, Attitudes, and Practices Related to Preoperative Chemoradiotherapy in Rectal Cancer Patients. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	0
2516	Is there a Role of Lateral Pelvic Lymph Node Dissection in the Current Era of Neoadjuvant Chemoradiotherapy for Rectal Cancer?. , 2016, 6, .		1
2517	Transanal Local Excision for Patients With Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 173-178.	0.7	22
2518	Safety and efficacy of intraoperative iodine-125 seed implantation brachytherapy for rectal cancer patients: A retrospective clinical research. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1076-1084.	1.4	8

#	ARTICLE	IF	CITATIONS
2519	Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 377-385.	0.7	23
2520	Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy. <i>Histopathology</i> , 2016, 69, 839-848.	1.6	10
2521	Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival. <i>Annals of Surgery</i> , 2016, 263, 1143-1147.	2.1	53
2523	MRI In rectal cancer: Correlations between MRI features and molecular markers Ki-67, HIF-1 α , and VEGF. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 594-600.	1.9	33
2524	Importance of surgical margins in rectal cancer. <i>Journal of Surgical Oncology</i> , 2016, 113, 323-332.	0.8	41
2525	High nodal positivity rates even in good clinical responders after chemoradiation of rectal cancer: is organ preservation feasible?. <i>Colorectal Disease</i> , 2016, 18, 976-982.	0.7	6
2526	Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. <i>Colorectal Disease</i> , 2016, 18, 763-772.	0.7	32
2527	Correlation of standard diffusion-weighted imaging and diffusion kurtosis imaging with distant metastases of rectal carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 221-229.	1.9	24
2528	An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 702-712.	1.4	26
2529	Influence of neoadjuvant chemoradiotherapy on the anal sphincter: ultrastructural damage may be critical. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1427-1430.	1.0	4
2530	Quality of Life and Timing of Stoma Closure in Patients With Rectal Cancer Undergoing Low Anterior Resection With Diverting Stoma. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 281-290.	0.7	94
2531	Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer. <i>Medicine (United States)</i> , 2016, 95, e3718.	0.4	12
2532	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1528-1534.	2.3	17
2533	Semiquantitative Volumetry by Sequential PET/CT May Improve Prediction of Complete Response to Neoadjuvant Chemoradiation in Patients With Distal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 805-812.	0.7	30
2534	Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy. <i>Scientific Reports</i> , 2016, 6, 34923.	1.6	16
2535	Incidence of Metachronous Distant Metastasis and ypN Classification Influence Patient Survival in Endosonographically Confirmed uT3 Rectal Cancer after Neoadjuvant Therapy and R0 Resection: A Historical Cohort Analysis. <i>Visceral Medicine</i> , 2016, 32, 131-136.	0.5	0
2536	Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). <i>BMJ Open</i> , 2016, 6, e012496.	0.8	4
2537	SEOM Clinical Guideline of localized rectal cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1163-1171.	1.2	10

#	ARTICLE	IF	CITATIONS
2538	Efficacy of repeat hepatectomy for recurrence following curative hepatectomy for colorectal liver metastases: A Retrospective Cohort Study of 128 patients. <i>International Journal of Surgery</i> , 2016, 36, 96-103.	1.1	12
2539	Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1729-1736.	1.6	19
2540	Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation—a propensity score-matched analysis of an observational database. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 1179-1190.	0.8	10
2541	Programmed death-ligand 1 expression in rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 352-356.	0.3	15
2542	Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies. <i>Scientific Reports</i> , 2016, 6, 35589.	1.6	8
2543	Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 147-153.	0.6	5
2544	Rectal Cancer: Neoadjuvant Therapy. , 2016, , 481-494.		1
2545	Rectal Cancer: Watch and Wait. , 2016, , 507-515.		1
2546	Rectal Cancer Decision-Making. , 2016, , 535-545.		0
2547	Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine+Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. <i>Clinical Colorectal Cancer</i> , 2016, 15, 128-134.	1.0	3
2548	Circumferential resection margin positivity after preoperative chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer: implication of boost radiotherapy to the involved mesorectal fascia. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 316-322.	0.6	8
2549	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
2550	Revisiting the treatment strategy for rectal cancer through the pattern of local recurrence. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1674-1679.	0.5	16
2551	Toward Restored Bowel Health in Rectal Cancer Survivors. <i>Seminars in Radiation Oncology</i> , 2016, 26, 236-250.	1.0	15
2552	Surgery for Locally Advanced T4 Rectal Cancer: Strategies and Techniques. <i>Clinics in Colon and Rectal Surgery</i> , 2016, 29, 106-113.	0.5	22
2553	Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. <i>Pathology Research and Practice</i> , 2016, 212, 598-603.	1.0	12
2554	Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer — A comparison of magnetic resonance imaging at two time points and histopathological responses. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1350-1358.	0.5	19
2555	Drug Combinations in Preoperative Chemoradiation for Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 211-219.	1.0	1

#	ARTICLE	IF	CITATIONS
2556	The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3609-3615.	0.7	37
2557	Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using 18fluorine-2-deoxy-d-glucose positron emission tomographyâ€“computed tomography and serum carcinoembryonic antigen: a prospective study. <i>Abdominal Radiology</i> , 2016, 41, 1448-1455.	1.0	17
2558	Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results. <i>Drugs and Aging</i> , 2016, 33, 419-425.	1.3	15
2559	Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. <i>Practical Radiation Oncology</i> , 2016, 6, 360-366.	1.1	19
2560	Adjuvant chemotherapy for rectal cancer: time to change the guidelines. <i>Future Oncology</i> , 2016, 12, 1009-1013.	1.1	2
2561	Watch and Wait: Is Surgery Always Necessary for Rectal Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 22.	1.3	15
2562	The curative management of synchronous rectal and prostate cancer. <i>British Journal of Radiology</i> , 2016, 89, 20150292.	1.0	14
2563	Definitive Chemoradiotherapy (â€œWatch-and-Waitâ€ Approach). <i>Seminars in Radiation Oncology</i> , 2016, 26, 205-210.	1.0	9
2564	Advancing Techniques of Radiation Therapy for Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 220-225.	1.0	5
2565	Preoperative Treatment of Locally Advanced Rectal Cancer: Assets and Drawbacks of Short Course and Long Course in Clinical Practice. <i>Seminars in Radiation Oncology</i> , 2016, 26, 186-192.	1.0	9
2566	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. <i>Seminars in Radiation Oncology</i> , 2016, 26, 176-185.	1.0	6
2567	Robotic surgery with high dissection and low ligation technique for consecutive patients with rectal cancer following preoperative concurrent chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1169-1177.	1.0	23
2568	<i>Surgical Oncology Manual</i> . , 2016, , .		1
2569	Neoadjuvant Radiotherapy: A Risk Factor for Short-Term Wound Complications after Radical Resection for Rectal Cancer?. <i>Journal of the American College of Surgeons</i> , 2016, 223, 291-298.	0.2	14
2570	Pre-operative staging of rectal cancer: a review of imaging techniques. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1011-1025.	1.4	13
2572	The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 327-336.	0.8	27
2573	An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis. <i>Molecular and Clinical Oncology</i> , 2016, 4, 733-739.	0.4	5
2574	Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2841-2848.	0.7	40

#	ARTICLE	IF	CITATIONS
2575	Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: A multi-institutional study for optimal surgical timing in rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 512-518.	0.3	35
2576	Prognostic impact of the number of resected lymph node on survival in Colorectal Cancer. <i>Journal of Coloproctology</i> , 2016, 36, 130-138.	0.1	2
2577	Differentiating locally recurrent rectal cancer from scar tissue: Value of diffusion-weighted MRI. <i>European Journal of Radiology</i> , 2016, 85, 1265-1270.	1.2	23
2579	Association of pretreatment serum carcinoembryonic antigen levels with chemoradiation-induced downstaging and downsizing of rectal cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 631-635.	0.4	3
2580	Extramural Venous Invasion (EMVI) and Tumour Regression Grading (TRG) as Potential Prognostic Factors for Risk Stratification and Treatment Decision in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 130-140.	1.0	5
2582	Chances, risks and limitations of neoadjuvant therapy in surgical oncology. <i>Innovative Surgical Sciences</i> , 2016, 1, 3-11.	0.4	6
2583	Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2551-2560.	1.2	35
2584	Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3724-3728.	0.8	6
2585	Rectal cancer: Neoadjuvant chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 629-639.	1.0	49
2586	The Symptom Experience in Rectal Cancer Survivors. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 709-718.	0.6	13
2588	Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer—a real-world outcome study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1108-1117.	0.6	16
2589	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. <i>European Journal of Cancer</i> , 2016, 68, 70-72.	1.3	0
2590	Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer. <i>Surgery</i> , 2016, 160, 1326-1332.	1.0	5
2591	Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3300-3307.	0.8	307
2592	Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1595-1601.	1.0	11
2593	Functional outcome and quality of life following treatment for rectal cancer. <i>Journal of Coloproctology</i> , 2016, 36, 251-261.	0.1	10
2594	Management of radiation and chemotherapy related acute toxicity in gastrointestinal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 655-664.	1.0	36
2595	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. <i>Medical Radiology</i> , 2016, , 47-73.	0.0	0

#	ARTICLE	IF	CITATIONS
2596	Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 172-177.	0.5	48
2597	Treatment of locally advanced low rectal cancer. <i>Formosan Journal of Surgery</i> , 2016, 49, 83-88.	0.1	0
2598	The impact of metabolic syndrome on outcome and response to neoadjuvant chemoradiation in locally advanced rectal cancer patients. <i>International Journal of Surgery</i> , 2016, 33, 8-12.	1.1	8
2599	Prognostic significance of lymph node yield in ypN0 rectal cancer. <i>British Journal of Surgery</i> , 2016, 103, 1731-1737.	0.1	20
2600	Histological differences between preoperative chemoradiotherapy and chemotherapy for rectal cancer: a clinicopathological study. <i>Pathology International</i> , 2016, 66, 273-280.	0.6	18
2601	Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response. <i>Annals of Surgical Oncology</i> , 2016, 23, 4302-4309.	0.7	14
2602	Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 809-816.	1.7	7
2604	An update on the multimodality of localized rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 23-32.	2.0	5
2605	Two countries – Two treatment strategies for rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 357-363.	0.3	48
2606	A Retrospective Analysis on Two-week Short-course Pre-operative Radiotherapy in Elderly Patients with Resectable Locally Advanced Rectal Cancer. <i>Scientific Reports</i> , 2016, 6, 37866.	1.6	4
2607	What is most relevant in preoperative rectal cancer chemoradiotherapy – the chemotherapy, the radiation dose or the timing to surgery?. <i>Acta Oncologica</i> , 2016, 55, 1381-1385.	0.8	9
2608	Surgical Principles. , 2016, , 159-170.e2.		0
2609	Principles of Chemotherapy. , 2016, , 171-185.e2.		0
2610	Intraoperative Irradiation. , 2016, , 325-340.e3.		1
2612	Long-term outcome of extralevator abdominoperineal excision (ELAPE) for low rectal cancer. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1729-1737.	1.0	25
2613	Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 10-16.	0.9	10
2614	Treatment of High Rectal Cancers: Do We Need Radiation?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 266-273.	1.0	1
2615	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	1.0	0

#	ARTICLE	IF	CITATIONS
2616	Neoadjuvant treatment of rectal cancer: where are we now?. <i>Gastroenterology Report</i> , 2016, 4, 206-209.	0.6	28
2618	Surgical Results and Oncologic Outcomes for Rectal Cancer with Tailored Mesorectal Excision over Two Decades. <i>World Journal of Surgery</i> , 2016, 40, 1500-1508.	0.8	3
2619	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Pathologic Response to Preoperative Chemoradiotherapy and Prognosis in Patients With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, e213-e219.	1.0	14
2620	Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer. <i>Radiation Oncology</i> , 2016, 11, 114.	1.2	22
2621	Novel Radiation Approaches for the Treatment of Rectal Cancer: Where Are We Now?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 314-323.	1.0	1
2622	The Role of Adjuvant Treatment in Resected T3N0 Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 324-331.	1.0	0
2623	Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 252-257.	0.3	31
2624	Role of pelvic radiotherapy for locally advanced rectal cancer and synchronous unresectable distant metastases. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 805-810.	0.6	9
2625	Why is neoadjuvant chemoradiation therapy underused for locally advanced rectal cancer?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1317-1319.	1.4	4
2626	Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. <i>Acta OncolÃ³gica</i> , 2016, 55, 1392-1399.	0.8	43
2627	Local and Locally Advanced Rectal Cancer. , 2016, , 339-361.		0
2628	Sequential Boost in Neoadjuvant Irradiation for T3N0-1 Rectal Cancer: Long-Term Results from a Single-Center Experience. <i>Tumori</i> , 2016, 102, 316-322.	0.6	2
2629	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. <i>Tumori</i> , 2016, 102, 114-121.	0.6	9
2630	A Nomogram to Predict Lymph Node Positivity Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 710-717.	0.7	22
2631	The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer. <i>Medicine (United States)</i> , 2016, 95, e4891.	0.4	14
2632	Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 65.	4.9	22
2633	Correlates and trends of IMRT use in locally advanced rectal cancer. <i>Journal of Radiation Oncology</i> , 2016, 5, 427-435.	0.7	1
2634	Combined Modality Therapy for Rectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 211-217.	1.0	6

#	ARTICLE	IF	CITATIONS
2635	Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 934-942.	0.7	102
2636	Lessons Learned From the Quest for Gene Signatures That Predict Treatment Response in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 898-900.	0.7	4
2637	Adjuvant chemotherapy for ypTONOMO rectal cancer following chemoradiotherapy and total mesorectal excision. <i>Anti-Cancer Drugs</i> , 2016, 27, 819-823.	0.7	4
2638	Local recurrence after curative resection for rectal carcinoma. <i>Medicine (United States)</i> , 2016, 95, e3942.	0.4	34
2639	Predicting a pathological complete response in rectal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 709-710.	0.7	1
2640	Personalizing Rectal Cancer Management. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 1227-1229.	0.7	3
2641	Is Preoperative Chemoradiotherapy Beneficial for Sphincter Preservation in Low-Lying Rectal Cancer Patients?. <i>Medicine (United States)</i> , 2016, 95, e3463.	0.4	6
2642	The Effect of Biofeedback Therapy on Anorectal Function After the Reversal of Temporary Stoma When Administered During the Temporary Stoma Period in Rectal Cancer Patients With Sphincter-Saving Surgery. <i>Medicine (United States)</i> , 2016, 95, e3611.	0.4	18
2643	The outcomes of therapeutic decision in lower 3rd rectal cancer patients. <i>Medicine (United States)</i> , 2016, 95, e4638.	0.4	7
2644	Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy. <i>Medicine (United States)</i> , 2016, 95, e5463.	0.4	17
2645	Pathologic stage following preoperative chemoradiotherapy underestimates the risk of developing distant metastasis in rectal cancer: A comparison to staging without preoperative chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2016, 113, 692-699.	0.8	18
2646	Impact of multimodal therapy in locally recurrent rectal cancer. <i>British Journal of Surgery</i> , 2016, 103, 753-762.	0.1	49
2647	Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 148-156.	0.7	42
2648	Nursing implications: symptom presentation and quality of life in rectal cancer patients. <i>Journal of Clinical Nursing</i> , 2016, 25, 1395-1404.	1.4	3
2649	Correlation Between Apparent Diffusion Coefficients and Standardized Uptake Values in Hybrid 18F-FDG PET/MR: Preliminary Results in Rectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 150-156.	0.6	22
2650	Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1213-1222.	0.9	22
2651	Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina. <i>Digestive and Liver Disease</i> , 2016, 48, 1372-1377.	0.4	16
2652	Is There a Best Radiosensitizing Agent in the Treatment of Locally Advanced Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 189-200.	1.0	2

#	ARTICLE	IF	CITATIONS
2653	Clinical impact of tumor volume reduction in rectal cancer following preoperative chemoradiation. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 843-850.	1.8	17
2654	The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 243-247.	0.6	5
2655	Prognosis Can Be Predicted More Accurately Using Pre- and Postchemoradiotherapy Carcinoembryonic Antigen Levels Compared to Only Prechemoradiotherapy Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer Patients Who Received Neoadjuvant Chemoradiotherapy. <i>Medicine (United States)</i> , 2016, 95, e2965.	0.4	7
2656	Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer. <i>Journal of Radiation Oncology</i> , 2016, 5, 279-286.	0.7	10
2657	Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 946-952.	1.0	42
2659	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	1.3	73
2660	Induction Chemotherapy. , 2016, , .		3
2661	Can clinical factors be used as a selection tool for an organ-preserving strategy in rectal cancer?. <i>Acta OncolÁgica</i> , 2016, 55, 1047-1052.	0.8	17
2662	Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. <i>Journal of Geriatric Oncology</i> , 2016, 7, 176-186.	0.5	8
2663	Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 894-899.	0.7	9
2664	Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer. <i>Integrative Cancer Therapies</i> , 2016, 15, 285-307.	0.8	13
2665	Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy. <i>BMC Cancer</i> , 2016, 16, 207.	1.1	10
2666	Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients. <i>World Journal of Surgical Oncology</i> , 2016, 14, 136.	0.8	6
2667	Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. <i>Radiation Oncology</i> , 2016, 11, 24.	1.2	42
2668	Interaction of Chemotherapy and Radiation. , 2016, , 63-79.e4.		4
2669	Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report. <i>BMC Cancer</i> , 2016, 16, 243.	1.1	10
2670	CT-based adaptive high-dose-rate endorectal brachytherapy in the preoperative treatment of locally advanced rectal cancer: Technical and practical aspects. <i>Brachytherapy</i> , 2016, 15, 477-484.	0.2	20
2671	Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 1996-2003.	2.0	73

#	ARTICLE	IF	CITATIONS
2672	Noadjuvant treatment for rectal cancerâ€”A valueâ€¢based proposition. Journal of Surgical Oncology, 2016, 114, 304-310.	0.8	2
2673	EphA4-mediated signaling regulates the aggressive phenotype of irradiation survivor colorectal cancer cells. Tumor Biology, 2016, 37, 12411-12422.	0.8	26
2674	Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer. Diseases of the Colon and Rectum, 2016, 59, 270-280.	0.7	154
2675	Pathologic Complete Response in Rectal Cancer. Diseases of the Colon and Rectum, 2016, 59, 255-263.	0.7	88
2676	Controversies in the management of rectal cancer. A survey of French surgeons, oncologists and radiotherapists. Colorectal Disease, 2016, 18, 128-134.	0.7	6
2678	Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer. Surgery Today, 2016, 46, 90-96.	0.7	4
2679	Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer. Cancer Research and Treatment, 2016, 48, 232-239.	1.3	32
2680	Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. International Journal of Hyperthermia, 2016, 32, 187-192.	1.1	22
2681	Oxygen Transport to Tissue XXXVII. Advances in Experimental Medicine and Biology, 2016, , .	0.8	8
2682	Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy. Advances in Experimental Medicine and Biology, 2016, 876, 195-200.	0.8	0
2683	Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 425-430.	1.4	15
2684	Update on advances and controversy in rectal cancer treatment. Techniques in Coloproctology, 2016, 20, 145-152.	0.8	4
2686	Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy. Clinical Oncology, 2016, 28, 140-145.	0.6	15
2687	Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer. Clinical Oncology, 2016, 28, 103-115.	0.6	10
2688	Current Controversies in the Management of Colon and Rectal Cancer. , 2016, , 51-65.		1
2689	Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-institutional retrospective study. Radiotherapy and Oncology, 2016, 118, 387-392.	0.3	14
2690	Role of Radiotherapy. Updates in Surgery Series, 2016, , 49-55.	0.0	1
2691	Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. Clinical Oncology, 2016, 28, 73-82.	0.6	5

#	ARTICLE	IF	CITATIONS
2692	Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation—Interim Analysis of the German OCUM Trial (NCT01325649). <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 25-33.	0.9	47
2693	Rectal Radiotherapy — Intensity-modulated Radiotherapy Delivery, Delineation and Doses. <i>Clinical Oncology</i> , 2016, 28, 93-102.	0.6	23
2694	Citrulline as a biomarker of gastrointestinal toxicity in patients with rectal carcinoma treated with chemoradiation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 305-14.	1.4	20
2695	Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. <i>Tumor Biology</i> , 2016, 37, 6389-6402.	0.8	16
2696	Complete Response after Chemoradiotherapy in Rectal Cancer (Watch-and-Wait): Have we Cracked the Code?. <i>Clinical Oncology</i> , 2016, 28, 152-160.	0.6	38
2697	Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision. <i>Medicine (United States)</i> , 2016, 95, e2988.	0.4	17
2698	Can tumor regression grade influence survival outcome in ypT3 rectal cancer?. <i>Clinical and Translational Oncology</i> , 2016, 18, 693-699.	1.2	2
2699	Current topics in the multimodality treatment of locally advanced rectal cancer. <i>Future Oncology</i> , 2016, 12, 963-979.	1.1	1
2700	Medical Practice Variations in Cancer Surgery. , 2016, , 361-381.		0
2701	Nonoperative management of rectal cancer. <i>Cancer</i> , 2016, 122, 34-41.	2.0	21
2702	Laparoscopic versus open surgery for rectal cancer: a meta-analysis of 3-year follow-up outcomes. <i>International Journal of Colorectal Disease</i> , 2016, 31, 805-811.	1.0	25
2703	Postoperative complications in the treatment of rectal neoplasia by transanal endoscopic microsurgery: a prospective study of risk factors and time course. <i>International Journal of Colorectal Disease</i> , 2016, 31, 833-841.	1.0	15
2704	The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2323-2328.	3.2	28
2705	Illustrative Handbook of General Surgery. , 2016, , .		1
2706	Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients. <i>Human Pathology</i> , 2016, 52, 164-172.	1.1	14
2707	Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 350-358.	1.0	6
2708	Which Patients With Rectal Cancer Do Not Need Radiotherapy?. <i>Seminars in Radiation Oncology</i> , 2016, 26, 199-204.	1.0	9
2709	Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status. <i>Tumor Biology</i> , 2016, 37, 10209-10218.	0.8	4

#	ARTICLE	IF	CITATIONS
2710	The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes. <i>Annals of Diagnostic Pathology</i> , 2016, 20, 29-35.	0.6	13
2711	Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 170-178.e3.	1.0	70
2712	Cytotoxic chemotherapy: clinical aspects. <i>Medicine</i> , 2016, 44, 25-29.	0.2	9
2713	Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer. <i>Clinical Oncology</i> , 2016, 28, 116-139.	0.6	17
2714	Adjuvant therapy. <i>Medicine</i> , 2016, 44, 39-41.	0.2	1
2715	Optimal therapy for resectable rectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 285-302.	1.1	0
2716	PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium. <i>Clinical Colorectal Cancer</i> , 2016, 15, 243-249.	1.0	29
2717	Endoluminal contrast for abdomen and pelvis magnetic resonance imaging. <i>Abdominal Radiology</i> , 2016, 41, 1378-1398.	1.0	3
2718	Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2016, 222, 367-374.	0.2	63
2719	Irradiation of Very Locally Advanced and Recurrent Rectal Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 226-235.	1.0	7
2720	¹⁸ F-Fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>Surgery Today</i> , 2016, 46, 1152-1158.	0.7	7
2721	The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. <i>Oral Oncology</i> , 2016, 56, 84-92.	0.8	141
2722	Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1052-1060.	0.4	32
2723	Prediction of Lateral Pelvic Lymph Node Metastasis in Low Rectal Cancer by Magnetic Resonance Imaging. <i>World Journal of Surgery</i> , 2016, 40, 995-1001.	0.8	37
2726	Patterns and management of distant failure in locally advanced rectal cancer: a cohort study. <i>Clinical and Translational Oncology</i> , 2016, 18, 909-914.	1.2	7
2727	Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study. <i>World Journal of Surgery</i> , 2016, 40, 447-455.	0.8	15
2728	Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. <i>Practical Radiation Oncology</i> , 2016, 6, 166-175.	1.1	26
2729	The anthropometric definition of the rectum is highly variable. <i>International Journal of Colorectal Disease</i> , 2016, 31, 189-195.	1.0	20

#	ARTICLE	IF	CITATIONS
2731	Partial Mesorectal Excision for Rectal Adenocarcinoma: Morbidity and Oncological Outcome. <i>Clinical Colorectal Cancer</i> , 2016, 15, 82-90.e1.	1.0	32
2733	Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. <i>Clinical Imaging</i> , 2016, 40, 57-62.	0.8	3
2734	Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 666-671.	1.2	9
2735	The impact of surgical quality on prognosis in patients undergoing rectal carcinoma surgery after preoperative chemoradiation. <i>International Journal of Colorectal Disease</i> , 2016, 31, 247-255.	1.0	7
2736	Optimal Timing of Surgical Resection After Radiation in Locally Advanced Rectal Adenocarcinoma: An Analysis of the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 877-887.	0.7	51
2737	Phase II study of computed tomography-guided 125I-seed implantation plus chemotherapy for locally recurrent rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 375-381.	0.3	6
2738	Risk factors for permanent stoma after rectal cancer surgery with temporary ileostomy. <i>Surgery</i> , 2016, 159, 721-727.	1.0	71
2739	Management of Colorectal Cancer in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 97-111.	1.0	16
2740	Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 106-113.	0.7	17
2741	Rectal Cancer: Time for Precision Medicine?. <i>Annals of Surgical Oncology</i> , 2016, 23, 12-15.	0.7	2
2742	Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer. <i>Tumor Biology</i> , 2016, 37, 3571-3580.	0.8	9
2743	Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv284.	3.0	34
2744	Radiosensitization of Human Colorectal Cancer Cells by MLN4924. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 527-534.	0.8	26
2745	Neoadjuvant treatment for locally advanced rectal cancer: a systematic review. <i>Surgery Today</i> , 2016, 46, 161-168.	0.7	21
2746	Magnetization transfer imaging to assess tumour response after chemoradiotherapy in rectal cancer. <i>European Radiology</i> , 2016, 26, 390-397.	2.3	13
2747	Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2017, 17, 265-273.	0.9	8
2748	The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 531-534.	0.6	11
2749	Complete Neoadjuvant Treatment for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 283-287.	0.6	60

#	ARTICLE	IF	CITATIONS
2750	Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 535-542.	0.6	21
2751	Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 561-568.	0.6	21
2752	Two-week Course of Preoperative Radiotherapy for Locally Advanced Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 266-273.	0.6	2
2753	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 277-282.	0.6	20
2754	Oncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 512-516.	0.6	5
2755	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 189-196.	1.2	30
2756	Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. <i>British Journal of Radiology</i> , 2017, 90, 20160739.	1.0	43
2757	Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer. , 2017, , 1-16.		0
2758	Organ Preservation Using Contact Radiotherapy for Early Rectal Cancer: Outcomes of Patients Treated at a Single Centre in the UK. <i>Clinical Oncology</i> , 2017, 29, 198-204.	0.6	35
2759	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017, 122, 146-151.	0.3	45
2760	Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 31, 128-131.	0.2	9
2761	A nomogram to predict distant metastasis after neoadjuvant chemoradiotherapy and radical surgery in patients with locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2017, 115, 462-469.	0.8	26
2762	Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 519-525.	1.1	31
2763	Intraoperative radiation therapy for colon and rectal cancers: a clinical review. <i>Radiation Oncology</i> , 2017, 12, 11.	1.2	45
2764	Chasing Surgical Value. <i>American Journal of Surgery</i> , 2017, 213, 439-442.	0.9	1
2765	Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 853-857.	1.2	2
2766	Management of the Patient with Rectal Cancer Presenting with Synchronous Liver Metastasis. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2017, , 205-232.	0.0	0
2767	Small bowel protection in IMRT for rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 578-588.	1.0	10

#	ARTICLE	IF	CITATIONS
2768	Predicting pathologic response: the "œbottom line" in the management of locally advanced rectal cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 675-676.	0.5	0
2769	Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients. <i>Modern Pathology</i> , 2017, 30, 897-904.	2.9	33
2770	Rectal and Colon Cancer: Background and Clinical Evidence. , 2017, , 155-169.		0
2771	Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. <i>JAMA Surgery</i> , 2017, 152, 558.	2.2	18
2772	Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. <i>Radiation Oncology</i> , 2017, 12, 48.	1.2	38
2773	Molecular effectors of radiation resistance in colorectal cancer. <i>Precision Radiation Oncology</i> , 2017, 1, 27-33.	0.4	18
2774	Acute toxicity and surgical complications after preoperative (chemo)radiation therapy for rectal cancer in patients with inflammatory bowel disease. <i>Radiotherapy and Oncology</i> , 2017, 123, 147-153.	0.3	21
2775	Laparoscopic surgery for rectal cancer: the verdict is not final yet!. <i>Techniques in Coloproctology</i> , 2017, 21, 241-243.	0.8	3
2776	Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design. <i>Current Treatment Options in Oncology</i> , 2017, 18, 13.	1.3	11
2777	Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study. <i>Clinical and Translational Oncology</i> , 2017, 19, 969-975.	1.2	11
2778	Colorectal cancer statistics, 2017. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 177-193.	157.7	3,300
2779	Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score. <i>Gut</i> , 2018, 67, gutjnl-2016-312695.	6.1	127
2780	Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 336-346.	5.1	447
2781	Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?. <i>Colorectal Disease</i> , 2017, 19, 237-242.	0.7	1
2782	Optimal Sequencing of Neoadjuvant Therapies (NAT) in Rectal Cancer: Upfront Chemotherapy vs. Upfront Chemoradiation. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 154-164.	1.0	3
2783	Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival. <i>Colorectal Disease</i> , 2017, 19, 731-738.	0.7	21
2784	Dual-energy CT can detect malignant lymph nodes in rectal cancer. <i>European Journal of Radiology</i> , 2017, 90, 81-88.	1.2	31
2785	On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. <i>Upsala Journal of Medical Sciences</i> , 2017, 122, 1-10.	0.4	27

#	ARTICLE	IF	CITATIONS
2786	Risk Factors Associated With Nonclosure of Defunctioning Stomas After Sphincter-Preserving Low Anterior Resection of Rectal Cancer: A Meta-Analysis. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 544-554.	0.7	54
2787	Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1461-1467.	1.2	22
2788	Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy. <i>Histopathology</i> , 2017, 71, 393-405.	1.6	18
2789	Is Fecal Diversion Needed in Pelvic Anastomoses During Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? <i>Annals of Surgical Oncology</i> , 2017, 24, 2122-2128.	0.7	17
2790	Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum. <i>Annals of Surgery</i> , 2017, 265, 882-888.	2.1	77
2791	The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy. <i>Colorectal Disease</i> , 2017, 19, 980-986.	0.7	7
2792	Short-Course Radiation Therapy Versus Long-Course Chemoradiation in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: New Insights from Randomized Trials. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 165-174.	1.0	5
2793	Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis. <i>BMC Cancer</i> , 2017, 17, 325.	1.1	35
2794	Tumor Size as an Independent Risk Factor for Postoperative Complications in Laparoscopic Low Anterior Resection for Advanced Rectal Cancer: A Multicenter Japanese Study. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, 98-103.	0.4	19
2795	Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer. <i>Surgery Today</i> , 2017, 47, 1372-1377.	0.7	15
2796	Prospective randomized trial of neoadjuvant chemotherapy during the "wait period" following preoperative chemoradiotherapy for rectal cancer: results of the <scp>WAIT</scp> trial. <i>Colorectal Disease</i> , 2017, 19, 973-979.	0.7	37
2799	Current Views on the Interval Between Neoadjuvant Chemoradiation and Surgery for Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 234-239.	1.0	0
2800	Controversies in the multimodality management of locally advanced rectal cancer. <i>Medical Oncology</i> , 2017, 34, 102.	1.2	16
2801	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , 2017, 2, 455-464.	0.6	18
2802	Avoiding Radical Surgery in Elderly Patients With Rectal Cancer Is Cost-Effective. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 30-42.	0.7	25
2803	A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2017, 32, 341-348.	1.0	11
2804	Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified?. <i>American Journal of Surgery</i> , 2017, 213, 478-483.	0.9	26
2805	Adjuvant Chemotherapy Improves Overall Survival of Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Regardless of Pathologic Nodal Status. <i>Annals of Surgical Oncology</i> , 2017, 24, 1281-1288.	0.7	11

#	ARTICLE	IF	CITATIONS
2806	Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review. EPMA Journal, 2017, 8, 61-67.	3.3	12
2807	Do patients requiring a multivisceral resection for rectal cancer have worse oncologic outcomes than patients undergoing only abdominoperineal resection?. American Journal of Surgery, 2017, 214, 416-420.	0.9	4
2808	Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients. Clinical and Translational Radiation Oncology, 2017, 4, 8-14.	0.9	47
2809	Evolving Role of Radiotherapy in the Management of Rectal Carcinoma. Surgical Oncology Clinics of North America, 2017, 26, 455-466.	0.6	5
2810	Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study. British Journal of Radiology, 2017, 90, 20160731.	1.0	4
2811	Neoadjuvant chemoradiotherapy of the rectal carcinoma â€” The correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings. Reports of Practical Oncology and Radiotherapy, 2017, 22, 265-276.	0.3	3
2812	The good, the bad and the ugly: rectal cancers in the twenty-first century. Techniques in Coloproctology, 2017, 21, 573-575.	0.8	10
2813	Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. Scientific Reports, 2017, 7, 3471.	1.6	8
2814	Accuracy of MRI in Restaging Locally Advanced Rectal Cancer After Preoperative Chemoradiation. Diseases of the Colon and Rectum, 2017, 60, 274-283.	0.7	66
2815	<i>In vivo</i> Portal Imaging Dosimetry Identifies Delivery Errors in Rectal Cancer Radiotherapy on the Belly Board Device. Technology in Cancer Research and Treatment, 2017, 16, 956-963.	0.8	8
2816	Sphincterâ€”Preserving Surgery for Low Rectal Cancers: Incidence and Risk Factors for Permanent Stoma. World Journal of Surgery, 2017, 41, 2912-2922.	0.8	22
2817	Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 417-426.	0.4	67
2818	Local recurrence after five years is associated with preoperative chemoradiotherapy treatment in patients diagnosed with stage II and III rectal cancer. International Journal of Surgery, 2017, 44, 15-20.	1.1	8
2819	Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Disease, 2017, 19, 1058-1066.	0.7	13
2820	Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer. European Journal of Surgical Oncology, 2017, 43, 1488-1493.	0.5	12
2821	Clinical implications of preoperative chemoradiotherapy prior to laparoscopic surgery for locally advanced low rectal cancer. Molecular and Clinical Oncology, 2017, 6, 23-28.	0.4	2
2822	Prognostic value of programmed deathâ€”ligand 1 expression in patients with stage III colorectal cancer. Cancer Science, 2017, 108, 853-858.	1.7	46
2823	Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study. Annals of Surgical Oncology, 2017, 24, 2632-2638.	0.7	44

#	ARTICLE	IF	CITATIONS
2824	Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. <i>World Journal of Surgery</i> , 2017, 41, 2884-2897.	0.8	14
2825	Bowel Dysfunction After Low Anterior Resection With Neoadjuvant Chemoradiotherapy or Chemotherapy Alone for Rectal Cancer: A Cross-Sectional Study from China. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 697-705.	0.7	42
2826	Treatment of Locally Advanced Rectal Cancer: Turning Good Rationale Into Good Evidence?. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 649-650.	0.7	0
2827	Radiographic predictors of response to endoluminal brachytherapy for the treatment of rectal cancer. <i>Journal of Radiation Oncology</i> , 2017, 6, 287-294.	0.7	0
2828	Organ preservation in rectal cancer – Challenges and future strategies. <i>Clinical and Translational Radiation Oncology</i> , 2017, 3, 9-15.	0.9	29
2829	PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1164-1173.	0.4	26
2830	Possible role of nuclear β -catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Histopathology</i> , 2017, 71, 227-237.	1.6	14
2831	Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. <i>Surgery</i> , 2017, 162, 303-314.	1.0	74
2832	Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?. <i>Chronobiology International</i> , 2017, 34, 492-503.	0.9	23
2833	Current Status of the Watch-and-Wait Policy for Patients with Complete Clinical Response Following Neoadjuvant Chemoradiation in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 17-26.	1.0	1
2834	Effectiveness of a Tailored Anterior Saturation Band in the Improvement of the Image Quality of Pelvic Magnetic Resonance for Assessing Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 187-194.	1.0	1
2836	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , 2017, 16, 410-415.e1.	1.0	7
2837	Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. <i>Journal of Surgical Oncology</i> , 2017, 115, 1033-1044.	0.8	9
2838	Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients. <i>Journal of Digestive Diseases</i> , 2017, 18, 283-291.	0.7	2
2839	Total neoadjuvant therapy for rectal cancer: An emerging option. <i>Cancer</i> , 2017, 123, 1497-1506.	2.0	146
2840	Comparison of 5-FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e123-e139.	1.0	17
2842	A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines. <i>Surgery Today</i> , 2017, 47, 1086-1093.	0.7	10
2843	Additional chemotherapy and salvage surgery for poor response to chemoradiotherapy in rectal cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 322-328.	0.7	5

#	ARTICLE	IF	CITATIONS
2844	Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 169-174.	2.9	80
2845	Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 72, 84-94.	1.3	77
2846	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypNO Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1304-1311.	0.7	9
2847	Single Nucleotide Polymorphism TGF β 21 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 924-930.	0.4	10
2848	Understanding the factors associated with reduction in the number of lymph nodes in rectal cancer patients treated by neoadjuvant treatment. <i>International Journal of Colorectal Disease</i> , 2017, 32, 925-927.	1.0	18
2849	Perfusion CT measurements predict tumor response in rectal carcinoma. <i>Abdominal Radiology</i> , 2017, 42, 1132-1140.	1.0	11
2850	Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin. <i>Cancer Letters</i> , 2017, 388, 312-319.	3.2	18
2851	Sphincter-Preserving Surgery for Low Rectal Cancer: Do We Overshoot the Mark?. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 885-891.	0.9	24
2852	Incidence of second tumors after treatment with or without radiation for rectal cancer. <i>Annals of Oncology</i> , 2017, 28, 535-540.	0.6	25
2853	Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 721-728.	0.7	9
2854	Outcomes of patients with abdominoperineal resection (APR) and low anterior resection (LAR) who had very low rectal cancer. <i>Medicine (United States)</i> , 2017, 96, e8249.	0.4	14
2855	Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence. <i>Gastrointestinal Tumors</i> , 2017, 4, 11-19.	0.3	17
2856	Hypofractionation in Patients with Rectal Cancer. <i>Medical Radiology</i> , 2017, , 229-239.	0.0	0
2857	Modified 3-Point MRI-Based Tumor Regression Grade Incorporating DWI for Locally Advanced Rectal Cancer. <i>American Journal of Roentgenology</i> , 2017, 209, 1247-1255.	1.0	30
2858	Prediction of NO Irradiated Rectal Cancer Comparing MRI Before and After Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1184-1191.	0.7	13
2859	Correlations between the iodine concentrations from dual energy computed tomography and molecular markers Ki-67 and HIF-1 β in rectal cancer: A preliminary study. <i>European Journal of Radiology</i> , 2017, 96, 109-114.	1.2	19
2860	Factors associated with degree of tumour response to neo-adjuvant radiotherapy in rectal cancer and subsequent corresponding outcomes. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2052-2059.	0.5	20
2861	Meta-analysis of the impact of surgical approach on the grade of mesorectal excision in rectal cancer. <i>British Journal of Surgery</i> , 2017, 104, 1609-1619.	0.1	43

#	ARTICLE	IF	CITATIONS
2862	One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer. <i>Techniques in Coloproctology</i> , 2017, 21, 745-754.	0.8	3
2863	Impact of body mass index on treatment outcome of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1828-1834.	0.5	30
2864	Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma. <i>Neuroendocrinology</i> , 2017, 105, 426-434.	1.2	41
2865	Preoperative radiotherapy improves survival in rectal signet-ring cell carcinoma-a population-based study. <i>Radiation Oncology</i> , 2017, 12, 141.	1.2	12
2866	Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3857-3864.	0.7	23
2867	Complete pathological response after neoadjuvant therapy in patients with rectal adenocarcinoma. <i>Revista Médica Del Hospital General De México</i> , 2017, 80, 212-217.	0.0	0
2868	Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. <i>Annals of Oncology</i> , 2017, 28, 2436-2442.	0.6	72
2869	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€“ Multidisciplinary Management. <i>Colorectal Disease</i> , 2017, 19, 37-66.	0.7	77
2870	Cancer Center Volume and Type Impact Stage-Specific Utilization of Neoadjuvant Therapy in Rectal Cancer. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1906-1912.	1.1	11
2871	Triple Testâ€”a Predictor of Anastomotic Integrity in Patients Undergoing Low Anterior Resection After Neoadjuvant Chemoradiotherapy. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 506-510.	0.3	0
2872	Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. <i>Tumor Biology</i> , 2017, 39, 101042831770963.	0.8	15
2873	Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study. <i>Techniques in Coloproctology</i> , 2017, 21, 633-640.	0.8	31
2874	Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1295-1301.	1.0	1
2875	Looking for the Good, Bad and the Ugly rectal cancers of the twenty-first centuryâ€” or â€œHow to avoid tears when peeling onionsâ€”. <i>Techniques in Coloproctology</i> , 2017, 21, 577-579.	0.8	3
2876	Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with midâ€”upper rectal cancer. <i>Journal of Radiation Research</i> , 2017, 58, 559-566.	0.8	4
2877	Health care disparities among octogenarians and nonagenarians with stage <scp>II</scp> and <scp>III</scp> rectal cancer. <i>Cancer</i> , 2017, 123, 4325-4336.	2.0	10
2878	Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2363-2373.	1.2	13
2880	A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer. <i>Cancer Investigation</i> , 2017, 35, 535-540.	0.6	4

#	ARTICLE	IF	CITATIONS
2881	Local Excision and Endoscopic Resections for Early Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2017, 30, 313-323.	0.5	11
2882	Management of the Complete Clinical Response. <i>Clinics in Colon and Rectal Surgery</i> , 2017, 30, 387-394.	0.5	21
2883	Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients. <i>Scientific Reports</i> , 2017, 7, 16043.	1.6	12
2884	Cancer Surgery and the Elderly. , 0, , 150-156.		0
2885	Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1260-1266.	0.7	16
2886	Local control of sphincterâ€preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis. <i>Annals of Gastroenterological Surgery</i> , 2017, 1, 199-207.	1.2	8
2887	Do Moderate Surgical Treatment Delays Influence Survival in Colon Cancer?. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1241-1249.	0.7	44
2888	Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831773097.	0.8	18
2889	Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. <i>British Journal of Cancer</i> , 2017, 117, 210-219.	2.9	40
2890	Uterine transposition: technique and a case report. <i>Fertility and Sterility</i> , 2017, 108, 320-324.e1.	0.5	39
2891	Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage IIâ€III resectable rectal cancer: 5-Year survival data of a randomized controlled trial. <i>Medicina (Lithuania)</i> , 2017, 53, 150-158.	0.8	17
2892	Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2017, 14, 201-209.	0.8	19
2893	Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. <i>Annals of Oncology</i> , 2017, 28, 2160-2168.	0.6	41
2894	Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	105
2895	The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review. <i>Chemotherapy</i> , 2017, 62, 314-322.	0.8	8
2896	The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 61-72.	1.0	7
2897	Personalizing Therapy for Locally Advanced Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 119-125.	1.0	0
2898	Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 175-182.	1.0	2

#	ARTICLE	IF	CITATIONS
2899	Laparoscopic Colorectal Surgery for Cancer: What Is the Role of Complete Mesocolic Excision and Splenic Flexure Mobilization?. <i>Indian Journal of Surgery</i> , 2017, 79, 338-343.	0.2	4
2900	Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Exploratory Single-Arm Phase 2 Study NEORIT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 867-875.	0.4	12
2901	Cancer mortality in former East and West Germany: a story of unification?. <i>BMC Cancer</i> , 2017, 17, 94.	1.1	7
2902	Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate. <i>BMC Cancer</i> , 2017, 17, 182.	1.1	1
2904	Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 49-55.	0.9	5
2905	Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 2997-3003.	1.3	9
2906	A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. <i>Journal of Radiation Research</i> , 2017, 58, 247-259.	0.8	27
2907	Radiation Oncology in India: Challenges and Opportunities. <i>Seminars in Radiation Oncology</i> , 2017, 27, 158-163.	1.0	19
2908	Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. <i>International Journal of Colorectal Disease</i> , 2017, 32, 255-264.	1.0	14
2909	Preoperative Chemoradiotherapy Might Improve the Prognosis of Patients with Locally Advanced Low Rectal Cancer and Lateral Pelvic Lymph Node Metastases. <i>World Journal of Surgery</i> , 2017, 41, 876-883.	0.8	35
2910	Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. <i>Cancer</i> , 2017, 123, 783-793.	2.0	15
2911	Activation of CXCL12/CXCR4 renders colorectal cancer cells less sensitive to radiotherapy via up-regulating the expression of survivin. <i>Experimental Biology and Medicine</i> , 2017, 242, 429-435.	1.1	22
2912	CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1 α . <i>Cancer Research</i> , 2017, 77, 112-122.	0.4	60
2913	Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. <i>Clinical and Translational Oncology</i> , 2017, 19, 379-385.	1.2	59
2914	Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 106-111.	0.9	12
2915	A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e23-e28.	1.0	4
2916	Manometric evaluation of anorectal function in patients treated with neoadjuvant chemoradiotherapy and total mesorectal excision for rectal cancer. <i>Digestive and Liver Disease</i> , 2017, 49, 91-97.	0.4	15
2917	Inferior mesenteric artery lymph node metastasis in rectal cancer treated with neoadjuvant chemoradiotherapy: Incidence, prediction and prognostic impact. <i>European Journal of Surgical Oncology</i> , 2017, 43, 85-91.	0.5	16

#	ARTICLE	IF	CITATIONS
2918	Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e7-e14.	1.0	10
2919	Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer. <i>Journal of Rural Health</i> , 2017, 33, 393-401.	1.6	33
2920	Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome. <i>Clinical Colorectal Cancer</i> , 2017, 16, 240-245.	1.0	6
2921	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2017, 16, e45-e54.	1.0	9
2922	Gallbladder. , 2017, , 397-414.		0
2923	Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2017, 32, 723-727.	1.0	9
2924	Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. <i>Acta Oncol</i> , 2017, 56, 391-397.	0.8	68
2925	The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1295-1303.	0.7	34
2927	The Role of EphA4 Signaling in Radiation-Induced EMT-Like Phenotype in Colorectal Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 442-445.	1.2	20
2928	Preoperative short-course radiation therapy for rectal cancer provides excellent disease control and toxicity: Results from a single US institution. <i>Practical Radiation Oncology</i> , 2017, 7, e51-e58.	1.1	11
2929	Impact of hospital volume on quality indicators for rectal cancer surgery in British Columbia, Canada. <i>American Journal of Surgery</i> , 2017, 213, 388-394.	0.9	10
2930	Management of surgical challenges in actively treated cancer patients. <i>Current Problems in Surgery</i> , 2017, 54, 612-654.	0.6	10
2931	The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1219-1226.	1.1	0
2932	Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study. <i>Pteridines</i> , 2017, 28, 233-241.	0.5	3
2934	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv22-iv40.	0.6	1,126
2936	10. Gastrointestinale Onkologie im Alter. , 2017, , .		0
2937	Is Neoadjuvant Radiotherapy Alone a Good Alternative to Neoadjuvant Chemoradiotherapy in Patients with Low Performance Status?. <i>American Surgeon</i> , 2017, 83, 63-65.	0.4	1
2938	High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. <i>Journal of Cancer</i> , 2017, 8, 1197-1204.	1.2	13

#	ARTICLE	IF	CITATIONS
2939	A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer. <i>Journal of Cancer</i> , 2017, 8, 3114-3121.	1.2	19
2940	The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer. <i>Journal of Cancer</i> , 2017, 8, 1229-1237.	1.2	1
2941	Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. <i>Theranostics</i> , 2017, 7, 1346-1359.	4.6	59
2942	Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 573.	1.8	130
2943	Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1140.	1.8	12
2944	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1622.	1.8	92
2945	Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	0.7	4
2946	Nomogram Prediction of Anastomotic Leakage and Determination of an Effective Surgical Strategy for Reducing Anastomotic Leakage after Laparoscopic Rectal Cancer Surgery. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-8.	0.7	32
2947	Adjuvant Second-Dose Chemotherapy before Surgery for Patients with Locally Advanced Rectal Malignancy Is Not Beneficial: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-8.	0.7	0
2948	Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-10.	0.7	2
2949	Survival after Abdominoperineal and Sphincter-Preserving Resection in Nonmetastatic Rectal Cancer: A Population-Based Time-Trend and Propensity Score-Matched SEER Analysis. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-12.	0.7	20
2950	Essential Items for Structured Reporting of Rectal Cancer MRI: 2016 Consensus Recommendation from the Korean Society of Abdominal Radiology. <i>Korean Journal of Radiology</i> , 2017, 18, 132.	1.5	58
2951	Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2017, 8, 114746-114755.	0.8	17
2952	Preoperative short- vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. <i>Oncotarget</i> , 2017, 8, 60479-60486.	0.8	17
2953	A review of preoperative chemoradiotherapy for lower rectal cancer. <i>Journal of the Anus, Rectum and Colon</i> , 2017, 1, 65-73.	0.4	4
2954	Pelvic Radiation and Normal Tissue Toxicity. <i>Seminars in Radiation Oncology</i> , 2017, 27, 358-369.	1.0	56
2955	Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy. <i>PLoS ONE</i> , 2017, 12, e0173955.	1.1	34
2956	Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth. <i>BMC Cancer</i> , 2017, 17, 899.	1.1	16

#	ARTICLE	IF	CITATIONS
2957	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. <i>BMC Cancer</i> , 2017, 17, 615.	1.1	9
2958	Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer. <i>BMC Surgery</i> , 2017, 17, 126.	0.6	18
2959	The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study. <i>World Journal of Surgical Oncology</i> , 2017, 15, 205.	0.8	18
2960	Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45ÂGy/55ÂGy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis. <i>Radiation Oncology</i> , 2017, 12, 156.	1.2	10
2961	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 177.	3.5	33
2962	Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 265-275.	1.0	0
2963	Controversial issues in radiotherapy for rectal cancer: a systematic review. <i>Radiation Oncology Journal</i> , 2017, 35, 295-305.	0.7	27
2964	Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study. <i>Oncology Letters</i> , 2017, 14, 4543-4550.	0.8	6
2965	Bacterial Transfer Associated with Blowing Out Candles on a Birthday Cake. <i>Journal of Food Research</i> , 2017, 6, 1.	0.1	1
2966	Differences in the survival rates of older patients with colorectal cancers in 2003 and 2009. <i>Annals of Surgical Treatment and Research</i> , 2017, 92, 191.	0.4	1
2967	Matched case-control analysis comparing oncologic outcomes between preoperative and postoperative chemoradiotherapy for rectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2017, 92, 200.	0.4	4
2968	High Immunoreactivity of DUOX2 Is Associated With Poor Response to Preoperative Chemoradiation Therapy and Worse Prognosis in Rectal Cancers. <i>Journal of Cancer</i> , 2017, 8, 2756-2764.	1.2	12
2969	Compared planning dosimetry of TOMO, VMAT and IMRT in rectal cancer with different simulated positions. <i>Oncotarget</i> , 2017, 8, 42020-42029.	0.8	16
2970	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. <i>Medical Science Monitor</i> , 2017, 23, 315-324.	0.5	30
2971	A critical reappraisal for the value of tumor size as a prognostic variable in rectal adenocarcinoma. <i>Journal of Cancer</i> , 2017, 8, 1927-1934.	1.2	25
2972	Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 17, 162-169.	0.7	19
2973	A nomogram predicting pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: implications for organ preservation strategies. <i>Oncotarget</i> , 2017, 8, 67732-67743.	0.8	18
2974	N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2. <i>Oncotarget</i> , 2017, 8, 47709-47724.	0.8	14

#	ARTICLE	IF	CITATIONS
2975	Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 232-245.	1.8	10
2976	Preoperative chemoradiotherapy for rectal cancer: the sensitizer role of the association between miR-375 and c-Myc. Oncotarget, 2017, 8, 82294-82302.	0.8	8
2977	Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas. Journal of Gastrointestinal Oncology, 2017, 8, 547-555.	0.6	2
2978	Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. Journal of Gastrointestinal Oncology, 2017, 8, 39-48.	0.6	35
2979	Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?. World Journal of Gastroenterology, 2017, 23, 1412.	1.4	29
2980	Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer. Oncotarget, 2017, 8, 100724-100733.	0.8	55
2981	Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. Journal of Gastrointestinal Oncology, 2017, 8, 998-1008.	0.6	15
2982	Clinical predictive factors associated with pathologic complete response in locally advanced rectal cancer. Journal of Oncological Science, 2018, 4, 5-10.	0.1	7
2983	Principles of cancer treatment by chemotherapy. Surgery, 2018, 36, 134-138.	0.1	55
2984	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. British Journal of Cancer, 2018, 118, 878-886.	2.9	20
2985	Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy. , 2018, , 37-63.		0
2986	The Proper Treatment for the Complete Responder After Neoadjuvant Therapy. , 2018, , 77-95.		0
2987	Adjuvant Chemotherapy. , 2018, , 97-109.		0
2989	MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. Radiology, 2018, 287, 833-843.	3.6	257
2990	Neoadjuvant Radiotherapy. , 2018, , 65-76.		0
2991	CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma. Academic Radiology, 2018, 25, 1285-1297.	1.3	51
2992	Decision-Making Strategy for Rectal Cancer Management Using Radiation Therapy for Elderly or Comorbid Patients. International Journal of Radiation Oncology Biology Physics, 2018, 100, 926-944.	0.4	23
2993	Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer. British Journal of Radiology, 2018, 91, 20170938.	1.0	13

#	ARTICLE	IF	CITATIONS
2994	Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 NO Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e519-e530.	1.0	6
2995	Is transanal total mesorectal excision really safe and better than laparoscopic total mesorectal excision with a perineal approach first in patients with low rectal cancer? A learning curve with case-matched study in 68 patients. <i>Colorectal Disease</i> , 2018, 20, O143-O151.	0.7	44
2996	A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 42-46.	0.9	3
2997	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2018, , 59-67.		0
2998	How Can We Identify Tumour Penetration?. , 2018, , 71-77.		0
2999	When Should Radiation Be Avoided in the Treatment of Rectal Cancer?. , 2018, , 153-158.		0
3001	What Are the Dose-Volume Constraints for Long-Course Radiochemotherapy to Apply for IMRT?. , 2018, , 193-197.		0
3002	When Could Preoperative Radiotherapy Be Proposed for cT2 Presentations?. , 2018, , 223-228.		0
3003	Should Upfront Chemotherapy Precede Preoperative Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer?. , 2018, , 287-297.		0
3004	Could Upfront Chemotherapy Substitute Preoperative Radiochemotherapy?. , 2018, , 299-305.		0
3005	How Can Extended Demolition in Primary Advanced Presentations Be Beneficial?. , 2018, , 411-437.		0
3006	What Are the Main Features of a TEM?. , 2018, , 475-484.		0
3007	What Is the Prognostic Value of the (Y)pN Status After Chemoradiotherapy in Rectal Cancer?. , 2018, , 539-552.		0
3008	How Many Nodes Have to Be Detected/Examined After Preoperative Radio(chemo) Therapy?. , 2018, , 553-564.		0
3009	Abdominoperineal Resection for Rectal Cancer in the Twenty-First Century: Indications, Techniques, and Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1477-1487.	0.9	54
3010	Survival and functional and oncological outcomes following intersphincteric resection for low rectal cancer: short-term results. <i>Journal of International Medical Research</i> , 2018, 46, 1617-1625.	0.4	6
3012	A CRITICAL period for chemoradiotherapy in gastric cancer. <i>Lancet Oncology</i> , The, 2018, 19, 581-583.	5.1	4
3013	Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update. , 2018, , 273-285.		0

#	ARTICLE	IF	CITATIONS
3014	When Should Preoperative Radiochemotherapy Be Performed?. , 2018, , 159-163.		0
3015	Intravoxel Incoherent Motion MRI of Rectal Cancer: Correlation of Diffusion and Perfusion Characteristics With Prognostic Tumor Markers. American Journal of Roentgenology, 2018, 210, W139-W147.	1.0	44
3017	Interaction between Medical Treatment and Minimally Invasive Surgical Treatment for the Malignancies of the Digestive Tract. Digestion, 2018, 97, 13-19.	1.2	3
3018	Novel radiomic signature as a prognostic biomarker for locally advanced rectal cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 605-614.	1.9	61
3019	Outcomes and prognostic factors of selective lateral pelvic lymph node dissection with preoperative chemoradiotherapy for locally advanced rectal cancer. International Journal of Colorectal Disease, 2018, 33, 367-374.	1.0	45
3020	Endoscopic ultrasound for rectal cancer staging: A populationâ€based study of utilization, impact on treatment patterns, and survival. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1469-1476.	1.4	8
3021	Feasibility of Assessing Prognostic Nutrition Index in Patients With Rectal Cancer Who Receive Preoperative Chemoradiotherapy. Journal of Parenteral and Enteral Nutrition, 2018, 42, 998-1007.	1.3	31
3022	Short-Term and Long-Term Outcomes of Laparoscopic Versus Open Surgery for Low Rectal Cancer. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 637-644.	0.5	7
3023	Current Trends in the Rate of Rectal Cancer Restorative Operations in the Era of Neoadjuvant Chemoradiation. Current Colorectal Cancer Reports, 2018, 14, 31-36.	1.0	1
3024	Neoadjuvant Radiation Therapy in Locally Advanced Colon Cancer: a Cohort Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 906-912.	0.9	23
3026	Value of FDGâ€PET/CT Volumetry After Chemoradiotherapy in Rectal Cancer. Diseases of the Colon and Rectum, 2018, 61, 320-327.	0.7	10
3027	Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes. Clinical and Translational Oncology, 2018, 20, 1018-1025.	1.2	10
3028	miR-145 Antagonizes SNAIL-Mediated Stemness and Radiation Resistance in Colorectal Cancer. Molecular Therapy, 2018, 26, 744-754.	3.7	88
3029	The negative impact of understaging rectal cancer patients. American Journal of Surgery, 2018, 216, 93-98.	0.9	2
3030	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. OncoImmunology, 2018, 7, e1393133.	2.1	17
3031	The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis. Current Problems in Cancer, 2018, 42, 95-106.	1.0	50
3032	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. Cancer Treatment Reviews, 2018, 63, 156-171.	3.4	34
3033	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer, 2018, 124, 1650-1659.	2.0	32

#	ARTICLE	IF	CITATIONS
3034	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 460-466.	3.0	17
3036	The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. <i>Clinical Proteomics</i> , 2018, 15, 16.	1.1	43
3037	A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 889-899.	0.4	44
3038	Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. <i>Medical Oncology</i> , 2018, 35, 83.	1.2	1
3039	Will There Be a Clinically Significant Role for Protons in Patients With Gastrointestinal Malignancies?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 125-130.	1.0	1
3040	MRI Linac and How It May Potentially Lead to More Complete Response in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 643-644.	0.7	4
3041	Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1521-1527.	0.6	61
3042	Outcome of bowel function following anterior resection for rectal cancer—an analysis using the low anterior resection syndrome (LARS) score. <i>International Journal of Colorectal Disease</i> , 2018, 33, 787-798.	1.0	56
3043	Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. <i>Journal of Proteomics</i> , 2018, 179, 53-60.	1.2	17
3044	Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 37-55.	1.0	52
3045	Preoperative short-course radiotherapy in rectal cancer patients: results and prognostic factors. <i>Journal of Radiation Oncology</i> , 2018, 7, 77-84.	0.7	14
3046	Safety and feasibility of single-port laparoscopic low anterior resection for upper rectal cancer. <i>American Journal of Surgery</i> , 2018, 216, 1101-1106.	0.9	15
3048	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 458-466.	0.6	31
3049	MR Imaging with Apparent Diffusion Coefficient Histogram Analysis: Evaluation of Locally Advanced Rectal Cancer after Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2018, 288, 129-137.	3.6	46
3050	Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer—The New Standard of Care?. <i>JAMA Oncology</i> , 2018, 4, e180070.	3.4	22
3051	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
3052	Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1119-1128.	1.2	7
3053	Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy. <i>Cancer Science</i> , 2018, 109, 871-878.	1.7	16

#	ARTICLE	IF	CITATIONS
3054	Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 179-186.	1.0	6
3055	Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). <i>Oncologist</i> , 2018, 23, 912-918.	1.9	16
3056	The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 565-582.	1.3	14
3057	Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases. <i>Clinical Colorectal Cancer</i> , 2018, 17, e307-e313.	1.0	10
3058	Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. <i>Journal of Surgical Research</i> , 2018, 226, 15-23.	0.8	11
3059	Factors Associated With Receipt of Radiation Therapy for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 227-229.	0.6	4
3060	Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 140-146.	0.6	5
3061	The Comparison of the Advantages of Neoadjuvant Chemoradiotherapy versus Postoperative Chemoradiotherapy: Outcomes in Esophageal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 50-56.	0.6	6
3062	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34.	1.0	1,187
3063	Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 643-648.	0.6	7
3064	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. <i>Clinical Colorectal Cancer</i> , 2018, 17, 1-12.	1.0	90
3065	External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia. <i>International Journal of Hyperthermia</i> , 2018, 34, 455-460.	1.1	6
3066	Anastomotic stricture after ultralow anterior resection or intersphincteric resection for very low-lying rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 660-666.	1.3	51
3067	Laparoscopic versus open surgery for rectal cancer after neoadjuvant chemoradiation: Long-term outcomes of a propensity score matched study. <i>Journal of Surgical Oncology</i> , 2018, 117, 506-513.	0.8	10
3068	FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 365-375.	3.3	125
3069	Surgical and oncological outcomes after complete mesocolic excision in right-sided colon cancer compared with conventional surgery: a retrospective, single-institution study. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1-8.	1.0	38
3070	Radiotherapy for Patients With Resected Tumor Deposits: Positive Colorectal Cancer: A Surveillance, Epidemiology, and End Results-Based Population Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 721-729.	1.2	15
3071	Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score. <i>Clinical Colorectal Cancer</i> , 2018, 17, 104-112.e2.	1.0	18

#	ARTICLE	IF	CITATIONS
3072	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 953-959.	0.6	14
3073	Prognostic significance of the distribution of lymph node metastasis in rectal cancer after neoadjuvant chemoradiation. <i>Journal of Surgical Oncology</i> , 2018, 117, 514-522.	0.8	2
3074	Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2442-2447.	1.3	73
3075	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. <i>Advances in Radiation Oncology</i> , 2018, 3, 34-41.	0.6	15
3076	Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 146-158.	0.4	13
3077	T3 subclassification using the EMD/mesorectum ratio predicts neoadjuvant chemoradiation outcome in T3 rectal cancer patients. <i>British Journal of Radiology</i> , 2018, 91, 20170617.	1.0	6
3078	Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment. <i>ANZ Journal of Surgery</i> , 2018, 88, 62-65.	0.3	5
3079	Pretreatment Serum Carbohydrate Antigen 19-9 Concentration Is a Predictor of Survival of Patients Who Have Undergone Curative Resection of Stage IV Rectal Cancer. <i>Digestive Surgery</i> , 2018, 35, 389-396.	0.6	7
3080	Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 53-59.	2.9	121
3081	Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis. <i>Digestive Surgery</i> , 2018, 35, 212-219.	0.6	3
3082	Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. <i>Clinical Colorectal Cancer</i> , 2018, 17, e13-e19.	1.0	26
3083	Simvastatin enhances radiation sensitivity of colorectal cancer cells. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1533-1539.	1.3	19
3084	Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer with Magnetic Resonance Imaging. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 146-153.	0.9	60
3085	Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model. <i>Journal of Surgical Oncology</i> , 2018, 117, 737-744.	0.8	26
3086	Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. <i>Clinical Colorectal Cancer</i> , 2018, 17, e121-e125.	1.0	19
3087	Tumor volume predicts local recurrence in early rectal cancer treated with radical resection: A retrospective observational study of 270 patients. <i>International Journal of Surgery</i> , 2018, 49, 68-73.	1.1	18
3088	Rectal perfusion parameters normalised to tumour-free rectal wall can predict response to neoadjuvant chemoradiotherapy. <i>Clinical Radiology</i> , 2018, 73, 151-157.	0.5	4
3089	Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). <i>International Journal of Colorectal Disease</i> , 2018, 33, 241-249.	1.0	24

#	ARTICLE	IF	CITATIONS
3090	Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 692-698.	0.8	16
3091	Intersphincteric Resection and Coloanal Reconstruction. , 2018, , 191-211.		2
3092	Optimizing Primary Tumor Management in Stage IV Rectal Cancer. , 2018, , 257-268.		0
3093	Maximizing Neoadjuvant Treatment Response and Watch and Wait. , 2018, , 277-293.		1
3094	Quality of Life After Multidisciplinary Management of Rectal Cancer. , 2018, , 313-334.		0
3095	Radiation Therapy for Rectal Cancer. , 2018, , 81-98.		0
3096	Management of stage II and III rectal cancer in British Columbia: Is there a rural-urban difference?. <i>American Journal of Surgery</i> , 2018, 216, 906-911.	0.9	4
3097	Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 825-832.	0.8	6
3098	Selective lateral pelvic lymph node dissection: a comparative study of the robotic versus laparoscopic approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2466-2473.	1.3	54
3099	Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018, 17, 13-24.	1.0	88
3100	Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 140-149.	1.5	81
3101	Inhibition of Notch1/Hes1 signaling pathway improves radiosensitivity of colorectal cancer cells. <i>European Journal of Pharmacology</i> , 2018, 818, 364-370.	1.7	13
3102	Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxMO) rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 41-49.	1.0	6
3103	Outcomes of rectal resection following neoadjuvant therapy in the elderly: Can rectal cancer patients be too old for a neoadjuvant approach?. <i>American Journal of Surgery</i> , 2018, 215, 436-439.	0.9	4
3104	Predictors of adherence to aerobic exercise in rectal cancer patients during and after neoadjuvant chemoradiotherapy. <i>Psychology, Health and Medicine</i> , 2018, 23, 224-231.	1.3	9
3105	A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 972-976.	0.6	6
3106	Comparison of MRI and colonoscopy in determining tumor height in rectal cancer. <i>United European Gastroenterology Journal</i> , 2018, 6, 131-137.	1.6	11
3107	Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. <i>Singapore Medical Journal</i> , 2018, 59, 305-310.	0.3	8

#	ARTICLE	IF	CITATIONS
3108	Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. <i>Oncotarget</i> , 2018, 9, 27256-27267.	0.8	28
3109	Does a fine line exist between regional and metastatic pelvic lymph nodes in rectal cancer? striking discordance between national guidelines and treatment recommendations by US radiation oncologists. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 441-447.	0.6	6
3110	Evolution of transanal total mesorectal excision for rectal cancer: From top to bottom. <i>World Journal of Gastrointestinal Surgery</i> , 2018, 10, 28-39.	0.8	40
3111	Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy. <i>Medicine (United States)</i> , 2018, 97, e13363.	0.4	32
3112	Clinical significance of the EMD/mesorectum ratio of T3 mid-low rectal cancer. <i>Medicine (United States)</i> , 2018, 97, e13363.	0.4	3
3113	Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. <i>International Journal of Oncology</i> , 2018, 53, 1667-1680.	1.4	12
3114	Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. <i>Medicine (United States)</i> , 2018, 97, e11435.	0.4	13
3115	Higher nuclear EGFR expression is a better predictor of survival in rectal cancer patients following neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression. <i>Oncology Letters</i> , 2018, 17, 1551-1558.	0.8	10
3116	Efficacy and safety of consolidation chemotherapy during the resting period in patients with local advanced rectal cancer. <i>Oncology Letters</i> , 2018, 17, 1655-1663.	0.8	10
3117	Individualized multimodal treatment strategy for metastatic rectal adenocarcinoma. <i>Porto Biomedical Journal</i> , 2018, 3, e20.	0.4	0
3118	The Prognostic Significance of the Expression Change of EGFR during Neoadjuvant Chemoradiotherapy in Patients with Rectal Carcinoma. , 2018, , .		0
3119	Colorectal cancer " heading to the future. <i>Innovative Surgical Sciences</i> , 2018, 3, 1-2.	0.4	7
3120	Feasibility Assessment of Physical Factors of Rectal Cancer Short-Course Chemoradiotherapy with Delayed Surgery. <i>Progress in Medical Physics</i> , 2018, 29, 143.	0.5	0
3122	Radiomics to Predict Response to Neoadjuvant Chemotherapy in Rectal Cancer: Influence of Simultaneous Feature Selection and Classifier Optimization. , 2018, , .		13
3123	Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results. <i>Radiation Oncology Journal</i> , 2018, 36, 17-24.	0.7	16
3124	Neoadjuvant therapy and subsequent treatment in rectal cancer: balance between oncological and functional outcomes. <i>Journal of the Anus, Rectum and Colon</i> , 2018, 2, 47-58.	0.4	3
3125	Patterns of Rectal Cancer Radiotherapy Adopting Evidence-Based Medicine: An Analysis of the National Database from 2005 to 2016. <i>Cancer Research and Treatment</i> , 2018, 50, 975-983.	1.3	5
3126	Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 363-376.	0.6	26

#	ARTICLE	IF	CITATIONS
3127	Comparative survival analysis of preoperative and postoperative radiotherapy in stage II-III rectal cancer on the basis of long-term population data. <i>Scientific Reports</i> , 2018, 8, 17153.	1.6	3
3128	CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. <i>BMC Cancer</i> , 2018, 18, 1145.	1.1	22
3129	Treatment of Rectal Cancer in Older Adults. <i>Current Oncology Reports</i> , 2018, 20, 102.	1.8	3
3130	Meta-analysis of the influence of time interval between radical operation and preoperative chemoradiotherapy on complete pathological response in rectal cancer patients. <i>Tropical Journal of Pharmaceutical Research</i> , 2018, 17, 1859.	0.2	0
3131	Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. <i>In Vivo</i> , 2018, 32, 1481-1484.	0.6	4
3132	Targeted Therapy of Colorectal Cancer Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
3133	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 75-100.	0.8	7
3134	PET imaging in adaptive radiotherapy of gastrointestinal tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 385-403.	0.4	8
3135	The Impact of Surgical Timing on Pathologic Tumor Response after Short Course and Long Course Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1039-1050.	1.3	11
3137	Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 145-158.	0.8	29
3138	Optimal Time Interval for Surgery After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer: Analysis of Health Insurance Review and Assessment Service Data. <i>Annals of Coloproctology</i> , 2018, 34, 241-247.	0.5	18
3139	Radiation Induced Exacerbation of Bullous Pemphigoid in Rectal Cancer. <i>Journal of Oncology Medicine & Practice</i> , 2018, 03, .	0.1	0
3140	Preoperative Stereotactic Radiosurgery for Brain Metastases. <i>Frontiers in Neurology</i> , 2018, 9, 959.	1.1	41
3141	Prognostic Significance of Survivin Expression and Combined Analysis with Cancer Stem Cell and Epithelialâ€Mesenchymal Transition-related Markers in Patients with Rectal Cancer Undergoing Preoperative Chemoradiotherapy. <i>Anticancer Research</i> , 2018, 38, 6881-6889.	0.5	6
3142	Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer. <i>Radiation Oncology</i> , 2018, 13, 237.	1.2	20
3143	Dosimetric comparison of fixedâ€field intensityâ€modulated radiotherapy and volumetricâ€modulated arc radiotherapy for preoperative rectal cancer. <i>Precision Radiation Oncology</i> , 2018, 2, 39-43.	0.4	2
3144	Reprint of: The natural history of rectal cancer 1908-2008: the evolving treatment of rectal cancer into the twenty-first century. <i>Seminars in Colon and Rectal Surgery</i> , 2018, 29, 136-150.	0.2	0
3145	Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 425-434.	0.6	4

#	ARTICLE	IF	CITATIONS
3146	A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers. <i>Anticancer Research</i> , 2018, 38, 6877-6880.	0.5	6
3147	Decrease in 30-day and one-year mortality over time in patients aged ≥ 75 years with stage III colon cancer: A population-based study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1889-1893.	0.5	16
3148	MRI-Based Apparent Diffusion Coefficient for Predicting Pathologic Response of Rectal Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2018, 211, W205-W216.	1.0	30
3149	Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. <i>Colorectal Disease</i> , 2018, 20, 58-68.	0.7	17
3150	The significance of mucin pools following neoadjuvant chemoradiotherapy for locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 1129-1134.	0.8	6
3151	SUV _{max} -based Parameters of FDG-PET/CT Reliably Predict Pathologic Complete Response After Preoperative Hyperthermo-chemoradiotherapy in Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 5909-5916.	0.5	8
3152	Chemo-Radiation After Upfront Rectal Resections—a Clinical Dilemma. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 495-500.	0.3	0
3153	Association of MUC1 rs4072037 Functional Polymorphism and Cancer Risk: Evidence from 12551 Cases and 13436 Controls. <i>Journal of Cancer</i> , 2018, 9, 3343-3351.	1.2	3
3154	Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1146-1155.	0.7	115
3155	Total Neoadjuvant Therapy (TNT) in Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 199-206.	1.0	0
3156	Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. <i>Radiotherapy and Oncology</i> , 2018, 129, 300-305.	0.3	19
3157	miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. <i>PLoS ONE</i> , 2018, 13, e0206542.	1.1	34
3158	The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial. <i>Cancer Management and Research</i> , 2018, Volume 10, 4363-4369.	0.9	9
3159	Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. <i>British Journal of Surgery</i> , 2018, 105, 1553-1572.	0.1	29
3160	Advanced nanomaterials targeting hypoxia to enhance radiotherapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5925-5936.	3.3	42
3161	Técnicas quirúrgicas para la preservación de esfínter en cáncer de recto bajo: revisión histórica y estado actual. <i>Revista Chilena De Cirugía</i> , 2018, 70, 178-184.	0.1	0
3162	Lymph Node Yield After Neoadjuvant Chemoradiotherapy in Rectal Cancer Specimens: A Randomized Trial Comparing Two Fixatives. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 888-896.	0.7	17
3163	Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1320-1332.	0.7	51

#	ARTICLE	IF	CITATIONS
3164	Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. <i>Cancers</i> , 2018, 10, 386.	1.7	11
3165	Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0–l after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3101-3108.	0.9	9
3166	Effect of preoperative chemotherapy on distal spread of low rectal cancer located close to the anus. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1685-1693.	1.0	3
3167	Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer. <i>Radiation Oncology</i> , 2018, 13, 169.	1.2	3
3168	Prognostic markers of recurrence and survival in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. <i>Colorectal Cancer</i> , 2018, 7, CRC02.	0.8	4
3169	Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System. <i>Cancers</i> , 2018, 10, 319.	1.7	45
3170	Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 5371-5377.	0.5	6
3171	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29–30 September 2017. <i>Current Oncology</i> , 2018, 25, 275-284.	0.9	3
3172	High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. <i>International Journal of Medical Sciences</i> , 2018, 15, 1171-1178.	1.1	8
3173	Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer – toxicities and response assessment. <i>Cancer Management and Research</i> , 2018, Volume 10, 519-526.	0.9	7
3174	Management of rectal neoplasia in hereditary colorectal cancer patients. <i>Seminars in Colon and Rectal Surgery</i> , 2018, 29, 116-119.	0.2	0
3175	Variation in landmarks for the rectum: an <scp>MRI</scp> study. <i>Colorectal Disease</i> , 2018, 20, O304-O309.	0.7	18
3176	Optimal management of localized rectal cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2018, 9, 696-704.	0.5	10
3177	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	2.9	92
3178	Local recurrence rate in a national Danish patient cohort after curative treatment for rectal cancer. <i>Acta Oncol&agrave;gica</i> , 2018, 57, 1639-1645.	0.8	7
3179	Oxaliplatin-containing adjuvant chemotherapy improves the survival of locally advanced rectal cancer patients with pathological complete response after pre-operative chemoradiotherapy. <i>Gastroenterology Report</i> , 2018, 6, 195-201.	0.6	7
3181	Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. <i>British Journal of Surgery</i> , 2018, 105, 1510-1518.	0.1	36
3182	Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e557-e568.	1.0	2

#	ARTICLE	IF	CITATIONS
3183	Âtreatment planning study of prone vs. supine positions for locally advanced rectal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 975-984.	1.0	6
3184	Tailored Surgical Treatment Based on Response to Neoadjuvant Therapy. , 2018, , 89-97.		0
3185	Oncologic treatment strategies and relative survival of patients with stage lâ€“III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1338-1343.	0.5	11
3187	Total neoadjuvant therapy for rectal cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 459-465.	0.6	21
3188	Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 548-556.	0.3	42
3189	Absolute Lymphocyte Count in Preoperative Chemoradiotherapy for Rectal Cancer: Changes Over Time and Prognostic Significance. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878006.	0.8	22
3190	â€˜Watch and waitâ€™ in rectal cancer: summary of the current evidence. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1159-1168.	1.0	20
3191	Prediction of lateral pelvic lymph node metastasis in patients with locally advanced rectal cancer with preoperative chemoradiotherapy: Focus on MR imaging findings. <i>PLoS ONE</i> , 2018, 13, e0195815.	1.1	31
3192	Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. <i>In Vivo</i> , 2018, 32, 937-943.	0.6	18
3193	Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. <i>Radiotherapy and Oncology</i> , 2018, 128, 557-563.	0.3	7
3194	Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2018, 33, 995-1000.	1.0	5
3195	Observation of â€œcomplete clinical responseâ€•in rectal cancer after neoadjuvant chemoradiation: <i>The Flinders experience</i>. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 439-445.	0.7	11
3196	Rectal MRI for Cancer Staging and Surveillance. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 537-552.	1.0	18
3197	Low- Versus High-Risk Rectal Cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy. <i>American Journal of Roentgenology</i> , 2018, 211, 327-334.	1.0	7
3198	Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. <i>World Journal of Surgical Oncology</i> , 2018, 16, 105.	0.8	10
3199	Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 707-716.	1.1	22
3200	Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers. <i>Tumori</i> , 2018, 104, 266-272.	0.6	1
3201	Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. <i>British Journal of Cancer</i> , 2018, 119, 517-522.	2.9	24

#	ARTICLE	IF	CITATIONS
3202	HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 413-423.	1.4	12
3203	Neoadjuvant Radiotherapy Versus No Radiotherapy for Stage IV Rectal Cancer: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 389-401.	0.6	11
3204	Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 1365-1370.	1.2	13
3205	Impact of adjuvant chemotherapy on patients with ypT0â€² ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital. <i>World Journal of Surgical Oncology</i> , 2018, 16, 156.	0.8	6
3206	Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long-term survival data. <i>PLoS ONE</i> , 2018, 13, e0200142.	1.1	19
3207	Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision. <i>International Journal of Surgery</i> , 2018, 56, 283-287.	1.1	12
3208	Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies. <i>Current Oncology Reports</i> , 2018, 20, 68.	1.8	4
3209	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 874-901.	2.3	698
3210	Rectal Cancer in 2018: A Primer for the Gastroenterologist. <i>American Journal of Gastroenterology</i> , 2018, 113, 1763-1771.	0.2	19
3211	Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional survey. <i>Scientific Reports</i> , 2018, 8, 10708.	1.6	11
3212	Rectal cancer in young patients: Time to take notice. <i>Cancer</i> , 2018, 124, 3474-3475.	2.0	1
3213	Cost analysis of aâ€²wait-and-see strategy after radiochemotherapy in distal rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 985-990.	1.0	5
3214	MR Imaging of Rectal Cancer. <i>Radiologic Clinics of North America</i> , 2018, 56, 751-774.	0.9	28
3215	Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy. <i>Oncology</i> , 2018, 95, 270-280.	0.9	7
3216	Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1359-1366.	1.0	7
3217	Surgical and oncological short-term outcomes of prone extralevator abdominoperineal excision for low rectal cancer. <i>Journal of Coloproctology</i> , 2018, 38, 124-131.	0.1	2
3218	Risk factors of stoma re-creation after closure of diverting ileostomy in patients with rectal cancer who underwent low anterior resection or intersphincteric resection with loop ileostomy. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 203.	0.4	13
3219	Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy?. <i>Clinical Radiology</i> , 2018, 73, 911.e1-911.e7.	0.5	13

#	ARTICLE	IF	CITATIONS
3220	Assessment of bowel and anal sphincter function after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Tumori</i> , 2018, 104, 121-127.	0.6	4
3221	Intersphincteric Resection and Coloanal Anastomosis. , 2018, , 187-207.		0
3222	Neoadjuvant Therapy for Locally Advanced Rectal Cancer. , 2018, , 75-88.		0
3223	Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 35.	0.7	14
3224	Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial. <i>BMC Cancer</i> , 2018, 18, 369.	1.1	5
3225	Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer. <i>Radiation Oncology</i> , 2018, 13, 53.	1.2	19
3226	Factors predictive of neoadjuvant versus adjuvant chemoradiotherapy in locally advanced rectal cancer and the impact on overall survival. <i>Journal of Radiation Oncology</i> , 2018, 7, 213-222.	0.7	0
3227	Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. <i>British Journal of Surgery</i> , 2018, 105, 1519-1529.	0.1	72
3228	Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer. <i>Oncologist</i> , 2018, 23, 2-e5.	1.9	14
3229	Korean Society of Coloproctology (KSCP) trial of cONSolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: a multicenter, randomized controlled trial (KONCLUDE). <i>BMC Cancer</i> , 2018, 18, 538.	1.1	12
3230	Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1858-1864.	0.5	5
3231	Feasibility of Selective Lateral Node Dissection Based on Magnetic Resonance Imaging in Rectal Cancer After Preoperative Chemoradiotherapy. <i>Journal of Surgical Research</i> , 2018, 232, 227-233.	0.8	12
3232	The prognostic significance of lymph node size in node-positive colon cancer. <i>PLoS ONE</i> , 2018, 13, e0201072.	1.1	20
3233	Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. <i>Cancer Communications</i> , 2018, 38, 1-9.	3.7	25
3234	Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 370-379.	3.9	10
3235	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. <i>European Journal of Surgical Oncology</i> . 2018. 44. 1685-1702.	0.5	100
3236	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 595-600.	0.6	4
3237	Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Journal of Cancer</i> , 2018, 9, 2687-2692.	1.2	21

#	ARTICLE	IF	CITATIONS
3238	The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 991-1006.	1.0	14
3239	Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1685-1694.	2.0	81
3240	Clinical and molecular diagnosis of pathologic complete response in rectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 887-896.	1.5	11
3241	2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. <i>World Journal of Emergency Surgery</i> , 2018, 13, 36.	2.1	212
3242	Patterns of failure in rectal cancer with positive circumferential resection margin after surgery following preoperative chemoradiation: a propensity score matching analysis. <i>British Journal of Radiology</i> , 2018, 91, 20180143.	1.0	6
3243	Nationwide Heterogeneity in Hospital-Specific Probabilities of Rectal Cancer Understaging and Its Effects on Outcomes. <i>Annals of Surgical Oncology</i> , 2018, 25, 2332-2339.	0.7	12
3244	Radiation Therapy in Rectal Cancer. , 2018, , 1-21.		0
3245	Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer. <i>JAMA Surgery</i> , 2018, 153, e181607.	2.2	77
3246	Putting down the scalpel in rectal cancer management – a historical perspective. <i>Colorectal Disease</i> , 2018, 20, 12-15.	0.7	3
3247	Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 361-369.	0.3	4
3248	Intensity modulated radiotherapy delivers competitive local control rate with limited acute toxicity in the adjuvant treatment of rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 653-660.	0.6	3
3249	SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1 α . <i>Anticancer Research</i> , 2018, 38, 3323-3331.	0.5	21
3250	Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer. <i>British Journal of Surgery</i> , 2018, 105, 1671-1679.	0.1	19
3251	Dosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer. <i>PLoS ONE</i> , 2018, 13, e0190883.	1.1	18
3252	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 765-774.	0.4	81
3253	The rectosigmoid problem. <i>Surgical Oncology</i> , 2018, 27, 521-525.	0.8	25
3254	Radical Resection of Locally Recurrent Colorectal Cancer Significantly Improves Overall Survival: A Single-Center Cohort Study. <i>Digestive Surgery</i> , 2019, 36, 470-478.	0.6	2
3255	Comparison Between Laparoscopic and Open Resection Following Neoadjuvant Chemoradiotherapy for Mid-Low Rectal Cancer Patients: A Meta-Analysis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 316-322.	0.5	5

#	ARTICLE	IF	CITATIONS
3256	Dose Escalation with Simultaneous Integrated Boost (SIB) Using Volumetric Modulated Arc Therapy (VMAT) in Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 735-739.	0.6	5
3257	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313.	2.7	38
3258	Neoadjuvant radiation for clinical T4 colon cancer: A potential improvement to overall survival. <i>Surgery</i> , 2019, 165, 469-475.	1.0	37
3259	Low Tie Compared to High Tie Vascular Ligation of the Inferior Mesenteric Artery in Rectal Cancer Surgery Decreases Postoperative Complications Without Affecting Overall Survival. <i>Anticancer Research</i> , 2019, 39, 4363-4370.	0.5	17
3260	U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2043-2050.	1.9	51
3262	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. <i>International Journal of Surgical Pathology</i> , 2019, 27, 816-835.	0.4	8
3263	Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1204.	1.7	11
3266	Impact of therapeutic delay in colorectal cancer on overall survival and cancer recurrence – is there a safe timeframe for prehabilitation?. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2295-2301.	0.5	36
3267	Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer. <i>Surgery</i> , 2019, 166, 648-654.	1.0	4
3268	Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0. <i>Cancer Management and Research</i> , 2019, Volume 11, 5221-5229.	0.9	4
3269	MR-guided radiotherapy in rectal cancer: First clinical experience of an innovative technology. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 80-86.	0.9	48
3270	A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 3641-3651.	1.0	9
3271	Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer. <i>Translational Cancer Research</i> , 2019, 8, 150-159.	0.4	2
3272	Clinical outcomes of preoperative chemoradiotherapy in octogenarian with locally advanced rectal cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 181-188.	0.4	1
3273	Adjuvant chemotherapy in rectal cancer patients who achieved a pathological complete response after preoperative chemoradiotherapy: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2019, 9, 10008.	1.6	15
3274	Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 238-244.	1.0	29
3275	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. <i>BMC Cancer</i> , 2019, 19, 664.	1.1	40
3276	Role of magnetic resonance imaging in organ-preserving strategies for the management of patients with rectal cancer. <i>Insights Into Imaging</i> , 2019, 10, 59.	1.6	11

#	ARTICLE	IF	CITATIONS
3277	Magnetic Resonance Imaging of Rectal Cancer. <i>Journal of Gastrointestinal and Abdominal Radiology</i> , 2019, 02, 018-032.	0.2	0
3278	Significance of lymph node involvement in local recurrence of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 722-728.	0.8	4
3279	Evolving Treatment Options and Future Directions for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 231-237.	1.0	7
3280	Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era. <i>British Journal of Surgery</i> , 2019, 106, 1685-1696.	0.1	24
3281	Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer. <i>BJS Open</i> , 2019, 3, 822-829.	0.7	27
3282	How to Achieve a Higher Pathologic Complete Response in Patients With Locally Advanced Rectal Cancer Who Receive Preoperative Chemoradiation Therapy. <i>Annals of Coloproctology</i> , 2019, 35, 3-8.	0.5	3
3283	Colorectal cancer in adolescents and young adults: Defining a growing threat. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27941.	0.8	29
3284	The minimum distal resection margin in rectal cancer surgery and its impact on local recurrence - A retrospective cohort analysis. <i>International Journal of Surgery</i> , 2019, 69, 77-83.	1.1	22
3285	Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. <i>Surgery</i> , 2019, 166, 1061-1067.	1.0	9
3286	Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 733.	1.1	12
3287	Artificial intelligence system of faster region-based convolutional neural network surpassing senior radiologists in evaluation of metastatic lymph nodes of rectal cancer. <i>Chinese Medical Journal</i> , 2019, 132, 379-387.	0.9	38
3288	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	3.2	64
3289	Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Cancer Medicine</i> , 2019, 8, 4615-4625.	1.3	16
3290	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
3291	Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. <i>JAMA Surgery</i> , 2019, 154, e192172.	2.2	141
3292	Neoadjuvant Stereotactic Radiosurgery: a Further Evolution in the Management of Brain Metastases. <i>Current Oncology Reports</i> , 2019, 21, 73.	1.8	18
3293	Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. <i>Radiation Oncology</i> , 2019, 14, 113.	1.2	14
3294	Emerging trends in the treatment of rectal cancer. <i>Acta Oncologica</i> , 2019, 58, 1343-1351.	0.8	9

#	ARTICLE	IF	CITATIONS
3295	A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer. <i>Oncology</i> , 2019, 97, 211-216.	0.9	7
3296	Effect of splenic flexure mobilization performed via medial-to-lateral and superior-to-inferior approach on early clinical outcomes in elective laparoscopic resection of rectal cancer. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2019, 14, 509-515.	0.3	2
3297	Treatment Strategy for Rectal Cancer Patients With Inguinal Lymph Node Metastasis. <i>Anticancer Research</i> , 2019, 39, 5767-5772.	0.5	4
3298	Should we favour the use of 5-Fluorouracil preoperative radiation in rectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101908.	3.4	12
3299	Population-based study of morbidity risk associated with pathological complete response after chemoradiotherapy for rectal cancer. <i>British Journal of Surgery</i> , 2019, 107, 131-139.	0.1	23
3300	Significance, diagnosis and treatment of lateral lymph nodes in rectal cancer: A systematic review. <i>International Journal of Surgery Open</i> , 2019, 21, 73-82.	0.2	2
3301	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3111-3123.	0.8	100
3302	Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 1484-1489.	0.4	5
3303	EUS-guided fiducial marker placement for radiotherapy in rectal cancer: feasibility of two placement strategies and four fiducial types. <i>Endoscopy International Open</i> , 2019, 07, E1357-E1364.	0.9	10
3304	Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: retrospective case series. <i>BMC Cancer</i> , 2019, 19, 1008.	1.1	5
3305	Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>In Vivo</i> , 2019, 33, 1959-1965.	0.6	8
3306	Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy. <i>Theranostics</i> , 2019, 9, 6856-6866.	4.6	27
3307	Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 2129-2136.	1.0	9
3308	Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy. <i>BMC Cancer</i> , 2019, 19, 1033.	1.1	17
3309	Advances in the management of rectal cancer. <i>Current Problems in Surgery</i> , 2019, 56, 100648.	0.6	5
3313	Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 815.	1.1	2
3314	2D nanosheet-constructed hybrid nanofillers for polymer nanocomposites with synergistic dispersion and function. <i>APL Materials</i> , 2019, 7, .	2.2	22
3315	Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 880.	1.1	13

#	ARTICLE	IF	CITATIONS
3316	Type of preoperative therapy and stage-specific survival after surgery for rectal cancer: a nationwide population-based cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 745-755.	1.4	3
3317	Pathological complete response after preoperative chemotherapy including FOLFOX plus bevacizumab for locally advanced rectal cancer: A case report and literature review. <i>International Journal of Surgery Case Reports</i> , 2019, 62, 85-88.	0.2	4
3318	In Reply to Gerard. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1181-1182.	0.4	0
3319	Image-guided high-dose-rate interstitial brachytherapy for recurrent rectal cancer after salvage surgery: a case report. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 343-348.	0.4	1
3320	Rectal carcinoma with synchronous liver metastases. <i>Journal of Coloproctology</i> , 2019, 39, 365-372.	0.1	1
3321	Chemoradiotherapy with Concurrent Regional Arterial Chemotherapy for Locally Bulky Unresectable Rectal Cancer: A Case Series. <i>Oncology Research and Treatment</i> , 2019, 42, 678-683.	0.8	3
3322	Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome. <i>Anticancer Research</i> , 2019, 39, 5105-5113.	0.5	10
3323	Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study. <i>Journal of the Anus, Rectum and Colon</i> , 2019, 3, 43-48.	0.4	0
3324	The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity. <i>Frontiers in Oncology</i> , 2019, 9, 974.	1.3	20
3325	Formation of Polyploid Giant Cancer Cells Involves in the Prognostic Value of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	0.6	32
3326	Prediction of tumor response of rectal cancer cells via 3D cell culture and <i>in vitro</i> cytotoxicity assay before initiating preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2019, 18, 3863-3872.	0.8	0
3327	Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer. <i>Abdominal Radiology</i> , 2019, 44, 3632-3640.	1.0	31
3328	Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. <i>Radiotherapy and Oncology</i> , 2019, 132, 79-84.	0.3	40
3329	Clinical Implications of Pretreatment: Lymphocyte-to-Monocyte Ratio in Patients With Rectal Cancer Receiving Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 171-180.	0.7	18
3330	Significance of perineural and lymphovascular invasion in locally advanced rectal cancer treated by preoperative chemoradiotherapy and radical surgery: Can perineural invasion be an indication of adjuvant chemotherapy?. <i>Radiotherapy and Oncology</i> , 2019, 133, 125-131.	0.3	33
3332	Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 24-33.	1.2	7
3333	National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. <i>Journal of Surgical Research</i> , 2019, 237, 41-49.	0.8	5
3335	Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 563-575.	2.0	22

#	ARTICLE	IF	CITATIONS
3336	Noadjuvant chemoradiation in locally advanced rectal cancer: the surgeon's perspective. <i>Journal of Clinical Pathology</i> , 2019, 72, 133-134.	1.0	5
3337	Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 186-191.	1.2	4
3338	Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 659-669.	0.9	9
3339	Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019, 108, 97-99.	1.3	5
3340	Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer. <i>British Journal of Surgery</i> , 2019, 106, 1298-1310.	0.1	65
3341	Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation. <i>Journal of Surgical Research</i> , 2019, 243, 242-248.	0.8	10
3342	The Effect of Formalin Fixation on Resection Margins in Colorectal Cancer. <i>International Journal of Surgical Pathology</i> , 2019, 27, 700-705.	0.4	10
3343	MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer. <i>European Journal of Radiology</i> , 2019, 118, 1-9.	1.2	58
3344	Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity. <i>Cancer Medicine</i> , 2019, 8, 3855-3863.	1.3	18
3345	Impact of Length of Distal Margin on Outcomes Following Sphincter Preserving Surgery for Middle and Lower Third Rectal Cancers. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 335-341.	0.3	5
3346	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 102-111.	2.0	31
3347	ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Anticancer Research</i> , 2019, 39, 2845-2853.	0.5	6
3348	Reevaluation of Preoperative Chemoradiotherapy for Clinical T3 Lower Rectal Cancer: A Multicenter Collaborative Retrospective Clinical Study. <i>Anticancer Research</i> , 2019, 39, 3047-3052.	0.5	2
3349	Assessment of the non-surgical treatment of patients with rectal cancer who underwent neoadjuvant treatment with chemotherapy and radiotherapy at the oncology department. <i>Journal of Coloproctology</i> , 2019, 39, 127-131.	0.1	1
3350	Critical assessment of the surgical treatment of low rectal adenocarcinoma in a reference hospital in Recife. <i>Journal of Coloproctology</i> , 2019, 39, 163-168.	0.1	0
3351	Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial. <i>BMJ Open</i> , 2019, 9, e025944.	0.8	9
3353	Stability of radiomic features of apparent diffusion coefficient (ADC) maps for locally advanced rectal cancer in response to image pre-processing. <i>Physica Medica</i> , 2019, 61, 44-51.	0.4	42
3354	Net survival of patients with colorectal cancer: a comparison of two periods. <i>Updates in Surgery</i> , 2019, 71, 687-694.	0.9	2

#	ARTICLE	IF	CITATIONS
3355	Impact of single nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. <i>International Journal of Cancer</i> , 2019, 145, 3163-3172.	2.3	11
3356	Rectal cancer MR staging: pearls and pitfalls at baseline examination. <i>Abdominal Radiology</i> , 2019, 44, 3536-3548.	1.0	32
3357	Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial. <i>BMC Cancer</i> , 2019, 19, 404.	1.1	4
3358	Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. <i>British Journal of Surgery</i> , 2019, 106, 979-987.	0.1	57
3359	Increased risk of pelvic fracture after radiotherapy in rectal cancer survivors: A propensity matched study. <i>Cancer Medicine</i> , 2019, 8, 3639-3647.	1.3	11
3360	Reproducibility of rectal tumor volume delineation using diffusion-weighted MRI: Agreement on volumes between observers. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 216-221.	0.6	21
3361	A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases. <i>International Journal of Surgical Oncology</i> , 2019, 2019, 1-11.	0.3	3
3362	Does a stoma reduce the risk of anastomotic leak and need for re-operation following low anterior resection for rectal cancer: systematic review and meta-analysis of randomized controlled trials. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 179-187.	0.6	56
3363	Genetics of rectal cancer and novel therapies: primer for radiologists. <i>Abdominal Radiology</i> , 2019, 44, 3743-3750.	1.0	10
3364	Effect of Responsiveness of Lymph Nodes to Preoperative Chemoradiotherapy in Patients With Rectal Cancer on Prognosis After Radical Resection. <i>Clinical Colorectal Cancer</i> , 2019, 18, e191-e199.	1.0	7
3365	CT Staging to Triage Selection of Patients With Poor-Prognosis Rectal Cancer for Neoadjuvant Treatment. <i>American Journal of Roentgenology</i> , 2019, 213, 358-364.	1.0	5
3367	Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). <i>Radiotherapy and Oncology</i> , 2019, 134, 199-203.	0.3	9
3368	Total neoadjuvant therapy for rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2019, 30, 63-67.	0.2	0
3369	Management of Stage IV rectal disease – How to incorporate radiation therapy, chemotherapy and surgery. <i>Seminars in Colon and Rectal Surgery</i> , 2019, 30, 89-93.	0.2	0
3370	Resting vector volume measured before ileostomy reversal may be a predictor of major fecal incontinence in patients with mid or low rectal cancer: a longitudinal cohort study using a prospective clinical database. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1079-1086.	1.0	1
3371	Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. <i>Radiotherapy and Oncology</i> , 2019, 136, 106-112.	0.3	10
3372	Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 308-315.	0.8	8
3373	Non-operative management of rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2019, 30, 79-84.	0.2	5

#	ARTICLE	IF	CITATIONS
3374	Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 39-47.	1.4	28
3375	Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases. <i>Case Reports in Surgery</i> , 2019, 2019, 1-7.	0.2	3
3376	Influence of Body Mass Index on Long-Term Outcome in Patients with Rectal Cancer—A Single Centre Experience. <i>Cancers</i> , 2019, 11, 609.	1.7	22
3377	Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. <i>Clinical Colorectal Cancer</i> , 2019, 18, 200-208.e1.	1.0	12
3378	Predicting the pathological response to chemoradiotherapy of non-mucinous rectal cancer using pretreatment texture features based on intravoxel incoherent motion diffusion-weighted imaging. <i>Abdominal Radiology</i> , 2019, 44, 2689-2698.	1.0	15
3379	Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 357-361.	0.6	7
3380	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). <i>BMC Cancer</i> , 2019, 19, 390.	1.1	83
3381	Impact of Chemotherapy Regimens on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Rectal Cancer Patients Receiving Intensity Modulated Radiation Therapy With Concurrent Chemotherapy From a Prospective Phase III Clinical Trial. <i>Frontiers in Oncology</i> , 2019, 9, 244.	1.3	4
3382	Susceptibility Perturbation MRI Maps Tumor Infiltration into Mesorectal Lymph Nodes. <i>Cancer Research</i> , 2019, 79, 2435-2444.	0.4	4
3383	Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: A propensity score matching analysis. <i>PLoS ONE</i> , 2019, 14, e0214415.	1.1	18
3384	Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 118-137.	1.4	28
3385	Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIRO. <i>Radiologia Medica</i> , 2019, 124, 671-681.	4.7	6
3386	MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. <i>Radiographics</i> , 2019, 39, 538-556.	1.4	56
3387	Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>PLoS ONE</i> , 2019, 14, e0212978.	1.1	41
3388	Pancreatic Cancer and Possible Therapeutic Options. , 2019, , 57-85.		0
3389	The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. <i>Theranostics</i> , 2019, 9, 1303-1322.	4.6	554
3390	Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1075-1084.	1.2	3
3392	The Epidemiology of Rectal Cancer. , 2019, , 3-20.		0

#	ARTICLE	IF	CITATIONS
3393	Phase I/II study of preoperative chemoradiotherapy with sequential oxaliplatin and irinotecan with Sâ€™1 for locally advanced rectal cancer. <i>Oncology Letters</i> , 2019, 17, 3930-3936.	0.8	0
3394	Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated With Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study. <i>Journal of Cancer</i> , 2019, 10, 1307-1312.	1.2	4
3395	Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 116.	0.4	15
3396	Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381882436.	0.8	6
3397	Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1225-1231.	0.5	20
3398	Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1524-1531.	1.2	32
3399	Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 102-109.	1.0	25
3400	<p>Concomitant dose escalation with image–guided Tomotherapy in locally advanced mid–low rectal cancer: a single-center study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1579-1586.	0.9	5
3401	Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1047-1050.	0.8	21
3402	Nonsurgical Management of Rectal Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, 123-131.	2.5	16
3403	Rab5C enhances resistance to ionizing radiation in rectal cancer. <i>Journal of Molecular Medicine</i> , 2019, 97, 855-869.	1.7	16
3404	Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e192249.	2.8	37
3405	History of neoadjuvant therapy for rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2019, 30, 58-62.	0.2	1
3406	Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With â€™Good Prognosisâ€™ Rectal Cancer Eligible for Primary Surgery. <i>JAMA Oncology</i> , 2019, 5, 961.	3.4	71
3407	Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint. , 2019, , 195-211.		0
3408	Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 189-195.	1.7	37
3409	Feasibility of neoadjuvant therapy for elderly patients with locally advanced rectal cancer. <i>Surgery Today</i> , 2019, 49, 694-703.	0.7	4
3410	Colorectal Surgery Consultation. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
3411	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 167-174.	1.0	3
3412	Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 33-43.	0.8	308
3413	Candidate genes and potential mechanisms for chemoradiotherapy sensitivity in locally advanced rectal cancer. <i>Oncology Letters</i> , 2019, 17, 4494-4504.	0.8	3
3414	Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 478-486.	0.6	7
3415	Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy. <i>Cancer Medicine</i> , 2019, 8, 1508-1520.	1.3	21
3416	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	0.9	2
3417	Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Acta Oncologica</i> , 2019, 58, 588-595.	0.8	55
3418	The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor. <i>PLoS ONE</i> , 2019, 14, e0211830.	1.1	29
3419	Gastrointestinal Cancers. , 2019, , 265-311.		0
3420	Timing of neoadjuvant therapy and surgical treatment in rectal cancer. <i>Journal of Coloproctology</i> , 2019, 39, 178-183.	0.1	0
3421	Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 294-301.	0.7	6
3422	Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis. <i>Clinical Colorectal Cancer</i> , 2019, 18, e237-e243.	1.0	5
3423	Early colorectal cancer: diagnosis, treatment and survivorship care. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 20-30.	2.0	117
3424	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 111-125.	1.0	4
3425	The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer. <i>Journal of Cancer</i> , 2019, 10, 730-736.	1.2	4
3426	Response of locally advanced rectal cancer (LARC) to radiochemotherapy: DW-MRI and multiparametric PET/CT in correlation with histopathology. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 28-38.	0.3	16
3427	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)â€“cT3 rectal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 110-118.	0.3	48
3428	Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 161-168.	2.3	17

#	ARTICLE	IF	CITATIONS
3429	The clinical significance of a pathologically positive lymph node at the circumferential resection margin in rectal cancer. <i>Techniques in Coloproctology</i> , 2019, 23, 151-159.	0.8	16
3430	Does total regression of primary rectal cancer after preoperative chemoradiotherapy represent "tumor-free" status?. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 78.	0.4	1
3432	MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. <i>Radiographics</i> , 2019, 39, 367-387.	1.4	256
3433	Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy. <i>Gastroenterology Report</i> , 2019, 7, 283-290.	0.6	17
3434	Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018. <i>Current Oncology</i> , 2019, 26, 773-784.	0.9	1
3435	The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1073-1079.	0.6	0
3436	The Increasingly Complicated Approach to Rectal Cancer. <i>Oncologist</i> , 2019, 24, 728-729.	1.9	1
3437	Mr Image Processing to Predict Complete Responders by Evaluating the Tumor Regression Grade: A Sensitivity Analysis. , 2019, , .		0
3438	Radiation therapy for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1238-1250.	0.6	6
3439	Making sense of adjuvant chemotherapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1183-1192.	0.6	52
3440	25 Kolorektales Karzinom. , 2019, , 99-128.		0
3441	26 Rektumkarzinom. , 2019, , 129-146.		0
3442	ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial. <i>BMC Cancer</i> , 2019, 19, 1117.	1.1	4
3443	Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients. <i>Anticancer Research</i> , 2019, 39, 6217-6222.	0.5	3
3444	Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 2161-2169.	1.0	2
3445	Standard (8%weeks) vs long (12%weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). <i>BMC Cancer</i> , 2019, 19, 1215.	1.1	10
3446	Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. <i>BMC Cancer</i> , 2019, 19, 1222.	1.1	21
3447	Lateral Lymph Node Metastases in Locally Advanced Low Rectal Cancers May Not Be Treated Effectively With Neoadjuvant (Chemo)Radiotherapy Only. <i>Frontiers in Oncology</i> , 2019, 9, 1355.	1.3	12

#	ARTICLE	IF	CITATIONS
3448	Selection of Patients With Rectal Cancer for Preoperative Chemoradiotherapy: Are T Category and Nodal Status All That Matters?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 447-453.	0.7	8
3449	Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002). <i>Radiation Oncology</i> , 2019, 14, 215.	1.2	10
3450	Challenges and Promises of Radiomics for Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 175-180.	1.0	6
3452	Rectal cancer treatment by transanal total mesorectal excision: Results in 100 consecutive patients. <i>CirugÃa EspaÃ±ola (English Edition)</i> , 2019, 97, 510-516.	0.1	2
3453	Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy. <i>Medicine (United States)</i> , 2019, 98, e16614.	0.4	9
3454	Rectal Cancer Invasiveness: Whole-Lesion Diffusion-Weighted Imaging (DWI) Histogram Analysis by Comparison of Reduced Field-of-View and Conventional DWI Techniques. <i>Scientific Reports</i> , 2019, 9, 18760.	1.6	9
3455	How Reliable Is CT Scan in Staging Right Colon Cancer?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 960-964.	0.7	26
3456	Definition of the Rectum. <i>Annals of Surgery</i> , 2019, 270, 955-959.	2.1	96
3457	Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer. <i>Medicine (United States)</i> , 2019, 98, e15241.	0.4	7
3458	Fibrinogen and Albumin Score Changes during Preoperative Treatment Can Predict Prognosis in Patients with Locally Advanced Rectal Cancer. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	0.7	5
3459	Definitive Chemoradiation for Rectal Cancer: Is There a Role for Dose Escalation? A National Cancer Database Study. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1336-1343.	0.7	4
3460	Can Less Be More? Organ Preservation Strategies in the Management of Rectal Cancer. <i>Current Oncology</i> , 2019, 26, 16-23.	0.9	15
3461	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-16.	1.0	16
3462	Operations for Rectal Cancer. , 2019, , 2005-2034.		0
3463	Prognostic Impact of Perineural Invasion in Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>World Journal of Surgery</i> , 2019, 43, 260-272.	0.8	25
3464	Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy. <i>Oncology</i> , 2019, 96, 70-78.	0.9	1
3465	Laparoscopic Surgery for Colorectal Cancer. , 2019, , 39-48.		0
3466	Hospital volume and outcome in rectal cancer patients; results of a population-based study in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2019, 45, 613-619.	0.5	13

#	ARTICLE	IF	CITATIONS
3467	Long-term Outcomes of Surgery for Colorectal Cancer: A 20-Year Study. <i>Journal of Surgical Research</i> , 2019, 235, 34-43.	0.8	3
3468	Incidence of extramural venous invasion in colorectal carcinoma as determined at the invasive tumor front and its prognostic impact. <i>Human Pathology</i> , 2019, 86, 102-107.	1.1	8
3469	A systematic review comparing radiation toxicity after various endorectal techniques. <i>Brachytherapy</i> , 2019, 18, 71-86.e5.	0.2	10
3470	Facility Variation in Local Staging of Rectal Adenocarcinoma and its Contribution to Underutilization of Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1206-1217.	0.9	4
3471	Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 403-410.	1.0	20
3472	MRI morphologic and clinicopathologic characteristics for predicting outcomes in patients with locally advanced rectal cancer. <i>Abdominal Radiology</i> , 2019, 44, 3652-3663.	1.0	8
3473	Improved survival in rectal cancer patients who are treated with long-course versus short-course neoadjuvant radiotherapy: A propensity-matched analysis of the NCDB. <i>Journal of Surgical Oncology</i> , 2019, 119, 518-531.	0.8	6
3474	A Systematic Review and Bayesian Network Meta-Analysis: Short-Term and Long-Term Outcomes of Three Surgery Procedures Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>Journal of Laparoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 663-670.	0.5	5
3475	Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 565-573.	0.4	4
3476	Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 1029-1033.	0.6	0
3477	Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1614-1622.	0.9	23
3478	Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 438-448.	0.4	12
3479	Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 878-888.	3.3	113
3480	Spin in articles about minimally invasive transanal total mesorectal excision: an assessment of the current literature. <i>Colorectal Disease</i> , 2019, 21, 8-14.	0.7	8
3481	Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy. <i>Stem Cells</i> , 2019, 37, 42-53.	1.4	15
3482	Delta radiomics for rectal cancer response prediction with hybrid 0.35T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. <i>Radiologia Medica</i> , 2019, 124, 145-153.	4.7	112
3483	Nadir/pre-chemoradiotherapy ratio of white blood-cell count can predict tumor response and recurrence-free survival in locally advanced rectal cancer: a multi-institutional analysis. <i>International Journal of Colorectal Disease</i> , 2019, 34, 105-112.	1.0	2
3484	Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. <i>Surgery</i> , 2019, 165, 579-585.	1.0	25

#	ARTICLE	IF	CITATIONS
3485	Global trends in colorectal cancer mortality: projections to the year 2035. <i>International Journal of Cancer</i> , 2019, 144, 2992-3000.	2.3	348
3486	Impact of Long-Course Neoadjuvant Radiation on Postoperative Low Anterior Resection Syndrome and Quality of Life in Rectal Cancer: Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 746-755.	0.7	80
3487	SOX9, miR-495, miR-590-3p, and miR-320d were identified as chemoradiotherapy-sensitive genes and miRNAs in colorectal cancer patients based on a microarray dataset. <i>Neoplasma</i> , 2019, 66, 8-19.	0.7	15
3488	Neoadjuvant therapy in rectal cancer: how are we choosing?. <i>ANZ Journal of Surgery</i> , 2019, 89, 68-73.	0.3	3
3489	Does external beam radiation therapy to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative study. <i>Colorectal Disease</i> , 2019, 21, 219-225.	0.7	8
3490	Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer. <i>JAMA Surgery</i> , 2019, 154, 47.	2.2	151
3491	Oncologic Outcome and Morbidity in the Elderly Rectal Cancer Patients After Preoperative Chemoradiotherapy and Total Mesorectal Excision. <i>Annals of Surgery</i> , 2019, 269, 108-113.	2.1	15
3492	Surgical and Survival Outcomes Following Pelvic Exenteration for Locally Advanced Primary Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 315-321.	2.1	156
3493	Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer. <i>Pathology and Oncology Research</i> , 2019, 25, 279-288.	0.9	5
3494	Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 678-685.	2.1	37
3495	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
3496	How Is Rectal Cancer Managed: a Survey Exploring Current Practice Patterns in Canada. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 260-268.	0.6	8
3497	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123
3498	Planned Short-Course Radiation (scRT) is Superior to Upfront Concurrent Chemoradiation (CCRT) in Treating Metastatic Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1092-1100.	0.9	3
3499	Can rectal washout reduce anastomotic recurrence after anterior resection for rectal cancer? A review of the literature. <i>Surgery Today</i> , 2020, 50, 644-649.	0.7	15
3500	Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Clinical Nutrition</i> , 2020, 39, 820-828.	2.3	32
3501	Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2020, 271, 716-723.	2.1	92
3502	Nodal staging in the rectal cancer follow-up MRI after chemoradiotherapy: use of morphology, size, and diffusion criteria. <i>Clinical Radiology</i> , 2020, 75, 100-107.	0.5	6

#	ARTICLE	IF	CITATIONS
3503	The Time Between Chemoradiation and Surgery for Rectal Carcinoma Negatively Influences Mesorectal Excision Quality. <i>Pathology and Oncology Research</i> , 2020, 26, 1565-1572.	0.9	1
3504	Laparoscopic lateral pelvic lymph node dissection for lower rectal cancer treated with preoperative chemoradiotherapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 1425-1431.	1.3	14
3505	Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 655-661.	2.8	34
3506	Comparison of Changes in Disease-Free and Overall Survival of Resectable Rectal Adenocarcinoma between 2010 and 2015. <i>Visceral Medicine</i> , 2020, 36, 144-149.	0.5	1
3507	Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 110-117.	1.0	13
3508	MRI-Based Use of Neoadjuvant Chemoradiotherapy in Rectal Carcinoma: Surgical Quality and Histopathological Outcome of the OCUM Trial. <i>Annals of Surgical Oncology</i> , 2020, 27, 417-427.	0.7	19
3509	Intensity-Modulated Radiotherapy With a Simultaneous Integrated Boost in Rectal Cancer. <i>Clinical Oncology</i> , 2020, 32, 35-42.	0.6	23
3510	Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection. <i>American Journal of Surgery</i> , 2020, 219, 406-410.	0.9	1
3511	Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis. <i>Digestive Surgery</i> , 2020, 37, 292-301.	0.6	30
3512	Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. <i>European Journal of Surgical Oncology</i> , 2020, 46, 448-454.	0.5	34
3513	Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data. <i>Radiotherapy and Oncology</i> , 2020, 144, 37-45.	0.3	4
3514	CoA Synthase (<i>COASY</i>) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer. <i>Cancer Research</i> , 2020, 80, 334-346.	0.4	33
3515	YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence. <i>Digestive and Liver Disease</i> , 2020, 52, 214-220.	0.4	3
3516	Neoadjuvant radiotherapy in rectal cancer “less is more?”. <i>Colorectal Disease</i> , 2020, 22, 261-268.	0.7	9
3517	The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1668-1672.	0.5	20
3518	Local versus Radical Excision of Early Distal Rectal Cancers: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 2169-2176.	0.7	12
3519	Implantation of tissue expander prior to irradiation in the era of intensity modulated radiotherapy: impact on the management of patients with pelvic digestive cancers. <i>International Journal of Colorectal Disease</i> , 2020, 35, 559-564.	1.0	1
3520	Clinical significance of an increased red blood cell distribution width in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. <i>Surgery Today</i> , 2020, 50, 551-559.	0.7	5

#	ARTICLE	IF	CITATIONS
3521	Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, e372-e377.	1.1	7
3522	The importance of mesorectum motion in determining PTV margins in rectal cancer patients treated with neoadjuvant radiotherapy. <i>Journal of Radiation Research</i> , 2020, 61, 335-342.	0.8	5
3523	Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. <i>Cancer Treatment Reviews</i> , 2020, 82, 101930.	3.4	13
3524	Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response. <i>Surgical Oncology</i> , 2020, 32, 35-40.	0.8	15
3525	Cancer of the Rectum. , 2020, , 1281-1299.e7.		0
3526	Rectal NETs and rectosigmoid junction NETs may need to be treated differently. <i>Cancer Medicine</i> , 2020, 9, 971-979.	1.3	8
3527	Higher-order diffusion MRI characterization of mesorectal lymph nodes in rectal cancer. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 348-364.	1.9	8
3528	Continued Improvement in Rectal Cancer Survival Outcomes Will Require True Multidisciplinary Treatment Approaches. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 742-747.	0.9	3
3529	Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 152-159.	0.8	12
3530	Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. <i>Cancer Treatment Reviews</i> , 2020, 83, 101948.	3.4	51
3531	Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. <i>Cancer Medicine</i> , 2020, 9, 912-919.	1.3	7
3532	Using Diffuse Reflectance Spectroscopy to Distinguish Tumor Tissue From Fibrosis in Rectal Cancer Patients as a Guide to Surgery. <i>Lasers in Surgery and Medicine</i> , 2020, 52, 604-611.	1.1	8
3533	The Predictive Value of Pre-/Postneoadjuvant Chemoradiotherapy MRI Characteristics for Patient Outcomes in Locally Advanced Rectal Cancer. <i>Academic Radiology</i> , 2020, 27, e233-e243.	1.3	11
3534	Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction. <i>Colorectal Disease</i> , 2020, 22, 513-520.	0.7	3
3535	Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers. <i>International Journal of Colorectal Disease</i> , 2020, 35, 77-84.	1.0	3
3536	Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage Iâ€”III rectal cancer. <i>Cancer Medicine</i> , 2020, 9, 653-662.	1.3	27
3537	High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 105-115.	1.2	17
3538	Mucin Pools Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, 280-287.	2.1	2

#	ARTICLE	IF	CITATIONS
3539	Time interval between the completion of radiotherapy and robotic-assisted surgery among patients with stage III rectal cancer undergoing preoperative chemoradiotherapy. PLoS ONE, 2020, 15, e0240742.	1.1	7
3540	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
3541	MRI for Rectal Cancer Primary Staging and Restaging After Neoadjuvant Chemoradiation Therapy: How to Do It During Daily Clinical Practice. European Journal of Radiology, 2020, 131, 109238.	1.2	15
3542	Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study. Frontiers in Oncology, 2020, 10, 1682.	1.3	8
3543	The Elevated Pre-Treatment C-Reactive Protein Predicts Poor Prognosis in Patients with Locally Advanced Rectal Cancer Treated with Neo-Adjuvant Radiochemotherapy. Diagnostics, 2020, 10, 780.	1.3	5
3544	Perineal reconstruction following abdominoperineal resection: Comprehensive review of the literature. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2020, 73, 1924-1932.	0.5	14
3545	The role of surgery for locally recurrent and second recurrent rectal cancer with metastatic disease. Surgical Oncology, 2020, 35, 328-335.	0.8	7
3546	The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. Surgical Oncology, 2020, 35, 200-205.	0.8	2
3547	CEA Decline Predicts Tumor Regression and Prognosis in Locally Advanced Rectal Cancer Patients with Elevated Baseline CEA. Journal of Cancer, 2020, 11, 6565-6570.	1.2	9
3548	The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clinical Medicine Insights: Oncology, 2020, 14, 117955492091940.	0.6	2
3549	Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI. Radiation Oncology, 2020, 15, 171.	1.2	12
3550	Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial. Gastroenterology Report, 2020, 8, 234-241.	0.6	11
3551	Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Techniques in Coloproctology, 2020, 24, 1001-1015.	0.8	30
3552	Pre-Treatment T2-WI Based Radiomics Features for Prediction of Locally Advanced Rectal Cancer Non-Response to Neoadjuvant Chemoradiotherapy: A Preliminary Study. Cancers, 2020, 12, 1894.	1.7	38
3553	Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial. Journal of the American College of Surgeons, 2020, 231, 413-425e2.	0.2	41
3554	Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer: a systematic review. International Journal of Clinical Oncology, 2020, 25, 1570-1580.	1.0	9
3555	Rectal cancer among younger Egyptian patientsâ€”clinico-pathological features and oncologic outcomes: A single institution experience. Memo - Magazine of European Medical Oncology, 2020, 13, 314-323.	0.3	1
3556	Assessment of quality-of-care indicators for colorectal cancer surgery at a single centre in a developing country. Canadian Journal of Surgery, 2020, 63, E468-E474.	0.5	1

#	ARTICLE	IF	CITATIONS
3557	Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial. <i>BMJ Open</i> , 2020, 10, e038678.	0.8	1
3558	Pathologic complete response is associated with decreased morbidity following rectal cancer resection. <i>American Journal of Surgery</i> , 2021, 222, 390-394.	0.9	5
3559	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. <i>Hpb</i> , 2021, 23, 1072-1083.	0.1	16
3560	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. <i>BMC Cancer</i> , 2020, 20, 1164.	1.1	7
3561	MRI-Based Radiomics of Rectal Cancer: Assessment of the Local Recurrence at the Site of Anastomosis. <i>Academic Radiology</i> , 2021, 28, S87-S94.	1.3	19
3562	Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 313.	0.8	9
3563	Risk of nodal disease in patients with MRI-detected extramural vascular invasion in rectal cancer: a systematic review and meta-analysis. <i>Tumori</i> , 2020, 107, 030089162097586.	0.6	1
3564	Oncological Outcomes of Robotic-Assisted Surgery With High Dissection and Selective Ligation Technique for Sigmoid Colon and Rectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570376.	1.3	5
3565	Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4273-4283.	0.7	40
3566	Modeling precision genomic-based radiation dose response in rectal cancer. <i>Future Oncology</i> , 2020, 16, 2411-2420.	1.1	2
3567	Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, e281-e287.	1.0	2
3568	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2020, 33, 287-297.	0.5	10
3569	Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 960.	1.6	15
3570	Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. <i>British Journal of Cancer</i> , 2020, 123, 1244-1252.	2.9	9
3571	Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer. <i>Scientific Reports</i> , 2020, 10, 12539.	1.6	3
3572	Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. <i>Scientific Reports</i> , 2020, 10, 12555.	1.6	18
3573	Determining whether postoperative chemoradiotherapy is required in patients with pathologic T3N0 rectal cancer with negative resection margin. <i>International Journal of Colorectal Disease</i> , 2020, 35, 2239-2248.	1.0	3
3574	Defining and predicting early recurrence in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2057-2063.	0.5	14

#	ARTICLE	IF	CITATIONS
3575	Do We Have to Treat All T3 Rectal Cancer the Same Way?. <i>Clinical Colorectal Cancer</i> , 2020, 19, 231-235.	1.0	5
3576	Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 198.	0.8	0
3577	Intratumoral HLA-DR α /CD33+/CD11b+ Myeloid-Derived Suppressor Cells Predict Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1375.	1.3	4
3578	Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4309-4318.	0.7	9
3579	Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 2227.	1.7	14
3580	Comparative Evaluation of the Short-Term Treatment Outcomes Between Open, Laparoscopic- and Robotic-Assisted Surgical Approaches for Rectal Cancer Treatment. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 649-652.	0.3	2
3581	Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. <i>Frontiers in Oncology</i> , 2020, 10, 1369.	1.3	13
3582	Playing With Dynamite? A Cautious Assessment of TNT. <i>Journal of Clinical Oncology</i> , 2021, 39, 103-106.	0.8	21
3583	The prognostic significance of the treatment response of regional lymph nodes and the refinement of the current TNM staging system in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. <i>Cancer Medicine</i> , 2020, 9, 9373-9384.	1.3	8
3584	Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by <i>UGT1A1</i> Status in Patients With Locally Advanced Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4231-4239.	0.8	61
3585	Evaluation of small bowel motion and feasibility of using the peritoneal space to replace bowel loops for dose constraints during intensity-modulated radiotherapy for rectal cancer. <i>Radiation Oncology</i> , 2020, 15, 211.	1.2	6
3586	Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 831.	1.1	9
3587	<p>Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7375-7382.	0.9	12
3588	Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	5
3589	The impact of anastomotic leakage on oncology after curative anterior resection for rectal cancer. <i>Medicine (United States)</i> , 2020, 99, e22139.	0.4	14
3590	Predictive value of changes in the level of carbohydrate antigen 19 α in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Colorectal Disease</i> , 2020, 22, 2068-2077.	0.7	8
3591	Characterization of FDG PET Images Using Texture Analysis in Tumors of the Gastro-Intestinal Tract: A Review. <i>Biomedicines</i> , 2020, 8, 304.	1.4	6
3592	Factors associated with metachronous metastases and survival in locally advanced and recurrent rectal cancer. <i>BJs Open</i> , 2020, 4, 1172-1179.	0.7	4

#	ARTICLE	IF	CITATIONS
3593	Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. <i>Cancer Science</i> , 2020, 111, 4205-4217.	1.7	5
3595	Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy. <i>Gastroenterology Report</i> , 2020, 8, 445-452.	0.6	4
3596	Lymph Node Harvest After Neoadjuvant Treatment for Rectal Cancer and Its Impact on Oncological Outcomes. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 692-698.	0.3	4
3598	Long term outcome of anastomotic leakage in patients undergoing low anterior resection for rectal cancer. <i>BMC Cancer</i> , 2020, 20, 780.	1.1	20
3599	Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097713.	1.4	1
3600	Real world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer. <i>Internal Medicine Journal</i> , 2020, 51, 1262-1268.	0.5	2
3601	Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management. <i>Cancer Control</i> , 2020, 27, 107327482096944.	0.7	8
3602	Intravoxel Incoherent Motion Model of Diffusion Weighted Imaging and Diffusion Kurtosis Imaging in Differentiating of Local Colorectal Cancer Recurrence from Scar/Fibrosis Tissue by Multivariate Logistic Regression Analysis. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 8609.	1.3	1
3603	An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications. <i>Clinical and Translational Medicine</i> , 2020, 10, e249.	1.7	12
3604	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3611.	1.7	30
3605	Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 3655.	1.7	31
3606	Radiosensitivity of Cancer Stem Cells Has Potential Predictive Value for Individual Responses to Radiotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3672.	1.7	9
3607	Nonoperative Management for T2 Low Rectal Cancer: A Western Approach. <i>Clinics in Colon and Rectal Surgery</i> , 2020, 33, 366-371.	0.5	3
3608	Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy. <i>Oncology</i> , 2020, 98, 869-875.	0.9	8
3609	Association of Adherence to Quality Metrics with Recurrence or Mortality among Veterans with Colorectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2055-2064.	0.9	4
3610	Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. <i>Cancer Letters</i> , 2020, 493, 179-188.	3.2	8
3611	Lateral lymph node and its association with distant recurrence in rectal cancer: A clue of systemic disease. <i>Surgical Oncology</i> , 2020, 35, 174-181.	0.8	16
3612	Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 311-318.	0.6	3

#	ARTICLE	IF	CITATIONS
3613	Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes. <i>In Vivo</i> , 2020, 34, 1223-1233.	0.6	4
3614	Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators. <i>Clinical Cancer Research</i> , 2020, 26, 3079-3090.	3.2	16
3615	Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer. <i>Radiation Oncology</i> , 2020, 15, 99.	1.2	3
3616	Intersphincteric Resection Versus Abdominoperineal Resection for Low Rectal Cancer: A Meta-Analysis. <i>Surgical Innovation</i> , 2020, 27, 392-401.	0.4	13
3617	Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM). <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2150-2159.	0.9	15
3618	Management of locally advanced synchronous colorectal and prostate cancers. <i>Medicine (United States)</i> , 2020, 99, e20245.	0.4	4
3619	MRI Radiomics for Prediction of Tumor Response and Downstaging in Rectal Cancer Patients after Preoperative Chemoradiation. <i>Advances in Radiation Oncology</i> , 2020, 5, 1286-1295.	0.6	21
3620	Predictive Value of FOLFOX-Based Regimen, Long Interval, Hemoglobin Levels and Clinical Negative Nodal Status, and Postchemoradiotherapy CEA Levels for Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	15
3621	The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 706.	1.6	4
3622	Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 865-870.	0.6	4
3623	Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis. <i>In Vivo</i> , 2020, 34, 1547-1553.	0.6	14
3624	Current Options in the Management of Colorectal Cancer in Developing Countries: Central America Experience. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 49-54.	1.0	1
3625	Preoperative chemoradiotherapy versus surgery alone for advanced low rectal cancer: a large multicenter cohort study in Japan. <i>Surgery Today</i> , 2020, 50, 1507-1514.	0.7	3
3626	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). <i>Radiation Oncology</i> , 2020, 15, 151.	1.2	14
3627	Short-Course Radiotherapy in Locally Advanced Rectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00162.	1.3	7
3628	Neoadjuvant Treatment in Upper Rectal Cancer Does Not Improve Oncologic Outcomes But Increases Postoperative Morbidity. <i>Anticancer Research</i> , 2020, 40, 3579-3587.	0.5	12
3629	Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery for patients with locally advanced rectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1355-1369.	1.0	6
3630	A controlled study on the efficacy and quality of life of laparoscopic intersphincteric resection (ISR) and extralevator abdominoperineal resection (ELAPE) in the treatment of extremely low rectal cancer. <i>Medicine (United States)</i> , 2020, 99, e20245.	0.4	4

#	ARTICLE	IF	CITATIONS
3631	Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 918-926.	0.7	23
3632	National postoperative and oncologic outcomes after pelvic exenteration for T4b rectal cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 739-744.	0.8	2
3633	Predictive factors for tumour response after the neoadjuvant-treatment of rectal adenocarcinoma. <i>Journal of Coloproctology</i> , 2020, 40, 112-119.	0.1	1
3634	Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review. <i>SAGE Open Medicine</i> , 2020, 8, 205031212092265.	0.7	29
3635	Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer. <i>PLoS ONE</i> , 2020, 15, e0234310.	1.1	1
3636	Pathologic Complete Response Despite Nodal Yield Has Best Survival in Locally Advanced Rectal Cancer. <i>Journal of Surgical Research</i> , 2020, 251, 220-227.	0.8	5
3637	Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1281-1297.	0.5	109
3638	The influence of postoperative complications on long-term prognosis in patients with colorectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1055-1066.	1.0	19
3640	Proton beam radiotherapy for anal and rectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 176-186.	0.6	17
3641	Patterns of care and outcomes for adjuvant treatment of pT3N0 rectal cancer using the National Cancer Database. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 1-12.	0.6	6
3642	Patient-reported and physician-recorded bowel dysfunction following colorectal resection and radical cystectomy: a prospective, comparative study. <i>Colorectal Disease</i> , 2020, 22, 1336-1347.	0.7	3
3643	Prognosis and risk factors for the development of pulmonary metastases after preoperative chemoradiotherapy and radical resection in patients with locally advanced rectal cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 117-117.	0.7	0
3644	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
3645	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
3646	Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). <i>British Journal of Surgery</i> , 2020, 107, 586-594.	0.1	73
3647	Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1716618.	0.3	11
3648	Locally advanced rectal cancer: The past, present, and future. <i>Seminars in Oncology</i> , 2020, 47, 85-92.	0.8	51
3649	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853

#	ARTICLE	IF	CITATIONS
3650	Impact on Health-Related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: Results from a Randomized Controlled Trial. <i>Oncologist</i> , 2020, 25, e843-e851.	1.9	44
3651	Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 324-328.	0.3	1
3652	The multidisciplinary management of rectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 414-429.	8.2	149
3653	Dose-time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090753.	1.4	10
3654	Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 427-440.	0.7	20
3655	Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy. <i>Colorectal Cancer</i> , 2020, 9, .	0.8	0
3656	Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>In Vivo</i> , 2020, 34, 1993-1999.	0.6	9
3657	Sequencing Treatments for Cancer During the COVID-19 Pandemic. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 457-458.	0.6	2
3658	Comparison of the sigmoid take-off with other definitions of the rectosigmoid junction: A retrospective comparative cohort analysis. <i>International Journal of Surgery</i> , 2020, 80, 168-174.	1.1	9
3659	The use of intraoperative radiation therapy in the management of locally recurrent rectal cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2020, 31, 100763.	0.2	1
3660	The prognostic impact of neoadjuvant chemoradiotherapy on lymph node sampling in patients with locally advanced rectal cancer. <i>Updates in Surgery</i> , 2020, 72, 793-800.	0.9	4
3661	Complete Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cirug�a Espa�ola (English Edition)</i> , 2020, 98, 168-170.	0.1	1
3662	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 1808.	1.7	13
3663	Risk factors for nonclosure of defunctioning stoma and stoma-related complications among low rectal cancer patients after sphincter-preserving surgery. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 188-197.	0.9	4
3664	The impact of driving time, distance, and socioeconomic factors on outcomes of patients with locally advanced rectal cancer. <i>Public Health in Practice</i> , 2020, 1, 100012.	0.7	3
3665	<i>Fusobacterium nucleatum</i> persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1366-1375.	0.6	80
3666	MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. <i>Cancers</i> , 2020, 12, 1655.	1.7	14
3667	Downregulation of miR-1 in colorectal cancer promotes radioresistance and aggressive phenotypes. <i>Journal of Cancer</i> , 2020, 11, 4832-4840.	1.2	21

#	ARTICLE	IF	CITATIONS
3668	Outcomes of surgical treatment for patients with distal rectal cancer: A retrospective review from a single university hospital. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2020, 85, 180-189.	0.1	0
3669	Short-term outcomes of laparoscopic intersphincteric resection with intraoperative radiotherapy using low-energy X-rays for primary locally advanced low rectal cancer: a single center experience. <i>World Journal of Surgical Oncology</i> , 2020, 18, 26.	0.8	2
3670	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	1.3	68
3671	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1763-1773.	0.8	665
3672	Accuracy of magnetic resonance imaging in predicting dentate line invasion in low rectal cancer. <i>Japanese Journal of Radiology</i> , 2020, 38, 539-546.	1.0	4
3673	Challenges of improving treatment outcomes for colorectal and anal cancers in Japan: the Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 368-378.	0.6	7
3674	Desenlaces de tratamiento quirÃºrgico para pacientes con cÃ¡ncer de recto distal: Una revisiÃ³n retrospectiva en un hospital universitario. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2020, 85, 180-189.	0.4	0
3675	MRI predicts increased eligibility for sphincter preservation after CRT in low rectal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 223-228.	0.3	5
3676	The Effect of Lymph Nodesâ€™ Histologic Response on Survival Outcomes in Moroccan Patients with Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2020, 2020, 1-7.	0.3	0
3677	Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20300 patients. <i>Radiation Oncology</i> , 2020, 15, 49.	1.2	19
3678	The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer. <i>In Vivo</i> , 2020, 34, 863-868.	0.6	16
3679	Respuesta patolÃ³gica completa tras quimioterapia neoadyuvante en cÃ¡ncer de colon localmente avanzado. <i>CirugÃa EspaÃ±ola</i> , 2020, 98, 168-170.	0.1	2
3680	Intraoperative radiotherapy as an immediate adjuvant treatment of rectal cancer due to limited access to external-beam radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 11.	1.2	9
3681	Nonoperative Management of Rectal Cancer Shows Cost-Effectiveness, but Can Comparative Effectiveness Be Established?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 771-772.	3.0	1
3682	Baseline and early 3D-CUBE volume reconstruction of locally advanced rectal cancer to predict tumor response after neoadjuvant chemotherapy. <i>Journal of X-Ray Science and Technology</i> , 2020, 28, 231-241.	0.7	0
3683	Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles. <i>Cells</i> , 2020, 9, 130.	1.8	21
3684	Modeling rectal cancer to advance neoadjuvant precision therapy. <i>International Journal of Cancer</i> , 2020, 147, 1405-1418.	2.3	25
3685	Laparoscopic and robotic lateral lymph node dissection for rectal cancer. <i>Surgery Today</i> , 2020, 50, 209-216.	0.7	22

#	ARTICLE	IF	CITATIONS
3686	Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ Rectalcarcinoma registry. <i>BMC Cancer</i> , 2020, 20, 49.	1.1	18
3687	Comparison of sequential, delayed and simultaneous resection strategies for synchronous colorectal liver metastases. <i>BMC Surgery</i> , 2020, 20, 16.	0.6	16
3688	Quality of Life After Radiotherapy for Rectal and Anal Cancer. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 1-10.	1.0	11
3689	A NSQIP analysis of trends in surgical outcomes for rectal cancer: What can we improve upon?. <i>American Journal of Surgery</i> , 2020, 220, 401-407.	0.9	12
3690	Predictive value of serum and tissue carcinoembryonic antigens for radiologic response and oncologic outcome of rectal cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152834.	1.0	7
3691	Superoxide Dismutase Mimic, MnTE-2-PyP Enhances Rectal Anastomotic Strength in Rats after Preoperative Chemoradiotherapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-11.	1.9	4
3692	What is the role of lateral lymph node dissection in rectal cancer patients with clinically suspected lateral lymph node metastasis after preoperative chemoradiotherapy? A meta-analysis and systematic review. <i>Cancer Medicine</i> , 2020, 9, 4477-4489.	1.3	20
3693	Neoadjuvant Radio(chemo)therapy for Breast Cancer: An Old Concept Revisited. <i>Breast Care</i> , 2020, 15, 112-117.	0.8	8
3694	<p>PCSK1 Overexpression in Rectal Cancer Correlates with Poor Response to Preoperative Chemoradiotherapy and Prognosis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3141-3150.	1.0	8
3695	Prognostic Impact of Lymph Node Ratio in Patients Undergoing Preoperative Chemoradiotherapy Followed by Curative Resection for Locally Advanced Rectal Cancer. <i>In Vivo</i> , 2020, 34, 1247-1253.	0.6	4
3696	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	5.1	56
3698	Gut Microbiome Composition Is Associated with a Pathologic Response After Preoperative Chemoradiation in Patients with Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 736-746.	0.4	44
3699	Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2020, 34, 57-62.	0.8	21
3700	The influence of anastomotic leakage for rectal cancer oncologic outcome: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2020, 121, 1283-1297.	0.8	49
3702	Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. <i>Pathology Research and Practice</i> , 2020, 216, 152922.	1.0	0
3703	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. <i>Radiotherapy and Oncology</i> , 2020, 147, 75-83.	0.3	132
3704	Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. <i>Experimental Cell Research</i> , 2020, 391, 111956.	1.2	61
3705	Adding Boost to Standard Neoadjuvant Radiation for Rectal Cancer Improves Likelihood of Complete Response. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1655-1662.	0.9	1

#	ARTICLE	IF	CITATIONS
3706	The Evolving Landscape of Neoadjuvant Radiation Therapy for Locally Advanced Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 39-48.	1.0	1
3707	Prognostic value of pretreatment tumor-to-blood standardized uptake ratio (SUR) in rectal cancer. <i>Annals of Nuclear Medicine</i> , 2020, 34, 432-440.	1.2	3
3708	The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response. <i>Clinical Colorectal Cancer</i> , 2020, 19, e164-e180.	1.0	11
3709	Organ Preservation in Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1880-1888.	0.9	17
3710	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 687-689.	0.6	33
3711	Predicting pathological complete response in rectal cancer after chemoradiotherapy with a random forest using 18F-fluorodeoxyglucose positron emission tomography and computed tomography radiomics. <i>Annals of Translational Medicine</i> , 2020, 8, 207-207.	0.7	22
3712	Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. <i>Trials</i> , 2020, 21, 320.	0.7	5
3713	Short-Term Clinical and Oncological Outcome of Prolonging Operation Interval After Neoadjuvant Chemoradiotherapy for Locally Advanced Middle and Low Rectal Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 2315-2325.	0.9	5
3714	Cone-beam computed tomography for organ motion evaluation in locally advanced rectal cancer patients. <i>Radiologia Medica</i> , 2021, 126, 147-154.	4.7	13
3715	Short-term outcomes of laparoscopic lateral pelvic node dissection for advanced lower rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1572-1578.	1.3	8
3716	Factores de riesgo y tratamiento endoscópico para estenosis de anastomosis posterior a resección en pacientes con cáncer colorrectal. <i>Revista De Gastroenterología De México</i> , 2021, 86, 44-50.	0.4	2
3717	Prognostic Potential of Lymphocyte-C-Reactive Protein Ratio in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 492-502.	0.9	24
3718	Tumor Microenvironment Mediators CD8+ and FOXP3+ Labeled T Lymphocytes Are Prospective Prognosticators in Curatively Treated Rectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 177-186.	0.6	5
3719	The Relationship between Primary Gross Tumor Volume and Tumor Response of Locally Advanced Rectal Cancer: pGTV as a More Accurate Tumor Size Indicator. <i>Journal of Investigative Surgery</i> , 2021, 34, 181-190.	0.6	14
3720	Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2801-2808.	0.7	14
3721	Diffusion-weighted MR volume and apparent diffusion coefficient for discriminating lymph node metastases and good response after chemoradiation therapy in locally advanced rectal cancer. <i>European Radiology</i> , 2021, 31, 200-211.	2.3	6
3722	Colorectal Cancer Imaging and Management: A Surgeon's Perspective. <i>Seminars in Roentgenology</i> , 2021, 56, 158-163.	0.2	1
3723	Optimising functional outcomes in rectal cancer surgery. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 233-250.	0.8	19

#	ARTICLE	IF	CITATIONS
3724	Accuracy of high-resolution rectal magnetic resonance imaging re-staging with histopathology in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. <i>Asian Journal of Surgery</i> , 2021, 44, 275-279.	0.2	2
3725	Early recurrence after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: Characteristics and risk factors. <i>Asian Journal of Surgery</i> , 2021, 44, 298-302.	0.2	10
3726	Development of the "PREDICT"™ score through a systematic review and meta-analysis of the predictive parameters for locoregional recurrence after total mesorectal excision. <i>Updates in Surgery</i> , 2021, 73, 35-46.	0.9	2
3727	Neoadjuvant Radiotherapy Dose Escalation in Locally Advanced Rectal Cancer: a Systematic Review and Meta-analysis of Modern Treatment Approaches and Outcomes. <i>Clinical Oncology</i> , 2021, 33, e1-e14.	0.6	21
3728	A Snapshot of the International Views of the Treatment of Rectal Cancer Patients, a Multi-regional Survey: International Tendencies in Rectal Cancer. <i>World Journal of Surgery</i> , 2021, 45, 302-312.	0.8	5
3729	Ten-year survival after pathologic complete response in rectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 293-298.	0.8	12
3730	Oncological outcomes of lateral lymph node dissection (LLND) for locally advanced rectal cancer: is LLND alone sufficient?. <i>International Journal of Colorectal Disease</i> , 2021, 36, 293-301.	1.0	5
3731	Impact of Postoperative Complications on Oncologic Outcomes After Rectal Cancer Surgery: An Analysis of the US Rectal Cancer Consortium. <i>Annals of Surgical Oncology</i> , 2021, 28, 1712-1721.	0.7	20
3732	Prognostic Impact of Extranodal Extension in Rectal Cancer Patients Undergoing Radical Resection After Preoperative Chemoradiotherapy. <i>Clinical Colorectal Cancer</i> , 2021, 20, e35-e42.	1.0	5
3733	Clinical outcomes in elderly rectal cancer patients treated with neoadjuvant chemoradiotherapy: impact of tumor regression grade. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1179-1188.	1.2	7
3734	Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2021, 11, 13-25.	1.1	67
3735	Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). <i>Radiotherapy and Oncology</i> , 2021, 155, 27-32.	0.3	5
3736	Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 278-285.	0.8	13
3737	Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2021, 123, 286-292.	0.8	1
3738	A comparison of oncological outcomes after abdominoperineal excision before and after the implementation of a selective perineal flap closure program. <i>Journal of Surgical Oncology</i> , 2021, 123, 614-621.	0.8	0
3739	The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 100964.	1.7	9
3740	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103190.	2.0	5
3741	Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 155, 237-245.	0.3	13

#	ARTICLE	IF	CITATIONS
3742	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
3743	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. Translational Research, 2021, 231, 124-138.	2.2	11
3744	Circumferential Resection Margin Status as a Predictive Factor for Recurrence in Preoperative MRI for Advanced Lower Rectal Cancer Without Preoperative Therapy. Diseases of the Colon and Rectum, 2021, 64, 71-80.	0.7	2
3745	Risk Stratification Using Neoadjuvant Rectal Score in the Era of Neoadjuvant Chemoradiotherapy: Validation With Long-term Outcome Data. Diseases of the Colon and Rectum, 2021, 64, 60-70.	0.7	4
3746	Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cancer Letters, 2021, 500, 119-131.	3.2	8
3747	Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review. Journal of Small Animal Practice, 2021, 62, 237-243.	0.5	8
3748	Curative therapy for rectal cancer. Expert Review of Anticancer Therapy, 2021, 21, 193-203.	1.1	7
3749	Reirradiation for Rectal Cancer Using Pencil Beam Scanning Proton Therapy: A Single Institutional Experience. Advances in Radiation Oncology, 2021, 6, 100595.	0.6	9
3750	Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit. International Journal of Colorectal Disease, 2021, 36, 517-533.	1.0	11
3751	Management of the adenocarcinoma of the upper rectum: a reappraisal. Updates in Surgery, 2021, 73, 513-526.	0.9	2
3752	Advances in the treatment of locally advanced rectal cancer. Annals of Gastroenterological Surgery, 2021, 5, 32-38.	1.2	21
3753	Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiotherapy and Oncology, 2021, 154, 154-160.	0.3	45
3754	Dosimetric Parameters Predicting Late Small Bowel Toxicity in Patients With Rectal Cancer Receiving Neoadjuvant Chemoradiation. Practical Radiation Oncology, 2021, 11, e70-e79.	1.1	3
3755	Design, synthesis, and evaluation of novel coumarin-dithiocarbamate derivatives (IDs) as anti-colorectal cancer agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 593-604.	2.5	7
3756	Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. Journal of Cancer, 2021, 12, 417-427.	1.2	2
3757	High plateletâ€”C-reactive protein level multiplier is a negative prognostic marker in rectal cancer treated by neoadjuvant chemoradiotherapy. International Journal of Clinical Oncology, 2021, 26, 708-716.	1.0	3
3758	Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms. Techniques in Coloproctology, 2021, 25, 319-331.	0.8	10
3759	The outcome of transanal endoscopic microsurgery and adjuvant radiotherapy in patients with high-risk T1 rectal cancer. Journal of Minimal Access Surgery, 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3760	The experience of dealing with defecation dysfunction by changing the eating behaviours of people with rectal cancer following sphincter-saving surgery: A qualitative study. <i>Nursing Open</i> , 2021, 8, 1501-1509.	1.1	7
3761	Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience. <i>Radiotherapy and Oncology</i> , 2021, 154, 172-178.	0.3	58
3762	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. <i>Journal of Clinical Oncology</i> , 2021, 39, 17-29.	0.8	58
3763	NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy. <i>Cancers</i> , 2021, 13, 455.	1.7	8
3764	Clinical predictors of pathological good response in locally advanced rectal cancer. <i>Radiation Oncology</i> , 2021, 16, 10.	1.2	8
3765	Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma. <i>Advances in Cancer Research</i> , 2021, 151, 39-67.	1.9	2
3766	Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>In Vivo</i> , 2021, 35, 977-985.	0.6	4
3767	Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 6, 100087.	1.3	23
3768	Risk factors and endoscopic treatment for anastomotic stricture after resection in patients with colorectal cancer. <i>Revista De Gastroenterolog�a De M�xico (English Edition)</i> , 2021, 86, 44-50.	0.1	2
3770	Apparent diffusion coefficient for the prediction of tumor response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer. <i>Radiation Oncology</i> , 2021, 16, 17.	1.2	5
3771	Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy. <i>Translational Cancer Research</i> , 2021, 10, 88-98.	0.4	2
3772	An exercise trial for adults undergoing neoadjuvant chemoradiotherapy for rectal cancer proves not feasible: recommendations for future trials. <i>Trials</i> , 2021, 22, 26.	0.7	3
3773	Omission of or Poor Response to Preoperative Chemoradiotherapy Impacts Radial Margin Positivity Rates in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, 669-676.	0.7	1
3774	Development and validation of magnetic resonance imaging- based radiomics models for preoperative prediction of microsatellite instability in rectal cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 134-134.	0.7	27
3775	Provisional Clinical Opinions for Radiation Therapy in Prefrail Elderly Colorectal Cancer Patients: Part One. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 413-421.	0.1	0
3776	Prognostic Role of Peripheral Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 151-160.	0.6	16
3777	Urogenital function following robotic and laparoscopic rectal cancer surgery: meta-analysis. <i>British Journal of Surgery</i> , 2021, 108, 128-137.	0.1	33
3778	Inaccurate Clinical Stage Is Common for Gastric Adenocarcinoma and Is Associated with Undertreatment and Worse Outcomes. <i>Annals of Surgical Oncology</i> , 2021, 28, 2831-2843.	0.7	10

#	ARTICLE	IF	CITATIONS
3780	Possibilities for and limits of upfront surgical strategy with lateral pelvic node dissection for low rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 713-721.	0.6	2
3781	Treatment and subsequent prognosis in locally recurrent rectal cancer: a multicenter retrospective study of 498 patients. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1243-1250.	1.0	7
3782	Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer. <i>Journal of Cancer</i> , 2021, 12, 4418-4423.	1.2	1
3783	Chemoradiotherapy for Gastrointestinal Malignancies. , 2021, , 1991-2003.		0
3784	Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 511-522.	1.1	6
3785	Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 707-712.	0.6	2
3787	The middle rectal artery detected by contrast-enhanced magnetic resonance imaging predicts lateral lymph node metastasis in lower rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1677-1684.	1.0	6
3788	College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2021, 26, e780-e793.	1.9	21
3789	Neoadjuvant therapy of cetuximab combined with chemoradiotherapy in rectal cancer. <i>Medicine (United States)</i> , 2021, 100, e24649.	0.4	1
3790	Urological complications after radiation therapy“nothing ventured, nothing gained: a Narrative Review. <i>Translational Cancer Research</i> , 2021, 10, 1096-1118.	0.4	14
3791	Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1279-1286.	1.0	4
3792	Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 198-208.	157.7	14
3793	Neoadjuvant Chemotherapy and Concomitant Boost Radiotherapy in the Treatment of Locally Advanced Rectal Cancer. <i>Journal of Cancer and Tumor International</i> , 0, , 1-19.	0.1	1
3794	Can normalized carcinoembryonic antigen following neoadjuvant chemoradiation predict tumour recurrence after curative resection for locally advanced rectal cancer?. <i>Colorectal Disease</i> , 2021, 23, 1346-1356.	0.7	2
3795	Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 6725-6735.	0.7	23
3796	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
3798	CEA, EpCAM, β 26 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy. <i>Diagnostics</i> , 2021, 11, 516.	1.3	5
3799	Factors determining the quality of life in patients undergoing radical surgery due to malignant tumors of the rectum. <i>Polski Przegląd Chirurgiczny</i> , 2021, 93, 1-5.	0.2	2

#	ARTICLE	IF	CITATIONS
3800	Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2937-2950.	2.0	9
3801	Strategies to Minimize Late Effects From Pelvic Radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 158-168.	1.8	6
3802	MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. <i>Scientific Reports</i> , 2021, 11, 5379.	1.6	53
3803	Pretreatment Inflammatory-Nutritional Biomarkers Predict Responses to Neoadjuvant Chemoradiotherapy and Survival in Locally Advanced Rectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 639909.	1.3	19
3804	Clinical Reality and Treatment for Local Recurrence of Rectal Cancer: A Single-Center Retrospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 286.	0.8	7
3806	Triumph against cancer: invading colorectal cancer with nanotechnology. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1169-1192.	2.4	13
3807	National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016. <i>JAMA Network Open</i> , 2021, 4, e211031.	2.8	18
3808	Short-course radiotherapy with consolidation chemotherapy <i>versus</i> conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. <i>British Journal of Surgery</i> , 2021, 108, 511-520.	0.1	24
3809	Oncological outcomes of laparoscopic versus open rectal cancer resections: meta-analysis of randomized clinical trials. <i>British Journal of Surgery</i> , 2021, 108, 469-476.	0.1	22
3810	Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer. <i>Cancers</i> , 2021, 13, 1279.	1.7	21
3811	Clinical staging accuracy and the use of neoadjuvant chemoradiotherapy for cT3N0 rectal cancer: Propensity score matched National Cancer Database analysis. <i>American Journal of Surgery</i> , 2021, 221, 561-565.	0.9	1
3812	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 86-104.	0.6	0
3813	Trends and Factors Associated With Receipt of Upfront Surgery for Stage II to III Rectal Adenocarcinoma in the United States, 2006 to 2016. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 187-194.	0.6	0
3814	Long-term oncological outcomes of the sphincter preserving total mesorectal excision with varying distal resection margins. <i>Journal of Surgical Oncology</i> , 2021, 123, 1784-1791.	0.8	3
3815	Stage III colon cancer: is neoadjuvant chemotherapy ready for prime time? A narrative review of neoadjuvant chemotherapy for colon cancer. <i>Digestive Medicine Research</i> , 0, 4, 16-16.	0.2	1
3816	Comparison of Survival between Single-Access and Conventional Laparoscopic Surgery in Rectal Cancer. <i>Minimally Invasive Surgery</i> , 2021, 2021, 1-7.	0.1	2
3817	Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. <i>Clinical Colorectal Cancer</i> , 2021, 20, 29-41.	1.0	18
3818	Long-Term Results of a Prospective Phase 2 Study on Volume De-Escalation in Neoadjuvant Chemoradiotherapy of Rectal Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e186-e194.	1.1	2

#	ARTICLE	IF	CITATIONS
3820	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2567-2579.	0.9	25
3821	Identification of Patients with Locally Advanced Rectal Cancer in Whom Preoperative Radiotherapy Can Be Omitted: A Multicenter Retrospective Study at Yokohama Clinical Oncology Group (YCOG1307). <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 173-180.	0.4	2
3822	Log odds of positive lymph nodes is an excellent prognostic factor for patients with rectal cancer after neoadjuvant chemoradiotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 637-637.	0.7	10
3823	Principles of cancer treatment by chemotherapy. <i>Surgery</i> , 2021, 39, 215-220.	0.1	5
3824	Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. <i>Science Progress</i> , 2021, 104, 003685042110106.	1.0	12
3827	Development of a dual-energy spectral computed tomography-based nomogram for the preoperative discrimination of histological grade in colorectal adenocarcinoma patients. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 544-555.	0.6	3
3828	Current Trends in the Quality Assessment of Colorectal Cancer Practice and Treatment in South Korea during 2012-2017. <i>Cancer Research and Treatment</i> , 2021, 53, 487-496.	1.3	6
3829	Morphometric assessment of the mesorectal fat in Chinese Han population: A clinical MRI study. <i>Science Progress</i> , 2021, 104, 003685042110162.	1.0	3
3830	Positive lateral pelvic lymph nodes in low rectal cancer: should we change our practice now?. <i>ANZ Journal of Surgery</i> , 2021, 91, 947-953.	0.3	1
3831	Distinguishing Rectal Cancer from Colon Cancer Based on the Support Vector Machine Method and RNA-sequencing Data. <i>Current Medical Science</i> , 2021, 41, 368-374.	0.7	8
3832	Radiotherapeutic Management of Synchronous Prostate and Rectal Cancers Using Proton Beam Therapy. <i>International Journal of Particle Therapy</i> , 2021, 8, 82-88.	0.9	1
3833	Fertility Preservation in Young Adults with Gastrointestinal and Hematological Malignancies. , 2021, , 116-126.		0
3834	Non-operative Management (NOM) of Rectal Cancer: Literature Review and Translation of Evidence into Practice. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 23-41.	1.0	0
3835	Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6189-6198.	0.7	10
3836	Prone Versus Supine Position in Abdominoperineal Resection: Outcomes in the Laparoscopic Era. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 382-389.	0.5	1
3838	The role of modern neoadjuvant radiotherapy in the combined treatment of locally advanced rectal cancer. <i>Voprosy Onkologii</i> , 2021, 67, 190-201.	0.1	0
3839	MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone. <i>British Journal of Radiology</i> , 2021, 94, 20201221.	1.0	2
3840	Multi-parametric magnetic resonance imaging assessment of whole tumour heterogeneity for chemoradiotherapy response prediction in rectal cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 18, 26-33.	1.2	8

#	ARTICLE	IF	CITATIONS
3841	Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!. <i>Colorectal Disease</i> , 2021, 23, 1662-1669.	0.7	5
3842	MRI Staging in an Evolving Management Paradigm for Rectal Cancer, From the <i>AJR</i> Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1282-1293.	1.0	7
3843	Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1607-1611.	0.5	8
3844	Does preoperative neoadjuvant chemotherapy impact short-term surgical outcomes in patients with locally advanced colon cancer?. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2127-2134.	1.0	3
3845	Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2063-2070.	1.0	46
3846	Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2814-2820.	0.5	2
3847	Comparison of dosimetric characteristics between flattening filter-free and flattening filter mode volumetric-modulated arc therapy plans in rectal cancer. <i>Precision Radiation Oncology</i> , 2021, 5, 100-105.	0.4	2
3848	Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19â€9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. <i>Colorectal Disease</i> , 2021, 23, 2320-2330.	0.7	9
3850	Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible. <i>Annals of Surgical Oncology</i> , 2021, 28, 5194-5204.	0.7	9
3851	Chemo-Re-Irradiation and Salvage Surgery for Locally Recurrent Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4769-4771.	0.7	3
3852	Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?. <i>Diagnostics</i> , 2021, 11, 946.	1.3	0
3853	Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 383-387.	0.6	0
3854	Pathological Complete Response After Neoadjuvant Therapy in Rectal Adenocarcinoma: a 5-Year Follow-up. <i>Indian Journal of Surgery</i> , 2021, 83, 768-775.	0.2	4
3855	The Addition of Preoperative Radiation Is Insufficient for Lateral Pelvic Control in a Subgroup of Patients With Low Locally Advanced Rectal Cancer: A Post Hoc Study of a Randomized Controlled Trial. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1321-1330.	0.7	8
3856	Preparing Patients for Sexual Dysfunction After Radiation for Anorectal Cancers: A Systematic Review. <i>Practical Radiation Oncology</i> , 2021, 11, 193-201.	1.1	12
3857	FANCD2 mutation in a patient with early rectal cancer receiving definitive chemoradiation. <i>Advances in Radiation Oncology</i> , 2021, 6, 100717.	0.6	1
3858	Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1525-1534.	1.0	2
3859	MV CBCT-Based Synthetic CT Generation Using a Deep Learning Method for Rectal Cancer Adaptive Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 655325.	1.3	17

#	ARTICLE	IF	CITATIONS
3860	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. <i>Gland Surgery</i> , 2021, 10, 1564-1575.	0.5	10
3861	Direct comparison of F-18 FDG PET/CT and MRI to predict pathologic response to neoadjuvant treatment in locally advanced rectal cancer: a meta-analysis. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1038-1047.	1.2	5
3862	Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer. <i>Cells</i> , 2021, 10, 1539.	1.8	6
3863	More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, .	0.7	3
3864	Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies. <i>Oncology Reviews</i> , 2021, 15, 511.	0.8	4
3865	Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2411-2422.	0.9	3
3866	Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 178.	0.8	5
3867	Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review. <i>Radiation Oncology Journal</i> , 2021, 39, 83-90.	0.7	4
3868	Risk factors of symptomatic anastomotic leakage and its impacts on a long-term survival after laparoscopic low anterior resection for rectal cancer: a retrospective single-center study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 187.	0.8	2
3869	Gene Expression Profiles Associated with Radio-Responsiveness in Locally Advanced Rectal Cancer. <i>Biology</i> , 2021, 10, 500.	1.3	9
3870	Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. <i>Radiotherapy and Oncology</i> , 2021, 159, 91-97.	0.3	1
3871	Extraperitoneal colostomy after laparoscopic abdominoperineal resection using a cannula for tunnel creation through a trocar port. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 3178-3182.	1.3	1
3872	Sequential assessment of bowel function and anorectal physiology after anterior resection for cancer: a prospective cohort study. <i>Colorectal Disease</i> , 2021, 23, 2436-2446.	0.7	4
3873	Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 155-160.	0.3	16
3874	Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer. <i>Clinical Oncology</i> , 2021, 33, 391-399.	0.6	12
3875	Poor response at restaging MRI and high incomplete resection rates of locally advanced mucinous rectal cancer after chemoradiation therapy. <i>Colorectal Disease</i> , 2021, 23, 2341-2347.	0.7	9
3876	8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy. <i>Cancers</i> , 2021, 13, 2805.	1.7	1
3877	Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies. <i>Clinical Colorectal Cancer</i> , 2021, 20, e240-e248.	1.0	8

#	ARTICLE	IF	CITATIONS
3878	High-Risk Clinicopathological and Genetic Features and Outcomes in Patients Receiving Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer. <i>Cancers</i> , 2021, 13, 3166.	1.7	3
3879	Switching on prodrugs using radiotherapy. <i>Nature Chemistry</i> , 2021, 13, 805-810.	6.6	91
3880	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	0.6	22
3881	The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma. <i>Oncotarget</i> , 2021, 12, 1490-1498.	0.8	3
3882	A Patient-Derived Organoid-Based Radiosensitivity Model for the Prediction of Radiation Responses in Patients with Rectal Cancer. <i>Cancers</i> , 2021, 13, 3760.	1.7	21
3883	Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer. <i>World Journal of Surgical Oncology</i> , 2021, 19, 201.	0.8	13
3884	Mesorectal shape variation in rectal cancer radiotherapy in prone position using a belly board. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 120-125.	1.2	0
3885	The Evolving Field of Neoadjuvant Therapy in Locally-advanced Rectal Cancer: Evidence and Prospects. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	6
3886	Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of) Tj ETQqO 0 0 rgBT 4 Overlock 20 Tf 50 4		35.
3887	Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. <i>Asian Journal of Surgery</i> , 2021, 44, 957-963.	0.2	6
3888	The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer. <i>Iranian Journal of Pathology</i> , 2021, 16, 266-273.	0.2	1
3889	Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. <i>British Journal of Surgery</i> , 2021, 108, 1251-1258.	0.1	11
3890	Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center Experience. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2021, 31, 178-184.	0.1	0
3891	Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, , 1.	1.3	4
3892	Predicting Response to Total Neoadjuvant Treatment (TNT) in Locally Advanced Rectal Cancer Based on Multiparametric Magnetic Resonance Imaging: A Retrospective Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 5657-5669.	0.9	3
3893	Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 487-494.	0.6	3
3894	A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision – Preliminary results of the CONTEM1 study. <i>Radiotherapy and Oncology</i> , 2021, 162, 195-201.	0.3	13
3895	Influence of Psychological Nursing Intervention on Psychological State, Treatment Compliance, and Immune Function of Postoperative Patients with Rectal Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	0.6	4

#	ARTICLE	IF	CITATIONS
3896	The Survival Effect of Radiotherapy on Stage II/III Rectal Cancer in Different Age Groups: Formulating Radiotherapy Decision-Making Based on Age. <i>Frontiers in Oncology</i> , 2021, 11, 695640.	1.3	2
3897	High-Intensity vs Low-Intensity Knowledge Translation Interventions for Surgeons and Their Association With Process and Outcome Measures Among Patients Undergoing Rectal Cancer Surgery. <i>JAMA Network Open</i> , 2021, 4, e2117536.	2.8	4
3898	Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 50-50.	1.5	1
3899	The effect of patient positioning (prone or supine) on the dose received by small bowel in pelvic radiotherapy in rectal cancer patients. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 419-423.	0.6	0
3900	Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 482-486.	0.6	8
3901	The Effect of Facility Volume on Survival Following Proctectomy for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 150-160.	0.9	2
3902	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 383-402.	1.4	12
3903	Adherence to neoadjuvant therapy guidelines for locally advanced rectal cancers in a region with sociodemographic disparities. <i>American Journal of Surgery</i> , 2021, 222, 395-401.	0.9	2
3904	Short course radiotherapy and delayed surgery for locally advanced rectal cancer in frail patients: is it a valid option?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2046-2052.	0.5	1
3905	A Pipeline for Predicting the Treatment Response of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Single MRI Modality: Combining Deep Segmentation Network and Radiomics Analysis Based on "Suspicious Region". <i>Frontiers in Oncology</i> , 2021, 11, 711747.	1.3	13
3906	Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 313.	0.8	3
3907	Total neoadjuvant therapy in patients with locally advanced rectal cancer: A tertiary medical center experience. <i>Molecular and Clinical Oncology</i> , 2021, 15, 220.	0.4	2
3908	Texture Analysis of Tumor and Peritumoral Tissues Based on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Hybrid Imaging in Patients With Rectal Cancer. <i>Journal of Computer Assisted Tomography</i> , 2021, 45, 820-828.	0.5	5
3909	Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2022, 276, e819-e824.	2.1	12
3910	Can Elevated Pretreatment Serum Carcinoembryonic Antigen Levels Serve as a Potential Biomarker Guiding Adjuvant Chemotherapy in Rectal Cancer Patients With ypTis-3N0 After Neoadjuvant Radiotherapy and Surgery?. <i>Frontiers in Oncology</i> , 2021, 11, 705460.	1.3	1
3911	Survival rates and prognostic factors in right- and left-sided colon cancer stage "IV: an unselected retrospective single-center trial. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2683-2696.	1.0	2
3912	The predictive value of PET/CT for distant recurrences in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 917-924.	0.9	0
3913	Hypermethylation and Downregulation of UTP6 Are Associated With Stemness Properties, Chemoradiotherapy Resistance, and Prognosis in Rectal Cancer: A Co-expression Network Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 607782.	1.8	1

#	ARTICLE	IF	CITATIONS
3914	Re-evaluation of controversial issues in the treatment of cT3N0-2 rectal cancer: a 10-year cohort analysis using propensity-score matching. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2649-2659.	1.0	5
3915	A Multidisciplinary Approach to Rectal Cancer Treatment in Ulcerative Colitis Results in High Rate of Restorative Minimally Invasive Surgery. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 244-250.	0.6	1
3916	Pragmatic use of short-course radiotherapy, chemotherapy and surgery for stage IV rectal cancer with locally advanced or symptomatic primary tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 940-950.	0.9	1
3918	Watch and wait in locally advanced rectal cancer: Past, present and future. <i>World Journal of Meta-analysis</i> , 2021, 9, 327-332.	0.1	0
3919	Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9549.	1.8	13
3920	The Future of Cancer Therapy with X-rays: Patient Numbers, Innovations, Clinical Trials, and the Problem of Generating Evidence. <i>Strategies for Sustainability</i> , 2022, , 307-324.	0.2	0
3921	The sigmoid take-off as a landmark to distinguish rectal from sigmoid tumours on MRI: Reproducibility, pitfalls and potential impact on treatment stratification. <i>European Journal of Surgical Oncology</i> , 2022, 48, 237-244.	0.5	12
3922	The Evolution of Multimodality Treatment of Rectal Cancer. <i>JAMA Surgery</i> , 2021, 156, 1149-1150.	2.2	0
3923	Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. <i>Clinical Colorectal Cancer</i> , 2021, 20, e155-e164.	1.0	6
3924	Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 60-64.	0.9	2
3925	FDG-PET/CT and MR imaging for target volume delineation in rectal cancer radiotherapy treatment planning: a systematic review. <i>Journal of Radiotherapy in Practice</i> , 0, , 1-11.	0.2	0
3926	Brazilian society of surgical oncology: Guidelines for the surgical treatment of mid-low rectal cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 194-216.	0.8	4
3928	Outcomes of Ureteroneocystostomy in Patients with Cancer. <i>Urology</i> , 2021, , .	0.5	1
3929	Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 189-197.	0.7	2
3930	ctDNA on liquid biopsy for predicting response and prognosis in locally advanced rectal cancer: A systematic review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 218-227.	0.5	16
3931	Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>Cancers</i> , 2021, 13, 4589.	1.7	14
3932	Risk factors for the development of low anterior resection syndrome. <i>Seminars in Colon and Rectal Surgery</i> , 2021, 32, 100845.	0.2	1
3933	Neoadjuvant chemotherapy without radiation as a potential alternative treatment for locally advanced rectal cancer: A meta-analysis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1196-1209.	0.8	4

#	ARTICLE	IF	CITATIONS
3934	Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9673.	1.8	15
3935	Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2715-2727.	1.0	2
3936	Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy. <i>Advances in Surgery</i> , 2021, 55, 89-107.	0.6	8
3937	Transanal minimally invasive surgery to rescue anastomosis following leak after low anterior resection: A case report. <i>Laparoscopic, Endoscopic, and Robotic Surgery</i> , 2021, , .	0.3	1
3938	One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695726.	1.3	2
3939	Identification and Adjudication of Adverse Events Following Rectal Cancer Surgery: Observational Case Series in a Region of Ontario, Canada. <i>Annals of Surgical Oncology</i> , 2022, 29, 1182-1191.	0.7	2
3940	Trends in flap reconstruction of pelvic oncologic defects: Analysis of the national inpatient sample. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 2085-2094.	0.5	5
3941	Whatâ€™s the magic number? Impact of time to initiation of treatment for rectal cancer. <i>Surgery</i> , 2021, , .	1.0	5
3942	Computed tomography-derived biomarker for predicting the treatment response to neoadjuvant chemoradiotherapy of rectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2246-2254.	1.0	1
3943	Impact of neoadjuvant chemoradiotherapy on the local recurrence and distant metastasis pattern of locally advanced rectal cancer: a propensity score-matched analysis. <i>Chinese Medical Journal</i> , 2021, 134, 2196-2204.	0.9	3
3944	Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 265-272.	1.0	7
3946	Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment. <i>Medicine (United States)</i> , 2021, 100, e27366.	0.4	3
3947	Rates and predictors of repeat preoperative endoscopy for elective colorectal resections: how can we avoid repeated procedures?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, , 1.	1.3	6
3948	Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2441-2449.	0.5	21
3949	The impact of neoadjuvant chemotherapy on low anterior resection syndrome after rectal cancer resection: A 6Â-Months longitudinal follow-up. <i>Asian Journal of Surgery</i> , 2021, 44, 1260-1265.	0.2	4
3950	A Case of Radiation Recall Myositis and Neuropathy in Locally Advanced Rectal Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100770.	0.6	2
3951	Prognostic Implications of MRI-Detected EMVI and Tumor Deposits and Their Response to Neoadjuvant Therapy in cT3 and cT4 Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 816-825.	0.4	17
3952	A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling â€“ Rationale and first in human. <i>Radiotherapy and Oncology</i> , 2021, 164, 37-42.	0.3	12

#	ARTICLE	IF	CITATIONS
3954	Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 609313.	1.3	4
3955	Rectal cancer lateral lymph nodes: multicentre study of the impact of obturator and internal iliac nodes on oncological outcomes. <i>British Journal of Surgery</i> , 2021, 108, 205-213.	0.1	42
3956	Three dimensional cultivation increases chemo- and radioresistance of colorectal cancer cell lines. <i>PLoS ONE</i> , 2021, 16, e0244513.	1.1	23
3958	Transanal Surgery for benign tumor or early rectal cancer: state of the art and future prospects of the surgeon. <i>Annals of Laparoscopic and Endoscopic Surgery</i> , 0, 6, 6-6.	0.5	0
3959	Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. <i>Colorectal Disease</i> , 2021, 23, 1326-1333.	0.7	4
3960	The role of MRI and 18F-FDG PET/CT with respect to evaluation of pathological response in the rectal cancer patients after neoadjuvant chemoradiotherapy. <i>Indian Journal of Cancer</i> , 2023, 60, 52.	0.2	2
3961	How to Combine Diffusion-Weighted and T2-Weighted Imaging for MRI Assessment of Pathologic Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. <i>Korean Journal of Radiology</i> , 2021, 22, 1451.	1.5	6
3962	Preoperative radiotherapy and total neoadjuvant therapy in locally advanced rectal cancer management: So far, so good. <i>Journal of Radiation and Cancer Research</i> , 2021, .	0.0	0
3963	Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. <i>The Cochrane Library</i> , 2018, 2018, CD002102.	1.5	35
3964	Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer. <i>British Journal of Surgery</i> , 2020, 107, 537-545.	0.1	15
3965	Nationwide in-hospital mortality rate following rectal resection for rectal cancer according to annual hospital volume in Germany. <i>BJS Open</i> , 2020, 4, 310-319.	0.7	42
3966	Clinical Principles and Applications of Chemoradiation. , 2006, , 39-55.		3
3967	Surgical Treatment of Rectal Cancer. , 2007, , 413-436.		10
3968	Pre-operative Radio-Chemotherapy of Rectal Cancer: Toxicity and Preliminary Results with the Addition of Weekly Oxaliplatin. , 2009, , 295-306.		1
3970	Aims of Combined Modality Therapy in Rectal Cancer (M0). <i>Recent Results in Cancer Research</i> , 2014, 203, 153-169.	1.8	14
3971	Do T3 Rectal Cancers Always Need Radiochemotherapy?. <i>Recent Results in Cancer Research</i> , 2014, 203, 95-115.	1.8	7
3972	Rectal and Colon Cancer: Radiation Therapy Planning. , 2017, , 171-180.		2
3973	Gastrointestinal Brachytherapy: Anal and Rectal Cancer. , 2017, , 289-318.		2

#	ARTICLE	IF	CITATIONS
3975	Multimodality Therapy for Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third. Recent Results in Cancer Research, 2009, 182, 155-166.	1.8	2
3976	Quantitative Cell Kill of Radio- and Chemotherapy. Medical Radiology, 2009, , 169-190.	0.0	1
3977	Stomach, Small and Large Intestines. Medical Radiology, 2014, , 353-394.	0.0	1
3978	K�rperliche Bewegung in der onkologischen Palliativmedizin. , 2012, , 215-224.		2
3979	Neoadjuvant Treatment in Rectal Cancer: Do We Always Need Radiotherapy�or Can We Risk Assess Locally Advanced Rectal Cancer Better?. Recent Results in Cancer Research, 2012, 196, 21-36.	1.8	12
3980	Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer. Pathology and Oncology Research, 2019, 25, 1599-1605.	0.9	7
3981	Cancer of the Rectum. , 2008, , 1535-1556.		2
3983	Radiation Injury. , 2010, , 639-651.e5.		3
3985	Interaction of Chemotherapy and Radiation. , 2012, , 65-82.		9
3986	Tratamiento del c�ncer de recto mediante escisi�n completa del mesorrecto por v�a transanal. Resultados en 100 pacientes consecutivos. Cirug�a Espa�ola, 2019, 97, 510-516.	0.1	4
3987	Hospital variance in neoadjuvant rectal cancer treatment and the influence of a national guideline update: Results of a nationwide population-based study. Radiotherapy and Oncology, 2020, 145, 162-171.	0.3	8
3988	A Phase II Trial of Neoadjuvant Capecitabine Combined With Hyperfractionated Accelerated Radiation Therapy in Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 251-256.	0.6	16
3989	A Phase I Study of Capecitabine, Irinotecan, Celecoxib, and Radiation as Neoadjuvant Therapy of Patients With Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 242-245.	0.6	6
3990	Clinical Anastomotic Leakage After Rectal Cancer Resection Can Be Predicted by Pelvic Anatomic Features on Preoperative MRI Scans: A Secondary Analysis of a Randomized Controlled Trial. Diseases of the Colon and Rectum, 2019, 62, 1326-1335.	0.7	7
3991	Outcomes of robotic versus laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiation therapy and the effect of learning curve. Medicine (United States), 2017, 96, e8171.	0.4	46
3992	Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?. Asia-Pacific Journal of Clinical Oncology, 2014, 10, e108-13.	0.7	10
3993	Update on indications for lateral lymph node dissection in the management of lower rectal cancer. ANZ Journal of Surgery, 2020, 90, 1265-1269.	0.3	7
3994	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clinical Trials, 2019, 16, 165-175.	0.7	52

#	ARTICLE	IF	CITATIONS
3995	MRI of rectal cancer—relevant anatomy and staging key points. <i>Insights Into Imaging</i> , 2020, 11, 100.	1.6	26
3996	Optimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: An analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2015, 33, 510-510.	0.8	4
3997	Microarray Profiling of Mononuclear Peripheral Blood Cells Identifies Novel Candidate Genes Related to Chemoradiation Response in Rectal Cancer. <i>PLoS ONE</i> , 2013, 8, e74034.	1.1	10
3998	Human Phosphatidylethanolamine-Binding Protein 4 Promoted the Radioresistance of Human Rectal Cancer by Activating Akt in an ROS-Dependent Way. <i>PLoS ONE</i> , 2014, 9, e90062.	1.1	11
3999	Heterogeneity of KRAS Mutation Status in Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0153278.	1.1	14
4000	Long-term oncologic outcomes in pathologic tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. <i>Korean Journal of Clinical Oncology</i> , 2018, 14, 37-42.	0.1	7
4001	Proton Reirradiation of Recurrent Rectal Cancer: Dosimetric Comparison, Toxicities, and Preliminary Outcomes. <i>International Journal of Particle Therapy</i> , 2014, 1, 2-13.	0.9	30
4002	Preoperative Chemoradiation in Locally Advanced Rectal Cancer: Efficacy and Safety. <i>Gastroenterology Research</i> , 2015, 8, 303-308.	0.4	3
4003	Neoadjuvant Conformal Chemoradiation with Induction Chemotherapy for Rectal Adenocarcinoma. A Prospective Observational Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 171-178.	0.5	1
4004	Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia. <i>International Journal of Cancer Research and Molecular Mechanisms</i> , 2016, 2, .	0.2	3
4005	Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma. <i>Tumori</i> , 2011, 97, 717-23.	0.6	12
4006	Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. <i>Tumori</i> , 2012, 98, 622-9.	0.6	13
4007	Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy. <i>Tumori</i> , 2013, 99, 93-9.	0.6	12
4008	Neoadjuvant chemoradiotherapy for locally advanced rectal cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2015, 4, 13.	0.0	8
4009	Neoadjuvant therapy for locally advanced rectal cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 9.	0.0	3
4010	Comparison of long course and short course preoperative radiotherapy in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 17-27.	0.1	6
4011	Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study. <i>Oncotarget</i> , 2016, 7, 57317-57326.	0.8	5
4012	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686.	0.8	6

#	ARTICLE	IF	CITATIONS
4013	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016, 7, 53668-53678.	0.8	26
4014	Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. <i>Oncotarget</i> , 2016, 7, 66160-66169.	0.8	4
4015	Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2016, 7, 64233-64243.	0.8	39
4016	The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Oncotarget</i> , 2017, 8, 37845-37854.	0.8	5
4017	Monitoring neoadjuvant therapy responses in rectal cancer using multimodal nonlinear optical microscopy. <i>Oncotarget</i> , 2017, 8, 107323-107333.	0.8	7
4018	Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II-IV rectal cancer. <i>Oncotarget</i> , 2017, 8, 106913-106925.	0.8	6
4019	Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. <i>Oncotarget</i> , 2014, 5, 8123-8135.	0.8	20
4020	MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer. <i>Oncotarget</i> , 2018, 9, 11999-12008.	0.8	37
4021	Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2018, 9, 17906-17914.	0.8	5
4022	Intermediate neoadjuvant radiotherapy for T3 low/middle rectal cancer: postoperative outcomes of a non-controlled clinical trial. <i>Oncotarget</i> , 2014, 5, 11143-11153.	0.8	5
4023	Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation. <i>Oncotarget</i> , 2015, 6, 11714-11722.	0.8	8
4024	HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. <i>Oncotarget</i> , 2015, 6, 15065-15076.	0.8	21
4025	Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older. <i>Oncotarget</i> , 2015, 6, 30377-30383.	0.8	13
4026	Extramural depth of rectal cancer tumor invasion at thin-section MRI: predicting treatment response to neoadjuvant chemoradiation. <i>Oncotarget</i> , 2015, 6, 30277-30286.	0.8	7
4027	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial. <i>Oncotarget</i> , 2015, 6, 30394-30407.	0.8	44
4028	The value of forceps biopsy and core needle biopsy in prediction of pathologic complete remission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>Oncotarget</i> , 2015, 6, 33919-33925.	0.8	3
4029	Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study. <i>Oncotarget</i> , 2016, 7, 5053-5062.	0.8	12
4030	Lymph nodes regression grade is a predictive marker for rectal cancer after neoadjuvant therapy and radical surgery. <i>Oncotarget</i> , 2016, 7, 16975-16984.	0.8	10

#	ARTICLE	IF	CITATIONS
4031	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016, 7, 19781-19793.	0.8	14
4032	Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial. <i>Oncotarget</i> , 2016, 7, 25576-25584.	0.8	10
4033	Radiotherapy dose led to a substantial prolongation of survival in patients with locally advanced rectosigmoid junction cancer: a large population based study. <i>Oncotarget</i> , 2016, 7, 28408-28419.	0.8	15
4034	Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?. <i>Oncotarget</i> , 2016, 7, 34149-34157.	0.8	5
4035	Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). <i>Annals of Gastroenterology</i> , 2016, 29, 103-26.	0.4	17
4036	Alternative treatment to surgery for rectal cancer. <i>Annals of Laparoscopic and Endoscopic Surgery</i> , 2018, 3, 50-50.	0.5	4
4037	Genomic predictor of complete response after chemoradiotherapy in rectal cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 493-493.	0.7	7
4038	Preoperative assessment of lymph node metastasis in clinically node-negative rectal cancer patients based on a nomogram consisting of five clinical factors. <i>Annals of Translational Medicine</i> , 2019, 7, 543-543.	0.7	8
4039	Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 903-916.	0.6	22
4040	Synchronous primary carcinomas of the prostate, thyroid and rectum: case report and review of the literature. <i>Translational Cancer Research</i> , 2019, 8, 1006-1011.	0.4	1
4041	Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus de novo stage pI cohort: A propensity score-matched analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 373-381.	0.7	6
4042	Capecitabine in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2011, 3, 79.	0.9	52
4043	Circulating Biomarkers for Response Prediction of Rectal Cancer to Neoadjuvant Chemoradiotherapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 4274-4294.	1.2	10
4044	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 852-860.	0.9	14
4045	Gadovosfeset Trisodium (Vasovist®) Enhanced MR Lymph Node Detection: Initial Observations. <i>The Open Magnetic Resonance Journal</i> , 2009, 2, 28-32.	0.5	9
4046	mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 215-222.	0.5	12
4047	Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 1459-1466.	0.5	22
4048	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study. <i>Anticancer Research</i> , 2017, 37, 2683-2691.	0.5	10

#	ARTICLE	IF	CITATIONS
4049	A Scoring System to Predict the Development of Bone Metastasis After Radical Resection of Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 5169-5172.	0.5	11
4050	Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery. , 2017, 37, 5797-5804.		23
4051	Image Quality Assessment of 2D versus 3D T2WI and Evaluation of Ultra-high b-Value (b=2,000 mm/s ²) DWI for Response Assessment in Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 969-978.	0.5	13
4052	QuickSilver: A Phase II Study Using Magnetic Resonance Imaging Criteria to Identify "Good Prognosis" Rectal Cancer Patients Eligible for Primary Surgery. <i>JMIR Research Protocols</i> , 2015, 4, e41.	0.5	5
4053	Better surgery and better selection for adjuvants: Still the key to improving outcomes in rectal cancer. <i>Acta Chirurgica Iugoslavica</i> , 2006, 53, 35-37.	0.0	3
4054	Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2). <i>Acta Chirurgica Iugoslavica</i> , 2010, 57, 9-16.	0.0	7
4055	Quality assurance through outcome registration in colorectal cancer: An ECCO initiative for Europe. <i>Acta Chirurgica Iugoslavica</i> , 2010, 57, 17-21.	0.0	3
4056	Relationship of short-course preoperative radiotherapy and serum albumin level with postoperative complications in rectal cancer surgery. <i>Vojnosanitetski Pregled</i> , 2015, 72, 663-669.	0.1	4
4057	Non-operative management of rectal cancer: understanding tumor biology. <i>Minerva Chirurgica</i> , 2018, 73, 601-618.	0.8	3
4058	Selective use of radiation for locally advanced rectal cancer: one size does not fit all. <i>Minerva Chirurgica</i> , 2018, 73, 592-600.	0.8	3
4059	Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. <i>Acta Biomedica</i> , 2018, 89, 102-106.	0.2	7
4060	Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial. <i>Radiology and Oncology</i> , 2020, 54, 461-469.	0.6	4
4061	Predictive response biomarkers in rectal cancer neoadjuvant treatment. <i>Frontiers in Bioscience - Scholar</i> , 2014, S6, 110-119.	0.8	26
4062	Molecular biomarkers: multiple roles in radiotherapy. <i>Biocell</i> , 2020, 44, 513-524.	0.4	3
4063	A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. <i>Health Technology Assessment</i> , 2017, 21, 1-86.	1.3	44
4064	Diagnostic Accuracy of Computed Tomography and Magnetic Resonance Imaging Obtained after Neoadjuvant Chemoradiotherapy in Predicting the Local Tumor Stage and Circumferential Resection Margin Status of Rectal Cancer. <i>Journal of the Korean Society of Radiology</i> , 2014, 70, 123.	0.1	1
4065	A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Annals of Coloproctology</i> , 2013, 29, 192.	0.5	6
4066	Difference in Tumor Area as a Predictor of a Pathological Complete Response for Patients With Locally Advanced Rectal Cancer. <i>Annals of Coloproctology</i> , 2017, 33, 219-226.	0.5	4

#	ARTICLE	IF	CITATIONS
4067	Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation. <i>Annals of Coloproctology</i> , 2018, 34, 109-110.	0.5	1
4068	Variation in the Height of Rectal Cancers According to the Diagnostic Modalities. <i>Annals of Coloproctology</i> , 2019, 35, 24-29.	0.5	5
4069	Characteristics and Survival of Korean Patients With Colorectal Cancer Based on Data From the Korea Central Cancer Registry Data. <i>Annals of Coloproctology</i> , 2018, 34, 212-221.	0.5	38
4070	Early Systemic Failure After Preoperative Chemoradiotherapy for the Treatment of Patients With Rectal Cancer. <i>Annals of Coloproctology</i> , 2019, 35, 94-99.	0.5	2
4071	Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer. <i>Annals of Coloproctology</i> , 2019, 35, 137-143.	0.5	4
4072	Neutrophil to Lymphocyte Ratio: A Predictive Marker for Treatment Outcomes in Patients With Rectal Cancer Who Underwent Neoadjuvant Chemoradiation Followed by Surgery. <i>Annals of Coloproctology</i> , 2019, 35, 100-106.	0.5	17
4073	Combination Assessment of Clinical Complete Response of Patients With Rectal Cancer Following Chemoradiotherapy With Endoscopy and Magnetic Resonance Imaging. <i>Annals of Coloproctology</i> , 2019, 35, 202-208.	0.5	14
4074	Clinical Outcomes of Patients With Locally Advanced Rectal Cancer With Persistent Circumferential Resection Margin Invasion After Preoperative Chemoradiotherapy. <i>Annals of Coloproctology</i> , 2019, 35, 72-82.	0.5	12
4075	Oncologic Outcomes in Patients Who Undergo Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision for Locally Advanced Rectal Cancer: A 14-Year Experience in a Single Institution. <i>Annals of Coloproctology</i> , 2019, 35, 83-93.	0.5	15
4076	Beware of Early Relapse in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy. <i>Annals of Coloproctology</i> , 2020, 36, 382-389.	0.5	6
4077	Oncologic Outcomes and Safety after Tumor-specific Mesorectal Excision for Resectable Rectal Cancer: A Single Institution's Experience with 1,276 Patients with Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2008, 24, 121.	0.2	9
4078	Intraoperative Radiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2010, 26, 274.	0.9	5
4079	Prognostic Significance of Tumor Regression Grade after Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2011, 27, 1.	0.9	4
4080	Clinical Impact of Tumor Regression Grade after Preoperative Chemoradiation for Locally Advanced Rectal Cancer: Subset Analyses in Lymph Node Negative Patients. <i>Journal of the Korean Society of Coloproctology</i> , 2011, 27, 31.	0.9	15
4081	Prognostic Significance of Lymph Node Ratio in Stage III Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2011, 27, 252.	0.9	8
4082	Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases. <i>Journal of the Korean Society of Coloproctology</i> , 2012, 28, 100.	0.9	11
4083	An Update on Preoperative Radiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2012, 28, 179.	0.9	6
4084	Clinical Significance of Serial Serum Carcinoembryonic Antigen Values for Treating Rectal Cancer with Preoperative Chemoradiotherapy. <i>Journal of the Korean Society of Coloproctology</i> , 2012, 28, 205.	0.9	6

#	ARTICLE	IF	CITATIONS
4085	Colorectal cancer: from epidemiology to current treatment. <i>Libyan Journal of Medicine</i> , 2006, 1, 42-59.	0.8	1
4086	Predictors of Positive Radial Margin Status in a Population-Based Cohort of Patients with Rectal Cancer. <i>Current Oncology</i> , 2008, 15, 98-103.	0.9	10
4087	Neuro-regulation of lower esophageal sphincter Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. <i>World Journal of Gastroenterology</i> , 2008, 14, 1060.	1.4	63
4088	Evolving management of colorectal cancer. <i>World Journal of Gastroenterology</i> , 2008, 14, 3956.	1.4	22
4089	Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002). <i>World Journal of Gastroenterology</i> , 2006, 12, 1849.	1.4	5
4090	Sphincter-preserving R0 total mesorectal excision with resection of internal genitalia combined with pre- or postoperative chemoradiation for T4 rectal cancer in females. <i>World Journal of Gastroenterology</i> , 2007, 13, 2339.	1.4	8
4091	Adjuvant therapies for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 3799.	1.4	28
4092	Rectal cancer treatment: Improving the picture. <i>World Journal of Gastroenterology</i> , 2007, 13, 5805.	1.4	8
4093	Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. <i>World Journal of Gastroenterology</i> , 2010, 16, 3709.	1.4	16
4094	Colorectal cancer and 18FDG-PET/CT: What about adding the T to the N parameter in loco-regional staging?. <i>World Journal of Gastroenterology</i> , 2011, 17, 1427.	1.4	29
4095	Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. <i>World Journal of Gastroenterology</i> , 2011, 17, 2013.	1.4	65
4096	Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer. <i>World Journal of Gastroenterology</i> , 2011, 17, 5310.	1.4	39
4097	Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?. <i>World Journal of Gastroenterology</i> , 2011, 17, 848.	1.4	20
4098	Neoadjuvant-intensified treatment for rectal cancer: Time to change?. <i>World Journal of Gastroenterology</i> , 2013, 19, 3052.	1.4	38
4099	How reliable is current imaging in restaging rectal cancer after neoadjuvant therapy?. <i>World Journal of Gastroenterology</i> , 2013, 19, 5964.	1.4	37
4100	Overexpression of nuclear β -catenin in rectal adenocarcinoma is associated with radioresistance. <i>World Journal of Gastroenterology</i> , 2013, 19, 6876.	1.4	20
4101	Interval to surgery after neoadjuvant treatment for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 4256.	1.4	36
4102	Locally advanced rectal cancer: The importance of a multidisciplinary approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 17279.	1.4	24

#	ARTICLE	IF	CITATIONS
4103	Computed tomography perfusion imaging as a potential imaging biomarker of colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 17345.	1.4	11
4104	Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 563.	1.4	17
4105	Laparoscopic <i>vs</i> open abdominoperineal resection in the multimodality management of low rectal cancers. <i>World Journal of Gastroenterology</i> , 2015, 21, 10174-10183.	1.4	26
4106	Complete radiotherapy response in rectal cancer: A review of the evidence. <i>World Journal of Gastroenterology</i> , 2016, 22, 467.	1.4	7
4107	Smaller tumor size is associated with poor survival in T4b colon cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6726.	1.4	25
4108	Advanced gastric cancer: What we know and what we still have to learn. <i>World Journal of Gastroenterology</i> , 2016, 22, 1139.	1.4	59
4109	Neoadjuvant radiotherapy for rectal cancer management. <i>World Journal of Gastroenterology</i> , 2019, 25, 4850-4869.	1.4	128
4110	Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 2388-2402.	1.4	37
4111	Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 2877-2888.	1.4	17
4112	Watch and wait approach in rectal cancer: Current controversies and future directions. <i>World Journal of Gastroenterology</i> , 2020, 26, 4218-4239.	1.4	73
4113	Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 7022-7035.	1.4	15
4114	Results of Preoperative Concurrent Chemoradiotherapy for the Treatment of Rectal Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 247.	0.1	7
4115	Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer. <i>Radiation Oncology Journal</i> , 2012, 30, 99.	0.7	41
4116	The role of postoperative pelvic radiation in stage IV rectal cancer after resection of primary tumor. <i>Radiation Oncology Journal</i> , 2012, 30, 205.	0.7	12
4117	Bladder filling variations during concurrent chemotherapy and pelvic radiotherapy in rectal cancer patients: early experience of bladder volume assessment using ultrasound scanner. <i>Radiation Oncology Journal</i> , 2013, 31, 41.	0.7	23
4118	The location of locoregional recurrence in pathologic T3N0, non-irradiated lower rectal cancer. <i>Radiation Oncology Journal</i> , 2013, 31, 97.	0.7	7
4119	Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis. <i>Radiation Oncology Journal</i> , 2013, 31, 155.	0.7	16
4120	Dosimetric evaluation of Tomotherapy and four-box field conformal radiotherapy in locally advanced rectal cancer. <i>Radiation Oncology Journal</i> , 2013, 31, 252.	0.7	21

#	ARTICLE	IF	CITATIONS
4121	Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience. <i>Radiation Oncology Journal</i> , 2016, 34, 106-112.	0.7	15
4122	Morphologic change of rectosigmoid colon using belly board and distended bladder protocol. <i>Radiation Oncology Journal</i> , 2015, 33, 134.	0.7	1
4123	Preoperative chemoradiation for locally advanced rectal cancer: comparison of three radiation dose and fractionation schedules. <i>Radiation Oncology Journal</i> , 2016, 34, 96-105.	0.7	8
4124	Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 186-192.	0.7	4
4125	Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 305-312.	0.7	9
4126	Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta-analysis of randomized controlled trials. <i>Radiation Oncology Journal</i> , 2017, 35, 198-207.	0.7	44
4127	Trends in intensity-modulated radiation therapy use for rectal cancer in the neoadjuvant setting: a National Cancer Database analysis. <i>Radiation Oncology Journal</i> , 2018, 36, 276-284.	0.7	13
4128	Risk factors for locoregional recurrence in patients with pathologic T3N0 rectal cancer with negative resection margin treated by surgery alone. <i>Radiation Oncology Journal</i> , 2019, 37, 110-116.	0.7	9
4129	The effect of radiotherapy on rectal cancer: a histopathological appraisal and prognostic indicators. <i>Radiation Oncology Journal</i> , 2020, 38, 77-83.	0.7	5
4130	Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial. <i>Radiation Oncology Journal</i> , 2020, 38, 119-128.	0.7	9
4131	Short-term outcomes of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer. <i>Molecular and Clinical Oncology</i> , 2020, 14, 1-1.	0.4	1
4132	Patterns of recurrence in patients with curative resected rectal cancer according to different chemoradiotherapy strategies: Does preoperative chemoradiotherapy lower the risk of peritoneal recurrence?. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	1
4133	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 165-177.	0.7	20
4134	Management of stage II/III rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 112-9.	0.6	9
4135	Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 104-11.	0.6	32
4136	A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 345-52.	0.6	40
4137	Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 89-107.	0.6	16
4138	Predicting complete response: is there a role for non-operative management of rectal cancer?. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 241-6.	0.6	18

#	ARTICLE	IF	CITATIONS
4139	Neoadjuvant therapy for gastric cancer: current evidence and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 534-43.	0.6	58
4140	Urinary adverse effects of pelvic radiotherapy. <i>Translational Andrology and Urology</i> , 2014, 3, 186-95.	0.6	34
4141	Imaging in rectal cancer with emphasis on local staging with MRI. <i>Indian Journal of Radiology and Imaging</i> , 2015, 25, 148-161.	0.3	19
4142	Rectal cancer staging: Correlation between the evaluation with radial echoendoscope and rigid linear probe. <i>Endoscopic Ultrasound</i> , 2014, 3, 161.	0.6	12
4143	Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors. <i>Cancer Research and Treatment</i> , 2012, 44, 104-112.	1.3	15
4144	Identification of Hypoxanthine and Phosphoenolpyruvic Acid as Serum Markers of Chemoradiotherapy Response in Locally Advanced Rectal Cancer. <i>Cancer Research and Treatment</i> , 1970, 47, 78-89.	1.3	23
4145	Prognostic Significance of Serum Carcinoembryonic Antigen Normalization on Survival in Rectal Cancer Treated with Preoperative Chemoradiation. <i>Cancer Research and Treatment</i> , 2013, 45, 186-192.	1.3	14
4146	Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent Radiochemotherapy. <i>Cancer Research and Treatment</i> , 2014, 46, 148-157.	1.3	4
4147	Multimodal Assessments Are Needed for Restaging after Neoadjuvant Chemoradiation Therapy in Rectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 561-566.	1.3	8
4148	Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1198-1206.	1.3	10
4149	Phase I/II Study of Gefitinib and Concomitant Preoperative Radiotherapy in Patients with Locally Advanced Rectal Cancer. <i>Journal of Cancer Therapy</i> , 2012, 03, 970-976.	0.1	2
4150	Peripheral and Tissue Lymphocytes as Predictors of Pathological Response in Locally Advanced Rectal Cancer Post Neoadjuvant Chemoradiotherapy. <i>Journal of Cancer Therapy</i> , 2017, 08, 250-267.	0.1	1
4151	Management of synchronous lateral pelvic nodal metastasis in rectal cancer in the era of neoadjuvant chemoradiation: A systemic review. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 247-258.	0.8	4
4152	Proximal and distal rectal cancers differ in curative resectability and local recurrence. <i>World Journal of Gastrointestinal Surgery</i> , 2011, 3, 113.	0.8	5
4153	Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed?. <i>World Journal of Gastrointestinal Surgery</i> , 2012, 4, 32.	0.8	11
4154	Pelvic radiation therapy: Between delight and disaster. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 279.	0.8	82
4155	Quality of life in rectal cancer surgery: What do the patient ask?. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 349.	0.8	7
4156	Response to chemoradiotherapy and lymph node involvement in locally advanced rectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 196.	0.8	3

#	ARTICLE	IF	CITATIONS
4157	Trends with neoadjuvant radiotherapy and clinical staging for those with rectal malignancies. <i>World Journal of Gastrointestinal Surgery</i> , 2017, 9, 97.	0.8	4
4158	Prognostic impact of at least 12 lymph nodes after neoadjuvant therapy in rectal cancer: A meta-analysis. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1443-1455.	0.8	11
4159	Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 213.	0.8	7
4160	Surgical treatment of hepatic metastases from colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2011, 3, 1.	0.8	14
4161	Role of radiation therapy in neoadjuvant era in patients with locally advanced rectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 230.	0.8	8
4162	Current debate in the oncologic management of rectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 715.	0.8	8
4163	Neoadjuvant radiotherapeutic strategies in pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 186.	0.8	13
4164	Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 42.	0.8	13
4165	Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 209.	0.8	11
4166	Can diffusion-weighted MRI determine complete responders after neoadjuvant chemoradiation for locally advanced rectal cancer?. <i>Diagnostic and Interventional Radiology</i> , 2012, 18, 574-81.	0.7	34
4167	Dietary changes and colorectal cancer trends in Spain during 1951-2007. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 159-68.	0.1	11
4168	Multidisciplinary approach and multimodal therapy in resected pancreatic cancer: Observational study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 5-12.	0.1	10
4169	Chemoradiation as definitive treatment for primary squamous cell cancer of the rectum. <i>World Journal of Radiology</i> , 2010, 2, 329.	0.5	9
4170	Clinical significance of magnetic resonance imaging findings in rectal cancer. <i>World Journal of Radiology</i> , 2011, 3, 92.	0.5	17
4171	An elderly patient with marginally unresectable rectal cancer obtained pathological complete response by the treatment with mFOLFOX6. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 83-87.	0.1	2
4172	Prognostic Significance of the Lymph Node Ratio Regarding Recurrence and Survival in Rectal Cancer Patients Treated with Postoperative Chemoradiotherapy. <i>Gut and Liver</i> , 2012, 6, 203-209.	1.4	7
4173	Surgical Management of Colorectal Cancer. <i>Journal of the Korean Medical Association</i> , 2010, 53, 569.	0.1	3
4174	Five-year outcomes of preoperative chemoradiation for rectal carcinoma in Saudi population: single-institutional experience. <i>Annals of Saudi Medicine</i> , 2015, 35, 23-30.	0.5	1

#	ARTICLE	IF	CITATIONS
4175	Preoperative Computerized Tomographic Assessment of Regional Lymph Node and Extramural Vascular Invasion in Colonic Cancer. <i>Eurasian Journal of Medicine</i> , 2018, 50, 67-70.	0.2	1
4176	Adjuvant chemotherapy for rectal cancer: Is it needed?. <i>World Journal of Clinical Oncology</i> , 2015, 6, 225.	0.9	18
4177	Laparoscopic abdominoperineal resection with intraoperative radiotherapy for locally advanced low rectal cancer. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;</i> , Olomouc, Czechoslovakia, 2014, 158, 447-450.	0.2	3
4178	Early Postoperative Mortality Among Patients Aged 75 Years or Older With Stage II/III Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 443-451.	2.3	2
4179	Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer. <i>Clinics</i> , 2016, 71, 449-454.	0.6	13
4180	Circulating Lymphocytes as Predictors of Sensitivity to Preoperative Chemoradiotherapy in Rectal Cancer Cases. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3881-3885.	0.5	40
4181	Preoperative Long Course Chemoirradiation in a Developing Country for Rectal Carcinoma: Kuala Lumpur Hospital Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3941-3944.	0.5	6
4182	Lymph Node Ratio is an Independent Prognostic Factor in Node Positive Rectal Cancer Patients Treated with Preoperative Chemoradiotherapy Followed by Curative Resection. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 5365-5369.	0.5	11
4183	PDCD4 as a Predictor of Sensitivity to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 825-830.	0.5	9
4184	Short-course Versus Long-course Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5755-5762.	0.5	22
4185	Parecoxib: an Enhancer of Radiation Therapy for Colorectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 627-633.	0.5	11
4186	A Logistic Model Including Risk Factors for Lymph Node Metastasis Can Improve the Accuracy of Magnetic Resonance Imaging Diagnosis of Rectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 707-712.	0.5	7
4187	DNA Repair Gene Polymorphisms Do Not Predict Response to Radiotherapy-Based Multimodality Treatment of Patients with Rectal Cancer: a Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 713-718.	0.5	7
4188	Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3395-3402.	0.5	30
4189	Impact of Time Interval Between Chemoradiation and Surgery on Pathological Complete Response and Survival in Rectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 89-93.	0.5	9
4190	Treatment in locally advanced rectal cancer: a machine learning bibliometric analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110421.	1.4	2
4191	Colorectal Cancer: Locoregional Disease. <i>UNIPA Springer Series</i> , 2021, , 605-616.	0.1	0
4192	Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial. <i>British Journal of Surgery</i> , 2021, 109, 121-128.	0.1	8

#	ARTICLE	IF	CITATIONS
4193	A Molecular Biomarker Prediction Model for Preoperative Radio sensitivity in Rectal Cancer: An Analysis of 33 Patientsâ€™ Information. , 2021, 05, .		0
4195	Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy. Medicina (Lithuania), 2021, 57, 1044.	0.8	7
4198	Effect of delaying surgery by more than 10 weeks after neoadjuvant therapy in rectal cancer: a single institution experience. Updates in Surgery, 2022, 74, 145-151.	0.9	0
4199	A Nomogram for Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy Using Semiquantitative Parameters Derived From Sequential PET/CT in Locally Advanced Rectal Cancer. Frontiers in Oncology, 2021, 11, 742728.	1.3	7
4200	Lateral pelvic lymph nodes for rectal cancer: A review of diagnosis and management. World Journal of Gastrointestinal Oncology, 2021, 13, 1412-1424.	0.8	10
4201	The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, 1471-1478.	0.7	2
4202	The Correlation Between Survival Benefit of Preoperative Radiotherapy and Pretreatment Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer. Frontiers in Oncology, 2021, 11, 735882.	1.3	5
4203	Carbon Ion Radiotherapy for Locally Recurrent Rectal Cancer. Annals of Surgical Oncology, 2022, 29, 11-12.	0.7	2
4204	Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients. Cancers, 2021, 13, 5003.	1.7	2
4205	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, , .	1.0	0
4206	Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Disease, 2022, 24, 157-176.	0.7	9
4207	Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Frontiers in Oncology, 2021, 11, 743540.	1.3	12
4208	Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2022, 21, 3-9.	1.0	11
4209	Clinical Complete Response in Patients With Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Nonoperative Management. International Journal of Radiation Oncology Biology Physics, 2022, 112, 715-725.	0.4	28
4210	The time Interval Between the End of Radiotherapy and Surgery Does Not Affect Outcomes in Rectal Cancer. American Surgeon, 2023, 89, 831-836.	0.4	0
4211	miRNA-148a Enhances the Treatment Response of Patients with Rectal Cancer to Chemoradiation and Promotes Apoptosis by Directly Targeting c-Met. Biomedicines, 2021, 9, 1371.	1.4	7
4212	Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature. World Journal of Clinical Cases, 2021, 9, 9077-9089.	0.3	4
4213	Radiologic Factors and Areas of Local Recurrence in Locally Advanced Lower Rectal Cancer After Lateral Pelvic Lymph Node Dissection. Diseases of the Colon and Rectum, 2021, 64, 1479-1487.	0.7	5

#	ARTICLE	IF	CITATIONS
4214	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	0.8	17
4215	Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Outcomes of survival, toxicity, sphincter preserving and prognostic factors. <i>Transplant Immunology</i> , 2021, 69, 101489.	0.6	3
4216	Toxicidad en tratamientos combinados de abdomen y pelvis: riesgo/beneficio. <i>Oncologia</i> , 2005, 28, .	0.0	0
4217	Radiation therapy for rectal cancer: neoadjuvant or adjuvant?. , 2006, , 167-178.		0
4218	Preoperative Versus Postoperative Chemoradiotherapy for Rectal Cancer. <i>Yearbook of Medicine</i> , 2006, 2006, 149-150.	0.1	0
4219	A Case of Carcinoma Associated with Anal Fistula in Which Total Pelvic Exenteration was Performed after Neoadjuvant Chemoradiotherapy. <i>Japanese Journal of Gastroenterological Surgery</i> , 2006, 39, 1452-1457.	0.0	5
4220	Rektumkarzinom. , 2006, , 601-631.		0
4221	Kolorektales Karzinom. , 2006, , 3787-3937.		1
4223	Rectal Cancer: Adjuvant Therapy and New Directions. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 27-32.	0.4	0
4224	Distant Metastasis Identified Immediately after Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2007, 23, 327.	0.2	0
4225	Contemporary Management of Rectal Cancer. <i>Oncology & Hematology Review</i> , 2007, , 92.	0.2	0
4227	Long-term Result for Rectal Cancer in Cases of a Curative Resection after Preoperative Chemoradiotherapy. <i>Journal of the Korean Society of Coloproctology</i> , 2007, 23, 503.	0.2	1
4228	A Case Report of Lower Rectal Adenocarcinoma Treated by Transanal Endoscopic Microsurgery (TEM) in Combination with Preoperative Chemoradiation Therapy. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2007, 60, 276-280.	0.1	0
4230	Experiences of Preoperative Only Radiotherapy in Patients with Non-Metastasising Rectal Tumours. <i>Hungarian Medical Journal</i> , 2007, 1, 341-352.	0.0	0
4231	Combined Chemoradiotherapy Advances. <i>Cancer Treatment and Research</i> , 2008, , 277-301.	0.2	1
4232	Clinical Factors Predicting the Pathologic Tumor Response after Preoperative Concurrent Chemoradiotherapy for Rectal Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 213.	0.1	1
4233	Colon, Rectum, and Anus. , 2008, , 1011-1110.		26
4234	Could the surgeon trust to radiotherapy help in rectal cancer?. <i>Acta Chirurgica Iugoslavica</i> , 2008, 55, 55-59.	0.0	0

#	ARTICLE	IF	CITATIONS
4235	Long-term results of laparoscopic treatment for advanced rectal cancer. Acta Chirurgica Iugoslavica, 2008, 55, 31-37.	0.0	0
4236	The Clinical Significance of Cathepsin D and p53 Expression in Locally Advanced Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 56.	0.1	0
4237	Rectal Cancer: Function-preserving Surgery. Journal of the Korean Society of Coloproctology, 2008, 24, 394.	0.2	0
4238	RADIATION INJURY TO COLON AND RECTUM. , 2008, , 2149-2167.		0
4239	Prognostic Significance of the Circumferential Resection Margin in Invasive T3 Rectal Cancer. Journal of the Korean Society of Coloproctology, 2008, 24, 278.	0.2	2
4240	The use of PET/PET CT in the Management of Colorectal Cancer. , 2008, , 143-157.		0
4241	Radiation as an Adjunct to Surgery. , 2008, , 1985-2004.		0
4242	MANAGEMENT OF CARCINOMA OF THE RECTUM. , 2008, , 1115-1262.		0
4243	Oncologic Result as According to Tumor Regression Grade after Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer. Journal of the Korean Society of Coloproctology, 2008, 24, 422.	0.2	1
4244	Multidisciplinary management is strongly suggested in elderly patients with rectal carcinoma. Aging Health, 2008, 4, 287-298.	0.3	0
4245	Kolorektalkarzinom. Pharma-Kritik (discontinued), 2008, 30, .	0.0	0
4246	Surgery for Colorectal Metastases. , 2009, , 1-14.		2
4247	Resección anterior baja y resección abdominoperineal máximamente invasivas. , 2009, , 135-138.		0
4248	Efficacy of postoperative concurrent radiotherapy and chemotherapy with Xeloda for stage II/III rectal cancer. World Chinese Journal of Digestology, 2009, 17, 3351.	0.0	0
4249	Effect of Suboptimal Chemotherapy on Preoperative Chemoradiation in Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 78.	0.1	1
4251	RECTAL CANCER WITH PELVIC ABSCESS TREATED BY PREOPERATIVE CHEMORADIATION THERAPY-REPORT OF A CASE-. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2009, 70, 1782-1785.	0.0	1
4252	Kolorektale Karzinome. , 2009, , 29-35.		0
4253	Preoperative Chemoradiotherapy Allows for Local Control in Rectal Cancer " But Distant Metastases Remain an Unsolved Problem. , 2009, , 389-410.		0

#	ARTICLE	IF	CITATIONS
4254	A CASE OF ADVANCED CANCER OF THE RECTUM TREATED WITH PREOPERATIVE CHEMORAD10THERAPY WITH ADDITION OF mFOLFOX6, AVOIDING TOTAL PELVIC EXENTERATION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2009, 70, 2098-2103.	0.0	0
4256	The Medical Oncologist's Point of View. , 2009, , 37-47.		0
4257	Radiation Therapy in Geriatric Oncology. , 2009, , 263-291.		0
4258	Low Anterior Resection and Abdominoperineal Resection. , 2009, , 167-177.		0
4260	The Radiotherapist's Point of View. , 2009, , 49-67.		0
4261	Chemoradiation for Rectal Cancer. , 2009, , 357-373.		0
4262	Resectable Rectal Cancer: Preoperative Short-Course Radiation. , 2009, , 375-387.		0
4263	Role of Radiation Therapy as an Adjuvant Treatment in Rectal Cancer Management. Journal of the Korean Society of Coloproctology, 2009, 25, 273.	0.2	1
4264	The Usefulness of 18F-FDG PET/CT for Predicting the Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation Therapy. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 111.	0.1	1
4265	Magnetic Resonance Imaging of Rectal Cancer. , 2009, , 25-54.		0
4266	Locally Advanced Rectal Cancer: Combined Chemotherapy During Preoperative Radiation Therapy. , 2009, , 411-436.		2
4267	Rectum. , 2009, , 481-492.		0
4268	2-CONSERVATIVE TREATMENT OF RECTAL ADENOCARCINOMA AFTER NEOADJUVANT CHEMORAD10THERAPY, IS IT ACCEPTABLE?. Basrah Journal of Surgery, 2009, 15, 3-9.	0.0	0
4270	Multivisceral Resection in Rectal Cancer. , 2010, , 13-20.		0
4271	Current Clinical Trials in Radiotherapy for Rectal Cancer. , 2010, , 55-67.		0
4273	Chemoradiation Therapy: Nonoperative Approaches. , 2010, , 249-265.		0
4274	Diagnosis and Treatment of Rectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 389-407.	0.1	0
4275	Cancer of the Colon. , 2010, , 842-850.		0

#	ARTICLE	IF	CITATIONS
4276	Management of Malignant Colorectal Tumours. , 2010, , 561-583.		0
4277	Radiation Therapy: Technical Innovations. , 2010, , 289-305.		0
4278	Genetische Aberration, Genexpressionprofile und Epigenetik. , 2010, , 67-75.		0
4279	Clinical Decision Making in Pancreatic Cancer. , 2010, , 623-649.		2
4280	The Efficacy of the Change in Belly Board Aperture Location by the Addition of Bladder Compression Device for Radiotherapy of Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 231.	0.1	2
4281	Colorectal Cancer Surgery: Current Trends and Recent Innovations. , 2010, , 815-831.		0
4282	Abdominoperineal Resection in the Treatment of Locally-advanced Low Rectal Cancer: Is Preoperative Chemoradiation Advantageous?. Journal of the Korean Society of Coloproctology, 2010, 26, 129.	0.2	0
4283	Abdominoperineal Resection, Low Anterior Resection, and Beyond. , 2010, , 79-107.		0
4284	Radiotherapy and Chemotherapy. , 2010, , 82-94.		0
4285	MRI of the Rectum. Medical Radiology, 2010, , 205-227.	0.0	1
4286	Capecitabine-based Neoadjuvant Chemoradiation Therapy in Locally-advanced Rectal Cancer. Journal of the Korean Society of Coloproctology, 2010, 26, 137.	0.2	1
4287	Adjuvant and Neoadjuvant Therapy for Colorectal Carcinoma. , 2010, , 305-316.		0
4288	Cancer of the Rectum. , 2010, , 851-869.		0
4289	Prinzipien der Strahlentherapie und der kombinierten Radio-/Chemotherapie. , 2010, , 285-300.		0
4291	Contact X-Ray Therapy. , 2010, , 267-275.		0
4294	Treatment of Colorectal Cancer. , 2010, , 641-642.e1.		1
4295	A Case of Locally Advanced Rectal Cancer Resected Successfully after Preoperative mFOLFOX6 Chemotherapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2010, 63, 295-299.	0.1	2
4297	The Changing Role of Radiation in the Post-TME ERA of Rectal Cancer. Current Cancer Therapy Reviews, 2010, 6, 243-248.	0.2	0

#	ARTICLE	IF	CITATIONS
4299	Laparoscopic Rectal Procedures. , 2011, , 235-250.		0
4300	The Pathological and Clinical Effects of Preoperative Chemoradiation in Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2011, 29, 11.	0.1	2
4301	Neoadjuvant Chemoradiotherapy for a Locally Advanced Carcinoma with Anal Fistula. Japanese Journal of Gastroenterological Surgery, 2011, 44, 632-637.	0.0	3
4304	Colorectal Cancer: Adjuvant Therapy. , 2011, , 773-782.		0
4305	Surgical Treatment of Rectal Cancer. , 2011, , 743-759.		5
4308	Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions. Biological and Medical Physics Series, 2012, , 179-192.	0.3	0
4309	Principles of Medical Oncology and Chemotherapy. , 2012, , 3-13.		0
4310	The Treatment of Metastatic Liver Disease of Colorectal Origin. , 0, , .		0
4311	Current issues on the understanding of locally advanced colorectal cancer. Arquivos De Gastroenterologia, 2011, 48, 223-224.	0.3	2
4312	Evidence-Based Management of Rectal Cancer. , 2012, , 173-186.		0
4313	Adjuvant Therapy for Resectable Colorectal Cancer Liver Metastases. , 0, , .		0
4315	Surgical Principles. , 2012, , 153-163.		0
4316	Timing of Adjuvant Chemotherapy and Survival in Patients with Stage II/III Rectal Cancer. Journal of Cancer Therapy, 2012, 03, 956-965.	0.1	0
4317	The Role of the Radiation Oncologist in Systemic Therapy an Australian and New Zealand Perspective. Journal of Nuclear Medicine & Radiation Therapy, 2012, 01, .	0.2	0
4318	A Case of Laparoscopic Surgery That Completely Extirpated Locally-Advanced Rectal Carcinoma with Liver Metastases after Neoadjuvant Therapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2012, 65, 437-441.	0.1	0
4321	Prognostic and Predictive Biomolecular Markers in Rectal Cancer. Journal of Nuclear Medicine & Radiation Therapy, 2012, 01, .	0.2	0
4322	What Are the Dose-Volume Constraints to Reduce Late Toxicity?. , 2012, , 149-154.		0
4323	What Biochemical and Molecular Biological Factors Have Greater Relevance to Treatment Decisions?. , 2012, , 41-48.		1

#	ARTICLE	IF	CITATIONS
4324	Principles of Chemotherapy. , 2012, , 165-179.		0
4325	Two Cases of Locally Advanced Rectal Carcinoma with Liver Metastasis Who Received Preoperative Radiochemotherapy with S-1+CPT-11. Nihon Daicho Komonbyo Gakkai Zasshi, 2012, 65, 363-368.	0.1	0
4326	Medizinische Grundlagen. , 2012, , 19-30.		2
4327	Intraoperative Irradiation. , 2012, , 317-330.		0
4328	Developments in Neoadjuvant Chemotherapy and Radiotherapy in Rectal Cancer. , 0, , .		0
4330	Physical Exercise in Advanced Malignant Diseases. , 2013, , 143-158.		1
4331	The Prognostic Impact of Endoscopic Obstruction on Colorectal Cancer. Korean Journal of Clinical Oncology, 2012, 8, 37-43.	0.1	0
4332	Lymphatic drainage of the rectum, preoperative assessment and its relevance to malignant polyp and rectal cancer management. Colorectal Cancer, 2012, 1, 513-524.	0.8	0
4333	Radial Dose Function. , 2013, , 697-697.		0
4334	Neo- and Adjuvant Therapy. Updates in Surgery Series, 2013, , 63-71.	0.0	0
4335	Beckenperfusion bei Rektumkarzinomen. , 2013, , 249-260.		0
4337	Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy. Journal of Cancer Therapy, 2013, 04, 1452-1458.	0.1	0
4338	Colorectal Cancer â€“ Management of Metastatic Disease. European Oncology and Haematology, 2013, 09, 100.	0.0	1
4339	Role of Hyperthermia in the Treatment of Gastrointestinal Cancers. Thermal Medicine, 2013, 29, 25-36.	0.0	1
4341	Ultrasonographic Diagnosis of Anorectal Disease. , 2013, , 1756-1771.		0
4343	A Case of Locally Advanced Rectal Cancer in which Pathological CR was Achieved after XELOX Neoadjuvant Chemotherapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 251-257.	0.1	2
4344	Rectal Cancer Radiotherapy and Older Patients: Evidence-Based or Opinion-Based Treatment?. , 2013, , 95-109.		0
4345	Adjuvant and Neoadjuvant Therapy for Colorectal Cancer. , 2013, , 2199-2208.		0

#	ARTICLE	IF	CITATIONS
4346	Operations for Colorectal Cancer. , 2013, , 2094-2109.		0
4347	Rektumkarzinom. , 2013, , 663-688.		0
4348	Adenocarcinoma of the Colon and Rectum. , 2013, , 2051-2074.		0
4350	Anti-Angiogenic Therapy Combined with Chemoradiotherapy for Patients with Localized Advanced Rectal Cancer. <i>Advances in Cancer: Research & Treatment</i> , 2013, , 1-17.	0.0	0
4351	Lateral Pelvic Node Dissection for Advanced Rectal Cancer: Current Debates and Use of the Robotic Approach. , 2014, , 75-86.		0
4352	Comparison of short-term oncologic outcomes following laparoscopic versus conventional open surgery for rectal cancer. <i>Korean Journal of Clinical Oncology</i> , 2013, 9, 17-27.	0.1	0
4354	Colon, Rectum, and Anus. , 2014, , 415-454.		0
4355	THE IMPORTANCE OF CLINICAL TARGET VOLUME FOR RADIATION THERAPY IN RECTAL CANCER. <i>Jurnalul De Chirurgie</i> , 2013, 9, .	0.0	0
4356	Analysis of Body Mass Index on Set Up Errors Rectal Cancer in Radiotherapy. <i>The Journal of the Korea Contents Association</i> , 2013, 13, 412-418.	0.0	0
4358	PET/MR in Colorectal Cancer. , 2014, , 95-108.		1
4359	Polymorphisms in Genes of Drug Targets and Metabolism. <i>Cancer Drug Discovery and Development</i> , 2014, , 289-332.	0.2	0
4360	Neoadjuvant Chemoradiation in Patient with Locally Advanced Rectal Cancer. <i>Acta Chirurgica Latviensis</i> , 2013, 13, 9-13.	0.2	0
4361	Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trial. <i>Canadian Journal of Surgery</i> , 2013, 56, E148-E153.	0.5	1
4362	Locally Advanced Rectal Cancer: Does Assessment of Response After Neoadjuvant Chemoradiotherapy Impact Management?. <i>Journal of the Advanced Practitioner in Oncology</i> , 2013, 4, 438-44.	0.2	2
4363	The Approach to the Rectal Cancer Patient with a Suspected Complete Clinical Response: Selection of Patients to the Watch and Wait Strategy. , 2014, , 251-258.		0
4364	Recurrent Rectal Cancer. , 2014, , 231-249.		1
4365	The Failed Anastomosis. , 2014, , 277-304.		1
4366	Tumeurs du rectum. , 2014, , 31-50.		0

#	ARTICLE	IF	CITATIONS
4367	Adjuvant therapy for colorectal cancer. , 2014, , 82-94.		0
4368	Cancer of the Rectum. , 2014, , 1336-1359.e8.		0
4369	Imagerie post-thérapeutique du cancer du rectum. , 2014, , 119-135.		0
4370	Preoperative Chemoradiotherapy for Advanced Rectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2014, 67, 888-896.	0.1	0
4371	Medical Practice Variations in Cancer Surgery. , 2014, , 1-21.		0
4372	Long-course chemoradiation versus short-course radiation for rectal cancer and overall comparison. Asian Journal of Medical Sciences, 2014, 5, 122-124.	0.0	0
4375	Malignant Tumors of the Colon. Radiology Illustrated, 2015, , 477-510.	0.0	0
4378	Impact of neoadjuvant chemoradiation therapy on the postoperative complication rate in rectal cancer. Journal of Cancer Research & Therapy, 2014, 2, 169-173.	0.1	0
4379	Postoperative Chemoradiation for Rectal Cancer. , 2015, , 241-257.		0
4380	The Surgeon's Perspective on Neoadjuvant Chemoradiation for Rectal Cancer. , 2015, , 97-108.		0
4381	Locally Advanced Disease. , 2015, , 311-321.		0
4382	Pretreatment Serum Cea as a Predictive Biomarker for the Response to Neoadjuvant Chemoradiotherapy: A Meta-Analysis in Rectal Cancer. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0
4384	Prognostic Value of Negative Lymph Nodes (NLN) in Rectal Adenocarcinoma. Journal of Surgery (New Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	0
4385	MRI Evaluation of Rectal Carcinoma. , 2015, , 417-432.		0
4389	Rektumkarzinom. , 2015, , 359-386.		0
4390	Updates in Adjuvant Therapy. , 2015, , 215-225.		0
4391	Effect of a Purse-String Approximation Following Stoma Takedown on Wound Infection and Satisfaction. Annals of Coloproctology, 2015, 31, 7.	0.5	0
4392	Maligne Dickdarmtumoren. , 2015, , 503-510.		0

#	ARTICLE	IF	CITATIONS
4393	Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2015, 04, 54-63.	0.3	5
4394	Multimodale Therapieoptionen beim nichtmetastasierten Rektumkarzinom. , 2015, , 29-34.		0
4395	MULTIDISCIPLINARY APPROACH IN THE TREATMENT OF PATIENTS WITH RECTAL CANCER. Malignant Tumours, 2015, , 64.	0.1	1
4396	THE ACCURACY OF ENDORECTAL ULTRASONOGRAPHY IN RECTAL CANCER STAGING. Medicine and Pharmacy Reports, 2015, 88, 348-356.	0.2	4
4397	Multimodality Management of Colorectal Malignancies Beyond Endoscopy. , 2015, , 291-309.		0
4398	PREDICTION OF RISK FACTORS OF LATERAL LYMPH NODE METASTASIS IN RECTAL CANCER. Vestnik Khirurgii Imeni II Grekova, 2015, 174, 30-33.	0.0	2
4399	Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7315-7319.	0.5	0
4401	Neoadjuvant Chemoradiotherapy and Chemotherapy in Patients with Locally Advanced Rectal Cancer. Journal of Cancer and Tumor International, 2016, 3, 1-13.	0.1	1
4402	Low Anterior Resection and Abdominoperineal Resection. , 2016, , 429-448.		0
4403	A Comparison of Post-treatment Quality of Life Outcomes for Endoluminal Brachytherapy and Chemoradiation for the Treatment of Localized Rectal Cancer. Archives of Surgical Oncology, 2016, 02, .	0.1	0
4404	Local Failure After Conservative Treatment of Rectal Cancer. Updates in Surgery Series, 2016, , 169-178.	0.0	0
4407	Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. Oncotarget, 2016, 7, 46536-46544.	0.8	1
4409	Factors Influencing on Utilization of Folk Medicine in Patients with Colorectal Cancer. Asia-pacific Journal of Multimedia Services Convergent With Art Humanities and Sociology, 2016, , 73-80.	0.0	0
4410	Colorectal and Anal Tumors. Pediatric Oncology, 2017, , 319-333.	0.5	0
4411	Role of PET/CT in Radiotherapy Treatment Planning. , 2017, , 577-608.		1
4412	The effect of laparoscopic versus robotic low anterior resection of rectum on postoperative pain: A propensity score matching analysis. Korean Journal of Clinical Oncology, 2016, 12, 124-128.	0.1	0
4413	Neoadjuvant radiotherapy and chemotherapy in locally advanced rectal cancer. Rad Hrvatske Akademije Znanosti I Umjetnosti Medicinske Znanosti, 2017, 530, 89-102.	0.1	0
4414	Value of macrobiopsies and transanal endoscopic microsurgery in the histological work-up of rectal neoplasms; a retrospective study. World Journal of Gastrointestinal Oncology, 2017, 9, 251.	0.8	3

#	ARTICLE	IF	CITATIONS
4415	Endoscopic colostomy with percutaneous colopexy: an animal feasibility study. Revista Espanola De Enfermedades Digestivas, 2017, 109, 273-278.	0.1	0
4417	Assessing Outcomes in Colorectal Cancer Surgery. , 2017, , 287-309.		0
4418	Robotic-Assisted Transanal Microscopic Surgery. , 2017, , 93-104.		1
4419	Role of thymidylate synthase as a predictor of neoadjuvant chemoradiation therapy in rectal cancer. Kazan Medical Journal, 2017, 98, 576-580.	0.1	0
4420	Clinical Significance of Disseminated Pluripotent Tumor Cell Signature Expression in the Bone Marrow from Patients with Colorectal Cancer. Journal of Cancer Science & Therapy, 2017, 9, 669-674.	1.7	0
4421	Principles of Cancer Surgery in Older Adults. , 2017, , 1-20.		0
4423	Anastomotic leakage after sphincter-sparing surgery in a young woman diagnosed with low rectal cancer - case report. Journal of Clinical and Investigative Surgery, 2017, 2, 45-53.	0.1	0
4425	The importance of a multidisciplinary team in rectal cancer management. Medicine and Pharmacy Reports, 2017, 90, 279-285.	0.2	3
4426	Radiotherapy for stage IIA rectal cancer may not benefit all. Oncotarget, 2017, 8, 99438-99450.	0.8	0
4427	Peri-treatment change of anorectal function in patients with rectal cancer after preoperative chemoradiotherapy. Oncotarget, 2017, 8, 79982-79990.	0.8	4
4428	Principles of Radiation Therapy in Older Adults. , 2018, , 1-15.		0
4429	A PROSPECTIVE STUDY ON PREOPERATIVE CONCURRENT CHEMORADIATION WITH CAPECITABINE IN STAGE II/III CARCINOMA OF RECTUM. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 4492-4496.	0.0	0
4430	Pelvic recurrence after definitive surgery for locally advanced rectal cancer: a retrospective investigation of implications for precision radiotherapy field design. Oncotarget, 2017, 8, 95973-95980.	0.8	0
4432	Outcomes of Neoadjuvant Radiochemotherapy of Locally Advanced Rectal Adenocarcinoma: Results of 8 Year Experience in Iran Cancer Institute. International Journal of Cancer Management, 2017, 10, .	0.2	2
4433	The Application of Image Guided Radiotherapy on the Precision of Intensity Modulated Radiotherapy in Patients with Locally Advanced Rectal Cancer. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 07, 479-490.	0.3	0
4434	Laparoscopic vs Robotic Surgery in Colorectal Cases. World Journal of Laparoscopic Surgery, 2018, 11, 43-47.	0.2	0
4436	Changes in the Global Strategy and Future Perspectives in Surgical Treatment for Low Rectal Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 1583-1596.	0.0	0
4437	Short-Course Vs Long-Course Radiotherapy: Pros and Cons. , 2018, , 329-339.		0

#	ARTICLE	IF	CITATIONS
4438	Advances in Radiotherapy for Locally Advanced Rectal Cancer. <i>Advances in Clinical Medicine</i> , 2018, 08, 59-63.	0.0	0
4439	Preoperative Conformal Radiotherapy Concurrently with Paclitaxel/Carboplatin in Gastric Cancer. <i>Journal of Cancer Therapy</i> , 2018, 09, 503-515.	0.1	1
4440	Recent Update on the Role of Radiation Therapy in Colorectal Cancer. , 2018, , 345-359.		0
4441	Sphincter Saving Surgery in Locally Advanced Low Rectal Cancer after Neoadjuvant Chemoradiotherapy. <i>Medical Journal of the University of Cairo Faculty of Medicine</i> , 2018, 86, 187-193.	0.0	0
4442	RECENT MANAGEMENT IN PATIENTS OF CARCINOMA RECTUM WITH RESPECT TO QUALITY OF LIFE A RETROSPECTIVE AND PROSPECTIVE STUDY. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2018, 7, 1689-1694.	0.1	0
4443	A PROSPECTIVE OBSERVATIONAL STUDY OF MANAGEMENT PROTOCOL OF LOCALLY ADVANCED CARCINOMA RECTUM AT MGMMC AND MY HOSPITAL, INDORE. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2018, 7, 2628-2633.	0.1	0
4444	The diagnostic and therapeutic management of a peculiar case of rectal submucosal adenocarcinoma. <i>Journal of Clinical and Investigative Surgery</i> , 2018, 3, 47-52.	0.1	1
4445	Polyradiomodification in combined treatment for rectal cancer and the role of therapeutic pathomorphosis. <i>Onkologi i Aeska i Koloproktologi</i> , 2018, 8, 42-49.	0.1	1
4446	Laparoscopic Versus Conventional Open Rectum Amputation: a Clinical, Intraoperative, and Short-term Outcome Comparative Study. <i>Journal of Interdisciplinary Medicine</i> , 2018, 3, 98-101.	0.1	0
4447	Factors associated with rectal tumor and their influence on tumor regression grade after neoadjuvant chemoradiotherapy. <i>Kazan Medical Journal</i> , 2018, 99, 611-616.	0.1	0
4448	Waiting and Hope: Optimal Time Interval for Surgery After Long-Course Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Annals of Coloproctology</i> , 2018, 34, 227-228.	0.5	0
4449	Neoadjuvant chemotherapy in the combination treatment for locally advanced rectal cancer: currently available options. <i>Onkologi i Aeska i Koloproktologi</i> , 2018, 8, 36-41.	0.1	2
4450	PREDICTIVE FACTORS FOR THE RESPONSE OF LOCAL AND ADVANCED RECTAL CANCER TO NEOADJUVANT RADIOCHEMOTHERAPY. <i>Journal of Surgical Sciences</i> , 2019, 1, 89-94.	0.0	0
4451	Rectal Cancer: Operative Treatment Transabdominal. , 2019, , 419-444.		0
4452	Principles of Adjuvant and Neoadjuvant Therapy for Locally Advanced Rectal Cancer. , 2019, , 445-463.		0
4453	Lokal ileri ve/veya lenf dairesinde tutulumu olan rektum kanserinde neoadjuvan kemoradyoterapiye yanıt ve sfinkter koruyucu cerrahinin araştırılması. <i>Mersin Üniversitesi Sağık Bilimleri Dergisi</i> , 0, , 314-322.	0.2	0
4454	Treatment of Rectal Cancer. , 2019, , 161-174.		0
4455	Robotic-Assisted Surgery for Rectal Cancer. <i>Journal of Japan Society of Computer Aided Surgery</i> , 2019, 21, 119-123.	0.1	0

#	ARTICLE	IF	CITATIONS
4456	Molecular Guidance for Planning External Beam Radiation Therapy. , 2019, , 977-1006.		3
4457	Kolorektales Karzinom. , 2019, , 81-93.		0
4458	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
4459	Radiologic Report for Magnetic Resonance Imaging of Rectal Cancer before Treatment. Journal of the Korean Society of Radiology, 2019, 80, 425.	0.1	0
4460	Short-course or long-course radiation therapy as a part of a neoadjuvant regimen for stage II & III rectal adenocarcinoma?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 849-852.	0.7	1
4461	Evaluation of the Diagnostic Value of Digital Rectal Examination for Lymph Node Metastasis in Mid-Low Rectal Cancer. International Journal of Clinical Medicine, 2019, 10, 317-325.	0.1	0
4462	The Changing Face of Abdominoperineal Excision. , 2019, , 241-258.		0
4463	The Swedish Approach Towards Radiotherapy and Rectal Cancer: Making Sense of Where They Have Been and Where They Are Going. , 2019, , 355-364.		0
4464	Advances in Radiation Therapy for Gastrointestinal Cancers. , 2019, , 421-443.		0
4465	Preserving Fertility in Patients with Gastrointestinal Cancers. , 2019, , 633-653.		0
4466	Neoadjuvant Chemoradiation for Localized Pancreatic Cancer. , 2019, , 85-96.		0
4467	Role of Chemoradiation in Obstructing or Bleeding Anal and Rectal Cancers. , 2019, , 89-94.		0
4468	Surgery, Perioperative Treatment and Prognostic Factors Based on Genetic and Epigenetic Alterations in Colorectal Cancer. Juntendo Medical Journal, 2019, 65, 194-202.	0.1	0
4469	Chemoradiotherapy for Gastrointestinal Malignancies. , 2019, , 1-13.		0
4470	Gastrointestinal System Cancers. , 2019, , 197-268.		0
4471	The Swedish Approach. , 2019, , 335-353.		1
4472	The Role of MRI in Assessment of Rectal Cancers. , 2019, , 39-55.		0
4473	Evaluation of the efficiency of neoadjuvant chemoradiation therapy for colorectal cancer on the basis of texture analysis of T2-weighted MR images. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 243.	0.0	1

#	ARTICLE	IF	CITATIONS
4474	Adjuvant Therapy for Colorectal Cancer. , 2019, , 109-133.		0
4475	Computer Aided Effective Prediction of Complete Responders After Radiochemotherapy Based on Tumor Regression Grade Estimated by MR Imaging. Lecture Notes in Computational Vision and Biomechanics, 2019, , 257-266.	0.5	1
4476	The Surgeonâ€™s Perspective on Radiation Therapy. , 2019, , 325-333.		0
4477	Local Excision: Indications and Techniques. , 2019, , 161-178.		0
4478	Radiation Therapy: The North American Approach. , 2019, , 365-403.		1
4479	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
4480	Unexpected Findings: Intraoperatively Suspected Colon Cancer Turns Out to Be Rectal Cancer. , 2019, , 35-36.		0
4481	Intersphincteric Resection: Indications and Outcome. , 2019, , 231-240.		1
4482	Is it Possible to Successfully Treat Locally Advanced Colon Cancer Using Pre-Operative Chemoradiotherapy?. Clinical Endoscopy, 2019, 52, 191-195.	0.6	0
4483	STAGE DISTRIBUTION AND PATIENT RESPONSE POST NEO-ADJUVANT SHORT COURSE RADIOTHERAPY IN RECTAL CANCER, SINGLE CENTER STUDY. Journal of Sulaimani Medical College, 2019, 9, 53-60.	0.0	0
4484	Efficacy of preoperative chemoradiotherapy in downstaging rectal cancer and its impact on the long-term outcome. South Asian Journal of Cancer, 2019, 08, 098-101.	0.2	1
4485	Contemporary view to the principles of rectal cancer diagnostics and treatment according to MRI (literature review). Medical Visualization, 2019, , 7-26.	0.1	1
4486	The Effectiveness and Safety of Open Versus laparoscopic Surgery for Rectal Cancer after Preoperative Chemo-radiotherapy: A Meta-Analysis. Combinatorial Chemistry and High Throughput Screening, 2019, 22, 153-159.	0.6	1
4487	Controversia en neoadyuvancia y cncer de recto. Ciruga Espaola, 2019, 97, 361-363.	0.1	1
4488	KRAS Mutation as Predictor Factor in Locally Advanced Rectal Cancer. Annals of Clinical Oncology, 2019, , 1-4.	0.0	0
4489	Place de la chimiothrapie propratoire dans le traitement des cancers du rectum localement avancs. Colon and Rectum, 2019, 13, 137-146.	0.0	0
4490	Clinical Outcome of Laparoscopic Colorectal Resection after Neoadjuvant Chemo-Radiotherapy for Colorectal Carcinoma. Zagazig University Medical Journal, 2019, .	0.0	0
4491	Integral Dose and Dosimetric Comparison of NeoAdjuvant Simultaneous Integrated Boost (SIB) Radiotherapy Technique for Rectal Cancer Using Intensity-Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Helical Tomotherapy (HT). UHOD - Uluslararası Hematoloji-Onkoloji Dergisi. 2019, 29, 147-156.	0.1	1

#	ARTICLE	IF	CITATIONS
4492	Retrospective review of total neoadjuvant therapy. World Journal of Gastrointestinal Oncology, 2019, 11, 857-865.	0.8	6
4493	Laparoscopic Left and Sigmoid Colectomy: Options for Colonic and Colorectal Reconstruction. , 2020, , 271-290.		0
4494	Neoadjuvant chemoradiation therapy for locally advanced colorectal cancer in hypofractionation mode (case report). OnkologiÄeskaÄc KoloproktologiÄc, 2019, 9, 48-56.	0.1	0
4495	âœWatch and waitâ approach in rectal cancer patients following complete clinical response to neoadjuvant chemoradiotherapy does not compromise oncologic outcomes. Turkish Journal of Gastroenterology, 2019, 30, 951-956.	0.4	6
4496	Impact of Adjuvant Chemotherapy Completion on Oncologic Outcomes in ypTNMstage 2 Rectal Cancer Patients. Annals of Coloproctology, 2019, 35, 335-341.	0.5	3
4497	Adenocarcinoma of the Colon and Rectum. , 0, , .		0
4498	Perineal psÄdo-kontinan kolostomi Äzerinde alt rektal karsinom rekÄrrensini baÄyarÄ± tedavisi: Bir olgu sunumu ve literatÄrden geÅirilmesi. Archives of Clinical and Experimental Medicine, 2019, 4, 148-151.	0.1	0
4499	Locally Advanced Rectal Cancer. , 2020, , 341-349.		0
4500	Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series. Revista Espanola De Enfermedades Digestivas, 2020, 112, 307-312.	0.1	4
4501	Therapy Response Imaging in Gastrointestinal Malignancy. Medical Radiology, 2020, , 99-115.	0.0	0
4502	REKTUM KANSERÄNDE NEOADJUVAN KEMORADYOTERAPÄ SONRASI RADYOLOJÄK VE PATOLOJÄK YANIT PREDÄKTÄRLERÄN DEÄZERLENDÄRLMESÄ. SÄleyman Demirel Äeniversitesi TÄp FakÄltesi Dergisi, 2019, 26, 256-262.	0.0	0
4503	Immediate Results of a Prolonged Course of Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Comparison of Classical andÄHypofractionalÄRegimes. Medical Radiology and Radiation Safety, 2020, 65, 34-43.	0.0	0
4504	Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment. Diseases of the Colon and Rectum, 2020, 63, 598-605.	0.7	2
4505	Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs in Context, 2020, 9, 1-13.	1.0	6
4506	Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World Journal of Gastroenterology, 2020, 26, 2387-2401.	1.4	1
4507	ÎâH2AX as a potential indicator of radiosensitivity in colorectal cancer cells. Oncology Letters, 2020, 20, 2331-2337.	0.8	14
4508	Prognostic significance of early complete response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy: Multicentric study of Turkish Society for Radiation Oncology Group (TROD). Turkish Journal of Gastroenterology, 2020, 31, 368-377.	0.4	1
4509	Treatment monitoring of locally advanced rectal cancer based on multiparametric magnetic resonance tomography. OnkologiÄeskaÄc KoloproktologiÄc, 2020, 10, 20-27.	0.1	0

#	ARTICLE	IF	CITATIONS
4510	Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery. <i>European Journal of Surgical Oncology</i> , 2022, 48, 850-856.	0.5	10
4511	Proposal for Establishing a New Radiotherapy Facility. , 2022, , 41-55.		0
4512	The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. <i>Journal of Geriatric Oncology</i> , 2022, 13, 294-301.	0.5	4
4513	Revisiting neoadjuvant therapy in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2021, 22, e501-e516.	5.1	86
4514	Principles of Cancer Surgery in Older Adults. , 2020, , 825-844.		0
4515	Principles of Radiation Therapy in Older Adults. , 2020, , 845-859.		0
4516	Optionen der neoadjuvanten Therapie beim Rektumkarzinom. , 2020, , 79-88.		0
4517	The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management. <i>Oncology & Hematology Review</i> , 2020, 16, 43.	0.2	2
4518	Magnetresonanztomographie (MRT) â€“basierte Chirurgie des Rektumkarzinoms. , 2020, , 89-93.		0
4519	Rectal Conditions: Rectal Cancerâ€™Adjuvant and Neoadjuvant Therapy. , 2020, , 303-314.		0
4520	RevisiÃ³n sistemÃ¡tica sobre la administraciÃ³n de la quimioterapia en el perÃ­odo entre la quimiorradioterapia neoadyuvante y la cirugÃ­a en el cÃ¡ncer de recto localmente avanzado.. <i>Archivos De ColoproctologÃ­a</i> , 2020, 3, .	0.0	0
4521	Shifting Treatment Strategies to Prevent Early Relapse of Locally Advanced Rectal Cancer After Preoperative Chemoradiotherapy. <i>Annals of Coloproctology</i> , 2020, 36, 357-358.	0.5	2
4522	Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases. <i>Healthcare (Switzerland)</i> , 2021, 9, 1.	1.0	13
4523	Novel approaches to treatment of locally advanced rectal cancer. <i>OnkologiÄeskaÄ KoloproktologiÄ</i> , 2020, 10, 73-83.	0.1	0
4524	Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1428-1442.	0.8	8
4525	Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer. <i>Journal of Radiation Research</i> , 2021, 62, 300-308.	0.8	2
4527	Persistent High Rate of Positive Margins and Postoperative Complications After Surgery for cT4 Rectal Cancer at a National Level. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 389-398.	0.7	6
4528	New standard in locally advanced rectal cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 990-995.	0.9	4

#	ARTICLE	IF	CITATIONS
4529	Developing an electronic geriatric assessment to improve care of older adults with cancer receiving radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 16, 24-29.	0.6	6
4530	Neoadjuvant, adjuvant, and intraoperative radiotherapy for rectal cancer. , 2022, , 403-419.		0
4531	Palliative radiotherapy in CRC. , 2022, , 429-433.		0
4532	Adjuvant chemotherapy for colorectal cancer. , 2022, , 381-390.		0
4534	Total Neoadjuvant Therapy or Standard Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4535	Principles of Rectal Cancer Management: Preoperative Staging, Neoadjuvant Treatment, Basic Principles of TME, and Adjuvant Treatment. , 2020, , 331-351.		1
4536	Colorectal Cancer in Older Adults: Surgical Issues. , 2020, , 713-730.		0
4538	Current Status of Neoadjuvant Chemotherapy for Locally Advanced Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2020, 73, 417-423.	0.1	0
4539	: Differentielle Indikationsstellung für Diagnostik in der Onkologie (Röntgen, CT, MRT, Sonografie). <i>Springer Reference Medizin</i> , 2020, , 1-19.	0.0	0
4540	Current Status of Preoperative Preparation for Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2020, 73, 401-403.	0.1	1
4541	Factors affecting pathological response and survival following neoadjuvant chemoradiotherapy in rectal cancer patients. <i>Indian Journal of Cancer</i> , 2020, .	0.2	1
4543	Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy. <i>In Vivo</i> , 2020, 34, 3559-3564.	0.6	4
4544	"Watch and Wait" for complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer. <i>Minerva Chirurgica</i> , 2020, 74, 481-495.	0.8	2
4545	Possibilities of multi-parametric magnetic resonance tomography in the assessment of neoadjuvant treatment of rectal cancer. <i>Diagnostic Radiology and Radiotherapy</i> , 2020, , 49-56.	0.0	1
4546	Perioperative Complications After Proctectomy for Rectal Cancer. <i>Annals of Surgery</i> , 2022, 275, e428-e432.	2.1	7
4547	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 446-454.	1.3	5
4548	The role of radiation for pancreatic adenocarcinoma. <i>Journal of Pancreatology</i> , 2020, 3, 72-80.	0.3	6
4549	Can pretreatment blood biomarkers predict pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer?. <i>Future Oncology</i> , 2021, 17, 4947-4957.	1.1	3

#	ARTICLE	IF	CITATIONS
4550	Current Trends in the Treatment of Locally Advanced Rectal Cancer: Where We Are and How We Got Here. <i>Current Colorectal Cancer Reports</i> , 0, , 1.	1.0	0
4551	Predictors of undergoing multivisceral resection, margin status and survival in Dutch patients with locally advanced colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1144-1152.	0.5	5
4552	Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer. <i>PLoS ONE</i> , 2021, 16, e0259460.	1.1	5
4553	Risk Factors for Complications Following Lateral Pelvic Lymph Node Dissection for Rectal Cancer. <i>Anticancer Research</i> , 2021, 41, 5599-5604.	0.5	1
4554	Effect of Biofeedback Therapy during Temporary Stoma Period in Rectal Cancer Patients: A Prospective Randomized Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 5172.	1.0	8
4555	Current State of Neoadjuvant Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 63-70.	1.0	2
4556	Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1063-1071.	1.0	7
4557	Colorectal Cancer: From Epidemiology to Current Treatment. <i>Libyan Journal of Medicine</i> , 2006, 1, 42-59.	0.8	1
4558	Kolon - Rektum. , 2006, , 533-598.		0
4561	Antiangiogenesis Agents in Colorectal Cancer. , 2008, , 371-384.		0
4562	Management of Locally Advanced Rectal Cancer. , 2007, , 155-189.		0
4566	Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. <i>Abdominal Radiology</i> , 2021, 46, 1468-1477.	1.0	13
4567	Radiotherapy in Early-Stage and Local Advanced Rectal Cancer. , 2021, , 663-682.		0
4568	Neoadjuvant radiotherapy and brachytherapy in endometrial cancer with gross cervical involvement: a CHIRENDO research group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 78-84.	1.2	2
4570	Chemoradiotherapy for Locally Advanced T3/T4 Rectal Cancer: What Should We Do with Complete Responders?. , 2021, , 203-222.		0
4571	Treatment of a Total Obstructive Anastomosis Stricture Using a Transanal Laparoscopic Approach and Intraoperative Colonoscopic Balloon Dilatation. <i>Annals of Coloproctology</i> , 2020, 36, 353-356.	0.5	0
4572	The emerging role of neoadjuvant chemotherapy for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 362-73.	0.6	29
4573	Future of therapy for rectal cancer. <i>Chinese Clinical Oncology</i> , 2013, 2, 19.	0.4	1

#	ARTICLE	IF	CITATIONS
4574	The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 264-84.	0.6	22
4575	Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. <i>Croatian Medical Journal</i> , 2006, 47, 693-700.	0.2	25
4576	A review of the role of capecitabine in the treatment of colorectal cancer. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 421-31.	0.9	14
4577	Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 25-33.	0.8	25
4578	Adjuvant treatment of rectal cancer: improving patient selection. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 37-8.	0.8	2
4579	Preoperative Chemoradiotherapy for Stage III Rectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 302-4.	0.8	0
4580	Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 49-56.	0.8	5
4581	Contemporary management of rectal cancer: new standards, mounting questions, emerging challenges. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 66-7.	0.8	0
4582	Local recurrence after rectal cancer treatment in Manitoba. <i>Canadian Journal of Surgery</i> , 2009, 52, 45-50.	0.5	4
4583	Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S4-7.	0.8	1
4584	Defining preoperative treatment strategies in t3 rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S54-7.	0.8	1
4585	Adjuvant treatment of colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S42-6.	0.8	31
4586	Accomplishments in 2007 in the adjuvant treatment of rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S7-S12.	0.8	0
4587	Adjuvant chemoradiation for localized rectal cancer: current trends and future directions. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S64-72.	0.8	1
4588	Particle radiation therapy for gastrointestinal malignancies. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S50-9.	0.8	1
4589	Potential benefits of integration of therapies with chemoradiation in rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S73-80.	0.8	1
4590	Radiotherapy for cancer of the rectum: which patients stand to benefit?. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 81-3.	0.8	0
4591	Targeted therapy in rectal cancer. <i>Oncology</i> , 2007, 21, 1055-65; discussion 1065, 1070, 1075 passim.	0.4	16

#	ARTICLE	IF	CITATIONS
4592	Local Excision vs. Radical Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 105-14.	0.8	10
4593	Accomplishments in 2008 in the adjuvant treatment of rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S8-S14.	0.8	0
4594	Colorectal Cancer Association of Canada consensus meeting: raising the standards of care for early-stage rectal cancer. <i>Current Oncology</i> , 2009, 16, 50-6.	0.9	4
4595	Colorectal cancer treatment. <i>Clinical Evidence</i> , 2010, 2010, .	0.2	4
4596	Effects of change in rectal cancer management on outcomes in British Columbia. <i>Canadian Journal of Surgery</i> , 2010, 53, 225-31.	0.5	12
4597	Dramatic innovations in modern surgical subspecialties. <i>Canadian Journal of Surgery</i> , 2010, 53, 335-41.	0.5	19
4598	Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 33-5.	0.8	0
4600	A case for more intensive systemic therapy for patients with locally advanced rectal cancer: even in the face of a pathologic complete response. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 106-8.	0.8	0
4601	Low-lying rectal cancer with anal canal involvement: abdominoperineal or low anterior resection after neoadjuvant chemoradiotherapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 90-5.	0.8	5
4602	A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer. <i>Biomedical Imaging and Intervention Journal</i> , 2011, 7, e25.	0.5	4
4603	Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 45-54.	0.6	3
4604	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. <i>Puerto Rico Health Sciences Journal</i> , 2012, 31, 52-8.	0.2	0
4605	Management of a locally advanced rectal cancer in a patient who declined surgery. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 205-9.	0.8	0
4606	Can only chemoradiotherapy and chemotherapy treatment be applied to patients with rectal cancer who could not be operated?. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 193-7.	0.6	0
4607	Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?. <i>Oncology</i> , 2012, 26, 741-3.	0.4	0
4608	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 87-9.	0.8	1
4609	Retreatment of a patient who presented with synchronous multiple primary colorectal carcinoma: report of a case. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2013, 25, 482-5.	0.7	0
4610	Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 129-36.	0.8	13

#	ARTICLE	IF	CITATIONS
4611	Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 137-43.	0.8	26
4612	Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 3-8.	0.6	56
4613	Treatment of lateral pelvic nodes metastases from rectal cancer: the future prospective. <i>Giornale Di Chirurgia</i> , 2013, 34, 245-8.	0.5	8
4614	Neo-adjuvant chemoradiotherapy; an opportunity in sphincter preserving procedure for rectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2014, 7, 32-7.	0.6	3
4615	Abdominoperineal excision following preoperative radiotherapy for rectal cancer: unfavorable prognosis even with negative circumferential resection margin. <i>World Journal of Gastroenterology</i> , 2014, 20, 9138-45.	1.4	3
4616	Therapeutic approaches in the management of locally advanced rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 353-61.	0.6	11
4617	Rectal cancer: a truly multidisciplinary challenge. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 323-5.	0.6	0
4618	Outcomes of rectal cancer with liver oligometastases. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 414-20.	0.6	4
4619	Perioperative chemotherapy for resectable colorectal hepatic metastases-What does the EORTC 40983 trial update mean?. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 80-3.	0.7	0
4620	Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, E40-3.	0.6	4
4621	Rectal cancer: a review. <i>Medical Journal of the Islamic Republic of Iran</i> , 2015, 29, 171.	0.9	25
4622	Survival implications of pretreatment pelvic CT in rectal cancer patients after neoadjuvant chemoradiotherapy and surgery. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 12801-9.	1.3	2
4623	High preoperative serum globulin in rectal cancer treated with neoadjuvantive chemoradiation therapy is a risk factor for poor outcome. <i>American Journal of Cancer Research</i> , 2015, 5, 2856-64.	1.4	18
4624	Thymidine phosphorylase and hypoxia-inducible factor 1- β expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 10680-8.	0.5	12
4625	Circadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 10985-94.	0.5	9
4626	A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3231-40.	1.4	6
4627	The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 38.	0.7	0
4628	Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 148-53.	0.5	3

#	ARTICLE	IF	CITATIONS
4629	Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: long-term results from a single institution. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 1265-72.	0.0	3
4630	VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 4455-4463.	0.0	9
4633	The impact of surgical diversion before neoadjuvant therapy for rectal cancer. <i>American Surgeon</i> , 2015, 81, 444-9.	0.4	2
4635	High preoperative peripheral blood neutrophil predicts poor outcome in rectal cancer treated with neoadjuvantive chemoradiation therapy. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 7718-7725.	0.5	1
4636	The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management. <i>Oncology & Hematology Review</i> , 2020, 16, 43-51.	0.2	1
4637	Efficacy and Side Effects of Combined Capecitabine Plus Intensity Modulated Radiotherapy as an Effective Adjuvant Therapy for Gastric Cancers. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 365-371.	0.3	1
4638	SDF-1 expression after preoperative chemoradiotherapy is associated with prognosis in patients with advanced lower rectal cancer. <i>Journal of Medical Investigation</i> , 2021, 68, 309-314.	0.2	0
4639	Endoscopic Stricturotomy for Patients With Postoperative Benign Anastomotic Stricture for Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 590-598.	0.7	3
4640	Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial. <i>Annals of Surgical Oncology</i> , 2022, 29, 1493-1495.	0.7	4
4641	The Potential for Overtreatment With Total Neoadjuvant Therapy (TNT): Consider One Local Therapy Instead. <i>Clinical Colorectal Cancer</i> , 2022, 21, 19-35.	1.0	1
4642	Risk Factors for Anastomotic Leak, Consideration for Proximal Diversion, and Appropriate Use of Drains. <i>Clinics in Colon and Rectal Surgery</i> , 2021, 34, 366-370.	0.5	2
4643	Tumor regression grade as a prognostic factor in metastatic colon cancer following preoperative chemotherapy. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	2
4644	Rectal Cancer: Neoadjuvant Therapy. , 2022, , 463-477.		0
4645	Generalizability of Randomized Controlled Trials in Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 453-465.	0.9	4
4646	The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine. <i>Frontiers in Oncology</i> , 2021, 11, 758698.	1.3	0
4647	A Novel Scoring System for Response of Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer Using Early-Treatment Blood Features Derived From Machine Learning. <i>Frontiers in Oncology</i> , 2021, 11, 790894.	1.3	2
4648	Serum hsa-miR-30e As a Potential Biomarker to Predict the Effect of Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 696-706.	0.3	1
4649	Clinical Implication of Perineural and Lymphovascular Invasion in Rectal Cancer Patients Who Underwent Surgery After Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 1325-1334.	0.7	5

#	ARTICLE	IF	CITATIONS
4650	Colorectal Cancer: Postoperative Adjuvant Therapy and Surveillance. , 2022, , 529-545.		0
4651	Sexual Function After Colorectal Surgery in Women. , 2022, , 1055-1066.		1
4653	The Safety and Feasibility of Laparoscopic Surgery for Very Low Rectal Cancer: A Retrospective Analysis Based on a Single Center's Experience. Biomedicines, 2021, 9, 1720.	1.4	0
4654	Preoperative intensity-modulated chemoradiotherapy with simultaneous integrated boost in rectal cancer: five-year follow-up results of a phase II study. Radiology and Oncology, 2021, 55, 439-448.	0.6	0
4655	Current status of total neoadjuvant therapy for locally advanced rectal cancer. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	3
4656	Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 1788-1801.	1.5	4
4657	Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer. JAMA Network Open, 2021, 4, e2136116.	2.8	2
4658	Rapid Initiation of Neoadjuvant Chemoradiotherapy After Diagnosis is Associated With Improved Pathologic Response in Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, Publish Ahead of Print, .	0.6	0
4659	Recent Advances in Functional MRI to Predict Treatment Response for Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports, 0, , 1.	1.0	0
4660	LncRNAs Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer. Journal of Inflammation Research, 2021, Volume 14, 6275-6292.	1.6	5
4661	Robotic versus laparoscopic surgery for rectal cancer after neoadjuvant chemoradiotherapy: A propensity-score matching analysis. Journal of the Formosan Medical Association, 2022, 121, 1532-1540.	0.8	3
4662	Overexpression of MLPH in Rectal Cancer Patients Correlates with a Poorer Response to Preoperative Chemoradiotherapy and Reduced Patient Survival. Diagnostics, 2021, 11, 2132.	1.3	2
4663	Accuracy of MRI for predicting anterior peritoneal reflection involvement in locally advanced rectal cancer: a comparison with operative findings. Abdominal Radiology, 2021, 47, 508.	1.0	1
4664	Effects of exercise during and after neoadjuvant chemoradiation on symptom burden and quality of life in rectal cancer patients: a phase II randomized controlled trial. Journal of Cancer Survivorship, 2021, , 1.	1.5	8
4665	Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01). Anticancer Research, 2021, 41, 6247-6257.	0.5	1
4666	Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapyâ€”A matter of concern. European Journal of Cancer, 2021, 159, 275-282.	1.3	0
4667	Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial. Annals of Surgical Oncology, 2022, 29, 1880-1889.	0.7	19
4668	Changes in treatment intent and target definition for preoperative radiotherapy after 18F-Fluorodeoxyglucose positron emission tomography in rectal cancer: A Meta-analysis. European Journal of Radiology, 2021, 145, 110061.	1.2	1

#	ARTICLE	IF	CITATIONS
4669	Onkologika. , 2021, , 579-638.		0
4670	Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 801880.	1.3	5
4671	Robotic versus laparoscopic low anterior resection following neoadjuvant chemoradiation therapy for stage II–III locally advanced rectal cancer: a single-centre cohort study. <i>Journal of Robotic Surgery</i> , 2022, 16, 1133-1141.	1.0	2
4672	Collagen score in the tumor microenvironment predicts the prognosis of rectal cancer patients after neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 99-108.	0.3	2
4674	Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis. <i>Formosan Journal of Surgery</i> , 2018, 51, 1-8.	0.1	4
4675	Different Treatment Modalities of Colo-Rectal Cancer (Retrospective Study). <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 81, 1953-1957.	0.0	0
4676	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
4677	Postoperative hypofractionated “accelerated radiotherapy (HypoAR) for locally advanced rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 493-498.	0.6	1
4678	Locally Advanced Rectal Cancer: What We Learned in the Last Two Decades and the Future Perspectives. <i>Journal of Gastrointestinal Cancer</i> , 2022, , 1.	0.6	5
4679	Quality of Life after Rectal Cancer Resection Comparing Anterior Resection, Abdominoperineal Resection, and Complicated Cases. <i>Visceral Medicine</i> , 2022, 38, 138-149.	0.5	3
4680	Combination of extramural venous invasion and lateral lymph node size detected with magnetic resonance imaging is a reliable biomarker for lateral lymph node metastasis in patients with rectal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, 5.	0.8	6
4681	Quality of internet information to aid patient decision making in locally advanced and recurrent rectal cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, , .	0.8	4
4682	Updated systematic review of the approach to pelvic exenteration for locally advanced primary rectal cancer. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	2
4683	Assessment of clinical and pathological complete response after neoadjuvant chemoradiotherapy in rectal adenocarcinoma and its therapeutic implications. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 411-425.	0.4	4
4684	Short-course neoadjuvant in situ vaccination for murine melanoma. , 2022, 10, e003586.		7
4685	A comprehensive framework for early-onset colorectal cancer research. <i>Lancet Oncology</i> , The, 2022, 23, e116-e128.	5.1	49
4686	Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the Anus, Rectum and Colon</i> , 2022, 6, 24-31.	0.4	2
4687	Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial. <i>BMJ Open</i> , 2022, 12, e055364.	0.8	3

#	ARTICLE	IF	CITATIONS
4688	THUNDER 2: THERagnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy. BMC Cancer, 2022, 22, 67.	1.1	15
4689	The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density. Frontiers in Immunology, 2022, 13, 781222.	2.2	8
4690	Lymph Node Yield Is a Less Reliable Prognostic Marker Following Neoadjuvant Chemoradiotherapy Compared to Primary Surgery for Rectal Cancer. SN Comprehensive Clinical Medicine, 2022, 4, 1.	0.3	1
4691	Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis. Techniques in Coloproctology, 2022, 26, 163.	0.8	5
4692	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	3.2	62
4693	New Paradigms in Rectal Cancer Multidisciplinary Care: Special Issue Introduction. Clinical Colorectal Cancer, 2022, 21, 1-2.	1.0	1
4694	Adding Consolidation Capecitabine to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Propensity-Matched Comparative Study. Frontiers in Surgery, 2021, 8, 770767.	0.6	3
4695	Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in ypT0-1 Rectal Cancer After Preoperative Radiochemotherapy: Postoperative Morbidity, Functional Results, and Long-term Oncologic Outcome. Diseases of the Colon and Rectum, 2022, 65, 1306-1315.	0.7	7
4696	Clinical Implication of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. The Ewha Medical Journal, 2022, 45, 3-10.	0.1	1
4697	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opinion on Investigational Drugs, 2022, 31, 235-247.	1.9	3
4698	Correlative Significance of Tumor Regression Grade and ypT Category in Patients Undergoing Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2022, 21, 212-219.	1.0	2
4699	Evaluating potential delays and outcomes of patients undergoing surgical resection for locally advanced and recurrent colorectal cancer during a pandemic. Annals of the Royal College of Surgeons of England, 2022, , .	0.3	1
4700	Oncologic benefit of adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and curative surgery with selective lateral pelvic lymph node dissection: An international retrospective cohort study. European Journal of Surgical Oncology, 2022, 48, 1631-1637.	0.5	4
4701	Meta-Analysis on the Neutrophil-Lymphocyte Ratio in Rectal Cancer Treated With Preoperative Chemoradiotherapy: Prognostic Value of Pre- and Post-Chemoradiotherapy Neutrophil-Lymphocyte Ratio. Frontiers in Oncology, 2022, 12, 778607.	1.3	6
4702	Rectal cancer radiotherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 272-278.	0.6	8
4703	Can I control my bowel symptoms myself? The experience of controlling defaecation dysfunction among patients with rectal cancer after sphincter-saving surgery: a qualitative study. International Journal of Qualitative Studies on Health and Well-being, 2022, 17, 2031832.	0.6	1
4704	Management of the malignant colorectal polyp. Current Problems in Surgery, 2022, 59, 101124.	0.6	2
4705	Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer. Neoplasia, 2022, 25, 53-61.	2.3	10

#	ARTICLE	IF	CITATIONS
4706	Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Single-Center Experience and Literature Review. <i>Annals of Coloproctology</i> , 2021, 37, 382-394.	0.5	11
4708	Neoadjuvant treatment and lymph node metastasis in rectal cancer. , 2022, , 155-166.		0
4709	A treatment planning comparison of photon stereotactic ablative radiotherapy and proton beam therapy for the re-irradiation of pelvic cancer recurrence. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 21, 78-83.	1.2	2
4710	A Comprehensive Evaluation of the Application of the Halcyon(2.0) IMRT Technique in Long-Course Radiotherapy for Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210745.	0.8	1
4712	Rektumkarzinom. , 2022, , 335-361.		0
4713	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210779.	1.4	21
4714	Impact of Medicaid Expansion on the Diagnosis, Treatment, and Outcomes of Stage II and III Rectal Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2022, 234, 54-63.	0.2	3
4715	Káº¼T QUÁ«c Ä¸á»«EU TRÁ»Š HÃ¸A XÁº TRÁ»Š UNG THÆ¸ TRÁ»c TRÃ¸NG GIAI Ä¸OÁºN III TRÆ¸á»šC Má»¸. <i>Y Hoc VietNam</i> , 2022, 510, .		
4716	A Predictive Model of 2yDFS During MR-Guided RT Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 831712.	1.3	8
4717	Effect of Abdominal Circumference on the Irradiated Bowel Volume in Pelvic Radiotherapy for Rectal Cancer Patients: Implications for the Radiotherapy-Related Intestinal Toxicity. <i>Frontiers in Oncology</i> , 2022, 12, 843704.	1.3	2
4718	Cutting-Edge Research Trends in Colorectal Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 1036.	1.0	1
4719	New Frontiers in Management of Early and Advanced Rectal Cancer. <i>Cancers</i> , 2022, 14, 938.	1.7	4
4720	Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e220165.	2.8	7
4721	Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer. <i>Future Oncology</i> , 2022, 18, 691-700.	1.1	4
4722	Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer. <i>Discover Oncology</i> , 2022, 13, 10.	0.8	0
4723	The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 453-473.	1.3	4
4724	SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 646-657.	1.2	6
4725	Neoadjuvant therapy of metformin is associated with good tumor response after preoperative concurrent chemoradiotherapy for rectal cancer. <i>Scientific Reports</i> , 2022, 12, 3716.	1.6	3

#	ARTICLE	IF	CITATIONS
4726	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. <i>Frontiers in Oncology</i> , 2022, 12, 817692.	1.3	4
4727	Right colon, left colon, and rectal cancer have different oncologic and quality of life outcomes. <i>International Journal of Colorectal Disease</i> , 2022, 37, 939-948.	1.0	5
4728	Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4008.	1.2	3
4729	Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for <sc>MSIâ€H</sc> / <sc>dMMR</sc> rectal cancer: A prospective, multicenter, phase Ib study. <i>Cancer Medicine</i> , 2022, , .	1.3	5
4730	Top advances of the year in colorectal cancer. <i>Cancer</i> , 2022, 128, 2236-2239.	2.0	5
4731	Radiotherapy guidelines for rectal cancer in China (2020 Edition). <i>Precision Radiation Oncology</i> , 2022, 6, 4-31.	0.4	4
4732	CÃ¡ncer de recto: tendencias y cambios en el manejo. Conceptos para el gastroenterÃ³logo y el cirujano. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 66-77.	0.1	2
4733	The 100 Most-Cited Articles in the Field of Colorectal Diseases from 1955 to 2020: A Bibliometric Analysis. , 2022, 33, 221-232.		1
4734	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. <i>BMC Cancer</i> , 2022, 22, 222.	1.1	3
4735	Predictors of Lateral Pelvic Lymph Node Metastasis in Advanced Low Rectal Cancer Treated With Neoadjuvant Chemotherapy. <i>Anticancer Research</i> , 2022, 42, 2113-2121.	0.5	1
4736	Complete Response Evaluation of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from T2 Weighted Imaging and ADC Maps. <i>Current Medical Imaging</i> , 2022, 18, 1061-1069.	0.4	2
4737	Surgical Efficacy and Safety of Patients with Locally Advanced Gastric Cancer following Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-6.	0.6	4
4738	Shortâ€term outcomes of roboticâ€assisted surgery following neoadjuvant chemotherapy for lower rectal cancer. <i>Asian Journal of Endoscopic Surgery</i> , 2022, , .	0.4	2
4739	Identifying the long-term survival beneficiary of preoperative radiotherapy for rectal cancer in the TME era. <i>Scientific Reports</i> , 2022, 12, 4617.	1.6	3
4740	Non-adherence to multi-modality cancer treatment guidelines in the United States. <i>Advances in Radiation Oncology</i> , 2022, 7, 100938.	0.6	3
4741	The importance of MRI for rectal cancer evaluation. <i>Surgical Oncology</i> , 2022, 43, 101739.	0.8	35
4742	Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 855674.	1.3	1
4743	Colorectal Cancer Mortality in Kazakhstan: Spatio-Temporal Epidemiological Assessment. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 953-960.	0.5	0

#	ARTICLE	IF	CITATIONS
4744	Can CCRT/RT Achieve Favorable Oncologic Outcome in Rectal Cancer Patients With High Risk Feature After Local Excision?. <i>Frontiers in Oncology</i> , 2022, 12, 767838.	1.3	0
4745	The Evolving Role of Hypofractionated Radiotherapy in Older Adults with Gastrointestinal Cancers. <i>Seminars in Radiation Oncology</i> , 2022, 32, 159-167.	1.0	0
4746	Efficacy of preoperative chemoradiotherapy in patients with cT2N0 distal rectal cancer. <i>Annals of Coloproctology</i> , 2023, 39, 250-259.	0.5	3
4747	Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103627.	2.0	12
4748	A practical framework for the targeted use of total neoadjuvant therapy for rectal cancer. <i>Cancer</i> , 2022, 128, 2064-2072.	2.0	6
4749	Neoadjuvant Therapy for Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 279-291.	0.6	3
4751	Nonoperative Management of Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 171-182.	0.6	8
4752	Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
4753	Targeted Therapy for Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 255-264.	0.6	19
4754	Prospective evaluation of bowel dysfunction after rectal cancer surgery. <i>Supportive Care in Cancer</i> , 2022, 30, 5939-5947.	1.0	4
4755	Comparative survival risks in patients undergoing abdominoperineal resection and sphincter-saving operation for rectal cancer: a 10-year cohort analysis using propensity score matching. <i>International Journal of Colorectal Disease</i> , 2022, , 1.	1.0	1
4756	The Long and the Short of it: the Role of Short-course Radiotherapy in the Neoadjuvant Management of Rectal Cancer. <i>Clinical Oncology</i> , 2022, 34, e210-e217.	0.6	3
4757	BRIDGE âˆ’1 TRIAL: BReak Interval Delayed surgery for Gastrointestinal Extrapertitoneal rectal cancer, a multicentric phase III randomized trial. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 30-36.	0.9	2
4758	Prognostic Value of the Distribution of Lymph Node Metastasis in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Frontiers in Surgery</i> , 2021, 8, 749575.	0.6	0
4759	Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. <i>BJS Open</i> , 2021, 5, .	0.7	3
4760	A prior-based method for colorectal lymph node region classification via deep neural network. , 2021, , .		0
4761	Functional outcomes after sphincter-preserving surgeries for low-lying rectal cancer: A review. <i>Precision and Future Medicine</i> , 2021, 5, 164-174.	0.5	1
4762	Short-course radiotherapy and chemotherapy for conversion surgery in patients with unresectable metastatic rectal cancer: a preliminary case series study. <i>Korean Journal of Clinical Oncology</i> , 2021, 17, 111-116.	0.1	0

#	ARTICLE	IF	CITATIONS
4763	Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis. <i>BMC Surgery</i> , 2021, 21, 441.	0.6	4
4764	Genomic evolution during locoregional recurrence in colorectal cancer determined by whole-exome sequencing. <i>Journal of Bio-X Research</i> , 2021, Publish Ahead of Print, .	0.3	0
4765	Watch and wait strategies for rectal cancer: A systematic review. <i>Precision and Future Medicine</i> , 2022, 6, 91-104.	0.5	2
4766	Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma. <i>Anticancer Research</i> , 2022, 42, 155-164.	0.5	2
4767	Rectal cancer: Maximizing local control and minimizing toxicity. <i>Journal of Surgical Oncology</i> , 2022, 125, 46-54.	0.8	3
4768	Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212). <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 114-121.	0.6	3
4769	Prediction of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer with Metric Learning Using Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography. <i>Cancers</i> , 2021, 13, 6350.	1.7	2
4771	Sigara Kullanma ve Lenf Nodu Metastaz ile Kolorektal Kanserlerde SaĖkal ile ĖliĖkisi. <i>Ahi Evran Medical Journal</i> , 0, , .	0.1	0
4772	The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	4
4773	Preoperative radiotherapy for rectal cancer: A bibliometric analysis of the 100 most-cited research articles. <i>Nigerian Journal of Clinical Practice</i> , 2022, 25, 448.	0.2	0
4774	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. <i>Radiotherapy and Oncology</i> , 2022, 171, 69-76.	0.3	20
4775	Preoperative risk stratification of permanent stoma in patients with non-metastatic mid and low rectal cancer undergoing curative resection and a temporary stoma. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1991-1999.	0.8	3
4776	Comprehensive Analysis of miRNA-Mediated Regulatory Network and Identification of Prognosis Biomarkers in Rectal Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 792984.	1.1	3
4777	Applicability of a pathological complete response magnetic resonance-based radiomics model for locally advanced rectal cancer in intercontinental cohort. <i>Radiation Oncology</i> , 2022, 17, 78.	1.2	11
4778	Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
4779	Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics. <i>Scientific Reports</i> , 2022, 12, 6167.	1.6	7
4780	Assessment of Textbook Oncologic Outcomes Following Proctectomy for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1286-1297.	0.9	7
4801	What can the Pathologist Tell the Multidisciplinary Team about Rectal Cancer Resection?. , 0, , 31-45.		0

#	ARTICLE	IF	CITATIONS
4802	MRI-Directed Rectal Cancer Surgery. , 0, , 46-59.		0
4803	18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy. Nuclear Medicine Communications, 2022, 43, 815-822.	0.5	9
4804	Robotic surgery contributes to the preservation of bowel and urinary function after total mesorectal excision: comparisons with transanal and conventional laparoscopic surgery. BMC Surgery, 2022, 22, 147.	0.6	6
4805	Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)". Tumori, 2013, 99, 61-7.	0.6	4
4806	Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: impact of residual tumor volume on the prediction of pathologic tumor regression. Tumori, 2014, 100, 158-62.	0.6	1
4819	Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer. Saudi Journal of Gastroenterology, 2016, 22, 148.	0.5	5
4820	Diagnosis and Treatment of Lack of Benign Anastomosis of Colorectal Cancer. Advances in Clinical Medicine, 2022, 12, 3770-3776.	0.0	0
4823	Endoscopy-Based Deep Convolutional Neural Network Predicts Response to Neoadjuvant Treatment for Locally Advanced Rectal Cancer. Frontiers in Physiology, 2022, 13, 880981.	1.3	0
4824	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer, 2022, 22, 462.	1.1	10
4825	Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer—INCA004. Supportive Care in Cancer, 2022, , 1.	1.0	0
4826	Watch and wait: Why, to whom and how. Surgical Oncology, 2022, 43, 101774.	0.8	12
4827	Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: a scoping review protocol. BMJ Open, 2022, 12, e061397.	0.8	3
4828	Total Neoadjuvant Strategies for Locally Advanced Rectal Cancer. Advances in Oncology, 2022, 2, 227-236.	0.1	1
4829	Nonoperative Management for Rectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 539-551.	0.9	5
4830	Induction Chemotherapy and Chemoradiotherapy Combined to ASA versus Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial. Clinical Colorectal Cancer, 2022, , .	1.0	1
4831	Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma. International Journal of Colorectal Disease, 2022, , 1.	1.0	1
4832	MRI measurements predict major low anterior resection syndrome in rectal cancer patients. International Journal of Colorectal Disease, 2022, 37, 1239-1249.	1.0	1
4833	Protective ileostomy increased the incidence of rectal stenosis after anterior resection for rectal cancer. Radiation Oncology, 2022, 17, 93.	1.2	4

#	ARTICLE	IF	CITATIONS
4834	Omission of neoadjuvant radiotherapy for clinical T2/N1 and T3N0/1 middle and low rectal cancers with safe circumferential resection margins. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 281.	0.4	1
4835	The Multimodal Management of Locally Advanced Rectal Cancer: Making Sense of the New Data. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 264-277.	1.8	7
4838	A new technique for robotic lateral pelvic lymph node dissection for advanced low rectal cancer with emphasis on en bloc resection and inferior vesical vessel preservation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 7789-7793.	1.3	6
4839	The oncological outcomes of postoperative radiotherapy in patients with stage II and III upper rectal cancer. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
4840	Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. <i>British Journal of Cancer</i> , 2022, 127, 766-775.	2.9	6
4844	Abdominoperineal Excision in current era. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100580.	0.7	0
4845	Impact of time interval between neoadjuvant chemoradiotherapy and surgery on oncological outcomes of locally advanced rectal cancer. <i>Surgical Practice</i> , 0, , .	0.1	0
4846	Which radiotherapy technique is better for neoadjuvant treatment of rectal cancer: A dosimetric comparison. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
4847	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
4848	Towards personalized treatment of T2N0 rectal cancer: A systematic review of long-term oncological outcomes of neoadjuvant therapy followed by local excision. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1426-1433.	1.4	6
4852	The predictive value of tumor volume reduction ratio on three-dimensional endorectal ultrasound for tumor response to chemoradiotherapy for locally advanced rectal cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 666-666.	0.7	5
4853	The evolving treatment paradigm of locally advanced rectal cancer: a narrative review. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2033-2047.	0.6	3
4854	Armamentarium in drug delivery for colorectal cancer. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2022, , .	1.2	2
4855	<i>Gastrointestinal Surgery</i> , , 2022, , 97-135.		0
4857	Short-term outcomes of neoadjuvant chemotherapy with capecitabine plus oxaliplatin for patients with locally advanced rectal cancer followed by total or tumor-specific mesorectal excision with or without lateral pelvic lymph node dissection. <i>Fukushima Journal of Medical Sciences</i> , 2022, , .	0.1	0
4858	Nonoperative Management Following Complete Response in Rectal Cancer After Short-course Radiation Therapy and Consolidation Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 298-305.	0.6	3
4859	Rectal cancer eradication by proton beam therapy complicated by radiation proctitis: a case report. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
4860	Gastric collision tumour with probable ectopic pancreatic origin. <i>Ecancermedicalscience</i> , 0, 16, .	0.6	1

#	ARTICLE	IF	CITATIONS
4861	Staging and Restaging of Rectal Cancer with MRI: A Pictorial Review. <i>Seminars in Ultrasound, CT and MRI</i> , 2022, 43, 441-454.	0.7	5
4862	Prognostic value of sarcopenia in patients with rectal cancer: A meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270332.	1.1	10
4863	Cost analysis of total neoadjuvant therapy with 5 Å– 5 Gy radiation therapy versus conventional chemoradiotherapy for locally advanced rectal cancer among Peruvians. <i>Ecancermedalscience</i> , 0, 16, .	0.6	1
4864	Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4865	Multicenter validation of the PREDICT score for prediction of local recurrence after total mesorectal excision of rectal cancer. <i>Journal of Surgical Oncology</i> , 0, , .	0.8	0
4866	A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer. <i>Cancer Research and Treatment</i> , 0, , .	1.3	1
4867	Ká³/4T QUá²ç HÃ“A Xá² TRá»Š TIá»€N PHá²²U UNG THÆ“ TRá»°C TRÃ“NG GIAI ÄŒá²N II, III. <i>Y Hoc Viet Nam</i> , 2022, 514, .	0.1	0
4868	Neoadjuvant therapy for locally advanced rectal cancer. <i>Pelvic Surgery and Oncology</i> , 2022, 12, 36-45.	0.2	0
4869	Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2022, 109, 102419.	3.4	8
4871	Establishment of In Vitro and In Vivo Anticolorectal Cancer Efficacy of Lithocholic Acid-Based Imidazolium Salts. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7019.	1.8	4
4872	Editorial: Neoadjuvant Therapy in Rectal Cancer: Response Prediction and Organ Preservation Strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
4873	Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial. <i>Cancers</i> , 2022, 14, 3204.	1.7	11
4874	Early results from implementation of a â€˜watch and waitâ€™™ protocol for complete clinical response following chemoradiotherapy for rectal cancer. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	3
4875	Prognostic value of lymph node ratio in resectable rectal cancer after preoperative short-course radiotherapyâ€™ results from randomized clinical trial. <i>Langenbeck's Archives of Surgery</i> , 0, , .	0.8	1
4876	Predictors and histological effects of preoperative chemoradiotherapy for rectal cancer and control of lateral lymph node metastasis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	0
4877	Neoadjuvant Mfolfoxiri With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score Matched Comparison With Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 0, Publish Ahead of Print, .	0.7	1
4878	Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
4879	Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
4881	Neoadjuvant Therapy in the Post-“German Rectal Trial Era: Making Sense in the Absence of Consensus. <i>Practical Radiation Oncology</i> , 2023, 13, e54-e60.	1.1	2
4882	Rectosigmoid Cancer—Rectal Cancer or Sigmoid Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	4
4883	Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2227-2236.	0.9	2
4886	Oncologic Outcomes of Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Single-institution Experience. <i>Annals of the Academy of Medicine, Singapore</i> , 2014, 43, 569-575.	0.2	1
4887	Role of non-coding RNAs in radiosensitivity of colorectal cancer: A narrative review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4888	Are risk factors for anastomotic leakage influencing long-term oncological outcomes after low anterior resection of locally advanced rectal cancer with neoadjuvant therapy? A single-centre cohort study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2945-2957.	0.8	6
4889	Adult and Elderly Risk Factors of Mortality in 23,614 Emergently Admitted Patients with Rectal or Rectosigmoid Junction Malignancy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9203.	1.2	3
4890	A Predictive System to Classify Preoperative Grading of Rectal Cancer Using Radiomics Features. <i>Lecture Notes in Computer Science</i> , 2022, , 431-440.	1.0	1
4891	Presentation and management of a case of rectal cancer complicated by perforation and necrotizing soft tissue infection. <i>Journal of Surgical Case Reports</i> , 2022, 2022, .	0.2	0
4892	The latest application progress of radiomics in prediction and diagnosis of liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-13.	1.4	0
4893	Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4894	Biologics in rectal cancer. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-13.	1.4	0
4895	Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1081-1098.	1.1	1
4896	Total neoadjuvant therapy or standard chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	5
4897	Pathologic Implications of Radial Resection Margin and Perineural Invasion to Adjuvant Chemotherapy after Preoperative Chemoradiotherapy and Surgery for Rectal Cancer: A Multi-Institutional and Case-Matched Control Study. <i>Cancers</i> , 2022, 14, 4112.	1.7	2
4898	Radiomics of locally advanced rectal cancer: machine learning-based prediction of response to neoadjuvant chemoradiotherapy using pre-treatment sagittal T2-weighted MRI. <i>Japanese Journal of Radiology</i> , 2023, 41, 71-82.	1.0	9
4899	Global status of research on radiotherapy for rectal cancer: A bibliometric and visual analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
4901	Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
4902	Multimodal treatment of rectal cancer. Deutsches Ärztblatt International, 0, , .	0.6	2
4903	Linear Tumor Regression of Rectal Cancer in Daily MRI during Preoperative Chemoradiotherapy: An Insight of Tumor Regression Velocity for Personalized Cancer Therapy. Cancers, 2022, 14, 3749.	1.7	2
4904	Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. World Journal of Gastrointestinal Oncology, 2022, 14, 1429-1445.	0.8	3
4905	Clinical applications of high dose rate endorectal brachytherapy for patients with rectal cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 879-883.	0.6	2
4906	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
4907	The value of diffusion kurtosis imaging and intravoxel incoherent motion quantitative parameters in predicting synchronous distant metastasis of rectal cancer. BMC Cancer, 2022, 22, ,	1.1	0
4908	Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy. JAMA Oncology, 2022, 8, 1466.	3.4	8
4909	Toxicity and feasibility of total neoadjuvant therapy using short course radiation followed by chemotherapy. International Journal of Health Sciences, 0, , .	0.0	0
4910	Epidemiology, incidence and treatment of rectal cancer in young women case serie about 11 cases (case) Tj ETQq0,0,0 rgBT /Overlock 1	0.5	0
4912	Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer. Journal of Contemporary Brachytherapy, 2022, 14, 370-378.	0.4	0
4913	Current status and role of robotic approach in patients with low-lying rectal cancer. Annals of Surgical Treatment and Research, 2022, 103, 1.	0.4	3
4914	Molecular Guidance for Planning External Beam Radiation Therapy in Oncology. , 2022, , 1687-1726.		0
4915	Rektumkarzinom: Indikationen zur neoadjuvanten und adjuvanten Therapie. Springer Reference Medizin, 2022, , 1-17.	0.0	0
4916	Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Meta-Analyses of Individual Patient Data. SSRN Electronic Journal, 0, , .	0.4	0
4917	An Unsupervised Learning Approach to 3D Rectal MRI Volume Registration. IEEE Access, 2022, 10, 87650-87660.	2.6	0
4918	A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. , 2022, , 3877-3895.		0
4919	Uterine Transposition. , 2022, , 211-226.		1
4920	Analysis of delay in adjuvant chemotherapy in locally advanced rectal cancer. Techniques in Coloproctology, 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
4921	A Tumoral and Peritumoral CT-Based Radiomics and Machine Learning Approach to Predict the Microsatellite Instability of Rectal Carcinoma. <i>Cancer Management and Research</i> , 0, Volume 14, 2409-2418.	0.9	8
4923	Protocol: The role of defunctioning stoma prior to neoadjuvant therapy for locally advanced colonic and rectal cancer-A systematic review. <i>PLoS ONE</i> , 2022, 17, e0275025.	1.1	1
4924	Personalized total neoadjuvant therapy (<sc>pTNT</sc>) for advanced rectal cancer with tailored treatment sequencing based on clinical stage at presentation. <i>ANZ Journal of Surgery</i> , 2023, 93, 173-181.	0.3	9
4926	Treatment Utilization and Outcomes for Locally Advanced Rectal Cancer in Older Patients. <i>JAMA Surgery</i> , 0, , e224456.	2.2	1
4927	Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1711-1726.	0.8	0
4928	Impact of endorectal filling on interobserver variability of MRI based rectal primary tumor delineation. <i>Clinical and Translational Radiation Oncology</i> , 2023, 38, 1-5.	0.9	1
4929	Presence and clinical significance of acellular mucin pools in resected rectal cancer with pathological complete response after preoperative chemoradiotherapy. <i>Histopathology</i> , 2022, 81, 569-576.	1.6	1
4930	Rectal <sc>MRI</sc> Interpretation After Neoadjuvant Therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 353-369.	1.9	10
4931	Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10353.	1.8	0
4932	Prolonged neoadjuvant chemotherapy without radiation versus total neoadjuvant therapy for locally advanced rectal cancer: A propensity score matched study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4933	Zebrafish Avatars of rectal cancer patients validate the radiosensitive effect of metformin. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4934	Mismatch repair deficiency in rectal cancer: an evolving scenario. <i>Annals of Translational Medicine</i> , 2022, 10, 951-951.	0.7	0
4936	STUDY OF ANORECTAL PHYSIOLOGY PRE AND POS NEOADJUVANT THERAPY FOR RECTAL CANCER BY ANORECTAL MANOMETRY AND JORGE-WEXNER SCORE. <i>Arquivos De Gastroenterologia</i> , 2022, 59, 334-339.	0.3	1
4937	The evaluation of postoperative bowel dysfunction in Japanese patients with rectal cancer. <i>Surgery Today</i> , 0, , .	0.7	1
4938	Long-term adverse effects and healthcare burden of rectal cancer radiotherapy: systematic review and <sc>meta-analysis</sc>. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	0
4939	Outcomes and Side Effects of Preoperative Chemoradiotherapy for Locally Advanced Upper Rectal Cancer. <i>Anticancer Research</i> , 2022, 42, 4833-4840.	0.5	1
4940	Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. <i>Journal of Investigative Surgery</i> , 2023, 36, .	0.6	54
4941	The effect of Mitomycin-C in neoadjuvant concurrent chemoradiotherapy for rectal cancer. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 1120-1125.	0.6	11

#	ARTICLE	IF	CITATIONS
4942	Impact of preoperative chemoradiation with higher dose intensity modulated radiotherapy on pathological complete response for locally advanced rectal cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1249-1259.	1.1	1
4943	Correlation between T stage and lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211326.	1.4	1
4944	Post-operative anastomotic leakage and collagen changes in patients with rectal cancer undergoing neoadjuvant chemotherapy vs chemoradiotherapy. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	1
4945	Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. <i>BJS Open</i> , 2022, 6, .	0.7	1
4946	TUMOUR GRADE REGRESSION (TRG) AND CORRELATION WITH MAGNETIC RESONANCE IMAGING (MRI) IN RECTAL CANCER. , 2022, , 11-14.		0
4947	Robotic Rectal Resection for Rectal Cancer: State of the Art. , 0, , .		0
4948	Validation of the Neoadjuvant Rectal Cancer (NAR) Score for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
4949	Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 1139-1167.	2.3	184
4950	Understanding the Philosophy, Anatomy, and Surgery of the Extra-TME Plane of Locally Advanced and Locally Recurrent Rectal Cancer; Single Institution Experience with International Benchmarking. <i>Cancers</i> , 2022, 14, 5058.	1.7	5
4951	Does neoadjuvant rectal score predict treatment outcomes better than the all grading systems used in neoadjuvantly treated rectal cancer?. <i>Asian Journal of Surgery</i> , 2023, 46, 4378-4384.	0.2	0
4952	Vimentin and tumorâ€™stroma ratio for neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer. <i>Cancer Science</i> , 2023, 114, 619-629.	1.7	3
4953	Quantification of organ motion in male and female patients undergoing long course radiotherapy for rectal cancer in the supine position. <i>Advances in Radiation Oncology</i> , 2022, , 101109.	0.6	0
4954	Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2022, 37, 2321-2333.	1.0	1
4955	An International Multicenter Prospective Study Evaluating the Long-term Oncological Impact of Adjuvant Chemotherapy in ypN+ Rectal Cancer. <i>Annals of Surgery</i> , 2023, 277, 299-304.	2.1	8
4956	Patterns and predictors of recurrence after laparoscopic resection of rectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4957	Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 2048-2060.	0.8	0
4958	Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 1177-1184.	2.3	9
4959	Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis. <i>Medicina (Lithuania)</i> , 2022, 58, 1505.	0.8	3

#	ARTICLE	IF	CITATIONS
4960	Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic factors in locally advanced rectal cancer. <i>Oncology</i> , 0, , .	0.9	2
4961	Lifestyle interventions after colorectal cancer surgery using a mobile digital device: A study protocol for a randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, e31264.	0.4	0
4962	Prognostic and Predictive Biomarkers in Patients with Locally Advanced Rectal Cancer (LARC) Treated with Preoperative Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 6091.	1.0	3
4963	Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). <i>Annals of Oncology</i> , 2023, 34, 78-90.	0.6	19
4964	Predictors of Definitive Treatment Interruptions of Long-Course Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Cureus</i> , 2022, , .	0.2	0
4965	Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2
4966	Sigmoid take-off in rectosigmoid cancer as a landmark identifying benefit from neoadjuvant chemoradiation: A retrospective comparative cohort study. <i>Asian Journal of Surgery</i> , 2023, 46, 4330-4336.	0.2	0
4968	ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	0
4969	High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT. <i>Pathology Research and Practice</i> , 2022, 239, 154158.	1.0	1
4970	Primary Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, , .	0.6	1
4971	Pathology and Pathogenesis of Radiation Bowel Disease: Histopathological Appraisal in the Clinical Setting. <i>European Medical Journal Gastroenterology</i> , 0, , 113-119.	0.0	3
4972	Bowel Functional Outcomes After Long-Course or Short-Course Radiation for Advanced Rectal Cancers: A Propensity-Matched Analysis. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 1494-1502.	0.7	4
4973	Toxicity Management in the Era of Changing Treatment Paradigms for Locally Advanced Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2022, 18, 55-59.	1.0	3
4974	Short-term outcomes of near-infrared imaging using indocyanine green in laparoscopic lateral pelvic lymph node dissection for middle-lower rectal cancer: A propensity score-matched cohort analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
4975	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
4976	Utilization of neoadjuvant stereotactic radiosurgery for the treatment of brain metastases requiring surgical resection: a topic review. <i>Journal of Neuro-Oncology</i> , 2022, 160, 691-705.	1.4	1
4977	Current status of transanal total mesorectal excision for rectal cancer and the expanding indications of the transanal approach for extended pelvic surgeries. <i>Digestive Endoscopy</i> , 2023, 35, 243-254.	1.3	1
4978	ElÁrehaladott vÃ©gbÃ©ldaganatok neoadjuvÃ©jns (preoperatÃ©v) kemoradioterÃ©piÃ©ja. <i>Orvosi Hetilap</i> , 2022, 163, 1196-1205.	0.1	1

#	ARTICLE	IF	CITATIONS
4979	KCNE4 expression is correlated with the pathological characteristics of colorectal cancer patients and associated with the radioresistance of cancer cells. <i>Pathology Research and Practice</i> , 2023, 241, 154234.	1.0	2
4980	Dentate line invasion as a predictive factor of poor distant relapse-free survival in locally advanced lower rectal cancer with anal sphincter involvement. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
4981	PRDM15 interacts with DNA-PK-Ku complex to promote radioresistance in rectal cancer by facilitating DNA damage repair. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
4985	Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103885.	2.0	1
4986	Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. <i>Bioactive Materials</i> , 2023, 24, 136-152.	8.6	14
4987	Impact of Neoadjuvant Therapy on Postoperative Complications in Patients Undergoing Resection for Rectal Adenocarcinoma. <i>American Surgeon</i> , 2004, 70, 1045-1049.	0.4	13
4988	Comparación cl�nica de radioterapia de intensidad modulada versus radioterapia 3D en tratamiento neoadyuvante del c�ncer de recto localmente avanzado. , 2018, 23, .		0
4989	A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2938-2950.	0.6	3
4990	Clinical study on risk factors related to postoperative recurrence or metastasis of rectal cancer: a retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2973-2988.	0.6	2
4991	Does Sarcopenia Predict Local Response Rates After Chemoradiotherapy for Locally Advanced Rectal Cancer?. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 965-972.	0.7	5
4992	Short-term outcomes of robot-assisted versus conventional laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiotherapy: a propensity score-matched analysis. <i>Journal of Robotic Surgery</i> , 2023, 17, 959-969.	1.0	4
4993	Total neoadjuvant therapy in rectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2023, 16, 21-30.	0.3	2
4997	18F-FDG PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer. <i>Nuclear Medicine Communications</i> , 2023, 44, 81-90.	0.5	1
4999	Assessment of Quality of Life in Rectal Cancer with Organ-Preservation Treatment: Are We There yet?. <i>Clinical Oncology</i> , 2022, , .	0.6	1
5000	Association of age with outcomes in locally advanced rectal cancer treated with neoadjuvant therapy followed by surgery. <i>American Journal of Surgery</i> , 2023, 225, 1029-1035.	0.9	4
5001	Lymph node yield less than 12 is not a poor predictor of survival in locally advanced rectal cancer after laparoscopic TME following neoadjuvant chemoradiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
5002	Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
5003	Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing <i>Escherichia coli</i> in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE). <i>BMJ Open</i> , 2022, 12, e061527.	0.8	0

#	ARTICLE	IF	CITATIONS
5004	Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial. <i>Annals of Surgery</i> , 2023, 277, 557-564.	2.1	12
5005	Escalación de dosis de radioterapia con intensidad modulada y boost simultáneo integrado, asociada a capecitabine concurrente para cáncer de recto localmente avanzado. , 2022, 27, .		0
5006	Incidence and Risk Factors of Surgical Complications and Anastomotic Leakage After Transanal Total Mesorectal Excision for Middle and Low Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 373-381.	0.9	2
5007	Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist's perspective. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
5008	Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
5009	Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	1
5011	Retrospective Evaluation of the Impact of Dose Escalation Using Pre-operative Simultaneous Integrated Boost Volumetric Modulated Arc Therapy on the Outcome of Locally Advanced Rectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
5012	Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1102-1115.	0.6	3
5013	Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?. <i>Cancers</i> , 2023, 15, 432.	1.7	8
5014	Downregulation of CEMIP enhances radiosensitivity by promoting DNA damage and apoptosis in colorectal cancer. , 2023, 40, .		4
5015	Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
5016	Significance of Wnt/ β -Catenin Signal Activation for Resistance to Neoadjuvant Chemoradiotherapy in Rectal Cancer. <i>Biomedicines</i> , 2023, 11, 174.	1.4	1
5017	circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	2
5018	Analysis of Survival in Complete Pathological Response after Long-Course Chemoradiotherapy in Patients with Advanced Rectal Cancer. <i>Current Oncology</i> , 2023, 30, 1054-1064.	0.9	1
5019	Long-term results of a phase 2 study of neoadjuvant chemotherapy with molecularly targeted agents for locally advanced rectal cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 392-399.	1.0	0
5020	Gastrointestinal imaging. , 2023, , 333-364.		0
5021	The effect of anti-spasmodic administration on the accuracy of magnetic resonance imaging staging of rectal cancer. <i>ANZ Journal of Surgery</i> , 2023, 93, 1613-1619.	0.3	1
5022	Preoperative Radiosurgical Management of Brain Metastases: Evidence and Challenges. , 0, , 75-91.		0

#	ARTICLE	IF	CITATIONS
5023	MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
5024	Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) â€“ A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100579.	0.9	5
5025	â€œWATCH & WAITâ€•ESPERAR Y VER EN EL CÃNCER DE RECTO. <i>Archivos De ColoproctologÃa</i> , 2021, 4, .	0.0	0
5026	Lateral Lymph Node Size and Tumor Distance From Anal Verge Accurately Predict Positive Lateral Pelvic Lymph Nodes in Rectal Cancer: A Multi-Institutional Retrospective Cohort Study. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 785-795.	0.7	2
5027	Personalized total neoadjuvant therapy versus chemotherapy during the â€“wait periodâ€™ versus standard chemoradiotherapy for locally advanced rectal cancer. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	2
5028	Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019. <i>JAMA Oncology</i> , 2023, 9, 355.	3.4	11
5029	Omentoplasty in Patients Undergoing Abdominoperineal Resection After Long-Course Chemoradiation for Locally Advanced and Locally Recurrent Rectal Cancer: A Comparative Single-Institution Cohort Study. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 994-1002.	0.7	3
5030	What Rectal Cancer Patients May Be Able to Safely Avoid Radiation?. <i>Current Colorectal Cancer Reports</i> , 2022, 18, 61-67.	1.0	0
5032	A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1140-1150.	0.6	2
5033	Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full?. <i>European Urology</i> , 2023, 83, 519-520.	0.9	0
5035	Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy. <i>Chonnam Medical Journal</i> , 2023, 59, 76.	0.5	2
5036	Lateral pelvic lymph node metastasis in T2 low rectal cancer: is TME alone sufficient for cure?. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
5037	Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under â€œReal Worldâ€œ Conditions?. <i>Cells</i> , 2023, 12, 399.	1.8	1
5038	Preoperative Workup, Staging, and Treatment Planning of Colorectal Cancer. <i>Digestive Disease Interventions</i> , 2023, 07, 003-009.	0.3	1
5039	Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial. <i>BMJ Open</i> , 2023, 13, e062659.	0.8	1
5040	Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery. <i>Annals of Surgery</i> , 2023, 278, e766-e772.	2.1	63
5041	Management of Rectal Cancer. , 2013, , 265-286.		0
5042	Implications of the new MRI-based rectum definition according to the sigmoid take-off: multicentre cohort study. <i>BJS Open</i> , 2023, 7, .	0.7	4

#	ARTICLE	IF	CITATIONS
5043	Are we in the era of total neoadjuvant treatment in rectal cancer?. <i>Onkologie (Czech Republic)</i> , 2023, 17, 35-39.	0.0	0
5044	Guidance for Treating the Older Adults with Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 644-666.	1.3	0
5045	Current status of locally advanced rectal cancer therapy and future prospects. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103992.	2.0	1
5046	Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 422-431.	3.7	24
5047	FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients. <i>Cancer Letters</i> , 2023, 562, 216145.	3.2	1
5048	Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy. <i>Advances in Radiation Oncology</i> , 2023, 8, 101192.	0.6	0
5049	Organ Preservation in MSS Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 0, , .	0.5	0
5050	A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103927.	2.0	4
5051	Neoadjuvant Treatment for Rectal Cancer and Nonoperative Management/Total Neoadjuvant Therapy. <i>Digestive Disease Interventions</i> , 2023, 07, 030-036.	0.3	0
5052	Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
5054	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
5055	Prognostic effect of sarcopenia in patients undergoing laparoscopic rectal cancer resection. <i>ANZ Journal of Surgery</i> , 2023, 93, 1631-1637.	0.3	2
5056	Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. <i>Current Oncology Reports</i> , 2023, 25, 341-352.	1.8	2
5057	Determinants of Pre-Surgical Treatment in Primary Rectal Cancer: A Population-Based Study. <i>Cancers</i> , 2023, 15, 1154.	1.7	1
5058	Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. <i>Clinical Colorectal Cancer</i> , 2023, 22, 211-221.	1.0	3
5059	Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2â€“cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> . 2023. 8. 356-367.	3.7	35
5060	Predicting the prognosis of lower rectal cancer using preoperative magnetic resonance imaging with artificial intelligence. <i>Techniques in Coloproctology</i> , 0, , .	0.8	0
5061	Downsizing of rectal cancer following neoadjuvant radiotherapy (5â€“5 Gy) and long interval surgery evaluated using MRI semiautomated volumetric measurements, a retrospective study. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	0

#	ARTICLE	IF	CITATIONS
5062	Morbidity and oncological outcomes after intersphincteric resection of the rectum for low-lying rectal cancer: experience of a single center in a lower-middle-income country. <i>BMC Surgery</i> , 2023, 23, .	0.6	0
5063	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. <i>Cancers</i> , 2023, 15, 1284.	1.7	5
5064	Air-liquid interface cultures trigger a metabolic shift in intestinal epithelial cells (IPEC-1). <i>Histochemistry and Cell Biology</i> , 2023, 159, 389-400.	0.8	3
5065	CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, .		0
5066	Global productivity and research trends of colorectal carcinoma: A scientometric analysis of studies published between 1980 and 2021. <i>Medicine (United States)</i> , 2023, 102, e33037.	0.4	3
5067	“Watch and wait” strategy after neoadjuvant chemoradiotherapy in rectal cancer: opportunities and challenges. , 2023, 2, .		0
5069	One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials. <i>Cancer Research and Treatment</i> , 2023, 55, 918-926.	1.3	0
5070	An optimised liver-first strategy for synchronous metastatic rectal cancer leads to higher protocol completion and lower surgical morbidity. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
5071	Radiomic Features from Post-Operative 18F-FDG PET/CT and CT Imaging Associated with Locally Recurrent Rectal Cancer: Preliminary Findings. <i>Journal of Clinical Medicine</i> , 2023, 12, 2058.	1.0	1
5072	Circumferential Resection Margin as Predictor of Nonclinical Complete Response in Nonoperative Management of Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 973-982.	0.7	2
5073	Watch-and-Wait Approach to Rectal Cancer: The Role of Imaging. <i>Radiology</i> , 2023, 307, .	3.6	7
5074	Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer. <i>Cancer Research Communications</i> , 2023, 3, 548-557.	0.7	0
5077	Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial. <i>BMJ Open</i> , 2023, 13, e066976.	0.8	1
5078	Restaging MRI of Rectal Adenocarcinoma after Neoadjuvant Chemoradiotherapy: Imaging Findings and Potential Pitfalls. <i>Radiographics</i> , 2023, 43, .	1.4	5
5080	Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. <i>European Journal of Cancer</i> , 2023, 186, 211-221.	1.3	5
5081	Comparison between preoperative chemoradiotherapy and lateral pelvic lymph node dissection in clinical T3 low rectal cancer without enlarged lateral lymph nodes. <i>Colorectal Disease</i> , 0, , .	0.7	0
5082	The Effectiveness and Safety of Rectal Modular Resection in Low Rectal Cancer: A Retrospective Study. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 0, , .	0.5	0
5083	Determining the survival benefit of postoperative radiotherapy in patients with pT1-3N1M0 rectal cancer undergoing total mesorectal excision: a retrospective analysis. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0

#	ARTICLE	IF	CITATIONS
5084	Supine bottom-up extralevator abdominoperineal excision for anorectal adenocarcinoma is not inferior to standard approach and may be thus safely performed. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 5226-5235.	1.3	1
5085	Towards targeted colorectal cancer biopsy based on tissue morphology assessment by compression optical coherence elastography. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
5087	Impact of a digital surgical workflow including Digital Device Briefing Tool on morbidity and mortality in a patient population undergoing primary stapled colorectal anastomosis for benign or malignant colorectal disease: protocol for a multicentre prospective cohort study. <i>BMJ Open</i> , 2023, 13, e070053.	0.8	0
5088	A practical review of watch-and-wait approach in rectal cancer. <i>Radiation Oncology Journal</i> , 2023, 41, 4-11.	0.7	2
5089	Efficacy of concurrent radiotherapy in patients with locally advanced rectal cancer and synchronous metastasis receiving systemic therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
5090	MRI-based radiomic score increased mrTRG accuracy in predicting rectal cancer response to neoadjuvant therapy. <i>Abdominal Radiology</i> , 2023, 48, 1911-1920.	1.0	2
5091	DSTN Hypomethylation Promotes Radiotherapy Resistance of Rectal Cancer by Activating the Wnt/ β^2 -Catenin Signaling Pathway. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 117, 198-210.	0.4	4
5092	Advances in Radiotherapy for Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2023, , .	0.6	0
5093	Robotic and laparoscopic salvage lateral pelvic node dissection for the treatment of recurrent rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 4954-4961.	1.3	1
5094	Difference in prognostic impact of lateral pelvic lymph node metastasis between pre- and post-neoadjuvant chemoradiotherapy in rectal cancer patients. <i>Annals of Surgical Treatment and Research</i> , 2023, 104, 205.	0.4	2
5095	Value of apparent diffusion coefficient on MRI for prediction of histopathological type in anal fistula cancer. <i>Medicine (United States)</i> , 2023, 102, e33281.	0.4	0
5096	Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. <i>Annals of Coloproctology</i> , 2023, 39, 289-300.	0.5	2
5097	Watch and Wait Approach for Rectal Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2873.	1.0	2
5098	Lateral pelvic lymphadenectomy for low rectal cancer. <i>International Journal of Health Sciences</i> , 2023, 7, 135-144.	0.0	0
5099	Simultaneous, Multi-Channel, Near-Infrared Fluorescence Visualization of Mesenteric Lymph Nodes Using Indocyanine Green and Methylene Blue: A Demonstration in a Porcine Model. <i>Diagnostics</i> , 2023, 13, 1469.	1.3	0
5100	Proton beam therapy for rectal cancer: a literature review. , 2023, 13, 33-38.		0
5101	MRI radiomics signature to predict lymph node metastasis after neoadjuvant chemoradiation therapy in locally advanced rectal cancer. <i>Abdominal Radiology</i> , 2023, 48, 2270-2283.	1.0	1
5114	Key clinical trials in rectal cancer shaping the current treatment paradigms: reference guide for radiologists. <i>Abdominal Radiology</i> , 2023, 48, 2825-2835.	1.0	0

#	ARTICLE	IF	CITATIONS
5132	Combining radiation and systemic therapy. , 2024, , 99-126.		0
5148	Staging and Treatment. II-2. Overview of Treatment of CRC. , 2023, , 245-248.		0
5149	Staging and Treatment. II-7. Overview of Treatment of Rectal Cancer. , 2023, , 279-286.		0
5164	Schistosoma japonicum Associated Colorectal Cancer and Its Management. Acta Parasitologica, 2023, 68, 723-734.	0.4	1
5195	Combined and Complex Treatment-Optimal Therapies in Rectal Cancer. IFMBE Proceedings, 2024, , 351-361.	0.2	0
5216	Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors. Journal of Neuro-Oncology, 2023, 165, 21-28.	1.4	0
5250	Total neoadjuvant therapy for each locally advanced rectal cancer?. Memo - Magazine of European Medical Oncology, 2024, 17, 15-19.	0.3	1
5258	Which Patients Are the Right Candidates for Total Neoadjuvant Therapy (TNT)?. Difficult Decisions in Surgery: an Evidence-based Approach, 2023, , 281-292.	0.0	0
5275	Colorectal Cancer: Colonoscopy and Follow Up. , 0, , .		0
5281	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0